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Abstract 
 
Androgen receptor (AR) cell signalling is active in most castration-resistant 
prostate cancer (PCa) tumours and suppression is hypothesized to impede cell 
proliferation. Hey1, a corepressor of AR is being investigated as a therapeutic 
transgene for late-stage PCa. A replication-defective recombinant adenovirus 
deleted for E1 and E3 and expressing Hey1 under a CMV promoter was 
constructed (Ad5Hey1). A dual luciferase reporter system demonstrated that 
Ad5Hey1 repressed AR activity in a dose dependent manner in mibolerone-
stimulated 22Rv1 cells. Ad5Hey1 was cytotoxic in both AR-positive 22Rv1 and 
LNCaP and AR-negative DU145 cells. The doses required to kill 50% of cells 
(EC50) were comparable to those of AdE1A12S expressing the cytotoxic 
E1A12S gene from an identical vector.  
 
The mechanisms of Ad5Hey1-induced cell killing were investigated in 22Rv1 
and DU145 cells. Using RNA interference towards AR or p53 in 22Rv1 cells we 
concluded both proteins were required for optimal cell killing by Ad5Hey1. In 
DU145 cells, with non-functional p53, Ad5Hey1 decreased levels of phospho-
STAT3 and total STAT3 suggesting Ad5Hey1 might inhibit STAT3 signalling 
while the JAK1/2 inhibitor, AZD1480 was ineffective at sensitising DU145 cells 
to Ad5Hey1. Preliminary data therefore suggests Ad5Hey1 may interfere with 
JAK/STAT signalling in these cells. 
 
Cell-killing efficacy with Ad5Hey1 in combination with cytotoxic drugs currently 
used in the clinic for the treatment of late-stage PCa, mitoxantrone and 
docetaxel, resulted in a synergistic enhancement of cell death in 22Rv1 and 
DU145 cells. LNCaP cells were also sensitised to the drugs. Characterisation of 
the mode of cell killing demonstrated augmented mitochondrial membrane 
depolarisation and caspase-3 activation when combined with docetaxel in all cell 
lines and with mitoxantrone in 22Rv1 and LNCaP cells, typical of apoptotic 
death. In DU145 cells, the combination of Ad5Hey1 with mitoxantrone 
decreased the proportion of apoptotic cells suggesting cells are dying by 
alternative cell death mechanisms.  
 
In this thesis I have demonstrated that Ad5Hey1 potently eliminates PCa cells 
both in the presence and absence of functional AR or p53, and that cell killing is 
 6 
improved in combination with cytotoxic drugs. I demonstrate that the 
mechanisms by which Ad5Hey1 acts as a cell death enhancer is mainly through 
cooperation with drugs on apoptotic pathways while other factors such as 
inhibition of survival are also involved. In conclusion, these data suggest that it 
is feasible to develop a future replication-selective adenovirus expressing Hey1 
as a cytotoxic transgene to improve antitumour efficacy in vitro and in vivo, 
especially in combination with apoptosis-inducing drugs.   
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1. Introduction  
1.1. Prostate cancer 
1.1.1.  The normal prostate 
 
The prostate gland is located beneath the bladder and surrounds the urethra. In 
the presence of foetal androgens, the embryonic prostate develops from the 
embryonic urogenital sinus, which is composed of urogenital sinus epithelial 
cells and mesenchymal cells (Schulz, Burchardt et al. 2003). Interactions 
between these two cell types are obligatory for prostate development. 
Mesenchymal cells express the androgen receptor (AR) and upon stimulation by 
testosterone, paracrine signalling from the mesenchymal cells induces epithelial 
bud formation, growth and branching and promotes epithelial differentiation into 
secretory epithelial cells (Cunha, Hayward et al. 2003). Reciprocal signalling 
from epithelial cells results in spatial patterning and smooth muscle 
differentiation in the mesenchymal cells, which develops into mature prostatic 
stroma (Cunha, Hayward et al. 2003). The embryonic prostate remains 
quiescent until puberty when, under the stimulation of testosterone, the prostate 
gland grows to consist of 30-50 branched ducts lined with glandular epithelium 
(Giles 2010). The function of the prostate is to secrete factors required for sperm 
motility and viability. It also protects the male urinary and reproductive system 
from pathogens (Giles 2010). 
 
The adult prostate gland is composed of a fibromuscular stromal compartment 
surrounding glandular epithelial acini. The glandular epithelial compartment is 
composed of multiple differentiated cell types including basal, secretory luminal 
and neuroendocrine cells (Figure 1). The glandular compartment is made up of 
the large peripheral zone and the smaller central zone, which makes up 95% of 
the gland. Approximately 70% of prostate cancers develop in the peripheral 
zone (Schulz, Burchardt et al. 2003). In the adult prostate, the cells within the 
stromal compartment are responsible for inducing and maintaining epithelial 
differentiation. AR-expressing stromal cells respond to androgen thus 
stimulating the production and secretion of growth factors, which in turn signals 
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to epithelial cells to induce either intermediary transit-amplifying cells to 
progress through the cell cycle or repress apoptosis of secretory luminal cells 
(Litvinov, De Marzo et al. 2003). Luminal secretory cells express high levels and 
respond to androgen stimulation by producing and secreting of prostatic-specific 
differentiation proteins such as prostate specific antigen (PSA) and human 
glandular kallilrein-2 (hKh2) which influence proliferation and differentiation of 
stromal cells (Litvinov, De Marzo et al. 2003). It is a matter of debate whether 
basal cells express AR, however, an alternatively spliced AR variant termed 
AR3 has recently been detected in basal cells and stromal cells of benign 
prostate tissue. It is not known whether this variant has any influence on 
paracrine and autocrine signalling within the prostate (Guo and Qiu 2011). In the 
normal prostate, AR has been shown to function as a growth suppressor 
wherein AR-negative intermediate epithelial cells transgenically induced to 
express AR were inhibited to proliferate in vitro after androgen stimulation even 
in the presence of growth factors (Whitacre, Chauhan et al. 2002). Moreover, 
AR induces differentiation of transit-amplifying cells to a terminally differentiated 
phenotype through a mechanism related to AR up-regulation of p27 cyclin-
dependent kinase inhibitor and repression of the S phase kinase associated 
protein 2 (Skp2) (Litvinov, De Marzo et al. 2003). 
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Figure 1. Model of prostatic epithelial cell compartmentalisation 
The epithelial compartment consists of several types of cells: stem cells, basal, intermediate, 
neuroendocrine and luminal secretory which bear defining cytokeratin profiles and differ in 
expression in a number of proteins including AR, p63, Bcl-2, and p27. +, expression of marker, -
,lack of expression marker, NE (neuroendrocrine). Figure adapted from (Litvinov, De Marzo et al. 
2003). Stem cells are located in the basal epithelial layer and give rise to a progenitor (transit-
amplifying) cells, which either remain in the basal layer or differentiate and move into the secretory 
epithelial layer becoming terminally differentiated secretory luminal cells or neuroendocrine cells 
(Litvinov, De Marzo et al. 2003). Controversy exists about the hierarchical arrangement of 
prostatic stem and linear-specific progenitor cells. In this figure a linear arrangement is shown, 
however other models have been proposed (Taylor, Toivanen et al. 2010). 
 
1.1.2.  Natural progression of PCa 
 
Since the majority of prostate cancer (PCa) begins in the peripheral zone and 
retains some glandular structure, these are categorised as adenocarcinomas. 
The earliest precursor of PCa is detected as prostatic intraepithelial neoplasia 
(PIN) defined as a thickening of the epithelial layer with basal and secretory 
luminal layers becoming less distinct with cells expressing both basal and 
secretory markers such as cytokeratins, AR and PSA (Schulz, Burchardt et al. 
2003). Most adenocarcinomas arise from high grade PIN (HGPIN) that in turn 
arises from low grade PIN. While cell proliferation remains low in PIN, PCa is 
thought to occur due to low rate in apoptosis since the rate of cell growth 
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remains low during PCa development (Schulz, Burchardt et al. 2003). Both PCa 
and HGPIN have phenotypic and morphological characteristics that are similar 
to secretory luminal cells but have retained features of basal epithelium cells 
such as expression of anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), DNA 
replication and self-renewal capacity (Litvinov, De Marzo et al. 2003).  
 
PCa develops with a number of different foci occurring within the gland, which 
vary according to the amount of cellular dysplasia, tissue disorganisation and 
heterogeneity (Schulz, Burchardt et al. 2003). One third of PCas remain indolent 
with respect to growth and have no clinical symptoms however others are more 
aggressive, becoming locally invasive and spreading beyond the tissue capsule 
and/or metastasise to lymph nodes and distant organs such as the bone, liver 
and lung (Schulz, Burchardt et al. 2003). During the initial stages of PCa 
development, AR no longer functions as a growth suppressor. In contrast to 
normal prostate, the secretory luminal cells express higher levels of AR resulting 
in enhanced growth rather than terminal differentiation. During the initial stages 
of PCa, cell growth is still dependent on the binding of androgen to the AR 
receptor. However due to the heterogeneous nature of PCa, some cells will 
express AR that do not require androgen stimulation for growth. Androgen 
ablation therapy (ADT), discussed later on in this chapter, will only induce 
apoptosis in androgen-dependent cells (Figure 1) but will not eliminate 
androgen-independent PCa cells and this will eventually result in castration 
resistant prostate cancer (CRPC) phenotype (Figure 1) (Litvinov, De Marzo et 
al. 2003). 
 
1.1.3.  Aetiology of PCa 
 
PCa is the second cause of male cancer mortality in the United Kingdom (UK) 
and in 2010, 40975 new cases of PCa were recorded in the UK and 10721 
people died from it (www.cancerresearchuk.org). PCa incidence is strongly 
correlated to age; in the UK between 2008 and 2010, approximately 75% of 
cases were diagnosed in men over the age of 65 while only 1% of cases were 
diagnosed in the under-50 age group (www.cancerresearchuk.org). The highest 
incidence is in the 75-79 age group with 794 cases per 100000 men (Williams, 
Hughes et al. 2011).  
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As with many other cancers, PCa is a multifactorial disease and no definite 
cause has been demonstrated and both environmental factors and genetic 
predisposition play roles in PCa development (Kral, Rosinska et al. 2011). More 
than 85% of PCa are sporadic while only 10-15% are classified as familial or 
hereditary. PCa has become a significant problem in Western industrialized 
countries and immigrant studies have indicated that genetic causes can be 
partially attributed to this observation. The most important locus implicated in 
familial PCa was hereditary prostate cancer locus-1 (HPC-1) for which RNASEL 
was the candidate protein product of this locus. Carriers of mutant RNASEL 
develop PCa under the age of 65 and have a more aggressive cancer (Kral, 
Rosinska et al. 2011). In addition to Breast Cancer Antigens (BRCA) 1 and 2 
providing information as to a genetic predisposition for breast and ovarian 
cancer, mutations in these genes in men are also associated with a higher risk 
of hereditary PCa. Mutations in BRCA1 are often related to men younger than 
65 years developing PCa (Kral, Rosinska et al. 2011) and a germline mutation in 
BRCA2 has been associated with an increased susceptibility to PCa and may 
account for 2% of PCa cases in men less than 55 years of age (Edwards, Kote-
Jarai et al. 2003).  
 
The incidence and mortality of PCa also vary between countries; men in Asia 
have a low risk of developing PCa whereas men have a higher risk in the United 
States of America (USA) and Western Europe. Scandinavia has the highest 
incidence of PCa. This suggests that race and ethnicity are PCa risk factors. In 
the USA, the highest reported incidence of PCa from one ethnic group was in 
African-American men. The incidence in white and African-American men was 
156 and 248 per 100000 respectively and the difference in mortality rate was 25 
and 59 per 100000 respectively (Jemal, Siegel et al. 2008). African American 
men also have a worse staging, tumour grading and more aggressive 
phenotype compared with Caucasian men (Robbins, Torres et al. 2007). One 
study confirmed the association of genetic variants of chromosome 8q24 were 
linked to a high incidence of PCa in African populations (Robbins, Torres et al. 
2007). Genomic profiling of human PCa has demonstrated certain chromosome 
regions including regions p and q on chromosome 8 harbour PCa susceptibility 
genes. Mutations and sequence variants of genes in these regions have been 
reported to be associated with PCa risk and frequent genomic rearrangements 
are observed within these regions in prostate tumours (Shen and Abate-Shen 
2010). Epidemiological studies have also shown that men of African descent 
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have a higher incidence of polymorphism for the gene encoding 5α-reductase, 
the enzyme responsible for converting the androgen, testosterone to the more 
potent AR ligand, dihydrotestosterone (DHT). This polymorphism results in 
higher 5α-reductase enzyme activity and men of Asian descent who have a low 
risk of developing PCa also have a lower incidence of this polymorphism 
(Makridakis, Ross et al. 1997). 
 
Genomic profiling of human PCa has identified alterations in copy number and 
chromosomal rearrangements associated with prostate tumourigenesis. Somatic 
alterations have been identified by comparative genomic hybridisation as 
amplifications in chromosome 8q and losses in 3p, 8p, 10q, 13q and 17p. Key 
regulatory genes implicated in the development of PCa have been mapped to 
within these chromosome regions include Nkx3.1 at 8p21, phosphatase and 
tensin homologue deleted on chromosome 10 (PTEN) at 10q23, c-Myc at 8q24 
and CPY17 at 10q24. Chromosomal rearrangements have also been implicated 
as a novel pathogenic mechanism for PCa development. In 15% of high-grade 
PIN lesions and 50% of localised PCa cases, the TMPRSS2-ERG fusion is 
detected and leads to the overexpression of the transcription factor ERG from 
the androgen-regulated TMPRSS2 promoter. The fusion of these to genes is 
thought to arise by androgen stimulation (Tomlins, Rhodes et al. 2005; Bastus, 
Boyd et al. 2010). 
 
Additionally, lifestyle factors and in particular diet have also been implicated in 
contributing to PCa incidence. In the Western diet, there is an absence of 
protective elements such as selenium, folate and phytoestrogens from the diet 
while the ingestion of high levels fat, dairy and red meat have been found to be 
risk factors (Schulz, Burchardt et al. 2003). This has been demonstrated in 
Japanese men in the USA who had a higher risk of developing PCa compared 
with their counterparts in Japan, a country that has a lower rate of PCa 
incidence (Sim and Cheng 2005). Antioxidants such as vitamin E, β-carotene 
present in tomatoes and selenium have also been associated with a reduction in 
cancer risk when ingested by PCa patients. They operate as a reactive oxygen 
species that prevent DNA damage and mutation during oxidative stress that 
would otherwise result in cellular transformation (Chan, Gann et al. 2005). In 
autopsy studies, the Innuit population of Greenland had a very low prevalence of 
latent prostate carcinoma compared to other populations (including Asian 
populations). This was attributed to the high intake of omega-3 fatty acids and 
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selenium in their diet, reiterating significance of certain dietary components that 
are protective against prostate cancer (Dewailly, Mulvad et al. 2003). Other 
lifestyle factors determining the development of PCa include physical fitness. 
Epidemiological studies found that men who are physically active (measured by 
fitness) have between a 30 and 60% reduced risk of developing PCa compared 
with men who were physically inactive (Oliveria and Christos 1997).  
 
1.2. PCa treatment 
 
1.2.1.  Diagnosis and PCa staging 
 
Historically, diagnosis for PCa has been carried out using the digital rectal exam 
(DRE) and/or serum levels of PSA, an androgen-regulated serine protease 
present in the semen and used as a biomarker for PCa progression. However 
early stage PCa detection using PSA is lacking due to reduced specificity 
between levels of PSA in a normal individual vs. a PCa patient. Examination of 
histopathological biopsies from the prostate gland confirms the diagnosis. The 
Gleason Score, which measures the extent of tumour differentiation, is the most 
common method of grading PCa where a score of between 2 and 10 is given (2 
is the least aggressive while 10 is the most aggressive form). This score is the 
sum of the two most common patterns of tumour growth (grades 1-5). Local 
staging (T staging) of the cancer is carried out by the DRE, PSA levels and 
tumour grade and from this the risk of patients possessing locally advanced PCa 
are established (Bjartell 2006; Damber and Aus 2008). In the UK, patients are 
categorised into risk groups to estimate the post-treatment outcome for the 
particular treatment used. Low risk patients with PSA ≤ 10ng/ml, Gleason score 
of ≤ 6 and staged at T1c to T2a or who have a life expectancy of less than 10 
years are actively monitored as the first choice of treatment. Those patients with 
a longer life expectancy or in a higher risk group (intermediate risk: PSA 10-
20ng/ml, Gleason score of 7 and with T2b staged disease or high risk: PSA ≥ 
20ng/ml, Gleason score of 8 and T2c stage) are recommended a curative 
treatment (Damber and Aus 2008). In the USA, an aggressive screening policy 
has been adopted and this is often attributed to a reduced mortality rate for PCa. 
The updated outcome from the European Randomized Study of Screening for 
Prostate Cancer (ERSPC) concluded PSA-based screening reduced the risk of 
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death from PCa by 21% in the screening group but that this was linked to a high 
risk of over-diagnosis wherein 1410 men would need to be screened and 48 
cases of PCa to be treated to prevent one death (Heidenreich 2012; Schroder, 
Hugosson et al. 2012). The recent identification of 23 susceptibility loci through 
single nucleotide polymorphism (SNP) genotyping of >25000 PCa samples may 
be valuable biomarkers for PCa screening in the future (Eeles, Olama et al. 
2013). 
 
1.2.2.  Treatment of localised and locally 
advanced PCa 
 
Treatment options and regimens for PCa depend on clinical stage, Gleason 
score and PSA levels at time of presentation and patients can undergo a 
number of different treatments depending on their assessed risk of developing 
PCa. Previously, in the UK, “watchful waiting” was symptom-guided treatment 
management for early PCa however surgery provided a survival advantage over 
this treatment option (Bill-Axelson, Holmberg et al. 2005). Nevertheless, 
watchful waiting is a treatment option for patients with localised PCa with limited 
life expectancy (Heidenreich 2012), 2012 #100}. Another conservative method 
of treating PCa is with “active surveillance,” patients undergo PSA screening 
and prostate biopsies and are treated at thresholds defining disease progression 
(Heidenreich 2012). 
 
Approximately 25% of patients present with localised PCa and for these patients 
curative procedures are mainly single-modality treatments such as radical 
prostatectomy or radiotherapy (external-beam radiotherapy or brachytherapy). 
As PCa is driven in part by testosterone, ADT or androgen ablation therapy (see 
section 1.2.3) aims to reduce circulating testosterone and is used at all stages of 
the disease. AR antagonists are also used as initial treatment options and aim to 
inhibit AR activity within PCa cells. Patients presenting with higher Gleason 
scores and rising PSA levels can benefit from radiotherapy in conjunction with 
ADT and locally advanced PCa (extracapsular extensions of the tumour) are 
treated with combined treatment; either surgery and adjuvant radiotherapy or 
radiotherapy with ADT (Heidenreich 2012).. Recurrence of PCa after definitive 
treatment is also treated with ADT as a salvage treatment.  
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An alternative treatment for patients with localised PCa is cryosurgery ablation, 
a minimally invasive alternative to surgery. However long-term results are 
lacking and 5-year disease-free survival is inferior to that achieved by radical 
prostatectomy in low-risk PCa patients. Other minimally invasive experimental 
treatment options include high-intensity focused ultrasound, which heats 
malignant tissue to above 65°C thereby destroying it by coagulative necrosis 
(Heidenreich 2012).  
 
Despite technical advances in surgery, radiotherapy as single modality 
treatments or combined with hormone therapy, between 27-53% of patients 
develop local or distant recurrences within 10 years of initial therapy and 16-
35% of patients receive second-line treatment within 5 years of initial treatment 
(Heidenreich 2012). Treatment failure is defined as rising PSA level (Pound, 
Partin et al. 1999). Localised failure is characterized with a late PSA increase 
(>12months after treatment), long PSA-doubling time and a less aggressive 
disease at diagnosis having been made. Systemic failure is classified as a rapid 
PSA doubling time with significant pathological changes. Patients with local 
failure with a life expectancy of between 5 and 10 years are often offered a 
second treatment such as radiotherapy if their first-line treatment was surgery 
(Simmons, Stephenson et al. 2007).  Men who received radiotherapy as their 
initial treatment have the option of salvage radical prostatectomy, 
brachytherapy, cryotherapy or ultrasound. Patents who are at risk of systemic 
failure are treated with hormonal therapy (Heidenreich 2012). 
 
1.2.3.  Treatment of advanced androgen-
dependent PCa 
 
Historically ADT was the mainstay therapy for advanced PCa. Charles Huggins 
pioneered ADT in 1941 when he demonstrated that lowering testosterone by 
surgical castration or injection of oestrogens resulted in a major regression of 
PCa and relief in symptoms (Huggins 1941). In recent years there has been a 
move towards increasing the use of hormonal treatment in younger patients with 
earlier disease (non-metastatic) or recurrent disease after definitive treatment as 
a single agent or multi-modal approach. However, for patients with metastatic 
PCa, ADT is usually the first-line treatment. In more advanced forms (CRPC), 
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although it can effectively alleviate symptoms, it does not extend life 
(Heidenreich 2012). 
 
Testosterone release is regulated by the hypothalamic-pituitary-gonadal axis. 
Luteinizing hormone-releasing hormone (LHRH) when released in a pulsatile 
fashion stimulates the anterior pituitary gland to release luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH). LH induces the Leydig cells in the 
testes to secrete testosterone (Choi and Lee 2011). In prostate cells, 
testosterone is converted to the more potent androgen, DHT. By inhibiting 
secretion of testicular androgens or DHT prostate cells are deprived of 
androgenic stimulation and undergo apoptosis. There are several approaches 
treating androgen-dependent PCa: testosterone lowering therapy, 
antiandrogenss and complete androgen blockade. 
 
1.2.3.1. Testosterone lowering therapy 
 
Otherwise known as medical castration, LHRH agonists such as leuprolide 
(Lupron®; Eligard®) mimic LHRH by inhibiting LH production by continuous 
pituitary stimulation, overcoming the pulsatile release of LHRH (Allen, O'Shea et 
al. 1983; Choi and Lee 2011). Shutdown of testosterone production is however 
initially preceded with a surge of LH and testosterone (known as a “flare”) 
resulting in a temporary increase in PCa growth and worsening of symptoms. 
The flare effect can be inhibited if non-steroidal antiandrogens are given before 
the LHRH agonist. In contrast, LHRH antagonists (e.g. abarelix and degarelix) 
competitively bind to LHRH receptors in the pituitary gland (Mongiat-Artus and 
Teillac 2004) and decrease LH, FSH and testosterone without the “flare” effect. 
 
1.2.3.2. Antiandrogens 
 
There are two classes of antiandrogens, steroid and non-steroidal. Both are 
classed as AR antagonists as they compete with endogenous androgens for 
binding to ligand-binding domain (LBD) of the AR and to prevent AR 
transcription activity. Steroidal androgens include cyproterone acetate (CPA), 
which has partial agonist activity. It can also activate the progesterone and 
glucocorticoid receptors and is therefore not used as a first-line treatment. Non-
steroidal antiandrogens include flutamide, nilutamide and bicalutamide 
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(Casodex®) and were developed to circumvent off-target effects of steroidal 
antiandrogens. The exact mechanism by which AR antagonists block AR 
transcriptional activity remains elusive and recent studies have demonstrated 
the mechanism-of-action to be more complicated than simply competitive 
binding with DHT for AR binding. It has been suggested that bicalutamide 
mediates recruitment of AR corepressors (Masiello, Cheng et al. 2002; Shang, 
Myers et al. 2002; Hodgson, Astapova et al. 2005). Later, AR antagonist activity 
was proposed to be independent of AR coactivator-to-corepressor ratio and 
rather due to the failure of bicalutamide-liganded AR to recruit coactivators 
(Hodgson, Astapova et al. 2007). Bicalutamide was approved in 1995 by the 
Federal Drug Administration (FDA) and is the most commonly used 
antiandrogen. It has a 2-fold increased affinity to AR compared with flutamide 
and nilutamide, a longer half-life (>1 week) and significantly decreased toxicities 
(Schellhammer, Venner et al. 1997). 
 
1.2.3.3. Combined androgen blockade 
 
Although medical castration reduces serum testosterone levels by 95%, 
intraprostatic androgen is maintained due to circulating androgen of adrenal 
origin being converted into DHT. Adrenal androgens can be inhibited with the 
addition of antiandrogens to medical castration treatments. This approach is 
known as complete androgen blockade (CAB) (Hellerstedt and Pienta 2002). 
Systemic reviews and meta-analyses at a follow up of 5-years shows that the 
combined approach provides a small survival advantage (<5%) versus 
monotherapy (Heidenreich 2012). Antiandrogens as a monotherapy are better 
tolerated with fewer side effects (sexual dysfunction, hot flashes, weight gain, 
diabetes mellitus and coronary heart disease and decrease bone mineral 
density) than other androgen lowering approaches or CAB and is of benefit to 
patients treated with radiotherapy for locally advanced disease (Iversen, Tyrrell 
et al. 2000). However monotherapy was found to be inferior in patients with 
metastatic disease (Tyrrell, Kaisary et al. 1998) and a trend towards decreased 
survival in patients with early, localised disease (Iversen, Tyrrell et al. 2000). A 
limitation for all currently approved antiandrogens is that a certain proportion of 
patients will respond to selective discontinuation of the drug termed “androgen 
withdrawal syndrome” resulting in a decline in PSA and regression of the tumour 
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which is indicative of antiandrogens serving as AR agonists (Kelly and Scher 
1993; Schellhammer, Venner et al. 1997). 
 
1.2.3.4. Novel antiandrogens 
 
Due to the shortcomings of currently available antiandrogens, extensive 
research has focused on the development of novel AR antagonists. One such 
second-generation antiandrogen, enzalutamide (formerly MDV-3100), was 
approved by the FDA in 2012 for the treatment of patients with CRPC previously 
treated with chemotherapy after enzalutamide demonstrated a significant 
survival benefit in patients compared with placebo (Scher, Fizazi et al. 2012). 
Based on a non-steroidal thiohydantoin agonist, RU59063, it is able to bind AR 
with 8-fold higher affinity compared with bicalutamide and does not activate wild-
type AR or T877A or W741C AR mutants. Inhibition of AR-mediated 
transcription and cell growth in AR over expressing cell lines was superior to 
bicalutamide and induced tumour regression in LNCaP/AR xenografts model. 
Whereas bicalutamide causes AR to translocate to the nucleus and bind to 
androgen-response elements (ARE) within DNA, enzalutamide is less efficient 
at doing so and a significant fraction of AR remains in the cytosol with nucleus-
localised enzalutamide-bound AR not binding to DNA (Tran, Ouk et al. 2009). 
Most strategies involve targeting the C-terminal LBD of the AR, however Sadar 
et al have identified a compound (EPI-001) derived from marine sponge 
extracts, which targets the N-terminal domain (NTD). EPI-001 is able to inhibit 
regulation of androgen-regulated genes and significantly prevented ligand-
dependent and –independent transactivation of the AR as well as blocking 
constitutively active ΔLBD-AR mutants. Mechanistically, EPI-001 reduces the 
interaction of AR with AR-target genes and it decreased the interaction of AR 
coactivators p300/CBP and RAP74 thereby blocking protein-protein interactions 
required for stabilisation of AR on ARE. EPI-001 is still at the preclinical stage of 
development and was found to supress growth of LNCaP xenografts in non-
castrated mice and resulted in regression of an orthotopic LNCaP xenograft in 
castrated mice (Andersen, Mawji et al. 2010; Sadar 2011). 
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1.2.4.  Treatment of castration resistance 
cancer 
 
Despite achieving castrate levels of serum testosterone <50ng/dL or <1.7nmol/L 
prostate cancers that are progressing are considered castrate resistant (CRPC). 
CRPC however is still sensitive to low levels of androgens, derived by the 
conversion of weak adrenal androgens to testosterone or de novo androgen 
synthesis from cholesterol. As a result, patients are receptive to secondary 
hormone manipulations such as LHRH agonists, CAB, antiandrogen withdrawal 
and corticosteroids, which inhibit adrenal androgen synthesis (described below).  
 
After 12-18 months the tumour cells develop resistance and once men have 
developed metastatic CRPC, cytotoxic therapy is a treatment option alongside 
adrenal androgen suppressants. However, this form of PCa is the final stage of 
the disease and the goal is symptom palliation as opposed to cure. In this 
section current treatment options will be described as well as novel approaches 
which are currently in development. 
 
1.2.4.1. Steroid biosynthesis inhibitors 
 
Conventional hormonal therapies have focused on agents that block androgen 
signalling by either decreasing circulating testosterone or through competition 
for binding with the AR. Medical castration, reduces serum testosterone to 
10ng/ml but does not affect the levels of the androgens produced in the adrenal 
glands such as dehydroepiandrosterone-sulfate (DHEA-S) (Chen, Clegg et al. 
2009). Adrenal-derived androgens are synthesised from their respective 
precursors pregnenolone and progesterone, into DHEA-S and androstenedione 
by the cytochrome P450 CYP171A enzyme after which synthesis of 
testosterone and DHT from these weak androgens occurs in peripheral tissue, 
including PCa tumours (Cai and Balk 2011). Strategies for inhibiting adrenal 
androgen synthesis have involved blocking adrenal androgen production at 
several stages. Adrenocorticotropic hormone (ACTH) stimulates the conversion 
of cholesterol to pregnenolone. By administering glucocorticoids (e.g. 
prednisone) ACTH-mediated stimulus is inhibited resulting in a decrease in 
adrenal androgen production. Currently glucocorticoids are administered as an 
adjunct to chemotherapy. A non-selective inhibitor of P450 such as 
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ketoconazole was administered in combination with androgen withdrawal in a 
phase III trial and resulted in a longer time to PSA progression compared with 
androgen withdrawal alone.  However, there was no difference in overall 
survival (Small, Halabi et al. 2004). In contrast, abiraterone, a pregnenolone 
analogue, which binds specifically and irreversibly to CYP17A1, has afforded 
more success compared with ketoconazole. The FDA approved it in 2011 as a 
second-line treatment for CRPC after docetaxel treatment (Danila, Morris et al. 
2010; Reid, Attard et al. 2010; Fizazi, Scher et al. 2012) and approval was 
further expanded in 2012 for use as a first-line therapy for chemotherapy-naïve 
patients (de Bono, Logothetis et al. 2011; Ryan, Smith et al. 2013). However 
despite the relative success of abiraterone, patients in the initial Phase I/II trials 
have progressed as a result of AR activation. The recurrence of AR activity in 
these patients has been suggested to be as a result of increased activity of 
steroid compounds upstream of CYP171A in the steroidogenesis pathway, 
which may activate mutated AR proteins. It has been postulated that abiraterone 
may in fact become an agonist due to the steroid backbone structure of the 
compound (Chen, Clegg et al. 2009). 
 
1.2.4.2. Chemotherapy 
 
In the early 1990s, metastatic CRPC was considered a chemo-refractory 
disease. The chemotherapeutic drugs, mitoxantrone, estramustine and 
docetaxel are approved by the FDA for first-line treatment of metastatic CRPC. 
A landmark TAX-327 trial comparing docetaxel and mitoxantrone in combination 
with prednisone showed improved survival in the arm where patients received 
docetaxel every three weeks compared with weekly docetaxel or mitoxantrone 
(Berthold, Pond et al. 2008). In the Southwest Oncology Group (SWOG) 99-16 
trial docetaxel/estramustine and mitoxantrone/prednisone regimens were 
compared (Petrylak, Tangen et al. 2004). Docetaxel was reported to be superior 
to mitoxantrone in terms of median survival and time to progression although no 
objective tumour response differences were found. However it is more toxic than 
mitoxantrone and only improves median survival by 2 months (Tannock, de Wit 
et al. 2004). Patients who have failed doxetaxel treatment can be offered 
cabazitaxel, a novel taxane approved by the FDA in 2011 for the treatment of 
CRPC with prednisone (Galsky, Dritselis et al. 2010). It differs from docetaxel in 
that it is a poor substrate for the multi-drug resistant P-glycoprotein efflux pump 
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overexpressed in taxane-resistant tumours (Mita, Denis et al. 2009). 
Mitoxantrone decreases the length and severity of pain despite it having no 
effect on overall survival (Tannock, Osoba et al. 1996). Patients who fail first-line 
chemotherapy have limited treatment options and mitoxantrone is used for 
palliative care in men with CRPC. As docetaxel and mitoxantrone are first-line 
treatments for metastatic CRPC our research group have combined these drugs 
with adenoviral mutants to improve viral potency and tumour efficacy for the 
treatment of CRPC (Oberg, Yanover et al. 2010; Radhakrishnan, Miranda et al. 
2010; Miranda, Maya Pineda et al. 2012). 
 
1.2.4.2.1. Docetaxel 
 
Docetaxel is semi-synthetic analogue of paclitaxel and has high affinity to β-
tubulin monomers thereby stabilising microtubules and arresting their 
depolymerisation (Ringel and Horwitz 1991). Stabilisation of microtubules 
prevents cell processes such as mitosis, endosomal uptake, secretion and 
transport required for growth and proliferation. The therapeutic response of 
docetaxel (and paclitaxel) is mediated through apoptosis and mitotic catastrophe 
(Jordan, Wendell et al. 1996; Morse, Gray et al. 2005). Mitotic catastrophe, a 
process considered to be an irreversible trigger to cell death, occurs as a result 
of aberrant mitosis or missegregation of chromosomes following cell division. In 
androgen-independent PCa cells, DU145 and PC3, docetaxel induced G2/M 
arrest, which preceded mitotic exit followed by apoptosis (Fabbri, Amadori et al. 
2008). Docetaxel-induced apoptotic cell death is thought to occur as a result of 
inactivation of the Bcl-2 protein through phosphorylation (Haldar, Chintapalli et 
al. 1996; Herbst and Khuri 2003). Other mechanisms of anti-neoplastic action by 
docetaxel include anti-angiogenic activity possibly by inhibiting angiogenic 
growth factors such as vascular endothelial growth factor (VEGF) (Herbst and 
Khuri 2003). 
 
1.2.4.2.2. Mitoxantrone 
 
Mitoxantrone is a synthetic derivative of anthracycline originally synthesised in 
1979 and alongside doxorubicin, belongs to a class of agents known as the 
anthracenediones. It has numerous modes of action, possessing antiviral, 
antibacterial, immunomodulatory, and antitumor activity (Fox 2004). Its anti-
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tumour activity may be attributed to its inhibitory effects on DNA synthesis, 
intercalation into DNA and inducing DNA strand breaks (Durr, Wallace et al. 
1983). These abnormalities are ascribed to the function of mitoxantrone as a 
topoisomerase IIA inhibitor, an ATP-dependent nuclear enzyme that catalyzes 
changes in DNA tangles and supercoiling by cleaving and rejoining of DNA 
strands. It is implicated in processes such as DNA replication, recombination 
and chromatin reorganization. Mitoxantrone inhibits topoisomerase II by 
stabilizing the enzyme during the transient “cleavage complex” form and inhibits 
religation of cleaved DNA strands. As a consequence, high levels of enzyme-
mediated single-strand and double-strand DNA breaks are generated ultimately 
resulting in activation of cell death responses (Fortune and Osheroff 2000; 
Pommier, Leo et al. 2010). Mitoxantrone also inhibits cell proliferation by 
delaying cell cycle progression resulting in a G2/M arrest (Durr, Wallace et al. 
1983; Fox 2004) and in PCa cells resulted in accumulation of cells in G2/M 
(Miranda, Maya Pineda et al. 2012) suggesting it has a role as a cytostatic 
agent; one study demonstrated it had high affinity to tubulin and inhibited 
microtubule polymerization (Ho, Law et al. 1991). In addition, mitoxantrone 
displays broad immunosuppressive action, inhibiting proliferation of T- and B-
lymphocytes and macrophages. It also induces apoptosis in antigen-presenting 
cells and reduces proinflammatory cytokine secretion (Fox 2004) and is 
therefore used to treat adult acute myeloid leukaemia and multiple sclerosis. 
 
1.2.4.3. Novel therapies for CRPC 
 
Development of novel therapeutic agents has also focused on 
immunomodulatory therapy. One such treatment is Provenge (sipuleucel-T), 
which was approved by the FDA for asymptomatic or minimally symptomatic 
metastatic CRPC after the IMPACT trial found an increased survival advantage 
of 4.1 months over placebo (Plosker 2011). By procuring the patient’s own 
antigen-presenting cells and co-culturing them with prostatic acid phosphatase 
and infused back into the patient, a T-lymphocyte mediate immunity is elicited 
against the PCa tumour. Recently, cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) has emerged as a promising target. Ipilimumab, a human monoclonal 
antibody, which specifically blocks CTLA-4 from binding to its ligands 
CD80/CD86, was able to downregulate T-lymphocyte responses leading to a 
sustained immune response against the prostate tumour. This agent as 
 38 
completed phase II trials in patients with CRPC in combination with radiotherapy 
(Slovin, Higano et al. 2013). 
 
1.3. Progression to castration 
resistant prostate cancer 
 
Patients with androgen-dependent PCa will initially respond positively to ADT. At 
the cellular level, androgen ablation results in cell death and cell cycle arrest of 
prostatic secretory epithelial cells resulting in tumour regression. Clinically, 80-
90% of patients with localised PCa will respond to androgen ablation treatment 
with AR inhibition detected by a decrease in serum PSA levels and improvement 
in clinical symptoms. However ADT ultimately fails and patients progress to a 
CRPC phenotype which is commonly associated with overexpression of AR as 
well as expression of AR target genes such as PSA and the TMPRSS2:ERG 
fusion indicating AR signalling is intact (Ruizeveld de Winter, Janssen et al. 
1994; Gregory, Hamil et al. 1998; Wang, Cai et al. 2008). Initial indications of 
tumour progression to CRPC were found to be associated with an increase in 
serum PSA levels prior to tumour recurrence despite continued androgen 
ablation (Klotz 2000). 
 
It is not clear when and how castration resistance arises within PCa tumours. 
Two models have been proposed. The “adaption” model suggests that during 
androgen ablation, androgen-dependent cells are converted to a castration-
resistant phenotype through genetic and epigenetic mechanisms thus conferring 
a survival advantage to the CRPC cells. In support of this theory, the 
mechanisms underlying molecular changes during long-term androgen ablation 
were first investigated by Kokontis and Liao who observed an increase in AR 
mRNA and protein expression in an LNCaP sub-line after prolonged culture in 
androgen-depleted medium (Kokontis, Takakura et al. 1994). Chen et al 
provided a causal link between AR and emergence of a castration-resistant 
phenotype when it was demonstrated that an increase in AR mRNA and protein 
was both necessary and sufficient to produce resistance to antiandrogen 
therapy in animal models (Chen, Welsbie et al. 2004). In addition, antiandrogens 
such as bicalutamide and flutamide behaved as partial AR agonists in cells 
overexpressing AR (Chen, Welsbie et al. 2004). The consequence of this is 
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observed in patients who exhibit “androgen withdrawal syndrome” after the 
cessation of antiandrogen treatment (discussed in 1.3.2.2).  
 
The “clonal selection” model proposes CRPC emerges from the selection of a 
previously rare quiescent population of castration-resistant cells within an 
androgen-dependent tumour. Following androgen deprivation, androgen-
dependent cells would be eradicated leaving the castration-resistant cells to 
proliferate (Isaacs and Coffey 1981). The “adaptive” model reflects the more 
accepted viewpoint for the primary route for CRPC however the two models are 
not mutually exclusive and increased AR activity may be selected prior to ADT. 
Recently, castration-resistant Nkx3.1-expressing cells (CARNs); a rare 
androgen-independent population have been identified. CARNs are strictly 
luminal and demonstrated bi-potential and self-renewal capacity and may be 
putative cancer stem cells. Inducible PTEN and Nkx3.1 deletion in the CARN 
population of castrated mice resulted in HGPIN and PCa lesions, which were 
devoid of basal cells and exhibited enhanced proliferation (Wang, Kruithof-de 
Julio et al. 2009). 
 
Once PCa progresses to CRPC inappropriate AR signalling continues to sustain 
growth and prevent apoptosis. A number of mechanisms have been identified by 
which AR activity is maintained and can be either ligand-dependent or ligand-
independent. Furthermore, CRPC cells have developed AR-independent 
mechanisms to achieve androgen-independence involving up-regulation of cell 
survival and growth pathways and inhibition of apoptotic signalling. Several 
pathways are likely to contribute to the development of CRPC. To provide 
context for the AR-dependent mechanisms, the structure and function of the AR 
will first be described before discussing the mechanisms that contribute to the 
development of CRPC. 
 
1.3.1.  The androgen receptor 
 
The AR belongs to the steroid receptor subclass of the nuclear receptor 
superfamily. The gene is located at Xq11-12 and consists of 8 exons encoding a 
protein 919 amino acids in length (Figure 2); exon 1 encodes the NTD and is 
highly flexible with minimum secondary structure. Exons 2 and 3 code for the 
DNA-binding domain (DBD), which is made up of 3 α-helices organised into two 
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zinc-finger-like motifs. These are important for AR dimerization and recognition 
of specific DNA sequences within the AREs located within the regulatory regions 
of target genes. Exons 4-8 encode the hinge region and the C-terminal LBD and 
are central for recognition and binding of androgens. Activation of the AR is 
mediated through two activation domains; activation factor-1 (AF-1) located in 
the NTD and AF-2 situated in the LBD. AF-1 is the major domain responsible for 
transactivation activity of the AR. The bipartite nuclear localisation signal flanks 
the DBD and hinge region (Bennett, Gardiner et al. 2010; van de Wijngaart, 
Dubbink et al. 2012). 
 
 
Figure 2. Functional domains of the androgen receptor 
There are four structurally and functionally distinct domains; The N-terminal transactivation 
domain (NTD) is responsible for transcriptional activation. It consists of the activation function 1 
(AF-1) region within which transactivation unit (TAU) 1 and TAU5 reside. The DNA binding domain 
(DBD) is located C-terminal to the NTD and adjacent to the small hinge region. The C-terminal 
ligand-binding domain (LBD) contains AF-2 which allows for binding with FxxLF-like motifs present 
in many coactivators. The nuclear localization signal (NLS) flanks the DBD and the hinge region. 
Within the NTD two FxxLF-like motifs are present capable of binding to AF-2. Also within the NTD 
are amino acid stretches containing polymorphic tri-nucleotide repeat, CAG and GGC, which 
encode poly glutamine (polyQ) and poly glycine (polyG) tracts respectively. Numbers in red signify 
the amino acid number. Adapted from (van de Wijngaart, Dubbink et al. 2012). 
 
Prior to activation, the AR is diffuse throughout the cell, an unstable protein held 
inactive by chaperone proteins. Heat shock protein (HSP)90 binds to the LBD 
maintaining AR in a conformation that allows access for ligands to bind. Upon 
androgen binding, AR is activated and AR-induced transcription occurs by 
series of steps. Ligand binding induces a conformational change in 12 α-helices 
of the LBD with helix-12 changing position to form a lid over the ligand-binding 
socket thus stabilising the ligand within the LBD cavity. This in turn exposes a 
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hydrophobic groove in the AF-2 domain to serve as a docking site for LxxLL 
motifs (where x is any amino acid) present in AR coativators (e.g. p160-family 
member, steroid-receptor-coactivator 1; SRC1) and corepressors (e.g. nuclear 
receptor coreprepssor; NCoR) (Liao, Chen et al. 2003). The AR LBD 
disassociates from HSP90 and the AF-2 domain binds intra-molecularly to the 
LxxLL-like motif, FxxLF in the NTD (Klokk TI and Slagsvold T 2006). AF-2 
binding to FxxLF motifs occurs with higher affinity than binding to LxxLL-
containing motifs suggesting the N/C interaction is required for receptor stability 
and prevents coactivator from binding until the AR is bound to DNA (Li, Fu et al. 
2006). Ligand binds to the monomeric form of AR however dimerization is 
facilitated by inter-molecular interactions between D-box regions in the second 
zinc-finger of the DBDs (Verrijdt, Haelens et al. 2003). It is thought this 
interaction is required for inter-molecular N/C interaction, which may occur once 
the AR enters the nucleus (van Royen, van Cappellen et al. 2012). Dimerization 
of AR molecules via inter-molecular forces are thought to be necessary for AR 
binding to promoters containing AREs of varying affinities, although AR DBD 
mutants are able to stimulate high affinity AREs suggesting AR monomers are 
also functionally active (van Royen, van Cappellen et al. 2012). 
 
DNA binding is mediated through the first zinc-finger within the DBD containing 
the P-box, which interacts with the DNA major groove. Recognition sequences 
within the AREs are organized into spaced inverted or direct repeats of the core 
sequence 5’-TGTTCT-3’ (Denayer, Helsen et al. 2010). On binding to AREs, the 
N/C interaction is dissolved and this enables recruitment of cofactors including 
the basal transcription complex, chromatin modification enzymes with histone 
acetyltransferase (HAT) activity and histone deacetylases (HDAC) activity as 
well as coactivators and corepressors (Bennett, Gardiner et al. 2010). As 
mentioned above, AF-1 in the NTD has the main transactivation potential and 
has been mapped to two domains, transactivation domain 1 (TAU1) and TAU5. 
Transactivation of full-length AR is primarily mediated through TAU1 however it 
is TAU5 is responsible for the constitutive activation of LBD-truncated AR 
mutants (Jenster, van der Korput et al. 1995). Dissection of TAU5 identified the 
WxxLF motif to be responsible for the ligand-independent activity and functions 
as an autonomous transactivation domain. Conversely, it inhibits ligand-
dependent activity of full-length AR through N/C interaction with the LxxLL motif 
in AF-2. This indicates TAU5 as a negative regulatory domain in the context of 
ligand-dependent AR activity (Dehm, Regan et al. 2007). As well as regulating 
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the N/C interaction, these motifs also compete with LxxLL motif-containing AR 
coregulators for LBD binding in the presence of ligand. The TAU5 domain also 
mediates recruitment of SRC1. This interaction is regulated indirectly by TAU1 
although it binds neither SRC1 nor co-operates with TAU5 (Callewaert, Van 
Tilborgh et al. 2006). 
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1.3.2.  AR-dependent mechanisms of PCa 
recurrence 
 
Several pathways lead to the aberrant activation of AR in CRPC (Figure 3): (i) 
AR amplification, (ii) AR gain-of-function mutations that broaden ligand 
specificity and/or alter AR coactivator recruitment (iii) alternative splicing which 
renders the AR constitutively active, (iv) alterations in relative AR coregulator 
levels, (v) increased intratumoural de novo synthesis of androgens and (vi) 
activation of proliferation and cell survival pathways by growth factor and 
cytokine stimulation enhancing AR transcriptional activity independent of ligand 
activation.  
 
 
Figure 3. Possible pathways to CRPC involve AR reactivation (ligand-dependent and –
independent) and AR-independent mechanisms 
Prostate tumours evade androgen ablation therapy and adapt to low levels of androgen by 
reinstating AR activity through a number of mechanisms. Deregulation of tumour suppressor 
pathways and activation of oncogenic pathways also contribute to a CRPC phenotype. Adapted 
from (Knudsen and Kelly 2011). 
 
1.3.2.1. AR amplification 
 
Enhanced AR expression can arise from a number of mechanisms. AR gene 
amplification has been detected in approximately 30% of patients with recurrent 
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PCa (Koivisto, Kononen et al. 1997). The outcome of a recent study with a 
median follow-up of 12 years assessing AR levels from tumour samples derived 
prior to the start of treatment revealed that increased levels of AR present within 
the tumour nuclei correlated with increased risk of death from PCa (Donovan, 
Osman et al. 2010). Mechanistically, it is believed overexpression of AR reduces 
the amount of ligand needed for AR-mediated proliferation and survival and as 
consequence sensitises cells to the effects of residual prostatic androgens. 
LNCaP-ARhi, a LNCaP cell line stably expressing four to six times higher levels 
of AR than the parental cells were more sensitive to stimulation by 1nM DHT 
resulting in enhanced proliferation compared with the control cells and which 
also correlated with increased expression of cell cycle-associated genes 
(Waltering, Helenius et al. 2009).  
 
However few studies have addressed the process of how AR overexpression 
occurs. An unexpected link between AR expression and the retinoblastoma 
tumour suppressor protein (pRB) has provided a potential mechanism of loss of 
AR regulation during the development of CRPC. It was demonstrated that pRB 
was able to act as a transcriptional repressor at the AR gene with suppression 
of pRB resulting in an increase in AR expression in vivo and which was 
correlated to increased E2F1 expression. These findings were further validated 
using clinical specimens from patient with CRPC; pRB loss was found to be 
overrepresented in CRPC and this significantly inversely correlated with AR 
levels (Sharma, Yeow et al. 2010). It has also recently been demonstrated that 
ligand-bound AR is able to mediate a negative feedback loop on its own activity. 
In VCaP cells (derived from vertebral metastasis in a patient with CRPC), AR 
was able to enhance its own expression at low androgen levels through binding 
at an enhancer element within the second intron of the AR gene. Conversely, 
high levels of androgen resulted in ligand-bound AR functioning as a 
transcriptional repressor at this site resulting in the recruitment of the 
transcriptional coregulator, lysine specific demethylase (LSD1) and 
demethylation of histone mark, H3K4me1,2 (Cai, He et al. 2011). 
 
1.3.2.2. AR gain-of-function mutations 
 
The acquisition and selection of AR mutations and alternatively spliced isoforms 
during androgen ablation provide PCa cells with a mechanism of circumventing 
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growth regulation at low androgen levels and by activation by other ligand types. 
The precise frequency of somatic AR mutations during the development of 
CRPC is unclear due to cellular heterogeneity within tumours, variations in 
tumour staging and difficulty of accessing metastatic samples. However Marcelli 
et al. observed that patients in the early stages of PCa had no AR mutations 
whereas the frequency increased to 20% in localised metastatic samples and 
this escalated further to 50% in more distant metastatic samples suggesting AR 
mutations play a role in tumour progression (Marcelli, Ittmann et al. 2000). More 
recently, an assessment of AR mutations in circulating tumour cells showed AR 
alterations were present in 20 out of 35 patients highlighting the incidence of 
mutations may be higher in cells with metastatic potential (Jiang, Palma et al. 
2010).  
 
The number of different somatic AR mutations that have been found in patients 
with PCa tissues currently stands at 159 and are catalogued in the Androgen 
Receptor Gene Mutations Database (Gottlieb, Beitel et al. 2012). Gain-of-
function mutations are found either localised within region of the LBD (~45%) or 
a significant minority (~30%) are located in exon 1 of the AR (Gottlieb, Beitel et 
al. 2012). A large numbers of variant AR transcripts have been detected in PCa 
cell lines, CRPC xenografts and tissue specimens. These AR splice variants 
encode truncated AR isoforms, which retain NTD and DBD but lack the LBD and 
several are able to induce ligand-independent activation of ARE-driven reporters 
in the absence of androgens (Guo and Qiu 2011).  
 
The first AR mutation to be identified was a missense mutation resulting in the 
substitution of threonine for alanine at position 877 (T887A). This mutation is 
also found in the LNCaP cell line, established from lymph node metastases from 
a patient treated with hormonal therapy (Horoszewicz, Leong et al. 1980). X-ray 
crystallography studies mapped the amino acid substitution within the ligand-
binding pocket of the AR resulting in an altered size and shape of the binding 
pocket thus decreasing ligand specificity (Sack, Kish et al. 2001). As 
consequence, in addition to androgen-mediated activation, this promiscuous 
receptor can bind other steroid hormones (progestins and oestrogens) and 
antiandrogens (CPA and flutamide) (Veldscholte, Berrevoets et al. 1992). It is 
noteworthy to mention that the T877A mutation does not respond in the same 
way to other antiandrogens such as bicalutamide. Of 24 tumour samples 
examined from patients with metastatic PCa, 25% expressed this mutation 
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(Gaddipati, McLeod et al. 1994). A study a year later by Taplin and co-workers 
revealed that the frequency of mutations at amino acids 877 and 874 increased 
in metastatic PCa tumours derived from patients who had previously been 
treated with orchiectomy or LHRH agonist (Taplin, Bubley et al. 1995). The 
clinically observed Flutamide Withdrawal Syndrome where some patients 
treated with flutamide experience increasing PSA levels and worsening 
symptoms may have arisen from the selection of cells containing a flutamide-
activated mutant AR. In support of this theory, AR mutations developing in 
response to flutamide treatment was demonstrated when 5 out of 16 patients 
with bone metastases receiving androgen blockade with flutamide were found to 
have T877A mutations, which were stimulated to grow in vitro when flutamide 
was added. This was in contrast with patients not treated with flutamide 
harbouring different AR mutations (Taplin, Bubley et al. 1999).  
 
The AF-2 domain appears to be a hot spot for other mutations namely T877S 
and H874Y, which also exhibit broadened ligand specificity. The T877S AR 
mutant similarly shows altered an altered ligand-binding pocket in terms of size 
and shape (Matias, Donner et al. 2000). In the case of the H874Y mutation, the 
substitution of tyrosine at position 874 instead strengthens the interaction of 
helix 12 with the ligand-binding groove thus setting it in an active confirmation 
even when non-optimal ligands bind (McDonald, Brive et al. 2000). This 
particular mutation has also confers enhanced recruitment of p160 coactivators 
which also contributes to its enhanced activity (Duff and McEwan 2005). As 
demonstrated above with flutamide-based therapy, treatment with other AR 
antagonists similarly selects for mutations and results in these agents 
functioning as agonists. The W741C has been frequently found in bicalutamide-
treated patients and was induced in LNCaP cells when cells were cultured long-
term in the presence of bicalutamide (Haapala, Hyytinen et al. 2001; Hara, 
Miyazaki et al. 2003). The androgen-dependent KUCaP-1 xenograft, derived 
from the liver metastatic tissue of a patient treated with bicalutamide also 
harbours the W741C mutation. After castration, KUCaP-1 tumours regressed 
and did not grow. However when treated with bicalutamide after castration, 
these tumours regrew and only regressed two months after bicalutamide 
withdrawal (Terada, Shimizu et al. 2010). 
 
The hinge and the N-terminal region of the AR have also been found to harbour 
mutations. As these domains are not involved in ligand binding, these alterations 
 47 
impact on AR activity in other ways. AR mutations R629Q and K630T were 
identified from patients who had undergone ADT or who was treatment-naïve 
respectively and reside in the hinge region, which spans the DBD and NLS. 
Despite these mutants demonstrating a reduced nuclear localisation, they 
exhibit increased transcriptional activity. Mutational analysis of the hinge region 
revealed that deletion of amino acid residues 629-636 increased the 
transactivation potency of various reporters with the AR p160 coactivator, 
transcription intermediary factor 2 (TIF2) potentiating the effect compared with 
when the region was present. The deletion also enhanced the N/C interaction 
indicating this critical area serves to inhibit aberrant AR activation. These results 
suggest that mutations, which occur with this region, may increase the affinity of 
the AF-2 domain to interacting partners such at the NTD, TIF2 and other 
coactivators resulting in enhanced AR activity (Haelens, Tanner et al. 2007).  
 
There have been comparatively fewer studies assessing N-terminal mutations. 
One example was the identification of dual somatic missense mutations within 
the N-terminal polyglutamine (PolyQ) tract. This resulted in two leucine residues 
disrupting the tract thereby reducing the N/C interaction but unexpectedly, 
increasing AR activity compared with wild-type AR. The AR coactivator, AR-
associated (ARA) protein, ARA24 has been demonstrated to interact with the 
CAG repeat within the PolyQ tract thus increasing stability and folding of the 
tract and leading to enhanced transcriptional activity of the AR (Hsiao, Lin et al. 
1999; Buchanan, Yang et al. 2004). 
 
NTD AR variants were found to be prevalent in CRPC patients in a recent study 
by Steinkamp and co-workers. They compared AR variants in metastases 
obtained from patients treated with bicalutamide or flutamide with lymph node 
metastases from hormone-naïve patients (Steinkamp, O'Mahony et al. 2009). Of 
26 recurring mutations, the majority were located in the NTD and occurred in 
multiple tumours. One mutation, W435L, replaced the WxxLF motif in TAU5 for 
an LxxLF motif. As a result, this mutation strengthened the intramolecular N/C 
interaction leading to an enhancement of transcriptional activity. The mechanism 
by which this mutation increased AR activity has not been clarified however the 
authors postulate it may be as a result of increased ligand-dependent activity 
due to altered competition with the FxxLF motif or greater interactions with 
coactivators due to LxxLF-mediated binding. Another N-terminal mutation, 
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E255K, resulted in increased protein stability and nuclear localisation in the 
absence of androgen (Steinkamp, O'Mahony et al. 2009). 
 
Synthesis of truncated AR variant proteins through alternative splicing has 
recently emerged as a mechanism of resistance towards androgen ablation 
therapy. Since 1994, when 110kDa and 87kDa isoforms of the AR were first 
described in human genital skin fibroblasts, numerous alternatively spliced AR 
variants have been cloned and identified. The various isoforms have distinct 
functions, however many exhibit constitutively active, transactivation activity. 
This has been attributed to the TAU5 domain in the NTD region of the AR 
(Dehm, Regan et al. 2007). Dehm et al. reported three AR splice variants from 
the androgen-independent human PCa cell line, 22Rv1, derived form the 
relapsed CRW22 xenograft (Dehm, Schmidt et al. 2008). One variant produced 
a full length AR with a duplicated exon 3 (AR 1/2/3/CE3) and the other variants 
resulted in truncated isoforms (AR 1/2/2b and AR 1/2/3/2b), which lack a LBD 
but possess a novel exon 2b. Exon 2 encodes the first zinc finger of the DBD 
and this was sufficient for AR to bind to ARE on DNA thereby rendering the 
truncated isoforms constitutively active and promoting growth independent of 
androgen stimulation (Dehm, Schmidt et al. 2008). Another AR isoform, 
designated AR3 (containing the NTD and DBD regions only) has been revealed 
to be a principal constitutive isoform in PCa cell lines (including 22Rv1 cells) and 
was identified in human PCa tissue from two independent studies. Expression 
levels of AR3 have also been correlated to recurrence of PCa and survival time 
with depletion of androgen resulting in overexpression (Guo and Qiu 2011). 
Other AR variants that are implicated in the development of CRPC include 
ARv567es (exons Δ5-7), which is constitutively active and in the absence of ligand, 
binds to and stabilises wild-type AR resulting in enhanced activity. ARv567es 
VCwas initially identified from a number of different human PCa xenografts, 
termed the LuCaP series, derived from men with CRPC who have undergone 
ADT. Enhanced expression of this variant was found in the castration-resistant 
xenografts compared to androgen-dependent tumours. Later it was found that 
10 out of 13 CRPC patients had a minimum of one metastasis that was positive 
for ARv567es (Sun, Sprenger et al. 2010). Both AR3 and ARv567es regulate a 
distinct set of gene targets compared with those regulated by wild-type AR, 
which may be of significance for tumour initiation and progression (Guo and Qiu 
2011). 
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1.3.2.3. Altered expression of AR coregulators 
 
Besides mutations altering the activity of the AR which in some circumstances 
lead to the aberrant recruitment of coactivators, it also been recognised that the 
expression levels of AR coregulators can also be deregulated in a subset of 
PCas. On example is the overexpression of SRC1 and TIF2. Increased 
expression of these coactivators was found to correlate with disease 
progression and was higher in patients with recurrent PCa who had failed 
hormone therapy compared with androgen-dependent PCa samples (Gregory, 
He et al. 2001). Enhanced SRC1 and TIF2 expression was also associated with 
the regrowth of androgen-dependent CWR22 human prostate xenograft after 
castration and also paralleled an increase in AR expression in this tumour model 
(Gregory, He et al. 2001). A later study correlated SRC1 expression with 
increased tumour aggressiveness in localised androgen-dependent PCa 
samples. In vitro studies confirmed the role of SRC1 in AR-mediated cell growth 
since knockdown of SRC1 in androgen-dependent LNCaP cells and androgen-
independent subclone of LNCaP, C4-2 resulted in reduced growth and a 
decrease in AR-mediated gene regulation (Agoulnik, Vaid et al. 2005). Another 
coactivator that has been linked with PCa development is Tat-interactive protein 
60kDa (TIP60). This was found to accumulate in the nucleus of specimens 
derived from patients with CRPC compared with a more diffuse distribution in 
specimens of primary PCa. Moreover, in the xenograft CWR22 tumours and 
LNCaP cells, TIP60 was upregulated and localised to the nucleus after 
androgen withdrawal (Halkidou, Gnanapragasam et al. 2003). However due to 
the divergent nature of PCa, clinical results such as those described might not 
necessarily be representative. A recent microarray analysis comparing gene 
expression patterns between normal and tumour tissue found SRC1 to be 
elevated in two data sets but decreased in one and TIF2 to be elevated in one 
but not in another. TIP60 was decreased in the majority of data sets (Chmelar, 
Buchanan et al. 2007). 
 
In addition to upregulation of certain coactivators there is evidence that 
deregulation of AR corepressors may influence PCa development and 
progression. An example of AR antagonists converting to agonists is through the 
modulation of AR corepressor activity. In the presence of AR antagonists, 
interleukin (IL)-1β signalling from infiltrating macrophages resulted in TAB2, a 
component of the NCoR repressor complex, releasing NCoR from the AR 
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transcriptional complex thereby de-repressing AR activity (Zhu, Baek et al. 
2006). This finding is of significant clinical relevance since IL-1β is effectively 
converting AR antagonists into agonists (Zhu, Baek et al. 2006). As will be 
described section 1.4.1.2, cyclin D1 functions as an AR corepressor. Studies 
from a murine model have shown that cyclin D1 expression decreases as a 
function of disease development (Maddison, Huss et al. 2004). Characterisation 
of cyclin D1 status in patient samples found that increased cyclin D1 expression 
correlated with primary PCa compared with benign tissue and differential cellular 
distribution of cyclin D1 was associated with different grade of tumours; 
cytoplasmic in low grade tumours and nuclear in higher grades (Comstock, 
Revelo et al. 2007). Another AR corepressor, Notch effector protein, Hey1, is 
deregulated in PCa. Expression of both Notch and its ligand Jagged1 are 
repressed as a result of androgen stimulation while Hey1 localisation in PCa is 
either downregulated or excluded from the nucleus in PCa specimens (Belandia, 
Powell et al. 2005; Wang, Leow et al. 2006). Together this indicates a possible 
mechanism of reduced Hey1 signalling in PCa. This will be discussed in further 
detail in section 1.5.3.4. 
 
1.3.2.4. Intraprostatic androgen synthesis 
 
Another mechanism by which PCa cells adapt to ADT is through enhanced 
activity of enzymes that convert weak adrenal androgens (DHEA-S and 
androstenediol) into testosterone and DHT thus providing the necessary levels 
of agonist to re-establish AR activity. Analysis of metastatic tissue derived from 
patients with CRPC through a “warm autopsy” program distinguished higher 
testosterone levels in CRPC samples relative to control tissues. In parallel, gene 
expression studies have identified increased expression of enzymes involved in 
the conversion of weak adrenal androgens to testosterone in CRPC bone 
metastases compared with primary PCa samples (Cai and Balk 2011). 
 
PCa cells can either take up weak adrenal androgens from the blood stream or 
synthesise androgens de novo from cholesterol as was demonstrated in LNCaP 
xenografts model (Locke, Guns et al. 2008). LNCaP, PC3 and DU145 were all 
found to express CYP11A1 and CYP171A, both of which are integral to the 
steroidogenic pathway indicating PCa cells can divert to alternative methods 
when testosterone is low. These levels of these enzymes have also been found 
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to increase in castration resistant LNCaP sub-lines (Dillard, Lin et al. 2008). 
Despite demonstrating that de novo androgen synthesis occurred in cell lines 
and xenografts, testosterone levels were still low and PCa cells may produces 
DHT through a “back door” pathway. However since testosterone levels are high 
in clinical CRPC patients it is therefore questionable whether de novo synthesis 
occurs in CRPC patients to adequate levels that will lead to activation of the AR. 
However, in support of this theory, mRNA levels for CYP11A1 and CYP171A 
were detected in metastatic CRPC bone marrow samples (Stanbrough, Bubley 
et al. 2006). Nevertheless it is still to be defined to what extent de novo 
androgen synthesis plays are role in activating AR whereas circulating adrenal 
androgens provide a significant source of substrate to convert to testosterone 
and DHT. 
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1.3.2.5. Growth factor- and cytokine-mediated 
activation of AR 
 
It has been well documented that signalling cascades initiated by growth factors 
such as epidermal growth factor (EGF), insulin-like growth factor 1 (IGF-1) and 
cytokines like IL-6 can stimulate AR activity. These can activate transcriptional 
activity of AR independently of androgen or can sensitise AR to low 
concentrations of androgen. Initial experiments demonstrated stimulation by 
EGF and IGF-1 could crosstalk with AR signalling when ectopically expressed 
AR in DU145 cells mediated AR-dependent reporter gene transcription. 
Antagonising AR with bicalutamide in the presence of EGF blocked 
transactivation thus demonstrating the requirement of AR (Culig, Comuzzi et al. 
2004). Since this study, a number of groups have related the upregulation of 
members of the EGFR-family with enhanced AR activity. For example, ectopic 
expression of human epidermal growth factor receptor 2 (HER2/neu) in LNCaP 
cells resulted in activation of the AR pathway through AKT-mediated 
phosphorylation of AR (Wen, Hu et al. 2000). It was then proposed that the 
heterodimerisation of HER2 with HER3 resulted in optimal AR activity through 
increased AR stabilisation and DNA binding thereby increasing AR 
transactivation. Inhibition of HER2 rather than EGFR resulted in decreased AR 
activity suggesting HER2 was responsible for modulating AR function 
(Mellinghoff, Vivanco et al. 2004). In the clinic, overexpression of EGF and EGF 
receptor has been detected in patients with metastatic PCa and has been 
associated with progression to CRPC (Di Lorenzo, Tortora et al. 2002). The 
result of growth factor stimulation results in activation of several downstream 
signalling cascades including the mitogen-activated protein kinase (MAPK) 
pathway. Of the many downstream effectors of the MAPK pathway, the 
sarcoma-related kinase (Src) and the p42/44 extracellular-signal-regulated 
kinases (ERK) 1 and 2, have been shown to stimulate AR activity (Lonergan and 
Tindall 2011). Treatment of LNCaP cells with EGF resulted in phosphorylation of 
AR on a number of tyrosine residues, which were inhibited by Src kinase 
inhibitors (Guo, Dai et al. 2006). Mass spectrometry identified Y534 as a primary 
site on the AR for enhanced activity since mutation of this residue reduced Src-
induced phosphorylation. This may be significant for the progression of PCa 
since expression levels of phospho-Y534 and phospho-Src were greater in 
castration-resistant PCa tumours compared with hormone-naïve PCa or normal 
prostate samples (Guo, Dai et al. 2006). Activation of ERK1 and ERK2 has also 
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been correlated with tumour progression in PCa. The relationship between 
ERK1/2 activity and AR signalling was revealed when C4-2 cells, in steroid-
depleted conditions, were treated with the MAPK extracellular kinase (MEK) 
inhibitor, U0126, which blocks ERK1/2 activity. As a consequence of MEK 
inhibition, stimulation of the AR target genes, PSA and TMPRSS2 were 
decreased suggesting that the autocrine growth factor signalling influences AR 
activity in the absence of androgens. The reduction of AR activity by U0126 was 
attributed to a reduction in the interaction of AR and its coactivator, SRC1 as 
well as a decrease of MAPK-mediated phosphorylation of SRC1, which is 
important for interaction with another AR coactivator, cAMP response element 
binding protein (CREB)-binding protein (CBP) (Agoulnik and Weigel 2008).  
 
As mentioned above, growth factors and their cognate receptor tyrosine kinase 
(RTK) also activate the phosphatidylinositide 3-kinase (PI3K)/AKT pathway, an 
important regulator of cell survival. PI3K mediates production of the second 
messenger, phosphoinositol (3,4,5) triphosphate (PIP3). This recruits the 
threonine/serine kinase, AKT that acts downstream via mammalian target of 
rapamycin (mTOR) to regulate growth, proliferation and apoptosis. Initially 
activation of AKT was thought to correlate simply with increased AR activity 
through phosphorylation of AR. However, later it was appreciated the crosstalk 
between the pathways was more complex since AKT was found to block or 
enhance AR activity in a cell passage number-dependent manner (Lin, Hu et al. 
2003). Carver et al have recently determined that the PI3K/AKT and AR 
pathways regulate each other through complex reciprocal feedback 
mechanisms (Carver, Chapinski et al. 2011). They and others have shown that 
HER2 and HER3 are activated when the PI3K/AKT pathway is blocked (Carver, 
Chapinski et al. 2011; Chandarlapaty, Sawai et al. 2011). In LNCaP cells, 
treatment with either BEZ235 (a dual PI3K and mTORC1/2 inhibitor) or siRNA 
against AKT resulted in enhanced HER3 and AR expression which was blocked 
with the addition of a HER family kinase inhibitor. Conversely inhibition of AR 
activity using either MDV3100 or siRNA against AR resulted in enhanced AKT 
activity through the downregulation of the androgen-regulated FKBP5 protein, a 
chaperone protein for the AKT phosphatase PHLPP (Carver, Chapinski et al. 
2011).  
 
IL-6 is a pleiotropic cytokine produced by a number of different cell types 
including prostate, immune and osteoblast cells. It mediates differentiation of 
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lymphocytes, cell proliferation, cell survival and apoptotic signals. Depending on 
the cell type, it can transduce and activate MAPK and PI3K/AKT signalling 
cascades however it generally induces phosphorylation of the signal transducer 
and activator of transcription (STAT) protein, STAT3. In normal cells, IL-6 
signalling is strictly regulated and therefore transient. IL-6 binds to the IL-6 
receptor, which is composed of the immunoglobulin (Ig)-like ligand-binding 
subunit, gp80 and the signal-transducing gp130 subunit. This results in 
autophosphorylation and activation of the Janus kinase (JAK) family of proteins 
(particularly JAK2 but also JAK1 and TYK2) which then bind to and 
phosphorylate STAT3 inducing dimerization and translocation to the nucleus. 
STAT3 homodimers then bind to consensus sequences within the enhancer 
regions of target genes and in conjunction with other transcription factors, drive 
gene expression. Targets genes include c-Myc, Bcl-2, Bcl-xL and cyclin D1 
(Hodge, Hurt et al. 2005).  
 
IL-6 was implicated in PCa progression after elevated levels of serum IL-6 were 
detected in patients with CRPC and was associated with decreased survival. 
Furthermore, the IL-6 receptor is overexpressed in LNCaP, DU145 and PC3 
cells and has been correlated with progression to CRPC (Yang, Wang et al. 
2003; Lonergan and Tindall 2011). Initial studies suggesting AR could be 
regulated by IL-6 stimulation were derived from DU145 cells transfected with an 
AR expression vector and ARE-dependent reporter gene construct. Treatment 
with IL-6 resulted in AR-dependent gene transcription, which could be blocked 
with bicalutamide or tyrosine kinase inhibitors to MAPK, protein kinase A or C 
(Hobisch, Eder et al. 1998). In agreement with these results, IL-6 treatment of 
LNCaP cells in androgen-depleted conditions also increased levels of PSA 
mRNA and augmented PSA secretion (Hobisch, Eder et al. 1998). The potential 
mechanisms that mediate the interaction between IL-6 and AR signalling have 
been studied by a number of groups. Through the activation of the MAPK 
pathway, AR coactivator, p300 has been implicated in mediating AR 
transactivation. This was revealed after p300 depletion either by E1A-dependent 
sequestration or siRNA against p300 resulted in a reduction of AR activity in 
androgen-deprived LNCaP cells (Debes, Schmidt et al. 2002). In a separate 
study, the yeast Gal4 system identified that the NTD of AR was activated after 
IL-6 treatment of LNCaP cells and blocked by protein kinase inhibitors against 
MAPK and JAK (Ueda, Mawji et al. 2002). More specifically, the JAK kinase 
inhibitor, AG490 also inhibited MAPK phosphorylation as well as STAT3 
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phosphorylation indicating the JAK/STAT pathways plays a central role in 
mediating IL-6-dependent activation of AR NTD. This theory was supported 
when STAT3 was found to bind to the AF-1 region of AR (Ueda, Bruchovsky et 
al. 2002).  
 
It should be emphasised, activation of cell proliferation and survival pathways 
such as MAPK, PI3K/AKT and JAK/STAT do not always impinge on AR activity 
and through interactions with each other and other signalling cascades will 
contribute to the development of a more malignant PCa phenotype by 
mechanisms independent of AR. 
 
1.3.3.  AR-independent mechanisms of PCa 
recurrence 
 
The cellular mechanisms described so far require PCa cells to express the AR 
to achieve androgen independence however; complementary or alternative 
pathways have been ascertained that can circumvent AR.  
 
Many of the pathways resulting in tumour development and progression 
described above have involved deregulation of proliferation. In addition, 
defective apoptosis also plays a significant role in tumourigenesis. The anti-
apoptotic protein, Bcl-2 is frequently expressed in PIN and CRPC. In an LNCaP 
xenograft model, castration-resistant tumours expressed Bcl-2 and blocking Bcl-
2 with antisense oligonucleotides delayed the development of androgen-
independent tumours indicating Bcl-2 may bypass the signal for apoptosis 
normally generated during androgen ablation (Liu, Corey et al. 1996; Gleave, 
Tolcher et al. 1999). In advanced PCa, Bcl-2 was expressed in 70% of 
androgen-independent tumours and 34% of bone metastases in castration-
resistant patients suggesting Bcl-2 expression is an important factor in 
facilitating PCa cells to survive in an androgen-depleted environment (Feldman 
and Feldman 2001; Gurumurthy, Vasudevan et al. 2001). Bcl-xL another anti-
apoptotic protein is overexpressed in PCa and is associated with higher 
Gleason scores (Castilla, Congregado et al. 2006).  
 
In addition to the activation of oncogenic pathways, inactivation of tumour 
suppressor genes also contributes to PCa progression. Inactivation of p53 is 
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considered an important step in tumourigenesis of many cancers including PCa. 
The involvement of p53 in the progression of PCa progression was 
demonstrated using the mouse prostate reconstitution (MPR) model 
(Thompson, Park et al. 1995). PCa was identified in all mice heterozygous and 
homozygous for p53 mutations while no metastasis were found in wild-type p53 
mice (Thompson, Park et al. 1995). In vivo, LNCaP cells stably expressing 
dominant negative form of p53 readily formed tumours in castrated mice while 
parental LNCaP xenografts did not suggesting mutant p53 can contribute to the 
CRPC phenotype (Burchardt, Burchardt et al. 2001). It is widely accepted that 
p53 in DU145 is non-functioning in terms of the classical p53 signalling pathway. 
This has been attributed to two separate mutations on the different chromosome 
alleles resulting in co-expression of two mutant proteins with different amino 
acid substitutions (section 2.2, Table 5) (Isaacs, Carter et al. 1991). 
Characterisation studies of the DU145-derived, p53-mutant proteins in p53-
deficient cells, demonstrated that alone these proteins possessed properties 
that closely resembled wild-type p53 since they did not have dominant-negative 
effects against wild-type p53 (Gurova, Rokhlin et al. 2003). Co-expression of 
these mutants neutralized the other’s growth suppressive effects and converted 
the Fas-sensitive phenotype of p53-null, PC3 cells to a Fas-resistant one by 
downregulating Fas receptor (FasR) expression (Gurova, Rokhlin et al. 2003). 
 
As discussed above, the PI3K/AKT pathway has been correlated with 
progression to CRPC. Loss of the major negative regulator of this pathway, 
tumour suppressor gene, PTEN has been detected in approximately 25% of 
primary tumours and 79% of CRPC samples and correlates with advanced PCa 
and high Gleason score (Lonergan and Tindall 2011). Knockdown of PTEN in 
PCa cell lines and conditional deletion in mice have established that a loss of 
PTEN expression promotes resistance to androgen ablation therapies (Gao, 
Ouyang et al. 2006). 
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1.4. Androgen receptor signalling 
 
1.4.1.  Androgen receptor regulators 
 
Approximately 200 AR regulators have been identified and are categorised as 
coactivators or corepressors. The relative levels of coactivators versus 
corepressors modulate the activity of AR thereby regulating the cell’s response 
to changes in hormone levels. They do not typically bind DNA but function at AR 
target gene promoter and/or enhancer regions to: (i) assist DNA binding, (ii) 
induce chromatin remodelling and acetylation/deacetylation of chromatin via the 
recruitment of HAT and HDACs respectively (iii) control cofactor binding to the 
AF-2 coactivator binding groove by regulating the AR N/C interaction and (iv) 
recruit general transcription factors associated to facilitate the assembly of the 
preinitiation complex (PIC) (Figure 4). Many of the coregulators perform multiple 
functions and bind to other cofactors to either enhance either activation or 
repression of AR transcription (van de Wijngaart, Dubbink et al. 2012). A 
summary of the mechanisms of action for the coregulators discussed in this 
section is listed in Table 1.  
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Figure 4. Schematic diagram illustrating AR activation and protein-protein interactions 
regulating AR transcriptional activity 
Upon ligand binding to the LBD, intra-molecular N/C interaction occurs (as well as intermolecular 
binding, not shown). On binding to the ARE, the N/C interaction is disrupted resulting in 
interactions with cofactors guiding the recruitment of complexes that modulate chromatin 
remodelling and initiate transcription. AR LBD, androgen receptor ligand binding domain; ARE, 
androgen response element; DHT; dihydrotestosterone, GTF: general transcription factors, RNA 
pol II; RNA polymerase II, PIC; preinitiation complex. Adapted from (van de Wijngaart, Dubbink et 
al. 2012). 
 
1.4.1.1. AR coactivators 
 
The best-characterised coactivators of the AR are p300 and CBP protein and 
the p160/SRC-family proteins, both of which are overexpressed in PCa. p300 
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levels from tissue samples of patients who underwent prostatectomy correlated 
with proliferation in vivo and was associated with larger tumour volumes. In vitro, 
p300 levels increased under androgen deprivation resulting in a growth 
advantage. SRC1 has been found to be overexpressed in 50% of androgen-
dependent PCa samples compared with benign or normal prostate tissue and 
increased levels of SRC3 correlated to tumour grade in localised disease 
(Lonergan and Tindall 2011).  
 
AR transcriptional activation by p300/CBP arises from its dual role as a scaffold 
protein and its function as a HAT protein. It serves to link DNA-binding AR to 
basal transcription machinery and functions as a surface for nucleation of 
transcription factors (Iyer, Ozdag et al. 2004). Its HAT activity results in 
acetylation of lysine residues in histone proteins thereby reducing the interaction 
between histones and the DNA and allowing access for the basal transcription 
machinery (Iyer, Ozdag et al. 2004). The molecular features of p160/SRC 
proteins (SRC1, TIF2 and SRC3) augment transcriptional activity of AR as well 
as providing a structural base for recruiting other coregulators. SRCs contain 
three distinct structural domains, the N-terminal basic helix-loop-helix-PAS 
(bHLH-PAS) domain required for protein-protein interactions, a central region 
which contains LxxLL motifs for AR interaction and a C-terminal portion 
containing transcriptional activation domains (AD1 and AD2). AD1 binds 
p300/CBP proteins and AD2 interacts with proteins with histone 
methyltransferase activity. C-terminal regions of SRC1 and SRC3 also possess 
intrinsic HAT activity (Xu, Wu et al. 2009). SRC1 was found to enhance AR 
activity via two independent interactions. A weak interaction was found between 
its LxxLL motifs and the AF-2 region whereas a stronger interaction was 
observed between the glutamine-rich motif and AF-1 (Bevan, Hoare et al. 1999; 
Powell, Christiaens et al. 2004). Recruitment of p300/CBP and the intrinsic HAT 
activity of SRC1 further potentiated AR–mediated transcription resulting in 
chromatin acetylation which promoted the recruitment of another class of AR 
coactivator, chromatin remodelling complexes (e.g. SWI/SNF) which also loosen 
DNA-histone interactions (Smith, Onate et al. 1996; Becker and Horz 2002). 
Similarly, p300 was recently found to enhance AR transcriptional activity when 
AR was in a complex with the coregulator melanoma antigen gene protein-A11 
(MAGE-11) and TIF2. MAGE-11 interacted with the FxxLF motif of the AR-NTD 
via a F-box domain and also bound to the N-terminal region of p300 with AR 
transcriptional activity dependent on p300 HAT activity. The AR N/C interaction 
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is thought to be critical in mediating AR transcriptional activity as mutation of AF-
2 disrupted FxxLF motif binding and AR function. This suggests binding of 
MAGE-11 to FxxLF increases coactivator binding, providing better accessibility 
to LxxLL motifs in TIF2 (Askew, Bai et al. 2010).  
 
Direct modification of AR at the post-transcriptional level also regulates 
transcriptional activity. p300 and p300/CBP-associated factor (P/CAF) proteins 
have been found to directly acetylate the 630KLKK633 motif within the hinge 
region of the AR and is necessary for maximum activation of the AR (Fu, Wang 
et al. 2000; Lavery and Bevan 2011). Another protein involved in acetylating AR 
is the TIP60, which contains a HAT domain capable of acetylating several types 
of histone proteins, AR and possibly chromatin. In addition it also interacts with 
AR-LBD via a LxxLL motif in its C-terminus (Lavery and Bevan 2011). 
Ubiquitination of the AR by ubiquitin E3 ligase protein, RNF6 recruits and 
stabilises further AR coregulators. RNF6 induces polyubiquitination of K845 
within the AF-2 domain thereby recruiting coactivator, ARA54 (Xu, Shimelis et 
al. 2009). This protein binds to the C-terminus portion of the AR and mediates 
ligand-dependent AR (Kang, Yeh et al. 1999). Mutating K845 abolished ARA54 
binding to a subset of AREs indicating RNF6 has a role in promoter specificity of 
AR target genes (Xu, Shimelis et al. 2009). Other coactivators however have a 
stabilising function so AR may interact with the basal transcription machinery. 
One such multi-subunit complex is Mediator (MED) also known as 
TRAP/DRIP/ARC, which bridges the AR (via its LBD) to general transcription 
factors and RNA polymerase II via an LxxLL motif in the TRAP220/DRIP205 
protein residing within the complex (van de Wijngaart, Dubbink et al. 2012). 
 
1.4.1.2. AR corepressors 
 
Two well-characterised AR corepressors are nuclear receptor corepressor 
(NCoR) and the related silencing mediator of retinoic acid (SMRT), which 
mediate disruption of AR N/C interaction and competition with SRC/p160 
coactivators to repress AR activity. NCoR and SMRT are large scaffold proteins 
and contain LxxLL-like motifs, which interact with AR and bind to AF-2. 
Recruitment of these corepressors is dependent upon the conformational 
change induced by ligand binding either by AR antagonists such as flutamide or 
bicalutamide or by agonist binding (Liao, Chen et al. 2003; Hodgson, Astapova 
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et al. 2005). Disruption of AR N/C protein interactions and binding of 
coactivators assist in repression of AR activity, Since AR-NTD is the main region 
mediating transcriptional activation; this suggests corepressors recruited to this 
region are key for repressing AR function. NCoR has been found to interact 
strongly with the AR-NTD region thereby preventing SRC1 from interacting with 
the NTD region. Mutagenesis studies showed that NCoR interacted with an area 
distinct from FxxLF motif and TAU5, regions required for AR N/C interaction 
(Hodgson, Astapova et al. 2005). On the other hand, TAU5 has been defined as 
a SMRT binding region, the degree to which SMRT could repress AR activity 
increased proportionaly with the number of CAG repeats in the polyQ tract 
(Buchanan, Need et al. 2011). It is generally believed the transcriptional 
competence of AR correlates to the number of CAG repeats; an increase in the 
polyQ region inhibiting p160-mediated coactivation of the AR (Irvine, Ma et al. 
2000). Increasing the amount of SMRT in the assay abolished SMRT-mediated 
AR repression as a result of cofactor competition suggesting a functional link 
between CAG repeat length and AR activity with a balance between corepressor 
and coactivator occupancy for the LBD and NTD-binding (Buchanan, Need et al. 
2011). Another copressor that abrogates N/C interaction is cyclin D1, which 
binds directly to the FxxLF motif within the AR-NTD region preventing the 
conformational changes required for AR stabilisation on chromatin. Its ability to 
bind HDAC3 was also important for AR inhibition (Petre, Wetherill et al. 2002). 
Human checkpoint protein hRad9 also abrogates the N/C interaction due to its 
high affinity C-terminal FxxLF motif competing with LxxLL-like motifs in 
coactivators (Wang, Hsu et al. 2004). 
 
NCoR or SMRT further inhibit AR transcriptional activity due to the presence of 
at least two independent repressor domains in these proteins, which recruit 
primarily HDAC3 complexes (Fischle, Dequiedt et al. 2002). This results in 
deacetylation of lysine residues of histone proteins, tightening between 
nucleosomes and DNA leading to chromatin condensation and promoter 
inaccessibility. Other corepressors that require HDAC activity include protein 
inhibitor of activated STAT (PIASγ) and cyclin D1 since trichostatin A (TSA) an 
inhibitor of class I/II HDACs restored AR activity (Burd, Morey et al. 2006). Other 
corepressors such as ErbB3-binding protein (EBP1) and TG-interacting factor 
(TGIF) mediate their effect through Sin3, a protein that provides structural 
support for Sin3/HDAC complexes and other DNA-remodelling enzymes by 
directing Sin3 complexes to specific gene targets (Burd, Morey et al. 2006). AR 
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is equally susceptible to deacetylation as it is to acetylation; HDACs directly 
repress AR activity by deacetylation. HDAC1 has been reported to interact with 
the DBD/LBD region and is required for AR repression. Sirtuin 1 (SIRT1) a class 
3 HDAC is also able to regulate AR activity through direct deacetylation and 
could also abrogate p300-enhanced AR N/C interaction possibly by disrupting 
acetylation of the AR hinge region (Lavery and Bevan 2011). In summary, 
HDACs play a significant role in facilitating repression of AR while the 
corepressors lend specificity to the regulation of AR transcriptional activity. 
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Table 1. List of selected AR coregulators that directly modulate AR transcriptional activity 
Reviewed by the following: (van de Wijngaart, Dubbink et al. 2012) (Lavery and Bevan 2011) 
(Burd, Morey et al. 2006). ND, not determined 
 
 
  
Name Function Coac%vator/corepressor 
Region1in1AR1to1
which1coregulator1
binds 
SRC1, TIF2, SRC3 HAT (SRC1 and SRC3) Recruitment of HATs coactivator 
TAU5 and 
AF-2 
TIP60 HAT Chromatin remodelling coactivator AR-LBD 
p300/CBP/PCAF HAT coactivator  Indirect 
SWI/SNF complex Chromatin remodelling coactivator  
AR-LBD (via BAF57 
subunit) 
MAGE-11 Inhibition  of N/C interaction coactivator  FxxLL in AR-NTD 
RNF6 E3 ubiquitin-protein ligase coactivator Indirect 
TRAPP20/MED1 Recruitment of preinitiation complex coactivator  AR-LBD 
NCoR 
Recruitment of HDACs 
Inhibition of N/C interaction 
Competition with coactivators 
corepressor AF-2 AF-1 
SMRT 
Recruitment of HDACs 
Inhibition of N/C interaction 
Competition with coactivators 
corepressor 
 
AF-2 
TAU5 
Hey1, 2, L 
Recruitment of HDACs 
Competition with coactivators 
 
corepressor 
 AF-1 
PIASY Recruitment of HDACs 
corepressor 
 
ND 
 
SIRT1 HDAC corepressor ND  
HDACs (class I and 
II) HDAC 
corepressor 
 
ND 
 
Cyclin D1 
Inhibition of N/C interaction 
Recruitment of HDACs 
Competition with coactivators 
corepressor 
 
FxxLF in AR-NTD 
 
hRAD9 Inhibition of N/C interaction corepressor  AR-LBD 
EBP1 Recruitment of HDACs  
corepressor 
 
ND 
 
TGIF Recruitment of HDACs corepressor  
ND 
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1.4.2.  AR corepressor Hey1 
 
Drosophila hairy and Enhancer of split [E(spl)] bHLH proteins belong to bHLH 
super-family of DNA-binding transcription factors and all share the tandem 
arrangement of a bHLH and Orange domain (Figure 5). Mammalian 
counterparts have six E(spl) proteins, (hairy and enhancer of split) Hes1-6 and 
three Hairy/enhancer of split with YPRW-like motif proteins (Hey) proteins Hey1, 
2 and L. Hes and Hey proteins  are effectors genes which are expressed as a 
result of the Notch signalling pathway, a principal regulator of gene expression. 
All function as DNA-binding transcriptional repressors and regulate a variety of 
biological functions (Davis and Turner 2001; Fischer and Gessler 2007). These 
will be discussed in further detail in relation to the Hey family proteins in section 
1.5.1.1 
 
 
Figure 5. Protein domain structure of Hey1 
The N-terminus consists of a DNA-binding basic domain (b), which contains an invariant glycine 
residue and is contiguous with the α-helix-loop-helix (HLH) region. The latter serves as a 
dimerization domain for homodimer/heterodimer formation as well as for other additional protein 
interactions. It is followed by two more α-helical stretches (the Orange domain), which functions as 
an additional interface for protein interactions. At the C-terminus resides a conserved YRPW 
motif. The NLS and nuclear export sequence (NES) are located in the basic and orange domain 
respectively (Villaronga, Lavery et al. 2009; Lavery, Villaronga et al. 2011). Diagram adapted from 
(Fischer and Gessler 2007). 
 
1.4.2.1. Hey1, a bHLH –Orange transcriptional 
repressor 
 
The preferred DNA binding site for Hey1 proteins is the class B E-box 
sequence, CACGTG. N-box binding for Hey1 and Hey2 (which is the preferred 
sequence for Hes proteins) is very weak although binding to class C E-box sites 
(CACGCG) occurs when heterodimer Hey2/Hes1 is formed (Fischer and 
Gessler 2007). The HLH and orange domains mediate protein-protein 
interactions facilitating the recruitment of cofactors such as HDACs and/or 
Sin3A complexes and interactions with transcription factors often converting 
these into transcriptional repressors (Fischer and Gessler 2007). In contrast to 
b HLH Orange 
YPRW 
1 304 
NLS NES 
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the Hes family of proteins, which recruit corepressors TLE/Groucho via their C-
terminal WRPW motif, Hey proteins are unable to bind TLE proteins due to the 
tyrosine to tryptophan (Y ! W) exchange (Fischer and Gessler 2007). Instead, 
the transcriptional repressive activity of Hey proteins has been mapped to the 
bHLH domain. This activity was found to be associated with direct interaction 
with the mSin3A complex, which could indirectly recruit HDAC1. Transcriptional 
repression by Hey1 was also attributed to bHLH-mediated interaction with the 
NCoR corepressor (Iso, Sartorelli et al. 2001). In another study, Hey2 repressed 
its own gene expression by a HDAC1/II-independent mechanism and was later 
found to recruit SIRT1, an HDAC insensitive to TSA (Nakagawa, McFadden et 
al. 2000; Takata and Ishikawa 2003). In addition to HDAC-associated 
complexes, Hey proteins have also been demonstrated to interact with other 
transcription factors. For example, Hey1 was found to bind to the aryl 
hydrocarbon receptor nuclear transporter (ARNT) and was proposed to inhibit 
ARNT-dependent transcription from the VEGF promoter by mediating the 
release of the ARNT complex from DNA (Chin, Maemura et al. 2000). Both 
Hey1 and Hey2 have been reported to mediate repression of Myo-dependent 
transcription of the myogenin promoter through the sequestration of MyoD-E47 
complexes rendering them inactive. This repression was mapped to the Orange 
domain in Hey2 since neither the C-terminal or bHLH regions were required to 
mediate repression (Sun, Kamei et al. 2001). This illustrates the ability of Hey 
proteins to physically interact and antagonise the activity of other transcription 
factors. In fact, there have been few instances that implicate a role of DNA 
binding for Hey protein function. One such case is the binding of Hey1 to a 
putative E-box sequence within the proximal promoter of IL-6 resulting in 
repression of IL-6 transcription (Hu, Chung et al. 2008). Microarray expression 
and ChIPseq analyses studies in Hey1-inducible cell lines indicated Hey 
proteins act as direct transcriptional repressors and mutagenesis of putative 
class B E-box binding sites supported the notion of direct DNA binding. However 
only a fraction of Hey proteins bound box-E sequence sites suggesting Hey 
proteins can bind a more relaxed consensus sequence or depend on interacting 
proteins (Heisig, Weber et al. 2012). The microarray analysis also identified 
cases of gene activation. Since no direct Hey binding was associated with these 
genes, activation must be mediated by indirect/secondary mechanisms (Heisig, 
Weber et al. 2012).  
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1.4.2.2. Hey-family proteins are AR corepressors 
 
Characterisation of Hey1 as an AR corepressor commenced after Hey1 was 
identified to interact with the bHLH-PAS domain of SRC1 in a yeast two-hybrid 
screen (Belandia, Powell et al. 2005). Glutathione S-transferase (GST) pull 
down assays determined Hey1 could interact with the AF-1 region on the AR 
and repressed AF-1-mediated transcriptional activity. This repressive function of 
Hey1 was mapped to two distinct domains, the C-terminal portion and the N-
terminal bHLH region. Treatment with TSA completely reversed the repressive 
effects of a Hey1 mutant lacking the HLH domain but only partially reversed the 
repressive activity of full length Hey1 or C-terminal truncated Hey mutants 
indicating HLH-mediated repression was both class I/II HDAC-dependent and –
independent (Belandia, Powell et al. 2005). Results from other studies suggest 
Hey and Hes proteins can recruit HDAC1 using the bHLH domain and the C-
terminus while SIRT1 binds only to the bHLH domain (Takata and Ishikawa 
2003; Elagib, Xiao et al. 2004; Fischer, Klattig et al. 2005). This model presents 
a reasonable explanation for the Hey1-mediated AR repression. Hey1-mediated 
repression required both bHLH and C-terminal domains since the isolated 
domains failed to inhibit transcription from androgen-responsive promoters 
(Belandia, Powell et al. 2005). More recently, HeyL was found to be more potent 
than Hey1 or Hey2 in repressing AR activity and was not dependent on class I/II 
HDAC activity (Lavery, Villaronga et al. 2011). HeyL was also found to interact 
with the AF-1 region of AR and repressed its activity through this region too. 
Mutational analysis of AF-1 determined that deletion of either TAU1 or TAU5 
decreased repression of AR by HeyL. However, deletion of TAU5 resulted in a 
comparatively smaller decrease of repression than deletion of TAU1 suggesting 
TAU1 transactivation activity is the main region of AR which HeyL affects 
(Lavery, Villaronga et al. 2011). As discussed above, competition between 
coactivator and corepressor is also an important regulatory mechanism for AR 
activity. The functional significance of Hey1/HeyL or SRC1 binding to AF-1 is 
evident since both Hey1 and HeyL were able to compete with SRC1 for binding 
to AF-1 thereby blocking SRC1/AR interaction or sequestering SRC1 away from 
transcriptional complexes (Belandia, Powell et al. 2005; Lavery, Villaronga et al. 
2011). 
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1.5. Notch signalling 
 
1.5.1.  The Notch signalling pathway 
 
The Hey family of transcriptional repressor proteins are canonical targets of 
Notch signalling, an evolutionarily conserved local cell signalling pathway. Notch 
signalling regulates a variety of developmental processes that include cell fate 
specification, stem cell renewal, differentiation, proliferation, apoptosis, 
adhesion, epithelial mesenchymal transition (EMT), migration and angiogenesis 
(Moreno 2010). The Notch protein functions at the cell surface, receiving 
extracellular signals and in the nucleus, regulating gene expression. In 
mammals there are four Notch proteins (Notch 1-4) and five ligands, three 
Delta-like proteins (DLL 1, 3 and 4) and two Jagged proteins, Jagged1 and 
Jagged2 (Ranganathan, Weaver et al. 2011). Figure 6 summarises the 
activation of the Notch signalling pathway. In addition to the Hey protein family, 
downstream targets of Notch signalling include the Hes family of proteins, cyclin 
dependent kinase (CDK) inhibitor p21, cyclin D1, c-Myc, Bcl-2 as well as Notch 
receptors and ligands (Ranganathan, Weaver et al. 2011). 
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Figure 6. A basic outline of Notch signalling 
Delta-like and Jagged ligands and Notch are transmembrane proteins. Engagement of a Notch 
receptor with its ligand expressed on neighbouring cells initiates two successive cleavages in the 
signal-receiving cell: firstly by ADAM metalloproteinases at site S2 followed by intramembranous 
cleavage at site S3 by the protease γ-secretase. The S3 cleavage liberates the intracellular 
domain of Notch (Notchintra) and subsequently translocates to the nucleus. Prior to Notch 
activation, the transcriptional repressor, C protein binding factor 1/Suppressor of Hairless/Lag1 
(CSL) is bound to DNA along with other corepressors (CoR) such as SMRT/NCoR and HDAC1. 
Notchintra binds to CSL thus displacing the CoR complex and recruits coactivators (CoA) of the 
Mastermind-like (MAML) family, p300/CBP and other HATS converting the CSL complex into a 
transcriptional activator complex and driving Notch target genes. Target genes include Hes1, 
Hey1, cyclin D1, p21, c-Myc and Bcl-2 as well as Notch receptors and ligands. The activity of 
Notchintra is transitory since the signal is terminated with phosphorylation of the C-terminal PEST 
domain (red diamond) within Notchintra. This is followed by ubiquitination and Notchintra is targeted 
for proteasomal degradation. Adapted from (Lai 2004) (Ranganathan, Weaver et al. 2011).  
Delta-like/ 
Jagged 
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1.5.1.1. Hey proteins are Notch effector proteins 
 
In 2000, the Hey family of transcriptional repressor proteins in mouse and 
human were cloned and characterised as a subfamily of bHLH superfamily and 
shortly afterwards were identified as downstream effector proteins of Notch 
signalling alongside the Hes proteins (Steidl, Leimeister et al. 2000). The Hey 
genes are involved in transducing Notch signalling in a number of embryonic 
development pathways namely the cardiovascular system, angiogenesis, 
neurogenesis, gliogenesis and bone development (Davis and Turner 2001). Hey 
proteins are implicated in a wide-range of processes however it is beyond the 
scope of this thesis to comprehensively describe them all and so only key 
aspects in the biological activities of the Hey proteins will be discussed. 
 
All three Hey genes are active and expressed in the endocardium of the 
developing heart and blood vessels. A series of knockout mice have been 
generated to understand the molecular effects of Notch signalling in the heart. 
Hey1-/- and HeyL-/- mice are viable and show no apparent pathology (Fischer, 
Klamt et al. 2004; Fischer and Gessler 2007). However, Hey2-/- mice die within 
10 days of birth from defects in the ventricle septum and the combined loss of 
Hey1 and Hey2 results in embryonic death. These defects in double Hey null 
mice recapitulate phenotypes in Jagged1 and Notch1 knockout mice indicating 
Hey proteins are essential transducers of Notch signalling (Gessler, Knobeloch 
et al. 2002; Fischer, Klamt et al. 2004). Moreover, the combined Hey1/HeyL 
knockout animals have the same cardiac phenotypes as Hey2-/- mice suggesting 
all three Hey genes perform similar functions with partial redundancy between 
the family members (Fischer and Gessler 2007). Functional redundancy 
between the different Hey members at the target gene level was recently 
determined in vitro using ChIPseq analysis (Heisig, Weber et al. 2012). This 
may also be the case in the context of androgen signalling since no additive 
effects were observed with HeyL-induced repression of AR transcriptional 
activity when Hey1 or Hey2 were combined with HeyL (Lavery, Villaronga et al. 
2011).  
 
Hey1 has also been identified as a direct target of signalling induced from bone 
morphogenic protein (BMP) receptors. BMPs are members of the transforming 
growth factor-β (TGF-β) superfamily and play an important role in regulating 
osteoblast differentiation and bone formation. Hey1 is upregulated in the early 
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stages of osteogenic differentiation of mesenchymal stem cells in vitro and 
enhanced mineralisation of the bone matrix in vivo in response to BMP9. This is 
proposed to occur in synergy with Runx2, another Notch target (Sharff, Song et 
al. 2009). 
 
1.5.2.  Notch signalling and cancer 
 
Mutations in signalling pathways required for embryonic development often lead 
to the development of cancer. The presence of mutations or deregulation of the 
Notch pathway has been associated with a range of cancers. The prototypical 
Notch-associated cancer is human acute T-cell lymphoblastic/lymphoma (T-
ALL) which was originally associated with a chromosome translocation resulting 
in the expression of Notch1intra under the control of the T-cell receptor β 
promoter. This aberration is however rare and the majority of T-ALL have gain-
of-function mutations in Notch1 resulting in abnormal downstream signalling 
(Ranganathan, Weaver et al. 2011). A causative role of Notch signalling in the 
development of T-ALL is well established however evidence indicating that 
Notch signalling directly contributes to tumourigenesis of epithelial tissue 
remains elusive. While genetic alterations in Notch genes in solid tumours are 
uncommon, Notch signalling appears crucial in a number of tumours, including 
prostate, breast, colon, pancreas and cancers of the central nervous system 
(Ranganathan, Weaver et al. 2011). 
 
The outcome of altered Notch signalling is dependent on its normal function in a 
given tissue as well as interactions with the tumour microenvironment and 
crosstalk with other signalling pathways. Inappropriate activation of Notch 
signalling in tumourigenesis of solid tumours may occur by either the loss of 
negative regulators, indicating Notch has a tumour suppressor function or the 
deregulated expression of Notch receptor and ligands leading to aberrant 
activation of the pathway (Ranganathan, Weaver et al. 2011). Recent studies 
using T-ALL models have indicated Notch drives tumourigenesis by promoting 
cell cycle progression directing transcription of cyclin D1, c-Myc and Skp2. In 
glioma cells, Notch overexpression is observed which results in crosstalk and 
activation of the EGFR pathway since siRNA-mediated knockdown of Notch 
resulted in downregulation of EGFR as well as downstream signalling 
components including PI3K/AKT pathway, Ras and cyclin D1 (Xu, Qiu et al. 
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2010). In addition to activating cell proliferation and survival pathways, apoptosis 
is also inhibited as a consequence of a deregulated Notch pathway. In certain 
tumour types, PTEN activity is inhibited due to enhanced expression of the 
PTEN negative regulator, Hes1. As a consequence, enhanced PI3K/AKT 
signalling occurs which leads to the phosphorylation of the p53 negative 
regulator, HDM2 resulting in p53 inhibition (Nair, Somasundaram et al. 2003). In 
T-ALL, Notch activation also leads to the repression of the HDM2 negative 
regulator, p14ARF (Beverly, Felsher et al. 2005).  
 
In contrast, a tumour suppressor function for Notch has also been ascertained in 
a number of different tumour types. One of the first indications of this was in 
mouse keratinocytes where inactivation of Notch1 resulted in spontaneous and 
chemical-induced carcinogenesis in mouse skin (Nicolas, Wolfer et al. 2003). 
Inducible inactivation of Notch1 was also able to cause regenerative hyperplasia 
in mouse liver indicating loss of Notch signalling contributed factor to cancer 
progression in the liver. Consequently, overexpression of Notch1intra in a 
hepatocellular carcinoma model sensitised cells to p53-mediated apoptosis as a 
result blocking the AKT-HDM2 pathway and preventing proteasomal 
degradation of p53 (Wang, Qi et al. 2009; Ranganathan, Weaver et al. 2011). A 
further example comes from Ewing’s sarcoma, which develops in part, as a 
result of down-regulated Jagged1 expression and inhibition of Notch signalling 
as a result of EWS-FLI1, a fusion gene that has arisen from a chromosome 
translocation. Tumours retain wild-type p53 although it is poorly expressed as a 
consequence of the EWS-FLI1 oncogene. Knockdown of EWS-FLI1 was able to 
reactivate Notch signalling as demonstrated by Hey1 expression and increased 
p53 activity (Ban, Bennani-Baiti et al. 2008; Dotto 2009). The implication of 
Hey1 as regulator of p53 expression will be discussed later in this chapter. 
 
1.5.3.  Notch signalling and PCa 
 
1.5.3.1. Notch signalling in normal prostate 
development 
 
Notch signalling along with other developmental pathways including the AR, 
TGF-β, fibroblast growth factor (FGF), Hedgehog and Wnt play critical roles in 
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normal prostate development. Notch signalling regulates embryonic prostate 
development and postnatal prostate maturation. This was first shown using a 
Notch1-GFP transgenic mouse model where GFP was under the control of the 
Notch1 promoter. In situ hybridization demonstrated Notch1 activation was 
found in all cells of the epithelium at postnatal 3 days, however activity was 
down-regulated overtime and in the adult, GFP expression was only associated 
with the basal layer of prostate epithelium (Shou, Ross et al. 2001). The 
suggestion that Notch1 expression may be a significant characteristic of 
prostate progenitor cells was studied further using a transgenic mouse model 
that allowed the selective elimination of Notch1-expressing cells with a prodrug-
converting enzyme under the control of the Notch1 promoter. The ablation of 
Notch1-expressing cells resulted in inhibition of branching morphogenesis, 
growth and differentiation and prevented androgen-induced regrowth after 
castration (Wang, Shou et al. 2004). These data indicate Notch signalling 
elements are differentially expressed in the prostatic epithelium during postnatal 
prostate maturation and crucially, define Notch signalling in prostate 
development and regrowth. Furthermore it was subsequently established that 
Notch signalling is required for normal prostate epithelial proliferation and 
differentiation (Wang, Leow et al. 2006). Modulating Notch activity in early 
postnatal rat ventral prostates ex vivo with γ-secretase inhibitors resulted in 
reduced branching morphogenesis while staining with p63, an epithelial cell 
marker, revealed prostates treated with γ-secretase inhibitors exhibited less 
luminal and basal segregation. Prostates treated with inhibitors displayed a 
highly proliferative phenotype as well as co-expression of cytokeratin 8 and 14, 
markers that are normally mutually exclusive and are associated with luminal 
and basal cells respectively (Wang, Leow et al. 2006). This suggests Notch is 
essential for controlled prostate proliferation as well as effective differentiation. 
 
1.5.3.2. Notch signalling and PCa development 
 
Together with the requirement of Notch activity in normal prostate functioning, 
Notch signalling was also implicated as having a role in malignant prostate 
epithelial cells. In the transgenic adenocarcinoma of the mouse prostate 
(TRAMP) model, Notch1 was elevated in malignant prostate and metastatic 
epithelial cells. In PCa cells lines, Notch1 mRNA was expressed whereas Notch 
ligand expression was undetectable. By expressing constitutively active forms of 
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Notch1 in these cells Notch signalling was reactivated and resulted in cell 
growth inhibition (Shou, Ross et al. 2001). Later, the same group utilised a 
conditional Notch1 knockout mouse model and demonstrated Notch1 deletion 
was associated with a hyperplastic phenotype and prostate epithelial cells were 
in a predifferentiation development stage as indicated by the co-expression of 
cytokeratin 8 and 14 (Wang, Leow et al. 2006). This suggested disruption of 
Notch signalling might contribute to tumourigenesis since the Notch1 knockout 
model resembled the early stages of prostatic neoplasia (Wang, Leow et al. 
2006). Analysis of microarray data in the Gene Logic database found Notch1 
and its effector, Hey1 to be significantly lower in prostate adenocarcinoma 
compared with adjacent normal prostate tissue supporting the notion that Notch 
may play a tumour suppressive role (Wang, Leow et al. 2006). A more recent 
study concluded a similar outcome; Notch signalling was significantly 
downregulated in prostate adenocarcinoma foci since cleaved Notch1 was 
undetectable and Hey1 expression low compared with adjacent benign tissue 
(Whelan, Kellogg et al. 2009). 
 
In contrast another study found Notch1 ligand, Jagged1 to be overexpressed in 
human prostate tumour samples (Santagata, Demichelis et al. 2004). 
Previously, Jagged1 had been identified as an androgen-responsive gene in 
lymph node-derived LNCaP cells and this led to the interrogation of the 
comparative Jagged1 protein levels in benign tissue or tumour tissue from 
localised PCa or hormone- and refractory-metastatic PCa using 
immunohistochemistry (IHC). Jagged1 was significantly more highly expressed 
in localised PCa compared with benign tissue and in metastatic PCa compared 
with localised or benign tissue. Furthermore, increased Jagged1 expression 
correlated with PCa recurrence suggesting Jagged1 is involved in cancer 
progression (Santagata, Demichelis et al. 2004). In agreement with this, down-
regulation of Jagged1 in PCa cell lines correlated with inhibition of cell growth 
(Zhang, Wang et al. 2006). Notch1 is also overexpressed in osteoblastic 
prostate cancer metastatic cells compared with non-skeletal metastatic LNCaP 
and PC3 cells. Clinical samples of osteoblastic PCa metastases also express 
Notch1 (Zayzafoon, Abdulkadir et al. 2004). Together this suggests Jagged1 
and Notch1 are associated with PCa metastases and it is possible Jagged1-
mediated Notch1 activation could stimulate metastasis. In support of this 
hypothesis, inhibition of Notch signalling with a γ-secretase inhibitor or Notch1 
siRNA in a Notch-induced metastatic cells reduced PCa cell motility or invasion 
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respectively (Scorey, Fraser et al. 2006; Bin Hafeez, Adhami et al. 2009). In a 
different study, an increase in apoptosis and a decrease in migration and 
invasion were reported when Notch1 or Jagged1 activity was blocked. This 
effect was associated with inactivation of AKT, mTOR and nuclear factor-κB 
(NF-κB) (Wang, Li et al. 2010). These data suggest Notch may play an 
oncogenic role in PCa progression since inhibiting Notch signalling resulted in 
the growth inhibition of PCa cells. Nevertheless, Shou et al reported that 
introduction of constitutively active components of Notch signalling blocked cell 
growth while inhibitors of Notch activation enhanced proliferation. Furthermore, 
human PCa samples also demonstrate loss of Notch1 signalling as shown by a 
decrease in Hey1 and/or cleaved Notch expression suggestive of a tumour 
suppressor function. These contradictory findings for Notch signalling playing a 
tumour suppressor or oncogenic role may reflect the heterogeneity of PCa and 
Notch may play different roles within different tumour types at different stages of 
cancer progression (Leong and Gao 2008). 
 
1.5.3.3. Hey1 and cancer 
 
It is unsurprising that the essential and recognised role of Hey proteins in 
embryonic development translates to their association with the development of 
cancer. There is now a growing body of evidence that Hey1 is deregulated in 
cancers. The Hey1 gene is located on chromosome 8q21, which is amplified in 
a significant proportion of prostate tumours (DeMarzo, Nelson et al. 2003). In 
situ hybridisation of primary tumour microarrays revealed Hey1 to be 
upregulated in glioma and expression in glioblastoma multifome (GBM) 
correlating positively with tumour-grade and survival (Hulleman, Quarto et al. 
2009). pRb plays a crucial role in neurogenesis with neural precursor cells from 
pRb-/- mouse embryos exhibiting an increase in S-phase population and 
deregulated E2F activity. This underscores the alteration of the pRB/E2F 
pathway found in gliomas. Deregulated E2F activity was demonstrated to 
directly regulate Hey1 expression through E2F-binding sites present in the Hey1 
promoter. Moreover, ectopic expression of Hey1 in neural stem cells induced 
proliferation while knocking down Hey1 reduced growth suggesting Hey1 is an 
important factor in formation of GBM (Hulleman, Quarto et al. 2009).  
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Notch signalling has been implicated in modifying the EMT programme during 
embryogenesis and the signals responsible for stimulating EMT have also been 
associated with tumour invasion and metastasis. Fundamentally, EMT is a 
process by which cells from a primary epithelial tumour become mesenchymal 
and with that lose cell-adhesion and become motile. This model provides a 
method by which single cell carcinoma cells from primary epithelial tumours 
disseminate and facilitate metastasis. TGF-β signalling is involved in inducing 
EMT during development and is also reported to promote EMT in cancer cells 
allowing spread to other sites in vivo (Yang and Weinberg 2008). Hey1 has 
been identified as a direct target gene of TGF-β/SMAD signalling (Zavadil, 
Cermak et al. 2004). TGF-β stimulation of epithelial cells of mammary gland, 
kidney and epidermis resulted in Hey1 expression in a biphasic manner during 
the onset of EMT. The first phase of Hey1 expression was directed by SMAD3/4 
activating transcription from the Hey1 promoter while the second delayed wave 
of gene activation required Notch-dependent signalling with TGF-β signalling 
through SMAD3 and ERK/MAPK resulting in the expression of Jagged1. 
Silencing of Hey1 or Jagged1 blocked TGF-β-induced EMT preventing 
disassembly of E-cadherin adherens junctions (Zavadil, Cermak et al. 2004). 
This suggests that the coordinated expression of Hey1 by Notch and TGF-β 
signalling pathways are important for EMT, a process also observed in 
advanced tumourigenesis.  
 
The role of Hey1 functioning as a tumour suppressor was derived after a 
genome-wide screen for potential p53 regulators revealed Hey1 as positive 
regulator of p53. Overexpression of Hey1 in HCT116p53+/+ cells resulted in 
increased p53 activity due to a decrease in human homolog of murine double 
minute 2 (HDM2) expression at the transcriptional level thus blocking HDM2-
mediated degradation of p53. Hey1 was found not to bind to E-box or N-box 
sequences within the HDM2 promoter suggesting repression by Hey1 was 
independent of its DNA-binding abilities (Huang, Raya et al. 2004) and more 
likely to be a consequence of recruiting other HLH proteins, corepressors or 
HDAC proteins to the transcription complex. Evidence of Hey1 as a tumour 
suppressor was attained after ectopic expression of Hey1 in zebrafish increased 
p53 levels and induced apoptosis. In avian embryos, overexpression of Hey1 
resulted in truncation of developing wings. Furthermore, Hey1 was able to 
overcome Ras- and Myc-induced transformation of mouse embryonic fibroblast 
(MEF) cells in a p53-dependent manner but was ineffective in supressing 
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transformation in p53-deficient MEFs (Huang, Raya et al. 2004). Hey1-
dependent p53 activation was later demonstrated in Ewing’s sarcoma when 
knockdown of the EWS-FL1 fusion protein reactivated Notch signalling resulting 
in Hey1 expression, enhanced p53 activity and cell cycle arrest (Ban, Bennani-
Baiti et al. 2008). 
 
Recent studies investigating the ability of Hey1 to activate p53 signalling have 
been extended to include Hey1 with a naturally occurring non-synonymous 
polymorphism (SNP) present in 1% of the population. This SNP results in a 
leucine substitution to methionine at codon 94 (L94M) in the bHLH domain of 
Hey1. The SNP resulted in L94M acting as a coactivator of AR and was also 
unable to stimulate a p53-responsive reporter gene (Villaronga, Lavery et al. 
2009). Functional differences between Hey1 and L94M were examined by stably 
expressing inducible Hey1 or L94M in human osteosarcoma U2OS cells. 
Induction of Hey1 expression was found to inhibit cell proliferation and induce 
growth arrest concomitant with an increase in p53 expression whereas 
expression of L94M did not perturb cell homeostasis. Furthermore Hey1-
mediated increase in p53 activity was able to sensitise U2OS cells to cisplatin or 
doxorubicin in contrast to L94M, which had no effect on the sensitivity of cells to 
the cytotoxic drugs (Villaronga, Lavery et al. 2009). These results may have 
important implications in the outcome of cellular response to anticancer drugs 
for patients with this polymorphism. Since half of human cancers express wild-
type p53, it has been postulated that L94M could contribute to oncogenic 
transformation in a proportion of tumours. 
 
1.5.3.4. Hey1 and PCa 
 
As discussed previously, Hey1 expression as assessed by microarray and IHC 
found Hey1 to be significantly down regulated compared with normal tumour-
adjacent prostate tissue (Wang, Leow et al. 2006; Whelan, Kellogg et al. 2009). 
Wang et al also assessed the level of other Notch signalling components; Notch 
receptors (Notch 2, Notch3, and Notch4), Notch ligands (DLL1, Jagged1 and 
Jagged2) and downstream target genes (Hes1, Hes4, Hes6 and Hey2) and 
found equivalent mRNA levels to be expressed between normal and cancerous 
PCa tissue (Wang, Leow et al. 2006) implying Hey1-mediated Notch signalling 
may play a potential role in inhibiting prostate tumourigenesis. In contrast, 
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another study did not report a change in total Hey1 protein levels in cancerous 
prostate tissue but reported a difference in the subcellular localisation of Hey1. 
In 8 out of 10 PCa tumours, Hey1 protein expression was confined to the 
cytoplasm whereas in 13 out of 14 benign prostatic hyperplasia tissue samples, 
Hey1 was detected in both the cytoplasmic and nuclear compartments with the 
majority showing greater nuclear Hey1 expression (Belandia, Powell et al. 
2005). Later, another study determined HeyL was also excluded from the 
nucleus in human PCa tumour specimens with a concomitant increase in 
cytoplasmic expression in contrast to benign samples, where HeyL expression 
was exclusively nuclear (Lavery, Villaronga et al. 2011). These observations 
have led to the proposal that exclusion of Hey1 from the nucleus results in a 
reduction of this transcriptional repressor in the nucleus and consequently a 
decrease in the repression of target genes (Belandia, Powell et al. 2005; Powell, 
Brooke et al. 2006). The aberrant localisation of Hey1 and HeyL to the 
cytoplasmic compartment may be a mechanism to circumvent the repressive 
effects of nuclear Hey proteins and contribute to the development of androgen-
independence (Powell, Brooke et al. 2006; Lavery, Villaronga et al. 2011).  
Manipulation of the NLS sequence within Hey1 provided an insight into its 
effects on AR transcriptional activity when localised in the cytoplasm. Mutation 
of the NLS converted Hey1 to an AR transcriptional coactivator whereas the 
coactivation function of the Hey1 mutant, L94M was not altered (Villaronga, 
Lavery et al. 2009). This suggests that the mislocalisation of Hey1 and HeyL 
through undetermined mechanisms might contribute to disease progression 
thereby enhancing AR transcriptional activity. We and others have screened 
PCa AR-positive cells for Hey1 and HeyL expression and have found very low 
levels of mRNA transcripts for these proteins suggesting a loss of expression 
may have occurred during malignant progression (Lavery, Villaronga et al. 
2011)(Dr S.C. Cheong, unpublished observations). 
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1.6. Adenoviruses 
 
1.6.1.  Adenovirus classification 
 
Adenoviruses were first isolated in 1953 from human adenoids. They form part 
of the Adenoviridae family of viruses which can be divided into four genera: 
Mastadenovirus, Aviadenovirus, Atadenovirus and Siadenovirus. These 
classifications are based on the hosts for the viruses; viruses of the 
Mastadenovirus infect mammals, Aviadenovirus infect birds while the other two 
genera have a broader host range, which include reptiles and amphibians 
(Davison, Benko et al. 2003). Human adenoviruses fall into the Mastadenovirus 
genus and more than 52 different human adenovirus serotypes have been 
identified. These have been classified into seven different species according to 
biological, physiochemical and genetic properties (Table 2). Human 
adenoviruses are not considered to be highly pathogenic and generally cause 
self-contained disease such as respiratory infections, haemorrhagic cystitis and 
gastroenteritis. Ocular infections are also a principal cause of viral conjunctivitis. 
However, the incidence of adenoviral infections causing life-threatening disease 
is on the increase due to immunocompromised individuals as a consequence of 
transplantation in conjunction with immunosuppressive therapy and the HIV 
epidemic (Lenaerts, De Clercq et al. 2008). The most widely studied are 
adenoviruses from Group C, the closely related serotypes 2 and 5 (Ad2 and 
Ad5) and for this reason have been most commonly used for the development of 
viral gene therapy vectors (other serotypes have also been used). 
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Table 2. Classification human adenoviruses based on biological and physiochemical 
properties. 
 
CAR; Coxsackie adenovirus receptor, CD; cluster of differentiation, DPPC; diapalmitoyl 
phosphatidylcholine, FIX; coagulation factor IX, FX; coagulation factor X, HSPG; Heparan sulfate 
proteoglycans, Lf; lactoferrin, MHC1-α2; major histocompatibility complex 1- α2 domain, SA; sialic 
acid, VCAM-1; vascular cell adhesion molecule 1, ND; Not determined, DSG-2; Desmoglein-2 
(Wang, Li et al. 2011). Based on a table within Arnberg 2009. 
 
1.6.2.  Adenovirus structure 
 
1.6.2.1. The viral capsid 
 
Adenoviruses are non-enveloped, lytic, double-stranded DNA viruses. They 
have an icosahedral morphology made up of three primary capsid proteins and 
four minor proteins (Figure 7). The homotrimeric hexon protein is the most 
abundant with 240 on the faces and edges of the capsid, with a penton base 
residing at each of the 12 apices. From each penton base extends a trimeric 
fiber protein composed of three polypeptide (p) IV molecules consisting of of an 
N-terminal tail, a central shaft and a C-terminal knob region. The N-terminal 
region is attached to the penton via non-covalent interactions. Also associated 
with penton are five copies of the minor capsid protein, pIIIa which is located at 
Species Serotypes Receptors(s) Tropism Disease 
A 12, 18, 31 CAR, FIX, FX Cryptic (enteric and respiratory) 
Mainly 
asymptomatic 
B1 3, 7, 16, 21, 50 
CD46, DSG-2, 
FX, CD80, 
CD86 
Respiratory, 
ocular 
Respiratory and 
ocular diseases 
B2 11, 14, 34, 35 
CD46, DSG-2, 
FX, CD80, 
CD86 
Renal, ocular, 
respiratory 
Respiratory 
diseases 
C 1, 2, 5, 6 
CAR, FIX, FX, 
Lf, DPPC, 
VCAM-1, 
HSPG, MHC1-
α2 
Respiratory, 
ocular, 
lymphoid, 
Ocular 
diseases 
D 
8-10, 13, 15, 
17, 19, 20, 
22-30, 32, 33, 
36-39, 42-49, 
51 
SA, CD46, 
CAR, fx Ocular (enteric) 
Ocular 
diseases 
E 4 CAR Ocular, respiratory 
Respiratory and 
ocular diseases 
F 40, 41 CAR Enteric Gastroenteritis 
G 52 ND Enteric Gastroenteritis 
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the base of the penton. Other minor capsid proteins, pVI and pVIII bind hexon 
proteins on their underside although their exact locations have been difficult to 
resolve. pVIII is thought to provide a bond between hexons and the rest of the 
capsid while pIX stabilises interactions between adjacent hexons. Core proteins 
include pV and pVII, which associate with the viral DNA. The specific functions 
of pV remain unclear however in Ad5-infected cells it is directed to the nucleus 
and nucleolus and may facilitate dissociation of core proteins along with pre-pVII 
thereby revealing the viral DNA for replication/transcription. pVII, may play a role 
in mediating of nuclear import of the viral DNA, dampening early viral 
transcription and facilitating viral assembly at the end of the adenoviral life cycle. 
The function of another core protein, Mu is largely unknown however it can 
duplicate the nucleolar functions of pV and as part of a precursor (preMu) it may 
modulate the shift between early protein and late protein expression. The virion 
also contains approximately 10 copies of the adenovirus cysteine proteinase 
associated with viral DNA within the core. The protease is an essential feature 
of the virion; a defective mutant could not advance beyond initial stages of 
infection. In the latter stages of infection it is also required for cleaving structural 
proteins during virion maturation. Another core protein, IVa2 present in only a 
few copies, binds to the left hand end of the viral DNA and the major late 
promoter (MLP) via repeat sequences in the DNA. It mediates encapsidation 
along with pVII and the non-structural protein, L4 22K. IVa2 also regulates the 
switch to late transcription. The final structural protein, the terminal protein (TP) 
is covalently attached to the 5’ DNA termini. TP is made from precursor, pTP 
and serves as a primer for DNA replications as well as mediate binding of the 
viral genome to the nuclear matrix (Shenk 2001; Russell 2009). 
  
 81 
 
Figure 7. Adenovirus structure 
A schematic representation of the structure based on cryo-electron microscopy and 
crystallography. Image taken from Russell 2009. 
 
1.6.2.2. Genome organisation 
 
In 1984, Ad2 was the first adenovirus genome to be completely sequenced and 
Ad5 followed in 1992 and is 35935 base pairs (bp) in length. The linear, double-
stranded DNA molecule is characterised by inverted terminal repeats (ITR) 
which allow single stranded DNA to circularise by complementary base pairing 
with ITR sequences. This is important in forming panhandles, which is required 
for the replication of viral DNA (Shenk 2001). The genome also contains two 
origins of replication and one is present in each ITR. Additionally, a cis-acting 
packaging sequence situated at the left terminus, which interacts with structural 
proteins to direct the encapsidation of progeny virion (Shenk 2001). 
 
Adenovirus transcription can be categorised as a two-stage event, early and late 
occurring before and after DNA replication respectively (Figure 8). The viral 
chromosome is subdivided into five early transcription units (E1A, E1B, E2, E3 
and E4), which prepare the infected cell for efficient viral replication and modify 
the host immune response to the infected cells. Two delayed early units (IX and 
IVa2) are expressed shortly after the early genes and regulate transcription of 
late genes. The late genes are transcribed into a primary transcript from the 
major late promoter which its then processed into five families (L1 to L5). All 
penton bases and extended fibres on the 12 fivefold apices.
Other so-called ‘minor’ components: IIIa, VI, VIII and IX
are also associated with the capsid (Vellinga et al., 2005).
There are six other structural components situated in the
virus core, five are associated with the double stranded DNA
genome [V, VII, Mu, IVa2 and the terminal protein (TP)],
the remaining component is the 23K virion protease which
plays a vital role in the assembly of the virion (see below).
Most of the detailed structural analyses have been carried
out using human serotypes, although a recent study of
canine adenovirus 2 has indicated that, while the basic
features are retained, the capsid of the canine virus is much
smoother and the fibre is more complex (Schoehn et al.,
2008). A recent structural analysis of an atadenovirus by
cryo-electron microsco y has indicated that ther are some
differences from mastadenoviruses in capsid topology, but
the main characteristic adenovirus morphology is retained
(Pantelic et al., 2008). A more detailed description of these
structural proteins is given below as a forerunner for
consideration of their role in infection.
Hexon
The hexon capsomere is a pseudo-hexagonal trimer situated
on the 20 facets of the icosahedral capsid created by
threefold repetition of two b-barrels at the base of each
hexon molecule. The pseudo-hexagonal base allows close
alignment within the facets and there are three tower
regions that are presented to the exterior. There are 240
hexons in the capsid. Because of their different environ-
ments there are four kinds of hexon – designated H1, H2,
H3 and H4 (Burnett, 1985). Sixty H1 hexons associate
with the pentons at the 12 apices and are also termed
peripentonal hexons (Fig. 2a). The remaining hexons are
designated ‘groups of nine’ or GONs on the 20 faces of the
icosahedron and are further defined as H2 (on the twofold
axes), H3 (on the threefold axes) and the remaining ones as
H4 (Fig. 2a).
The size of the hexon molecule can vary with the serotype –
the largest described is from Ad2 and comprises 967 aa. Up
to nine hypervariable regions, determined by comparative
sequence analysis of serotypes, are present in each hexon
molecule. These are situated at the top of the molecule and
six can be resolved as a-helical rods in the 6 A˚ structure
(Saban et al., 2006). These relate to the type-specific
antigens of the hexon and at least one of them constitutes
the major part of the virus-neutralizing activity (Crawford-
Miksza & Schnurr, 1996; Pichla-Gollon et al., 2006; Roberts
et al., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
The base of each hexon molecule has one loop and two
eight-stranded ‘jelly rolls’ which provide the means for
interacting with neighbouring capsomeres, probably via
charged residues in interacting loops. There must be
considerable flexibility in these interactions given the
differing environments of the H1 to H4 hexons. The N
and C termini lie beneath the base and do not seem to take
part in interactions with other hexo s.
Penton
The penton capsomer is a covalent complex of two
proteins – the homopentameric penton base and the
homotrim ric fibre protein protrud g from the 12 vertices
of the icosahedron (Fig. 1). The fibre has three distinct
regions: tail, shaft and knob.
The penton base monomer in Ad2 comprises 471 aa and
its pentameric structure (Fig. 3b) has been determined to
3.3 A˚ (0.33 nm; Zubieta et al., 2005) and consists of two
domains: the lower one with the typical jelly roll of two
four-stranded anti-parallel b-sheets forming a b-barrel, and
the upper one with irregular folds formed by two insertions
arising from the lower jelly roll strands. The first insertion
contains the RGD loop (discussed later) and the other a
loop which is variable between serotypes. Pentamerization
can occur, providing stability by the burying of hydro-
phobic surfaces. A pore occurs along the fivefold axis of the
pentamer and the top n rrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A schematic depiction of the
structure based on cryo-electron microscopy and crystallography.
The locations of the capsid and minor components are reasonably
well defined and are not to scale. The disposition of the core proteins
and the virus DNA is largely conjectural. The symbols for IIIa and VIII
are based on the structures defined by Saban et al. (2006).
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are also associated with the capsid (Vellinga et al., 2005).
There are six other structural components situated in the
virus core, five are associated with the double stranded DNA
genome [V, VII, Mu, IVa2 and the terminal protein (TP)],
the remaining component is the 23K virion protease which
plays a vital role in the assembly of the virion (see below).
Most of the detailed structural analyses have been carried
out using human serotypes, although a recent study of
canine adenovirus 2 has indicated that, while the basic
features are retained, the capsid of the canine virus is much
smoother and the fibre is more complex (Schoehn et al.,
2008). A recent structural analysis of an atadenovirus by
cryo-electron microscopy has indicated that there are some
differences from mastadenoviruses in capsid topology, but
the main characteristic adenovirus morph logy is retained
(Pantelic et al., 2008). A more detailed description of these
structural proteins is given below as a forerunner for
consideration of their role in infection.
Hexon
The hexon capsomere is a pseudo-hexagonal trimer situated
on the 20 facets of the icosahedral capsid created by
threefold repetition of two b-barrels at the base of each
hexon molecule. The pseudo-hexagonal base allows close
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regions that are presented to the exterior. There are 240
hexons in the capsid. Because of their different environ-
ments there are four kinds of hexon – designated H1, H2,
H3 and H4 (Burnett, 1985). Sixty H1 hexons associate
with the pentons at the 12 apices and are also termed
peripentonal hexons (Fig. 2a). The remaining hexons are
designated ‘groups of nine’ or GONs on the 20 faces of the
icosahedron and are further defined as H2 (on the twofold
axes), H3 (on the threefold axes) and the remaining ones as
H4 (Fig. 2a).
The size of the hexon molecule can vary with the serotype –
the largest described is from Ad2 and comprises 967 aa. Up
to nine hypervariable regions, determined by comparative
sequence analysis of serotypes, are present in each hexon
molecule. These are situated at the top of the molecule and
six can be resolved as a-helical rods in the 6 A˚ structure
(Saban et al., 2006). These relate to the type-specific
antigens of the hexon and at least one of them constitutes
the major part of the virus-neutralizing activity (Crawford-
Miksza & Schnurr, 1996; Pichla-Gollon et al., 2006; Roberts
et al., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
The base of each hexon molecule has one loop and two
eight-stranded ‘jelly rolls’ which provide the means for
int racting with neighbouring capsomeres, probably via
charged residues in interacting loops. There must be
considerable flexibility in these interactions given the
differing environments of the H1 to H4 hexons. The N
and C termini lie beneath the base and do not seem to take
part in interactions with other hexons.
Penton
The penton capsomere is a covalent complex of two
proteins – the homopentameric penton base and the
homotrimeric fibre protein protruding from the 12 vertices
of the icosahedron (Fig. 1). The fibre has three distinct
regions: tail, shaft and knob.
The penton base monomer in Ad2 comprises 471 aa and
its pentameric structure (Fig. 3b) has been determined to
3.3 A˚ (0.33 nm; Zubieta et al., 2005) and consists of two
domains: the lower one with the typical jelly roll of two
four-stranded anti-parallel b-sheets forming a b-barrel, and
the upper one with irregular folds formed by two insertions
arising from the lower jelly roll strands. The first insertion
contains the RGD loop (discussed later) and the other a
loop which is variable between serotypes. Pentamerization
can occur, providing stability by the burying of hydro-
phobic surfaces. A pore occurs along the fivefold axis of the
pentamer and the top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A schematic depiction of the
structure based on cryo-electron microscopy and crystallography.
The locations of the capsid and minor components are reasonably
well defined and are not to scale. The disposition of the core proteins
and the virus DNA is largely conjectural. The symbols for IIIa and VIII
are based on the structures defined by Saban et al. (2006).
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penton bases and extended fibres on the 12 fivefold apices.
Other so-called ‘minor’ components: IIIa, VI, VIII and IX
are also associated with the capsid (Vellinga et al., 2005).
There are six other structural components situated in the
virus core, five are associated with the double stranded DNA
genome [V, VII, Mu, IVa2 and the terminal protein (TP)],
the remaining component is the 23K virion protease which
plays a vital role in the assembly of the virion (see below).
Most of the detailed structural analyses have been carried
out using human serotypes, although a recent study of
canine adenovirus 2 has indicated that, while the basic
features are retained, the capsi of the canine virus is much
smoother and the fibre is more complex (Schoehn et al.,
2008). A recent structural analysis of an atadenovirus by
cryo-electron microscopy has indicated that there are some
differences from mastadenoviruses in capsid topology, but
the main characteristic adenovirus morphology is retained
(Pantelic et al., 2008). A more detailed description of these
structural proteins is given below as a forerunner for
consideration of their role in infectio .
Hexon
The hexon capsomere is a pseudo-hex gonal trime si uated
on the 20 face s of the icosahedral capsid cr ated by
threefold repetition of two b barrels at the b se of each
hexon molecule. The pseudo-hexagonal b s allows clos
ali nment within the facets and there are th e tower
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ments there are four kinds of hexon – designated H1, H2,
H3 and H4 (Burne t, 1985). Sixty H1 hexons associate
with the pentons at the 1 apices and are also termed
p ripentonal hexons (Fig. 2a). The remaining hexons are
designated ‘groups of nine’ or GONs on the 20 faces of the
icosahedron and are further defined as H2 (on the twofold
axes), H3 (on the threefold axes) and the remaining ones as
H4 (Fig. 2a).
The size of the hexon molecule can vary with the serotype –
the largest described is from Ad2 and comprises 967 aa. Up
to nine hypervariable regions, determined by comparative
sequence analysis of serotypes, are present in each hexon
molecule. These are situated at the top of the molecule and
six can be resolved as a-helical rods in the 6 A˚ structure
(Saban et al., 2006). These relate to the type-specific
antigens of the hexon and at least one of them constitutes
the major part of the virus-neutralizing activity (Crawford-
Miksza & Schnurr, 1996; Pichla-Gollon et al., 2006; Roberts
et al., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
The base of each hexon molecule has one loop and two
eight-stranded ‘jelly rolls’ which provide the means for
interacting with neighbouring capsomeres, probably via
charged residues in interacting loops. There must be
considerable flexibility in these interactions given the
differing environments of the H1 to H4 hexons. The N
and C termini lie beneath the base and do not seem to take
part in interactions with other hexons.
Penton
The penton capsomere is a covalent complex of two
proteins – the homopentameric penton base and the
homotrimeric fibre protein protruding from the 12 vertices
of the icosahedron (Fig. 1). The fibre has three distinct
regions: tail, shaft and knob.
The penton base monomer in Ad2 comprises 471 aa and
its pentameric structure (Fig. 3b) has been determined to
3.3 A˚ (0.33 nm; Zubieta et al., 2005) and consists of two
domains: the lower one with the typical jelly roll of two
four-stranded anti-parallel b-sheets forming a b-barrel, and
the upper one with irregular folds formed by two insertions
arising from the lower jelly roll strands. The first insertion
contains the RGD loop (discussed later) and the other a
loop which is variable between serotypes. Pentamerization
can occur, providing stability by the burying of hydro-
phobic surfaces. A pore occurs along the fivefold axis of the
pentamer and the top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A schematic depiction of the
structure based on cryo-electron microscopy and crystallography.
The locations of the capsid and minor components are reasonably
well defined and are not to scale. The disposition of the core proteins
and the virus DNA is largely conjectural. The symbols for IIIa and VIII
are based on the structures defined by Saban et al. (2006).
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penton bases nd exte ded fibres o the 12 five old apices.
Other -called ‘minor’ components: IIIa, VI, VIII and IX
are also associated with the c psid (Velli ga et al., 2005).
There are six other tructural components situated in the
virus core, five are associated with double stranded DNA
genome [V, VII, Mu, IVa2 and the term nal protein (TP)],
the remaining component i the 23K virion protease which
plays a vital rol in the assembly of the virion (se below).
Most of the d tailed structural nalyses h v b en carri d
out using human serotypes, although a recent study of
canine adenovirus 2 has indicated that, while the basic
features a e retained, the capsid of the canine virus is much
smoother and the fibre is more complex (Schoehn et al.,
2008). A recent st uctural analysis of an tad novirus by
cryo-electron microscopy has indicated that there are some
diff rences fr m mastadenoviruses in capsid t pology, but
the main characteristic aden virus morphology is retained
(Pantelic et al., 2008). A more detailed description of these
structural proteins is giv n below as a forerunner for
consideration of their role in infection.
Hexon
The hexon capsomere is a pseudo-hexagonal trimer situated
on the 20 facets of the icosahedral capsid created by
threefold repetition of two b-barrels at the base of each
hexon olecule. The pseudo-hexagonal base allows close
alignment within the facets and there are three tower
regions that are presented to the exterior. There are 240
hexons in the capsid. Because of their different environ-
ments there are four kinds of hexon – designated H1, H2,
H3 and H4 (Burnett, 1985). Sixty H1 hexons associate
with the pentons at the 12 apices and are also termed
peripentonal hexons (Fig. 2a). The remaining hexons are
designated ‘groups of nine’ or GONs on the 20 faces of the
icosahedron and are further defined as H2 (on the twofold
axes), H3 (on the threefold axes) and the remaining ones as
H4 (Fig. 2a).
The size of the hexon molecule can vary with the serotype –
the largest described is from Ad2 and co prises 967 aa. Up
to nine hypervariable regions, determined by comparative
sequence analysis of serotypes, are present in each hexon
molecule. These are situated at the top of the molecule and
six can be resolved as a-helical rods in the 6 A˚ structure
(S ban et al., 2006). These relate to the type-specific
antigens of the hexon and at least one of them constitutes
the major part of the virus-neutralizing activity (Crawford-
Miksza & Schnurr, 1996; Pichla-Gollon et al., 2006; Roberts
et ., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
The base of each h xon molecule as ne loop and two
eight-stranded ‘jelly rolls’ which provide the means for
inter cting with neighbouring capsomeres, probably via
charged residues in interacting loops. There must be
considerable flexibility in thes interactions given the
differing environments of the H1 to H4 hex ns. The N
and C termini lie be eath the base and do not seem to take
part in interactions with other hexons.
Penton
The p nton capsomere is a covalent complex of two
proteins – the homopentame ic penton base and the
homotrimeric fibre protein protruding from the 12 v rtices
of the icosahedron (Fig. 1). The fibre has three distinct
regions: t il, shaft and knob.
The penton base monom r in Ad2 compris s 471 aa and
its pentameric struct re (Fig. 3b) has been eterm ned to
3.3 A˚ (0.33 nm; Zubieta et al., 2005) and consists f two
domain : the lower one with the typical jelly roll of two
four-stranded anti-parall l b-sheets forming a b-barrel, and
the upper one with irregular folds forme by two in ertions
arising from the lower jelly roll stran s. The first ins rtion
contains the RGD loop (discussed later) and the other a
loop which is variable between serotypes. Pentamerization
can ccur, providing stability by the bury ng of hydr -
phobic surfaces. A pore occurs long the fivefold axis of the
pentamer and the top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A schematic depiction f the
structure based on cryo-electron icros py a d crystallography.
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penton bases and extended fibres on the 12 fivefold pices.
Other so-called ‘minor’ components: IIIa, VI, VIII and IX
are also associated with th capsid (Vellinga et al., 2005).
There are six other structural components situated in the
virus core, five are associated with the double stranded DNA
genome [V, VII, Mu, IVa2 and the terminal protein (TP)],
the remaining component is the 23K virion protease which
plays a vital role in the assembly of the virion (see below).
Most of the detailed structural analyses have been carried
out using human serotypes, although a recent study of
canine adenovirus 2 has indicated that, while the basic
features are retained, the capsid of the c in virus is much
smoother and the fibre is more complex (Schoehn et al.,
2008). A recent structural analysis of an atadenovirus by
cryo-electron microscopy has indicated that there are some
differences from mastadenoviruses in capsid topology, but
the main characteristic adenovirus morphology is retained
(Pantelic et al., 2008). A more detailed description of these
structural proteins is given below as a forerunner for
consideration of their role in infection.
Hexon
The hexon capsomere is a pseudo-hexago l trimer situated
on the 20 facets of the icosahedral c psid cre ted by
threefold repetition of two b-barrels at the base of each
hexon molecule. The pseudo-hexag nal base allows close
alignment within the facets and there ar three tower
regions that are present d to the ext rio . There are 240
hexons in the capsid. Because of their different environ-
ments there are four kinds of hexon – designated H1, H2,
H3 and H4 (Burnett, 1985). Sixty H1 hexons associate
with the pentons at the 12 apices and are also termed
peripentonal hexons (Fig. 2a). The remaining hexons are
designated ‘groups of nine’ or GONs on the 20 faces of the
icosahedron and are further defined as H2 (on the twofold
axes), H3 (on the threefold axes) and the remaining ones as
H4 (Fig. 2a).
The size of the hexon molecule can vary with the serotype –
the largest described is from Ad2 and comprises 967 aa. Up
to nine hypervariable region , determined by comparativ
sequence analysis of serotypes, are present in each hexon
molecule. These are situated at the top of the molecule and
six can be resolved as a-helical rods in the 6 A˚ structure
(Saban et al., 2006). These late to the type-specific
antigens of the hexon and at least on of them constitutes
the major part of the virus-neutralizing activity (Crawford-
Miksza & Schnurr, 1996; Pichla-Gollon et al., 2006; Roberts
et al., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
The base f each hexon molecule has one loop and two
eight-stranded ‘jelly rolls’ which provide the means for
interacting with neighbouring capsomeres, probably via
charged residues in interacting loops. There must be
considerable flexibility in these interactions given the
differing environments of the H1 to H4 hexons. The N
and C termini lie beneath the base and do not seem to take
part in interactions with other hexons.
Pe on
The penton capsomere is a covale complex of two
proteins – the homop nt meric penton base and the
homotrimeric fibre protein pr truding from th 12 vertices
of the icosahedron (Fig. 1). The fibre has three disti ct
regions: tail, shaft and knob.
The penton base monomer in Ad2 comprises 471 aa and
its pentam ric structure (Fig. 3b) has been determined to
3.3 A˚ (0.33 nm; Zubieta et al., 2005) and consists of two
domains: the lower one with the typical jelly roll of two
four-stranded anti-parallel b-sheets forming a b-barrel, and
the upper one with irregular folds formed by two insertions
arising from the lower jelly roll strands. The first insertion
contains the RGD loop (discussed later) and the other a
loop which is variable between serotypes. Pentamerization
can occur, providing stability by the burying of hydro-
phobic surfaces. A por occurs along the fivefold axis of the
pentamer and the top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A sche atic depiction of the
structure based on cryo-electron microscopy and crystallography.
The locations of the capsid and minor c mponents are reasonably
well defined and are not to scale. The disposition of the core proteins
and the virus DNA is largely conj ctural. The symbols for IIIa and VIII
are based on the structures d fined by Saban et al. (2006).
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e t ases a exte ded fibres on the 12 fivefold apices.
t r s - ll ‘ i r’ co ponents: IIIa, VI, VIII and IX
l s i te it the capsid (Vellinga et al., 2 05).
si t er str ctural co ponents situated in the
, fi re ass ciated ith the double stranded DNA
[ , II, , I a2 and the ter inal protein (TP)],
i i ent is the 23K virion protease which
it l r le i t e asse bly of the virion (s e below).
f t t ile structural analyses have b n ca ried
i serotypes, although a recent study of
ir s 2 as indicated that, while the basic
f t r t i e , t e capsid of the ca ine virus is much
s t r t e fi re is ore co plex (Schoehn et al.,
). rece t str ct ral analysis of an atadenovirus by
cryo-electro icroscopy has indicated that there are some
differences fro astadenoviruses in capsid topology, but
the ain cha acteri tic adenovirus orphology is retained
(Pantelic et al., 2008). A ore detailed description of these
structural proteins is given below as a forerunner for
consideration of their role in infection.
Hexon
The hexon c psomere is a pseudo-hexagonal trim r situated
on the 20 facets f the ic sahedral capsid created by
threefold repetition of two b-barrels at the base of each
hexon molecule. The p eudo-hexagonal base allows close
alignment within the facets and there are three tower
regions that are presented to the exterior. There are 240
hexons in the capsid. Because of their different environ-
ments there are four kinds of xon – designat d H1, H2,
H3 and H4 (Burnett, 1985). Sixty H1 hexons associate
with the pentons at the 12 apices and are also t ed
peripentonal hexons (Fig. 2 ). The remaining hexons are
designated ‘groups of nine’ or GONs on the 20 faces of the
icosahedron and are further defined as H2 (on the twofold
axes), H3 (on the threefold axes) and the remaining ones as
H4 (Fig. 2a).
The size of the hexon molecule can vary with the serotype –
the largest described is from Ad2 and comprises 967 aa. Up
to nine hypervariable regions, determined by comparative
sequence analysis of serotypes, are present in each hexon
molecule. These are situated at the top of the molecule and
six can be resolv d as a-helical rods in the 6 A˚ structure
(Saban et al., 2006). These relate to the type-specific
antigens of the hexo and at least one of them constitutes
the major part of the virus-neutralizing activity (Crawf rd-
Miksza & Schnurr, 1996; Pichla-Gollon et al., 2006; Roberts
et al., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
The base of each hexon molecule has one loop and two
ight-str nded ‘jelly rolls’ which provide the means for
inter cting with neig bouri g capsomer s, probably via
ch rg residues in interacting loops. Th re ust b
consi rabl flexibility in th se interactions given the
differing environments of the H1 to H4 hexons. The N
and C term ni lie beneath the base and do not seem to take
part in interactions with other hexons.
P nton
The penton capsomere is a covalent complex of two
proteins – the homopentameric penton base and the
hom trimeric fibre protein protruding from the 12 vertices
of the icosahedron (Fig. 1). The fibre has three distinct
regions: tail, shaft and knob.
The penton base monomer in Ad2 comprises 471 aa and
its pentameric structure ( . b) has been d termined to
3.3 A˚ (0. 3 nm; Zubieta et al., 2 05) and con i ts of two
domains: the lower ne with the typical jelly roll of two
four-strande anti-parallel b-sh ets forming a b-barrel, and
the u per one with irregular folds formed by two insertio s
arising from the lower jelly roll strands. The first insertion
contains the RGD loop (discussed later) and the other a
loop which is variable between serotypes. Pentamerization
can occur, providing stability by the burying of hydro-
phobic surfaces. A pore occurs along the fivefold axis of the
pentamer and the top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A sch matic depiction of the
structure based on cryo-electron mi roscopy and rystallography.
The locations of the capsid and minor components are reasonably
well defined and are not to scale. The disposition of the core proteins
and the virus DNA is largely conjectural. The symbols for IIIa and VIII
are based on the structures defined by Saban et al. (2006).
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penton bases and extended fibres on th 12 fivefold apices.
Other so-called ‘minor’ components: IIIa, VI, VIII and IX
are also associated with the capsid (Vellinga et al., 2005).
There are six other structural components situated in the
virus core, five are associated with the double stranded DNA
genome [V, VII, Mu, IVa2 and the ter inal protein (TP)],
the remaining component is the 23K virion protease which
plays a vital role in the ssembly of the virion (see below).
Most of the detailed l analyses have bee carried
out using human ser types, although a recent study of
canine adenovirus 2 has indicated that, while the basic
features are retained, the capsid of the canine virus is much
smoother and the fibre is more complex (Schoehn et al.,
2008). A recent structural analysis of an atadenovirus by
cryo-elect on microscopy has indicated that ther are some
di fer nces from ma tadenoviruses in capsid topology, but
the main characteristic adenovirus morphology is retained
(Pantelic et al., 2008). A more detailed description of these
structural proteins is given below as a forerunner for
consideration of their role in infection.
Hexon
The hexon capsomere is a pseudo-hexagonal trimer situated
on the 20 facets of the icosahedral capsid created by
threefold repetition of two b-barrels at the base of each
hexon molecule. The pseudo-hexagonal base allows close
alignment within the facets and there are three tower
regions that are presented to the exterior. There are 240
hexons in the capsid. Because of their different environ-
ments there are four kinds of hexon – designated H1, H2,
H3 and H4 (Burnett, 1985). Sixty H1 hexons associate
with the pentons at the 12 apices nd are al o termed
peripentonal hexon (Fig. 2a). The remaining hexons a
designated ‘groups of nine’ or GONs on the 20 f ces of the
icosahedron and are further defined as H2 (on the tw f ld
axes), H3 (on the thre fold axes) and the remaining ones as
H4 (Fig. 2a).
The size of the hexon molecule can vary with the serotype –
the largest described is from Ad2 and comprises 967 aa. Up
to nine hypervariable regions, determined by comparative
sequence analysis of serotypes, are present in each hexon
molecule. These are situated at the top of the molecule and
ix can be resolved as a-helical rods in the 6 A˚ structure
(Saban et al., 2006). These relate to the type-specific
antigens of the hexon and at least one of them constitutes
the major part of the virus-neutralizing activity (Crawford-
Miksza & Schnurr, 1996; Pichla-Gollon et al., 2006; Roberts
et al., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
The base of each hexon molecule has one loop and two
eight-stranded ‘jelly rolls’ which provide the means for
inter cting with neighb uri g capsomeres, rob bly via
charged residues in interacting loops. There must be
considerable flexibility in these int ractions given the
differing environments of the H1 t H4 hexons. The N
and C termini lie beneath the base and do not seem to take
part in interactions wit other hexons.
Penton
The penton capsomere is a covalent complex of two
proteins – the homopentam ric penton base and the
homotrimeric fibre protein protruding from the 12 vertices
of the icosahedron (Fig. 1). The fibre has three distinct
regions: tail, shaft and knob.
The penton base monomer in Ad2 com rises 471 aa a d
its pentameric structur (Fig. 3b) has been determined to
3.3 A˚ (0.33 nm; Zubieta et al., 2005) and consists of two
domains: the lower one with the typical jelly roll of two
four-stranded anti-parallel b-sheets forming a b-barrel, and
the upper one with irregular folds formed by two insertions
arising from the lower jelly roll strands. The first insertion
contains th RGD loop (discussed later) and the other a
loop which is variable between serotypes. Pentamerization
can occur, providing stability by the burying of hydro-
phobic surfaces. A pore ccurs along the fivefold axis of the
pentamer and t top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A schematic depiction of the
structure based on cryo-electron microscopy and crystallography.
The locations of the capsid and minor components are reasonably
well defined and are not to scale. The disposition of th core proteins
and the virus DNA is largely conjectural. The symbols for IIIa and VIII
are based on the structures defined by Saban et al. (2006).
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penton bases and extended fibres on the 12 fivefold apices.
Other so-called ‘ inor’ co ponents: IIIa, VI, VIII and IX
are also associated ith the capsid ( ellinga et al., 2005).
ere are six t er str ct ral c e ts sit ate i t e
i , fi i t it t l t
l i ],
i
l .
f il l l i
t si a ser ty es, alt a rece t st y f
canine adenovirus 2 has indicated that, hile the basic
features are retained, t e capsid of the canine virus is uch
smoother and th fibr is more complex (Schoehn et al.,
2008). A recent structural analysis of an atadenovirus by
cryo-elect on micros opy h s indicated that there are some
differen es from mastadenoviruse in c psid topology, but
the main characteristic adenoviru morphology is retained
(Pantelic et l., 2008). A more detailed description of these
structural proteins is given below as a forerunner for
consideration of their role in infection.
Hexon
T e hexon capsomere is a ps udo-hexago al trimer situated
on the 20 facets of the ic sahed a capsid created by
threefold repetition of two b-barrels at the base f ea h
hexo molecule. The pseudo-hexagonal base allows close
ali nment within th facets and ther are th e tower
regi tha are re ented to the exte ior. There are 240
hexo s in the capsid. Because of their differ nt environ-
ments there are four kinds of hexon – e ignated H1, H2,
H3 and H4 (Burne t, 1985). Sixty H1 h xons associat
with the pentons at the 1 pice and a e also te m d
peripentonal hexons (Fig. 2a). The remaining hexons are
designated ‘groups of nine’ or GONs on the 20 faces of the
icosahedron and are further defined as H2 (on the twofold
axes), H3 (on the threefold axes) and the remaining ones as
H4 (Fig. 2a).
The size of the hexon molecule can vary with the serotype –
the largest described is from Ad2 and comprises 967 aa. Up
to nine hypervariable regions, determined by co parative
sequ nce analysis of s ro ypes, ar present in each xon
molecule. Th s are situ ted at the top of m lecule and
six c be resolved as a- elical ro s in the 6 A˚ structure
(Saban et al., 2006). These relate to the type-sp cific
antigens of the hexon and at least one of them constitutes
the major part of the virus-neutraliz ng activity (Crawford-
iksza Schnurr, 1996; Pichla- ollon et al., 2006; Roberts
et al., 2006; x et al., 2003; ake c i et al., 1999) (Fig. 3a).
lec le as one loop and two
‘j ll lls’ ic r vide the eans for
i ri ca s eres, probably via
i i t r ti l s. here ust be
si r l fl i ilit i t ese i teractions given the
differi g e viro e ts of the 1 to 4 hexons. The
and C ter ini lie beneath the base and do not see to take
part in interactions with other hexons.
Penton
The penton capso er is a covalent co plex of two
proteins – the ho openta eric penton base and the
tri eric fi re protein protruding fro the 12 vertices
f t e ic sa e r (Fig. 1). he fibre has three dist nct
r i s: tail, s aft a d knob.
e e t ase ono er in d2 co prise 471 aa nd
its e ta eric str ct re (Fig. 3b) has been deter ined to
. ˚ ( . ; bieta et al., 2005) and c nsists of two
do ains: the lo er ne ith the typical jelly roll of two
four-stranded anti-parallel b-sheets for ing a b- arrel, and
the upper one with irregular folds formed by two insertio s
arising from the lower jel y rol strands. The first i s rti
contains the RGD loop (discussed later) and the other a
loop whic is variable betwe serotyp s. Pentam rization
can occur, providing stability by the buryi g of hydr -
phobic s rfaces. A pore occurs along the fivefold axis of the
pentamer and the top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of a ir . i
structure based on cry - l tr i r ll .
The locations of the ca si i r t r r l
well defined and are not to scale. The disposition of th core proteins
and the virus DNA is largely conjectural. The symbols for IIIa and VIII
are based on the struc ur s defined by Saba et al. (2006).
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IIIa 
VI 
VIII 
IX 
Minor proteins 
Termi l prot in 
penton bases and exte ded fibres on the 12 f vefold apices.
Other so-called ‘minor’ components: IIIa, VI, VIII and IX
are also associated with the capsid (Vellinga et al., 2005).
There are six other structural components situ ted in the
virus core, five are ass ciated with the double stra ed DNA
genome [V, VII, Mu, IVa2 and the terminal protein (TP)],
the remaining component is the 23K virion pr tease which
plays a vital role in the assemb y of the virion (se below).
Most of the detailed structural analyse ha been carried
out using human serotypes, although a recent study of
canine adenovirus 2 has indicated that, while the basic
features are retained, the capsid of the canine virus is much
smoother and the fibre is more complex (Schoehn et al.,
2008). A recent structural analysis of an atadenovirus by
cryo-electron microscopy has indicated that there are some
differences from mastadenoviruses in capsid topology, but
the main characteristic adenovirus morphology is retained
(Pantelic et al., 2008). A more detailed description of these
structural proteins is given below as a forerunner for
consideration of their r le in infection.
Hexon
The hexon capsomere is a pseudo-hexagonal trimer situated
on the 20 facets of the icosahedral capsid created by
threefold repetition of two b-barrels at the base of each
hexon molecule. The pseudo-hexagonal base allows close
alignment within the facets and there ar three tower
regions that are presented to the exterior. There are 240
hexons in he capsid. B cause of their diff rent e vi on-
ments there are four kinds of hexon – designate H1, H2,
H3 and H4 (Burnett, 1985). Sixty H1 hexons associate
with the penton at the 12 apices and are also t rm d
peripentonal hexons (Fig. 2a). The rem ining hexons are
designated ‘groups of ni e’ o GONs on the 20 faces of the
icosahedron and are further defined as H2 (on the twof ld
axes), H3 (on the t reefold axes) and the remaining s as
H4 (Fig. 2a).
The size of th hexon molecule can vary with the serotype –
the largest described is from Ad2 and comprises 967 aa. Up
to nine hypervariable regions, determined by compar tive
sequence analysis of serotypes, ar present in each hexon
m lecule. These are situated at top of the molecule and
ix can be resolved as a-helical rods in he 6 A˚ structure
(Saban et al., 2006). Thes relate the typ -specifi
antige s of the hexon and at leas one of them cons itutes
the major part of the virus-neutralizi g ctivity (Crawford-
Miksza & Schnurr, 1996; Pichla-Gollon et al., 2006; Roberts
et al., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
The bas of each ex n molecule has one loop and t o
eight-stranded ‘jel y rolls’ whi h provide the means for
interac ing w th neighbouring capso eres, robably via
charged residues in int acting loops. There ust be
consider ble flexibility i t se interactions giv n the
differ ng environments f th H1 to H4 hexons. The N
a d C ter ini lie beneath the base and do n t seem to tak
part in int racti ns with ther hexons.
Penton
The penton caps mere is a covalent complex of two
proteins – the homo entameric penton base and the
homotri eric fibre protein protruding from the 12 v rtices
of the icosahedron (Fig. 1). The fi re has thre distinct
regions: tail, shaft and knob.
The penton bas m nome in Ad2 comprises 471 aa and
its pentameric structure (Fig. 3b) as been determined to
3.3 A˚ (0.33 nm; Zubieta et al , 2005) and consists of two
domains: the lower one with the typical jelly roll of two
four-stranded anti-parallel b-sheets forming a b-barrel, and
the upper one with irregular folds formed by two insertions
arising from the lower jelly roll strands. The first insertion
contains the RGD loop (discussed later) and the other a
loop which is variable between serotypes. Pentamerization
can occur, providing stability by the burying of hydro-
ph bic surfaces. A por occurs along e fivefold axis of the
pentamer and the top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A schem ic depiction of the
structure based on cryo-electron microscopy and c ystallography.
The locations of the capsid and minor components are reaso ably
well defined and are not to scale. The disposition of the c re proteins
and the virus DNA is larg ly conjectural. The symbols for IIIa and VIII
are based on the structures defined by Saban et al. (2006).
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penton bases and extended fibres on the 12 fivef ld apices.
Other so-called ‘minor’ components: IIIa, VI, VIII and IX
are also associated with the capsid (Vellinga et al., 2005).
There are six other structural components situated in the
virus core, five are associated with the double stranded DNA
genome [V, VII, Mu, IVa2 and the terminal protein (TP)],
the remaining component is the 23K virion protease which
plays a vital role in the assembly of the virio (see below).
Most of the detailed struc ural analyses have been carried
out using human serotypes, although a recent study of
canine adenovirus 2 has indicated that, while the basic
features are retained, the capsid of the canine virus is much
smoother and the fibre is more complex (Schoehn et al.,
2008). A rec nt structural analysis of an atadenovirus by
cryo-electron microscopy has indicated that there are some
differences from mastadenoviruses in capsid topology, but
the main characteristic denovirus morphology is retained
(Pantelic et al., 2008). A more detailed description of these
structural proteins is given below as forerun er for
consideration of their role in infection.
exon
The hexon capsomere is a pseudo-hexagonal trimer situated
on the 20 facets of the icosahedral capsid created by
threefold repetition of two b-barrels at he base of each
hexon molecule. The pseudo-hexagonal b se allows close
alignment within the facets and ther are three ower
regions that are presented to the exterior. Ther are 240
hex s in the capsid. Because of t ir diff r nt nviron-
ents there are four kinds of h xon – esignated H1, H2,
3 and H4 (Burnett, 1985). Sixty H1 hex associate
ith the pentons at the 12 apice and are also termed
peripentonal hexons (Fig. 2a). The main g hexons are
designated ‘groups of ni e’ or GONs on the 20 faces f the
icosahedro and are further defined as H2 (on the twof ld
axes), H3 ( n the thr f ld axes) and the remaini g ones a
4 (Fig. 2a).
The size of the hexon molecule can vary wi h the s otype –
the largest described is from Ad2 and comprises 967 aa. Up
to nine hypervariable regions, determined by comparative
sequence analysis of serotypes, are present in each ex n
lecule. These are situated at the top of the molecule and
six can be resolved s a-helical rods i th 6 A˚ structure
(Saban et al., 2006). These relate to the typ -specific
antigens of the hexon and at least one of m constitutes
the ajor part of the viru -neutralizing activity (Crawfor -
iksza & Sc nur , 1996; Pich a-Gollon et al., 2006; Ro erts
e al., 2006; Rux et al., 2003; Tak uchi et al., 1999) (Fig. 3a).
The base of each h xon molecule as one loop and two
eight-stranded ‘jelly rolls’ which r vid the means for
interacting with neighbouring caps meres, probably via
charged residues in inte acting loo s. There m st be
considerable flexibili y in these interactions giv n th
di fering enviro ments of the H1 to H4 hexons. The N
and C termini lie beneath the base and do not seem to take
part in interactions with o her hexons.
Pe ton
The penton capsom re is a covalent complex o two
pr teins – the homopenta eric penton base and the
homotri eric fibre pro ei protruding fr m the 12 vertices
f the icosahedron (Fig. 1). The fibre has thr distinct
regions: tail, shaft and knob.
The pent n base mono er in Ad2 comprises 471 aa and
its pentameric structu (Fig. 3b) as been determined to
3.3 A˚ (0.33 nm; Zubieta et al., 2005) and consists of two
domains: the lower one with the typical jelly roll f two
four-stranded anti-parallel b-sheets forming a b-barrel, and
the upper one with irregular folds formed by two insertions
arising from the lower jelly roll strands. The first insertion
contains the RGD loop (discussed later) and the other a
loop which is variable between serotypes. Pentamerization
can occur, providing stability by the burying of hydro-
phobic surfaces. A pore occurs along the fivefold axis of the
pentamer and the top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A schematic depiction of the
structure based on cryo-electron microscopy and crystallography.
The locations of the capsid and minor components are reasonably
well defined and are not to scale. The disposition of the core proteins
and the virus DNA is largely conjectural. The symbols for IIIa and VIII
are based on the structures defined by Saban et al. (2006).
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pento bases and extended fibres on t fi efold apices.
Other so-called ‘minor’ components: , , I and IX
are also associated with the capsid ( lli et al., 2 05).
There are ix other structura co p it ated in the
virus core, five are associated with the tranded DNA
genome [V, VII, Mu, IVa2 and the ter r tein (TP)],
the r maini g component is the 23 i tease which
plays a vital role in the assembly of t (s e below).
Most of the detailed structural analys een ca ried
out sing human serotypes, althou t study of
canine adenovirus 2 has indicated t ile the basic
features are tained, the capsid of the irus is much
smoother and the fibre is more co ehn et al.,
2008). A re nt structural analysis f enovirus by
cryo-electron microscopy has indicate ere are some
differences from mastadenoviruses i t ology, but
the main char cteristic adenovirus is retained
(Pantelic et al., 2008). A more detaile tion of these
struct ral proteins is given belo rerunner for
consideration of their ole in infectio .
Hexon
The hexon capsomer is a pseud -h xa on l trim r situated
on the 20 facets of the icosahedral capsid created by
threefold repet t n of two b-barrels t th base of each
hexon molecule. The pseudo- xagona b s llows close
alignment within the facets and there are three tower
regions that are presented to the exterior. There are 240
hexons in the capsid. Because of their differe t environ-
ments there are four kinds of h xon – designat H1, H2,
H3 and H4 (Bur tt, 1985). Sixty H1 hexons ssociate
with the pentons at the 12 apice and e als t rmed
peripentonal hex ns (Fig. 2a). The rem in hexo s are
designated ‘groups of nine’ or GONs on th 20 faces of the
icosahedron and re fur her defined s H2 (on the wofold
axes), H3 (on t th eef ld axes) a d the rem ng ones as
H4 (Fig. 2 ).
The size of the hexon molec le ca vary with the serotype –
the largest desc ibed is from Ad2 and co prises 967 aa. Up
to nine hypervar able egion , determined by comparative
sequence an lysis of serotypes, are present in each hexon
m lecule These are situated at the top of the mo ecule and
six can be resolved as -helical rods in the 6 A˚ s ructure
(Saban et al., 2006). These relate t type-specific
antigens of the hexon and at l ast one of them constitutes
the major part of the virus-neutralizing activity (Crawford-
Miksza & Sch urr, 1996; Pichla-Gollon et al., 2006; Roberts
et al., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
Th base of each exon molecule has one loop and two
eight-stranded ‘jelly rolls’ which p vide the means for
intera ting with neighbouring capsomeres, probably via
ch rged residues i interacting loops. There must be
considerable flexibility in these interactions given the
d ffering environments of the H1 t H4 exons. The N
nd C termini lie beneath th base and d not seem to take
part in interactions wit ot r hexons.
Pento
T e penton capsomer is a covalent c mplex f two
proteins – the h mopentam ric penton base and t
homotrimer c fibre protein protruding from th 12 v rtices
f the icosahedr n (Fig 1). The fibre as three distinct
regio s: tail, s ft and knob.
The penton base monomer in Ad2 comp ises 471 aa and
its pentameric str cture (Fig. 3b) has been det rmined to
.3 A˚ (0.33 nm; Zubi a et al., 2005) and consists of two
domains: the lower one with he typical je y roll f two
four-stran ed anti-parallel b-sheets forming b-b rrel, and
the upper one w th irregular folds formed by two insertions
arising from the low r jelly roll strands. The first insertion
contains the RGD loop (di cussed later) and e other a
loop which is varia le b twe n serotyp s. Pentamerization
can occur, providing stability by the burying of hydro-
phobic surfaces. A p re occurs along the fivefold axis of the
pentamer and the top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of aden virus. A sche atic depiction of the
structure based on cryo-electron microscopy and crystallography.
The locations of the capsid and minor co ponents are reasonably
well defined and are not t scale. The disposition of the core proteins
and the virus DNA is largely conjectural. The sy ols for IIIa and VIII
are based on the structures defined by Sa an et al. ( 006).
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penton bases and extended fibres on the 12 fivef l ic s.
Other so-called ‘ inor’ co pone ts: Ia, VI, II
are also associated wi the capsid (Ve linga et l.,
Th re are six other structural components sit t
virus core, five are associated with the d uble stra
genome [V, VII, Mu, IVa2 and the terminal pr t i ],
the remai ing component is the 23K virion pr tease ic
plays a vital role in th ass mbly of the virion (see be o ).
Most of the detailed structural analyse ha been carried
out using human serotypes, although a r cent study of
canine adenovirus 2 has indicated that, while the basic
features are retained, the capsid of the cani e virus is much
smoother and the ibr is more omplex (Scho hn et al.,
2008). A recent structural analysis of an atadenovirus by
cryo-electron micros opy h s indicated that there are some
diff rences from mastadenoviruses in capsid topology, but
th main characteri ic adenovirus morphology is retained
(P ntelic et l., 2008). A m re detailed description of thes
structural proteins is given b low as a forerunner for
onside ati of their rol i infection.
Hexon
The hexon capsomere is a pseudo-hexagonal trimer situated
on the 20 facets of the icosahedral capsid created by
threefold repetition of two b-barre s at the base of each
hexon olecule. The pseudo-hexagonal base allows close
alignment within the facets and t r are three tower
regions that are pres nted to the terior. There re 240
hexo s in the capsid. Because their differ t environ-
ments there re four ki ds of hexon – desi nated H1, H2,
H3 and H4 (Burnett, 1985). Sixty H1 hexons ssociat
with th p tons at the 12 apices and r also t rmed
peripent nal hexons (Fig. 2a). The remainin hexons are
desig ated ‘gr ups of ni ’ or GONs on the 20 faces of the
icosahe ron and are further d fi ed as H2 (on th tw fold
axes), H3 (on the threefold axes) and the remai ing ones as
H4 (Fig. 2 ).
T size of the hexon molecule can vary with the erotype –
the largest described is f om Ad2 nd comprises 967 aa. Up
to nine hypervar able regions, dete min d by comparative
sequ nc analy is of erotypes, are prese t in each hex n
molecule. These are situated at the t p of the molecule and
six can be resolved as a-helical rods in the 6 A˚ structure
(Saban et al., 2006). These relate to the type-specific
tige s of the hexo a d at least one of t em constitutes
the major part of the virus- ut lizing act vity (Crawf rd-
Miksza & Schnurr, 1996; Pichla-Gollon et al., 2006; Rob rts
et ., 2006; Rux et al., 2003; Takeuchi et al., 1999) (F g. 3a).
The b s of e ch hexon molecule has one l op and two
eight-strande ‘jelly roll ’ which provide the means for
interacting with neighbouring capsomeres, probably via
charged residues in i teracting loops. There ust be
c si era l fle i il ty i t ese i tera i s give t
if i i .
t
he penton capsomere is a covalent complex of two
roteins – the homo enta eric penton base and the
o otri eric fibre protein protruding from the 12 vertices
f the icosahedron (Fig. 1). The fibre has three distinct
regions: tail, shaft and knob.
The penton base mon mer in Ad2 comprises 471 a and
its pentame ic structure (Fig. 3b) has been determined to
3.3 A˚ (0.33 nm; Zubieta et al., 2005) and co sists f two
domains: the lower one with the typical jelly roll of two
four-stranded anti-parallel b-sheets forming a b-barrel, and
the upper one with irregular folds formed by two insertions
arising from the lower jelly roll strands. The first insertion
contai s the RGD loop (discussed later) and the other a
l op whic is variable betwee rotyp s. P ntamerization
can occur, providing stability by th buryi g of hydr -
phobi surfaces. A pore occurs a ong the fivefold axis of the
entamer nd the top na row part is pre ominantly
hydrop obic. Th b-barrels from the su rounding peri-
Fig. 1. Str cture of adenovirus. A schemati i tion of the
s ructure based on cryo-electron microscopy tal ography.
The locations of the capsid and inor co pon reasonably
w ll d fined and are not to scale. The is iti f t r r t i
and the virus DNA is largely conjectural. y l f r III III
are based on the structures define y t l. ( ).
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penton b ses and extended fibr s on the 12 fivefold api es.
Other so-called ‘min r’ components: IIIa, VI, VIII and IX
are also associat d with the apsid (V llinga et al., 2005).
There are six other structural components situated in the
virus core, five are associated wit the double stranded DNA
genome [V, VII, Mu, IVa2 and the termi al protein (TP)],
the remaining component is the 23K virion protease which
plays a vital role in the assembly of the virion (see below).
Most of the detailed structural analyses have been carried
out using human serotypes, although a recent study of
canin ad novirus 2 has in icated that, while the basic
features are retained, the capsid of the canine virus is much
smoother a d he fibre is more compl x (Schoehn t al.,
2008). A recent structural analysis of an a adenovirus by
c yo- lect icro copy has indicated t at there are some
differenc s from mas viruses in capsid topol gy, but
the ma n characteristic ade ovirus morphol gy is r tain d
(Pan elic et al., 2008). A more detailed descriptio of th se
structur l pro eins is given b low as a forerunner for
consideration of their role in infection.
exon
The hexon capso ere is a pseud -hexagona tri er situate
on the 20 facets of the icosahedral capsid creat d by
threefold repetition of two b-barrels at the ase f each
hexon molecule. The pseudo-hex gonal bas all ws close
alignment within the facets and there are th ee tower
regions that are pres nt d to the ex rior. Th re ar 240
hexons in the capsid. Because of their different vi on-
ment there are four kinds of hexon – signa e H1, 2
H3 and H4 (Burnett, 1985). Sixty H1 h xons s ociat
with the penton a he 12 apices and are lso termed
peripentonal hexons (Fig. 2a). Th r maining hex n are
esignated ‘groups of ni e’ r GONs on the 20 faces of he
icosahedr n and re furthe defined as H2 (on the wofold
axes), H3 (on the t reefold axes) and the remaining o es as
H4 (Fig. 2a).
The size of the hexon molecule can v ry with the s rotype –
the largest described is from Ad2 and comprises 967 aa. Up
to ni hypervariable r gio s, determined by comparative
sequ ce an ysis of sero ypes, are present in each hex n
mo ecule. Th se are situated a the top of th molecule and
six can b resolv d as a-helical rods n the 6 A˚ structu
(Saban e al., 2 06). These relate to the ype-sp cific
an igens of the hex n and at least on of em consti utes
the maj r part of the virus- eutral zing act vity (Crawf rd-
Miksza & Schnurr, 1 96; Pichla-Gollon et al., 2006; Roberts
et al., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
The base of each hexon molecule has one loop and two
eight-stranded ‘jelly rolls’ whi h provide the means for
interacting with neig bouring capsomeres, pr bably via
charged residu s i interacting loops. There must b
co sid rable flexibili y in these interact ons given the
differing env ronme ts of the H1 to H4 hexons. The N
and C ermini l e beneath the bas and do not seem to take
part in interactions with other hexons.
P nton
T e penton caps er is a ovalent complex of two
proteins – the hom pe tameric penton base and th
homotri er c fibre prote protruding from the 12 vertices
f the icosahedron (Fig. 1). The f r h s three distinct
regi ns: tail, shaft and knob.
The penton base monomer in Ad2 comprises 471 aa and
its pentameric str cture (Fig. 3b) has been determined to
3.3 A˚ (0.33 nm; Zubieta et al., 2005) and consists of two
d mains: the lower on wit the typical jelly roll of two
four-strand d anti-parallel b-sheets forming a b-bar el, and
the upp r ne with i regular folds formed by two insertions
arising from the lower jelly roll stran s. The first ins rtion
c ntains the RGD loop (discussed later) a d the other a
lo p which is ar abl between serotypes. Pent merization
can oc ur, providing stability by burying f hydro-
p obic surfaces. A pore occu s along he fivefol axis f the
pentamer and the top narrow part is pred minantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A sche ati depi tion of the
structure based on cryo-electron microscopy and c ystallograph .
The locations of the cap id and minor components are reas nably
well defined and are not to scale. Th disposition of the core proteins
and the virus DNA is largely co j ctural. The sy bols for IIIa and VIII
are based on the structures define by Saban et al. (2006).
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penton bases and extended fibres on the 12 fivefold apices.
Other so-called ‘minor’ components: IIIa, VI, VIII a I
are also associated wit the capsid (Vellinga et l., 0 ).
There are six other structural co ponents situ t i t
vir s c re, five are a s ciated ith the double stra
[ , II, , I a2 and th ter inal prot ],
i i ent is the 3K virion p ot
i l l i t e asse bly of the virio (s .
t ile structural analyses have b
ser types, although a recent f
ir s as indicated t at, while i
t i e , t e capsid of the c nine vir
t t e fi re is ore co plex (Scho l.,
). rec t str ct ral analysis of an atade ir s
cryo-electron icros opy h s indicated that there are s e
differences fro as adenoviruses in capsid top l gy, b t
the ain characteristic adenovirus orphology is retained
(Pantelic et al., 2008). A more detailed description of these
structural proteins is given below as a fo runner for
consideration of their role in infection.
H xon
The exon capsom e is a pseud -hexag nal trimer situ t
on the 20 facets of th ic sahedral capsid c ated by
t reefold r petition of tw b-barrels t the base of each
hexon molecule. The pseudo-hexagonal base allows close
alignment within the face s and the e are three tow r
regi s that are resented to the exterior. There are 240
hexons in the capsid. Because of th ir different environ-
ments there are four kinds of hexon – designated H1, H2,
H3 and H4 (Burnett, 1985). Sixty H1 hexons associate
with the pentons at the 12 apices and are als termed
peripentonal hexons (Fig. 2a). Th rem ining hex ns are
esignated ‘groups of nin ’ or GON on the 20 faces of he
ico ahedr a d e furthe d fi ed as H2 (o the tw fold
axes), H3 (on the threefold axes) and the remai ing ones s
H4 (Fig. 2a).
The siz of the h xon molecule can vary with the serotype –
the largest described is fr m Ad2 and compri es 967 a. Up
to ni e hypervariable regions, d t rmined by comp rative
s quenc analysis of serotypes, are pr sent in ea h xon
molecule. These are situated a the top of molecule and
six ca e resolved as a- ical rods in the 6 A˚ structure
(Saba et al., 2 06). Th se relate to the type-specific
a tige s f t e exo a at least e f the c stit tes
jo f i n li i i i fo
9
i t-str ‘j ll r lls’ i r i t s f r
interacting ith neighbouring capso er s, probably via
charged residues in interacting loops. The e ust be
co siderable flexibility in t se interactions given the
differing environments of the H1 to H4 hexons. The N
and C ter ini lie ben ath the and d not seem to take
part in nteraction with oth r hexons.
Penton
T e penton capsomere is a covalent complex of two
pr teins – the homopenta eric pento base and the
homotri eric fibre protein prot uding from the 12 vertices
of the icosahedron (Fig. 1). The fi r has three distinct
regions: tail, shaft a d knob.
The penton base monomer i Ad2 compri es 471 a and
its pentameric structure (Fig 3b) has een d ter ined to
3.3 A˚ (0. nm; Zubieta et al., 2 05) and con i ts of tw
domains: the lower one with the typical je ly roll f
four-stranded anti-par lle b-sheets forming a b-barrel, and
the u er one wi h irregu ar folds formed by two ins rtions
arising from the lower jelly r ll trands. The first insertion
contains the RGD loop (discus ed later) and the other a
loop whic is variable between serotypes. Penta erization
can occur, providing stability by the burying of hydro-
phobic surfaces. A pore occurs along the fivefold axis of the
pent er and the top narro part is predo inantly
hydro ic. e - arrels fr t e s rr ing peri-
Fig. 1. tructure of adenovirus. A schemati depi ti n of the
structure based on cryo-electron microscopy nd crystallography.
The locations of the capsid and minor components are reasonably
well defined and are not to scale. The disposition of the core proteins
and the virus DNA is largely conjectural. The symbols for III nd VIII
are based on the structures defined by Saban et al. (2006).
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viral genes are transcribed by RNA polymerase II with the exception of virus-
associated (VA) I and II genes. These are transcribed by RNA polymerase III 
and are expressed as short RNA molecules during the translation of viral mRNA 
(Shenk 2001). The functions of the viral genes are summarised in Table 3.  
 
 
Figure 8. A schematic map of transcription of the Ad5 genome 
The early genes (E1A, E1B and E3) which are involved in preparing the infected cell for DNA 
replication and modulating the immune response to the infected cell are outlined in red. The early 
genes E2A and E2B are involved in regulating viral DNA replication and are defined in blue. The 
last set of early genes (E4) have a disparate set of functions are outlined in green. The late genes 
are defined in grey and are transcribed from the MLP as one primary transcript which is 
subsequently processed by differential poly(A) site utilisation and splicing. The structural proteins 
encoded are termed II to IX. Arrows indicate the direction of transcription and both strands of DNA 
are transcribed. Adapted from Russell 2000. 
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Table 3. Protein products of Ad5 encoded genes and their functions 
 
Gene Protein Function 
E1A E1A12S 
•  Binds many cellular proteins including pRB 
(p107 &p130), p300/CBP & STAT1 
•  Represses transactivating function of E1A13S 
through p300 binding 
•  Activates p53 
E1A13S 
 
•  Transactivates viral genes 
•  Binds to cellular proteins TBP, Sp1, CREB, DR1 
•  Essential for viral replication 
E1B E1B19Kd •  Anti-apoptotic Bcl2 homolog 
E1B55Kd 
•  Binds to and blocks p53 activity 
•  Binds to and actively represses  transcriptional 
activity of p53  
•  Together with E4orf6, stimulates late viral 
nuclear export; inhibits host cell mRNA export 
•  Together with E4orf6 degrades cellular proteins 
in a E3 ubiquitin ligase complex 
E2A Polymerase •  Viral polymerase with 5’-to-3’ polymerase activity and 3’-to-5’ exonuclease activity 
DNA-binding protein (DBP) •  Chain elongation for DNA replication 
E2B Pre-terminal protein (Pre-TP) 
•  Covalently bound to 5’ DNA termini 
•  Primer for DNA replication 
•  Attachment to nuclear matrix 
E3A 12.5Kd •  Unknown 
E3A 6.7Kd •  Unknown 
E3A 
 gp19Kd 
•  Binds to MHC and sequesters it in the 
endoplasmic reticulum preventing presentation 
of viral antigens in infected cell 
Adenovirus death protein (ADP) •  Promotes viral release 
E3B 10.4/14.5Kd RID •  Mediate internalisation of  FAS receptor •  Inhibits pro-apoptotic phospholipase A2 
E3B 
 14.7Kd 
•  Inhibits FAS & TNF ligand-induced apoptosis by 
interacting with caspase-8 in FLICE 
•  Inhibits pro-apoptotic phospholipase A2 
•  Bind to and blocks pro-apoptotic FIP proteins 
E4 Orf 1 •  Facilitates transformation  
Orf 2 •  Unknown  
Orf 3 •  Interacts with E1B55K 
Orf 4 •  Inhibits E1A activation of E2F 
Orf 6 •  Interacts with E1B55K for late viral RNA export •  Shuts off cellular mRNA processing 
Orf 6/7 •  Modulates E2F activity; transactivates E2A promoter by binding to E2F-binding sites 
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Data summarised from Russell 2000; Gallimore and Turnell 2001; Shenk 2001; Wiethoff, Wodrich 
et al. 2005; Russell 2009 
  
!"#" $%&'"(# )*#+,&# 
Delayed  
early 
gene 
IX 
 
•  Stabilises hexon-hexon interactions 
IVa2 
 
•  Activates late viral gene transcription 
•  Mediates encapsidation process 
L1 IIIa •  Bridges hexon and hexon interaction between facets 
L2 III •  Penton base 
V 
•  Binds to penton base and may bridge the capsid 
and core 
•  Facilitates final uncoating stages of capsid 
proteins. May participate with pre-VII 
VII 
•  Mediates localisation of virion to nucleus 
•  Diminishes early transcription 
•  Facilitates viral assembly at the end of lytic cycle 
L3 II •  Associates in trimers to form hexon capsomere 
Protease 
•  Essential for uncoating during virion 
internalisation 
•  Cleaves precursor polypeptides generating 
mature and infectious virus particles 
VI 
•  Stabilises hexon-hexon interactions 
•  Bridges interaction between capsid and core 
•  Mediates escape of virion from endosome during 
infection process 
L4 100K 
•  Stimulates late viral translation 
•  Participates in association of hexons during 
virion assembly 
VIII •  Stabilises hexon-hexon interactions •  Bridges interaction between capsid and core 
L5 IV 
•  Associates in trimers to form penton 
•  Mediates attachment of virion to cell surface 
receptors 
VA RNA VA1 & VA2 
•  Blocks !- and "- interferon anti-viral response by 
inhibiting PKR activation 
•  Prevents PKR-mediated protein synthesis 
shutoff 
Mu 
•  Modulate E2 gene expression to switch from 
early to late viral transcription 
•  Condenses viral chromatin during packaging of 
virion particles 
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1.6.3.  Adenovirus life cycle 
 
1.6.3.1. Virus attachment, internalisation and 
trafficking to the nucleus 
 
Adenovirus infection in vitro is a two-step process; firstly the distal C-terminal 
fiber-knob domain docks onto a cellular receptor. The coxsackie adenovirus 
receptor (CAR), a member of the immunoglobulin superfamily has been found to 
serve as a high-affinity receptor for all human adenovirus species except 
species B and G (Table 2). Adenoviruses from species B and D use CD46, 
CD80 or CD86 and the recently identified desmoglein (previously called receptor 
X) as cellular receptors and from species D use both CD46 and CAR. Ad5 has 
been shown to have numerous docking receptors including heparan sulfate 
proteogylcans (HSPG), the α2 domain of the class I MHC and the vascular cell 
adhesion molecule 1 (VCAM-1) (Table 2). In vivo, adenovirus has been shown 
to bind more physiologically relevant receptors such as complement-4 binding 
protein (C4BP), coagulation factor IX (FIX) and factor X (FX). Bridging/docking 
receptors include sialic acid, lactoferrin and O-linked sulfate side chains on 
HSPGs  
 
Following the fiber-CAR interaction the second interaction requires an arginine-
glycine-aspartic acid (RGD) motif within the penton protein to interact with 
cellular integrins (αVβ3 or αVβ5) which is essential for subsequent internalisation 
of most adenoviruses except those of species F which do not contain a RGD 
motif. Binding of RGD to integrins result in integrin clustering, which 
subsequently initiates downstream signalling cascades resulting in PI3K/AKT 
activation. This triggers the Rho family of GTPases and reorganisation of the 
actin cytoskeleton for clathrin-mediated endocytosis. Other intracellular 
signalling pathways activated are the extracellular signal-related kinase 
(ERK1/2) cascade resulting in clustering of CAR and increasing the activation 
status of β-integrin subunits as well as the p38/MAPK pathway resulting in an 
increase in IL-8 production indicative of activation of the host defence system 
(Russell 2000; Coughlan, Alba et al. 2010). 
 
Disassembly of Ad5 occurs very soon after attachment as the fiber is released 
from the virion at the cell surface. The process of endocytosis allows for further 
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disassembly and acidification to pH4.6-6.0 induces conformational changes to 
the structure of the virion while proteolytic capsid maturation are thought to be 
essential for endosomal escape. Virus escapes from the endosome before the 
formation of the lysosome however the exact mechanism of endosome 
penetration has yet to be elucidated (Shenk 2001). Wiethoff et al demonstrated 
that pVI possessed 95% membrane lytic activity in vitro and consequently 
proposed that after hexons, penton, pIIIa and pVI are disassembled in the acidic 
endosome, pVI dissociates from the hexons and associates with the endosome 
membrane resulting in membrane disruption and release of the uncoated virions 
into the cytoplasm (Wiethoff, Wodrich et al. 2005). Once in the cytoplasm, the 
nucleocapsid-hexon core associates with cellular proteins including importins, 
histone H1 and HSP70. Transport to the nucleus occurs by way of the 
microtubule network using the microtubule-associated motor, dynein. pVII is 
thought to be the primary viral mediator of import to the nucleus (Russell 2009). 
 
1.6.3.2. Viral gene transcription 
 
As discussed in section 1.6.2.2, adenovirus transcription can be described as a 
two-phase event separated into early and late. There are three primary 
objectives of early gene transcription: firstly to induce S phase in the host cell 
thereby providing an optimal setting for viral replication, secondly allow 
expression of immunomodulatory viral genes to protect the cell from antiviral 
defences and lastly to enable synthesis of viral gene products required for DNA 
replication (Shenk 2001).  
 
The E1A gene is the first transcription unit to be expressed after the viral 
chromosome enters the nucleus. A constitutively active promoter controls 
expression of the E1A unit leading to the synthesis of E1A12S (243 amino 
acids) and E1A13S (289 amino acids) during the early phases of infection. 
These contain identical 5’ and 3’ ends but differ in the central region due to 
differential splicing. Three highly conserved regions (CR)1, CR2, CR3 and CR4 
are present in the E1A gene of human adenoviruses and along with conserved 
residues in the N-terminal region, facilitate protein-protein interactions with 
cellular proteins (Figure 9) (Shenk 2001). E1A12S and E1A13S differ only the 
presence of the CR3 region in E1A13S protein. The CR3 region within E1A13S 
acts as a strong activation domain, essential for activation of early viral 
 87 
promoters and binds proteins involved in transcriptional activation including 
TATA-binding protein (TBP), MED23, a subunit of the MED complex and CREB. 
As a consequence, stabilisation of preinitiation complexes (PICs) with RNA 
polymerase II is allowed to occur at early adenoviral promoters. E1A13S protein 
is produced during the early phases of infection and is more efficient than 
E1A12S at transactivating early gene expression due to the presence of the 
CR3 domain (Shenk 2001; Berk 2005). Transactivation capabilities of E1A12S 
(and therefore E1A13S) are mediated through TATA motifs and E2F-binding 
sites. E1A12S can alleviate transcriptional repression directed by Dr1 (a protein 
which binds to and inhibits TBP) by binding to and requisitioning Dr1 from TBP. 
The E2F-binding sites present in the adenovirus E1A and E2 promoters are 
activated through indirect E1A12S modulation. Both E1A proteins bind to the 
pRB via the CR1 or CR2 domain thus relieving the inhibitory effect of pRB on 
transcriptional activity of E2F. E2F-mediated transcription affects viral gene 
expression and influences cellular gene expression; most notably genes 
important for S phase and cell growth (Shenk 2001). The presence of E1A is 
however not an absolute requirement for the transcription of early viral genes in 
some cell types since an E1A-deleted mutant, dl312 was shown to replicate in 
HeLa cells to a similar extent as wild-type when infected at a high multiplicity of 
infection. The discovery of E2F and E4F sites in the viral E2 and E4 promoter 
respectively indicated cellular transcription factors could bind early viral 
promoters and stimulate low levels of transcription initiation in the absence of 
E1A (Shenk 2001). 
 
 
Figure 9. Schematic diagram of the protein domain structure of E1A13S 
Cellular proteins bind to conserved regions (CRs) of E1A and through conserved residues present 
within the N-terminus. Listed are the main E1A-interacting proteins although this is not an 
exhaustive compilation. 
CR1 CR2 CR3 
CR4 
p300, CBP, p400, 
TRRAP, hGCN5, 
PCAF, pRb, p21, 
p27, STAT1, 
proteosome 
pRb, p107, p130, 
UBC9 
CREB, p300, CBP, 
MED23, TBP, YY1, 
Sp1 
CtBP,  C-Jun 
CtBP, p27 
N C 
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1.6.3.3. Activation of the host cell 
 
1.6.3.3.1. E1A-stimulated S phase induction 
 
The protein products of early adenoviral genes modulate cellular metabolism to 
make the cell more receptive to virus replication. As illustrated in Figure 9, E1A 
interacts with many cellular proteins to generate the optimal cell environment for 
viral DNA replication. The most significant interactions for E1A are with pRb-
pocket proteins and the p300/CBP proteins.  
 
Entry into S phase is stimulated by primarily through E1A-binding to pRb via the 
CR2 domain. pRb, regulates the key effectors of proliferation, the transcription 
factor E2F family of proteins. When bound to E2F, pRb functions to inhibit E2F-1 
transcriptional activity and maintains cells in G1. In response to growth stimulus, 
hypophosphorylated pRb is phosphorylated sequentially by cyclin/CDK 
complexes resulting in the release of E2F allowing it to activate transcription of 
genes required for DNA synthesis (Munro, Carr et al. 2012). E1A bypasses the 
regulatory signals applied by growth factor stimulation and competes with E2F 
for access to the pocket domain in pRB or related proteins, p107 and p130 via 
its CR2 domain. Binding is mediated through a LxCxE-motif in CR2 interacting 
with same domain to which pRb binds E2F-1. CR1 can also weakly interact with 
pRb and plays an auxiliary role stabilising CR2–pRb interaction and is 
necessary for driving the cell cycle into mitosis (Berk 2005). Independent of E2F 
sequestration, pRb functions as a transcriptional repressor through its 
interactions with multi-subunit HDAC-containing complexes as well as binding to 
members of the SWI/SNF transcriptional regulators, hBRM and BRG1 to 
promoter complexes resulting in cell cycle arrest. E1A binding to pRB disrupts 
these interactions thereby modifying the transcriptional repression applied by 
these pRB-containing complexes (Gallimore and Turnell 2001). In addition to 
disrupting pRB-E2F complexes, E1A binds to CDK inhibitors p21 and p27 
preventing them from binding to and inhibiting G1 cyclin-CDK complexes (Shenk 
2001).  
 
A second pathway by which E1A enables cell cycle progression is through 
binding to p300 and CBP proteins. E1A binds to the transcriptional adapter motif 
(TRAM) of p300/CBP primarily through the CR1 and the N-terminal region 
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(O'Connor, Zimmermann et al. 1999). More recently the CR3 domain has also 
been shown to bind p300/CBP (Pelka, Ablack et al. 2009). p300/CBP proteins 
are multidomain proteins and as mentioned earlier in this chapter, exhibit 
intrinsic histone acetylase activity. They recruit other HAT proteins e.g. 
p300/CBP-associated factor (P/CAF) and serve as coactivators to numerous 
gene-specific transcription factors. Whether E1A inhibits HAT activity of 
p300/CBP is controversial and context-specific repression or elevation of HAT 
activity has been observed. In the context of S phase entry, p300/CBP acts as a 
coactivator of p53. By redirecting p300/CBP activity away from active sites of 
transcription the ability of p53 to induce cell cycle arrest through the transcription 
of CDK inhibitors or apoptosis via the expression of pro-apoptotic proteins is 
antagonized (Shenk 2001). However, this by itself does not stimulate S phase 
progression, it has been reported inhibition of p300 leads to an increase in c-
Myc expression hence driving quiescent cells into S phase. This is thought to 
occur by E1A binding to p300 causing dissociation of p300, YY1 and HDAC3 
from chromatin alleviating transcriptional repression of c-Myc promoter 
(Kadeppagari, Sankar et al. 2009). However HAT activity is crucially required for 
some of E1A functions; for example transcriptional activation of the viral E3 or 
E4 promoter is dependent on the recruitment of p300/CBP to E1A13S through 
its CR3 domain and was inhibited by the presence of E1A12S possibly by 
sequestering p300/CBP from the larger E1A protein (Pelka, Ablack et al. 2009). 
This suggests the transcriptional activity of p300/CBP depends on the ratio of 
E1A12S and E1A13S present with the CR1 domain of E1A12S repressing CR3-
mediated transcriptional activity.  
 
In addition to directing or sequestering p300/CBP towards or away from active 
sites of transcription, recruitment of p300/CBP may serve to facilitate acetylation 
of E1A itself. Acetylation of E1A at K239 or K285 on E1A12S and E1A13S 
respectively occurs proximal to the C-terminal Binding Protein (CtBP)-binding 
site. Mutation of this lysine residue blocked CtBP binding in vitro and disrupted 
E1A/CtBP interaction in vivo (Zhang, Yao et al. 2000). CtBP functions as a 
transcriptional repressor interacting directly with HDACS. The CR4 domain of 
E1A may disrupt this interaction by competing with HDACS for binding thereby 
requisitioning CtBP from transcriptional multimeric complexes (Sundqvist, 
Sollerbrant et al. 1998). Therefore, analogous to E1A-mediated inhibition of 
pRB-dependent repression, the CR4 domain might derepress cellular genes by 
sequestering CtBP. Conversely; E1A may repress cellular genes by tethering 
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CtBP to their promoter region possibly to counteract the activation capability of 
E1A-p300/CBP complexes (Berk 2005). Another mechanism by which E1A 
regulates the acetylation of histones is through the binding of chromatin 
remodeller, p400, a SWI2/SNF2 DNA-dependent ATPase that alters DNA-
histone interactions (Gallimore and Turnell 2001). It exists in multimeric protein 
complexes alongside transactivation/transformation domain-associated protein 
(TRAPP), which itself is a key component of several multiprotein HAT 
complexes such as TIP60 and hGCN5 (Berk 2005). Both p400 and 
TRAPP/hGCN5 have been associated with c-Myc activity. E1A-mediated 
stabilisation of c-Myc has been connected with its interaction with p400 and an 
E1A mutant unable to bind p400 did not stabilise c-Myc. p400 is known to 
induce c-Myc and E1A promotes the association between p400 and c-Myc 
reducing ubiquitin-mediated degradation of c-Myc thereby promoting the 
formation of p400-c-Myc complexes on promoters of c-Myc-target genes 
(Chakraborty and Tansey 2009). Equally, TRAPP also binds to the N-terminus 
of c-Myc promoting transcriptional activation through recruitment of HAT 
complexes. By means of the N-terminus of E1A, TRAPP and/or hGCN5 are 
sequestered resulting in reduced transcriptional activation of c-Myc and E2F 
thereby redirecting transcriptional coactivators to viral and cellular promoters 
(Lang and Hearing 2003). This is in conflict with the requirement of c-Myc 
activity for cell cycle progression, however inhibition of p300/CBP by E1A may 
alleviate p300/CBP-imposed repression on the c-Myc promoter (Berk 2005).  
 
The multidomain structure of E1A therefore allows recruitment of several binding 
proteins to form multi-component complex. E1A binding to pRB and p300/CBP 
are both required to drive quiescent cells into S phase and for cells to pass the 
G2/M checkpoint to progress into mitosis. Additionally, through differential 
regulation of p300/CBP and other binding proteins such as p400, the c-Myc 
pathway is also activated to drive cells into S-phase providing E1A with two 
methods of activating transcriptional networks that control cell growth. 
 
1.6.3.3.2. E1A-mediated induction of apoptosis by 
p53-dependent and –independent mechanisms 
 
In the absence of the E1B-encoded anti-apoptotic proteins, E1B55K and 
E1B19K, E1A induces apoptosis by stabilisation of p53 and through p53-
 91 
independent mechanisms. However, the functional significance of this in the 
context of the viral lifecycle remains unclear. Apoptosis undoubtedly occurs as a 
defence mechanism against E1A-mediated perturbation of cell cycle regulation. 
It has long been recognised that expression of E1A induces p53-dependent 
apoptosis as a result of E1A binding to p300/CBP and pRB for which at least 
three mechanisms have been proposed (Figure 10) (Debbas and White 1993; 
Lowe and Ruley 1993; Grand, Grant et al. 1994; Sabbatini, Lin et al. 1995; 
Querido, Teodoro et al. 1997). 
 
Firstly, E1A binding to pRB through either the CR1 or CR2 domains promotes 
E2F-dependent transcription of the potent tumour suppressor, p14ARF. p14ARF 
facilitates the accumulation of p53 by sequestering and directing the 
degradation of the p53-antagonist, HDM2 through the ubiquitin/proteasome 
pathway (de Stanchina, McCurrach et al. 1998; Deng, Kloosterbooer et al. 
2002). Intriguingly, E1A was later found to bind to p14ARF and could compete 
with the HDM2 for binding to p14ARF (Shen, Zhang et al. 2011). p14ARF also 
promoted ubiquitination and proteasomal degradation of E1A independent of 
p53 and HDM2 status and inhibited E1A-dependent entry into S phase. This 
suggested E1A might have evolved the ability to prevent p14ARF–HDM2 
interaction thus blocking p14ARF-mediated p53 stabilisation. Therefore, E1A has 
a mechanism of overcoming p53-dependent host anti-viral response by fine-
tuning its own replication activity (Shen, Zhang et al. 2011).  
 
Secondly, E1A binding via its N-terminus and CR1 domain to the TRAM motif of 
p300/CBP can disrupt p53-HDM2 complexes since p300 binds to HDM2 and is 
important for HDM2-mediated degradation of p53 (Grossman, Perez et al. 
1998). Later, studies revealed that E1A binding of p300 prevented the intrinsic 
ubiquitin ligase activity of p300 to polyubiquitinate p53 and with HDM2 mediate 
the degradation of p53 (Grossman, Deato et al. 2003). Reports have shown 
accumulation of p53 and induction of apoptosis by E1A12S is prevented by 
deletions in the N-terminus and CR1 domain which confer pRb and p300/CBP 
binding supporting the notion that a complex of E1A, pRb and p300 are involved 
in p53-dependent apoptosis (Querido, Teodoro et al. 1997). Another study 
however revealed that the CR1 domain was required for the interaction between 
E1A and MDMX (a HDM2-related, p53-binding protein) (Li, Day et al. 2004). 
This resulted in the stabilisation of p53 in a p14ARF-independent manner and 
 92 
protected MDMX from HDM2-mediated nuclear export and degradation of p53 
(Li, Day et al. 2004).  
 
Thirdly, p53 stabilisation can be induced by the interaction between E1A and 
26S proteasome. The 26 proteasome consists of a 20S proteasome and the 
19S regulatory complex. Through N-terminal interactions, E1A binds to S4 and 
S8 ATPases that make up the 19S regulatory complex. E1A inhibits the ATPase 
activity of S4, which acts as a “gatekeeper” for ubiquitin-tagged proteins 
however the consequence of E1A binding to S8 has yet to be established. 
Therefore E1A functions to inhibit entry of proteins into the proteasome and 
more specifically, can impede the proteasomal-mediated degradation of p53 
(Turnell, Grand et al. 2000). Other studies have inferred that p400 is crucial for 
efficient E1A-mediated cell death. In normal fibroblasts, E1A mutants that lacked 
p300 binding were dispensable for inducing p14ARF, p53 and apoptosis whereas 
deletion of the p400-binding region was defective in stimulating apoptosis 
(Samuelson, Narita et al. 2005).  
 
 
Figure 10. Mechanisms of E1A-mediated stabilisation of p53 
E1A targets and inhibits several regulatory components important in p53 degradation. Adapted 
from Gallimore and Turnell 2001. 
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Besides p53-dependent apoptosis, E1A expression induces cell death in p53-
deficient cells and E1A deletion mutants similarly confirmed the requirement of 
pRb- and p300-binding to E1A for this to occur. The mechanism of cell death 
implicated a mitochondrial-mediated cell death mechanism since apoptosis was 
significantly blocked with the addition of caspase inhibitors or co-expression with 
E1B19K or Bcl-2 (Putzer, Stiewe et al. 2000). Therefore presumably, E1A-
mediated inactivation of pRb in p53-deficient cells may also result in E2F 
transcriptional activation resulting in expression of p14ARF. Several lines of 
evidence indicate p14ARF exerts its tumour suppressive function independent of 
p53. For example, p14ARF interacts with and inhibits c-Myc function via a p53-
independent mechanism, preventing c-Myc from activating target genes 
involved in hyperproliferation and transformation (Qi, Gregory et al. 2004). In 
addition, overexpression of p14ARF in p53-deficient cells has been shown to 
induce proapoptotic Bcl-2-associated X protein (Bax)/Bcl-2-antagonist/killer-1 
(Bak)-dependent apoptosis (Hemmati, Guner et al. 2006). Interactions of the N-
terminus and CR1 domain of E1A with other cellular proteins have also been 
determined and include upregulation of the p53-related protein TAp73 resulting 
in activation of the p53/p73 pro-apoptotic target, p53 upregulated modulator of 
apoptosis (Puma) (Klanrit, Flinterman et al. 2008). Furthermore, binding of E1A 
to p400 has also been implicated in downregulating the EGFR in cancer cells 
with p400 binding important in E1A-induced apoptosis (Flinterman, Mymryk et 
al. 2007). 
 
Another mechanism of E1A-induced, p53-independent apoptosis is through the 
inhibition of antiapoptotic proteins. A screen of Bcl-2 family proteins during virus 
infection revealed that E1A down-regulated mRNA and protein levels of Bcl-2 
family member, myeloid cell leukaemia sequence 1 (Mcl-1). This decrease was 
accounted for by a virus-induced DNA damage response resulting in increased 
proteasome-mediated turnover of Mcl-1. As a consequence, Mcl-1-dependent 
suppression of the proapoptotic Bak protein was relieved leading to Bak 
activation and subsequent oligomerisation with the proapototic protein, Bax 
resulting in outer mitochondrial membrane pore formation and apoptosis 
(Cuconati, Mukherjee et al. 2003).  
 
E1A is also able to sensitise cells to TNF-α receptor mediated apoptosis. Host 
anti-viral production of TNF-α results in stimulation of the extrinsic apoptotic 
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pathway as well as the NF-κB-mediated survival pathway. Since a pro-survival 
pathway is elicited, TNF-α-induced cell death requires the inhibition of NF-κB-
dependent anti-apoptotic gene expression for TNF-α to induce apoptosis. The 
mechanism of E1A-dependent sensitisation was found to be as a result of down-
regulating the antiapoptotic cellular FLICE-inhibitory protein (c-FLIP), which 
functions to blocks activation of capspase-8 at the death-inducing signalling 
complex (DISC). E1A prevented c-FLIP expression by preventing transcription 
of c-FLIP mRNA and also promoting ubiquitination and proteasomal-degradation 
of c-FLIP proteins (Perez and White 2003). 
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1.6.3.3.3. Viral-mediated inhibition of adenovirus-
induced apoptosis 
 
As a consequence of E1A-induced deregulation of the cell cycle, E1A induces 
apoptosis through p53-dependent and –independent mechanisms. The 
presence of foreign DNA also induces the DNA damage response pathway. To 
ensure a productive lifecycle, adenoviruses have evolved mechanisms to 
counter these pathways. E1B55K and E1B19K the principle proteins encoded 
by E1B neutralise the effects of p53-dependent and p53-independent apoptosis 
(Shenk 2001).  
 
E1B19K is a functional homolog of cellular anti-apoptotic protein, Bcl-2 and 
inhibits p53-dependent and –independent apoptosis. As discussed in the 
previous section, during a productive infection, E1A is able to sensitise cells to 
killing by death receptor ligands, TNF-α, Fas ligand (FasL) and TRAIL, which is 
blocked when E1B19K is expressed (White 2001). Moreover, infection of an 
E1B19K-deleted mutant resulted in premature cell death of normal cells after 
treatment with TNF resulting in attenuation of viral replication (Cuconati, 
Degenhardt et al. 2002). E1B19K is able to bind Bax and Bak although only the 
interaction with Bak appearing to be constitutive. Upon TNF-α treatment, active 
caspase-8 cleaves BH3-interacting death protein (Bid) to tBid, which 
subsequently binds to and activates Bax and Bak. Binding of tBid to Bax 
induces a conformational change in Bax resulting in E1B19K binding. As a 
consequence, E1B19K is able to block mitochondrial pore formation by binding 
to both Bax and Bak preventing the release of apoptogenic factors and 
propagation of the intrinsic apoptotic pathway (White 2001).  
 
E1B55K functions to inhibit p53-dependent cell cycle arrest and apoptosis. This 
is mediated through high affinity binding of E1B55K to the transcriptional 
activation domain of p53 thereby preventing coactivators from binding p53 
(Shenk 2001). Additionally, E1B55K contains a C-terminus repression domain 
which when mutated was unable to inhibit p53-mediated transcriptional 
activation despite retaining the ability to bind p53 like wild-type E1B55K. This 
suggests by binding to p53, E1B55K converts p53 into a repressor of p53-target 
genes (Berk 2005). E1B55K is also found in a complex with viral encoded 
protein, E4orf6, which together are bound to E3 ubiquitin ligases to form a high 
molecular weight ubiquitin ligase complex. Two known substrates for 
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E1B55K/E4orf6 ubiquitin ligase complex include p53 and the cellular Mre11-
Rad50-Nbs1 (MRN) complex, involved in the processing of double-stranded 
DNA breaks prior to repair (Berk 2005). It is believed E1B55K mediates 
substrate recognition, since it is able to bind to p53 or the MRN complex and 
together with E4orf6 targets these proteins for proteasome-mediated 
degradation. Degradation of certain cellular proteins thus promotes efficient viral 
replication by abrogating p53-mediated apoptosis and preventing the activation 
of the DNA damage response that would result in concatamer formation of viral 
DNA and prevention of viral assembly (Schwartz, Lakdawala et al. 2008). 
 
1.6.3.3.4. Viral mechanisms to counter the host 
immune defence 
 
In response to adenoviral infection, the innate and adaptive immune responses 
are induced. The activation of the innate immune response involves 
upregulation of NF-κB, a key regulator of the antiviral response and activates 
transcription of cytokines such as interferon (IFN) (type I and II) and TNF-α as 
well as adhesion molecules. Adenoviruses encode three gene products that 
ensure persistence of the adenovirus within the host. E1A proteins and VA RNA 
I, which have generally been found to inhibit the cellular response to IFN and 
products encoded by the E3 region which protect infected cells from cytotoxic 
lymphocyte (CTL) and TNF-α-mediated cell killing (Shenk 2001).  
 
IFN is released early during viral infection and binds to cell receptors and 
activates cellular JAK/STAT pathway with the result of STAT proteins binding to 
interferon response elements (ISREs) and stimulating the transcription of RNA 
receptor, protein kinase R (PKR) and other immunomodulators. E1A inhibits the 
function of IFN by blocking transcription of IFN- and NF-κB-target genes, which 
can be attributed to E1A competing for binding with p300/CBP. This in turn 
represses the transactivation function of members of the STAT family, STAT1 
and STAT2 together with p65, a coactivator of the transcription factor NF-κB 
(Bhattacharya, Eckner et al. 1996; Zhang, Vinkemeier et al. 1996; Gerritsen, 
Williams et al. 1997). Additionally, E1A can bind STAT1 via its N-terminus, 
independent of the p300-binding region, blocking STAT1-dependent gene 
activation. These findings indicate that E1A can target STAT1-dependent events 
by several mechanisms (Look, Roswit et al. 1998). Another mechanism of 
 97 
impeding the IFN response is through the inhibition of PKR. Upon binding to 
double-stranded RNA, the kinase activity of PKR is activated resulting in the 
phosphorylation of the α-subunit of eukaryotic initiation factor 2 (eIF2). This 
prevents the exchange reaction of eIF-2-GDP to eIF-2-GTP resulting in 
inhibition of protein translation during viral infection. However, the conserved 
secondary structure adopted by VAI enables it to bind competitively with PKR 
and inhibit its kinase activity thus preventing symmetrical transcription of viral 
DNA from activating PKR (Shenk 2001).  
 
The protein products encoded by the E3 region are primarily involved in 
protecting infected cells from the immune system however the adenoviral death 
protein (ADP) is associated with mediating viral release at the end of the lytic 
cycle. The E3 and E2 promoters contain binding sites for cellular transcription 
factors NF-κB and nuclear factor-interleukin-6 (NF-IL6) respectively 
underpinning the intricate mechanisms adenoviruses have evolved to protect 
infected cells from host immune responses (Shenk 2001). Recognition and lysis 
of virus-infected cells by CTLs requires the recognition of virus antigen in a 
complex with major histocompatibility complex class I proteins on the cell 
surface. E3A viral-encoded protein, E3gp19K is a transmembrane protein that 
localises in the endoplasmic reticulum (ER) where it binds to the heavy chain of 
the major histocompatibility complex (MHC) class I proteins and prevents the 
transport of peptide antigens to the cell surface and subsequent detection by 
CTLs. It also binds and inhibits the transporter associated with antigen 
presenting (TAP), an ER-membrane protein whose function is to transport 
processed peptides from the cytosol into the ER lumen (Shenk 2001). On the 
other hand, evasion of immune surveillance can also be mediated by E1A 
sequestering CBP resulting in downregulation of the MHC class II protein 
expression (Kretsovali, Agalioti et al. 1998). E3B products, 10.4 and 14.5Kd 
(also known as the receptor internalisation and degradation complex (RID)-α/β) 
block TNF and FasL-induced apoptosis elicited by CTL-bearing FasL or TNF-α 
engagement by triggering internalisation and degradation of the respective 
death domain receptors (Shenk 2001). FasL and TNF-induced apoptosis is also 
blocked by the interaction of E3B-encoded 14.7Kd protein with the downstream 
effector, caspase-8/FLICE or through binding and inhibiting the pro-apoptotic 
FIP proteins which are ordinarily involved in keeping NF-κB associated with its 
inhibitor, IκBα (Shenk 2001). 
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1.6.3.4. Viral genome replication 
 
Viral genome replication proceeds after the products of the early genes have 
established optimum conditions for DNA synthesis and products encoded from 
the E2 region required for DNA replication have accumulated. DNA replication 
endures until the host cell dies. ITRs are located at either end of the DNA 
strands and contain the replication origin comprised of cis-acting sequences. 
Within this sequence, three functional domains have been defined; domain A 
recruits viral encoded pTP and DNA polymerase while domains B and C bind 
cellular proteins, nuclear factor (NF)I and NFIII respectively to increase initiation 
efficiency of DNA synthesis. pTP binds covalently to the 5’ termini of the DNA 
strands and serves as primer for DNA replication and maintains the integrity of 
the ITR sequence during multiple rounds of replication. pTP also interacts with 
the nuclear matrix and this is thought to anchor adenovirus DNA replication 
complexes near suitable cellular factors. pTP binds DNA polymerase which 
possesses 5’-to-3’ polymerase activity and 3’-to-5’ exonuclease, proofreading 
function. Once initiation of DNA synthesis has occurred, chain elongation is 
driven by the DNA-binding protein (DBP) enabling the DNA polymerase to be 
highly processive. The DBP is also required to maintain DNA strand separation. 
Another cellular factor, NFII, identified as having topoisomerase activity, may 
also assist in DNA replication to overcome problems in DNA topology that occur 
after extensive replication (Shenk 2001). 
 
1.6.3.5. Viral assembly and release 
 
Soon after DNA replication begins, transcription of a large transcript encoding 
the late genes occurs. Through a complex series of splicing reactions, mRNAs 
grouped into five families (L1 to L5) are generated and encode the structural 
components of the progeny virions as well as the components required for the 
maturation and encapsidation process (Table 3). The MLP controls the 
expression of the late genes and at the beginning of the lifecycle transcription 
occurs at a low level. However, after DNA replication ensues it becomes several 
hundred-fold more active. The shift in late gene expression from the MLP is 
controlled by the cellular transcription factor, USF/MLTF, which binds to a site 
upstream of the MLP after DNA synthesis begins with the viral protein, IVa2 
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cooperating with USF/MLTF to regulate the transition from early to late viral 
transcription (Shenk 2001).  
 
Once DNA replication is initiated and late viral mRNA are synthesised, the 
accumulation of cellular mRNAs in the cytoplasm is halted. This is attributed to 
late viral cycle function of E1B55K, which is able to facilitate shutdown of host 
protein synthesis. This occurs as a consequence of E1B55K-mediated export of 
the viral L4-100K protein. Once L4-100K has been exported out of the nucleus, 
it is able to inhibit the translation of capped cellular mRNA by preventing the 
phosphorylation and activation of the cellular initiation factor eIF-4F, which 
normally contributes to cellular mRNA translation (Cuesta, Laroia et al. 2000). 
On the other hand, viral mRNA translation is enabled due to the selective export 
of viral mRNA into the cytoplasm by the E1B55K/E4orf6 complex. E1B55K 
exhibits an intrinsic RNA-binding activity while E4orf6 contains a nuclear export 
sequence and shuttles between the nucleus and the cytoplasm. Viral mRNA is 
preferentially translated as they are not capped unlike cellular mRNA and 
possess a unique 5’-non-coding region termed the tripartite leader sequence. 
This 5’-UTR region allows the 40S ribosome to translate the mRNA using 
“ribosomal jumping” without requiring the helicase activity of eIF-4F that is 
required for cellular mRNA translation (Shenk 2001). 
 
The accumulation of synthesised viral DNA and structural proteins initiates viral 
assembly. Hexon monomers are assembled intro trimers with L4-100Kd serving 
as a scaffold while trimeric fiber structures and pentameric penton bases 
assemble more slowly. The hexon and penton capsomeres then accumulate in 
the nucleus where the packaging sequence within the DNA allows for DNA-
capsid recognition resulting in the viral genome entering the empty capsid. IVa2 
binds to viral DNA and plays a role on encapsidation along with L1 52/55Kd and 
pVII. The L3 encoded protease functions later in the assembly process and 
cleaves pVI, pVII, pVIII and pTP to stabilise the particle and render it infectious 
(Shenk 2001).  
 
Virus encapsidation is accompanied by changes to the nuclear infrastructure 
and permeabilisation of the nuclear membrane. Subsequent escape and spread 
of progeny virus occurs through the disruption of intermediate filaments, which 
include the cleavage of cytokeratins K7 and K18 by the viral protease preventing 
further polymerisation. Together with host protein synthesis shutoff, the cell is 
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incapable of replacing components of the cytoskeleton and consequently the 
structural integrity of the cell is compromised. The E3 ADP facilitates cytolysis of 
the cell. The mechanism by which this occurs is unclear however the localisation 
of ADP to the nuclear envelope and Golgi was lost in adenoviruses with mutated 
ADP. This correlated with regions important for N- and O-linked glycosylation 
resulting in lower protein stability and reduced lytic behaviour (Tollefson, Scaria 
et al. 2003). 
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1.7. Oncolytic adenovirus therapy 
 
Adenoviruses have been engineered as novel targeted anticancer agents. The 
intrinsic nature of viruses to infect, replicate and lyse cells causing cell death 
and release of viral particles to infect neighbouring cells make them ideal 
candidates for further development. Ad5 in particular is an attractive vector for 
genetic manipulation (see section 1.6.1). The adenoviral genome is genetically 
stable and does not integrate into the host. This prevents complications with 
insertional mutagenesis, which can occur with lentivirus or gammaretrovirus-
based-vectors, which have been used as gene delivery tools. However, 
insertional mutagenesis is unlikely to cause a problem in cancer cells which are 
already deregulated. The small size of its genome also enables easy 
modifications and can be exceeded by up to 5% by transgene-insertions. 
Engineered vectors can subsequently be produced in large quantities of high-
titre stocks (1012pt/ml) in the laboratory and good manufacturing practice (GMP) 
conditions. Ad5 is able to infect and replicate in cycling and non-cycling cells 
since the E1 gene is able to induce S phase. A rapid lytic lifecycle is completed 
within 18-24h and in a single replication cycle, up to 10000-fold amplification of 
progeny virus can be released. 
 
1.7.1.  Tumour selectivity 
 
Since wild-type adenoviruses target most epithelial cells as well as cancer cells 
this requires adenoviruses to be engineered to ensure tumour selectivity. One 
approach has been to engineer adenoviruses to complement mutations in 
cancers (for example proteins involved in cell cycle and apoptosis) with loss-of-
function mutations within the adenovirus genome that are essential for virus 
propagation in normal cells but are dispensable for replication in cancer cells 
with deregulated regulatory pathways (Figure 11). Complementation therefore 
renders the adenovirus selective for cancer cells and will be referred to hereafter 
as replication-selective oncolytic viruses. 
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Figure 11. Schematic diagram of cancer-selective killing by oncolytic adenoviruses 
Oncolytic adenoviral mutants contain gene deletions that are complemented in deregulated 
cancer cells resulting in a productive viral lifecycle thereby killing cancer cells and allowing virus 
spread. Normal cells do not support viral replication since the viral mutants lack essential proteins 
for cell cycle progression and inhibition of apoptosis. Adapted from Choi, Lee et al. 2012. 
 
During a productive wild-type adenovirus infection, E1A induces p53 
accumulation as discussed in section 1.6.3.3.2. To counteract this effect, 
E1B55K represses p53-mediated transactivation and together with E4orf6 
promote p53 degradation thereby preventing cell-cycle arrest and apoptosis. 
Replication-selective adenoviruses were initially based on the deletion of the 
E1B55K gene and resulted in the development of the archetypal oncolytic virus, 
dl1520 (Bischoff, Kirn et al. 1996) (also known as ONYX-015). This virus was 
designed to complement cancer cells with non-functional p53 either through 
direct p53 mutation or mutations in upstream or downstream p53 regulators and 
effectors such as p14ARF and Bax respectively. By deleting E1B55K, ONYX-015 
is unable to degrade p53 during viral replication thereby restricting replication in 
normal p53-expressig cells but able to replicate in p53-deficient cells. Further 
investigations into the selectivity of ONYX-015 found that the mutant was unable 
to efficiently replicate in some p53-deficient cell lines or cell lines mutated in 
p53-related genes (e.g. p14ARF) (Goodrum and Ornelles 1998; Edwards, Dix et 
al. 2002). In contrast, it was also found to replicate in certain cells retaining wild-
type p53 (Goodrum and Ornelles 1998; Rothmann, Hengstermann et al. 1998). 
Furthermore the mutant was shown to replicate in p53-expressing normal cells 
overriding G1/S and G2/M checkpoints, retarding mitosis thus resulting in the 
accumulation of aneuploid cells (Cherubini, Petouchoff et al. 2006). Selectivity of 
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ONXY-015 was later attributed to the unique ability of certain tumour cells to 
efficiently export late viral mRNA in the absence of E1B55K. As discussed in 
section 1.6.3.3.3, another function of E1B55K together with E4orf6, is to mediate 
the export of viral mRNA while shutting off protein synthesis of cellular proteins. 
In tumour cells that are not able to facilitate the export of viral mRNA transcripts, 
the absence of E1B55K would severely attenuate the replication of ONYX-015. 
This caveat in ONYX-015 replication-selectivity may go towards partially 
explaining the reported attenuation in replication of virus compared with wild-
type virus and therefore suboptimal antitumour efficacy (O'Shea, Johnson et al. 
2004).  
 
Nevertheless, 18 Phase I and II trials have been conducted with ONYX-015 
establishing safety for all routes of administration for a variety of indications. 
However, administration as a single agent ONYX-015 did not show therapeutic 
efficacy. Less than 15% of cases resulted in clinical benefit in patients with head 
and neck cancer who received intratumoural injection of ONYX-015 
(Nemunaitis, Khuri et al. 2001) and only when combined with standard 
chemotherapy could this oncolytic virus attain an objective response (Khuri, 
Nemunaitis et al. 2000). In a Phase III trial in China, a 79% response rate was 
achieved in patients receiving a near identical mutant, H101 (Oncorine, 
Shanghai Sunway, China) by intratumoural injection in combination with 
cisplatin or 5-fluorouracil (5-FU) compared with 40% with patients receiving 
chemotherapy alone (Xia, Chang et al. 2004). The favourable outcome in this 
trial resulted in the licensing of H101 in China for the treatment of head and 
neck squamous cell carcinoma in 2005 (Garber 2006) and revealed the potential 
of oncolytic adenoviral therapy as a promising anticancer agent. However, long-
term follow-up data and survival benefits have not been reported.   
 
Since ONYX-015 did not show clinical efficacy as a single therapy, this 
highlighted the requirement for further improvements of oncolytic adenoviruses. 
Enhanced response rates in combination with chemotherapy suggested that 
optimising combination therapies could increase efficacy while reducing the 
toxic side effects associated with chemotherapy treatment. Extensive knowledge 
of adenoviral biology and the historical use of replication-defective adenoviral 
vectors for cancer gene therapy defined the following strategies to engineer 
cancer-selective oncolytic mutants: (i) Restricting adenoviral replication using 
tissue/tumour-specific promoter and/or enhancer elements, (ii) retargeting 
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adenovirus attachment and infection and (iii) arming adenoviruses with 
therapeutic transgenes. These modifications have been based on viral 
backbones derived from ONYX-015 or more recently replication selective 
oncolytic adenoviruses with complementation-specific deletions in other areas of 
the adenoviral genome specifically deletions in the E1ACR2 gene and/or the 
E1B19K gene. 
 
1.7.1.1. Tissue/tumour-specific promoter/enhancer 
elements for PCa 
 
Controlling the expression of viral genes involved in replication provides another 
approach for ensuring oncolytic viruses selectively replicate in a specific tissue 
or tumour type. Since E1A is the first viral gene to be expressed, the expression 
of this gene has been placed under the control of an exogenous promoter active 
in a particular cancer. An early example is CG7060, in which a PSA 
promoter/enhancer element was inserted between the native E1A promoter and 
the E1A coding region. This resulted in replication of CG7060 being elevated in 
tissue with high levels of PSA expression (Rodriguez, Schuur et al. 1997). 
CG7060 was proven to be safe with evidence of decreases in PSA levels in a 
Phase I clinical trial for patients with recurrent localised PCa (DeWeese, van der 
Poel et al. 2001). Further modifications of this virus yielded CG7870, which uses 
a rat probasin promoter and a minimal PSA enhancer/promoter to drive E1A and 
E1B expression respectively. Furthermore, this virus contains an intact E3 
region required for modulating the immune response and preventing premature 
elimination of infected cells. In Phase I /II trials, intraprostatic delivery of 
CG7870 was well tolerated in patients with localised disease while intravenous 
delivery for metastatic CRPC resulted in a decrease of PSA levels and 27% 
patients were free from progression at 6 months. Despite this, significant 
efficacy was not reported (Small, Carducci et al. 2006). No further trials have 
been described for either CG7060 or CG7870.  
 
Other tissue specific promoters used to direct replication of oncolytic 
adenoviruses to tumour cells include osteocalcin (for bone metastases of PCa) 
and the human telomerase reverse transcriptase (hTERT) promoter, which 
restricts viral replication to telomerase-positive cancer cells. One such oncolytic 
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adenovirus is OBP-301 where E1A expression is under the control of the hTERT 
promoter (Huang, Watanabe et al. 2008). 
 
1.7.1.2. Retargeting and detargeting of adenoviruses 
 
CAR is known to serve as a receptor for efficient infection in vitro of 
adenoviruses species A, C, D, E and F but not species B. Adenoviral vectors 
(mainly Ad2 and Ad5) have been shown to be inefficient at infecting cells in vivo 
due to neutralisation by pre-existing antibodies. A growing body of evidence has 
also indicated CAR may not be the primary receptor for in vivo binding. For 
example, species C adenoviruses infect cells in the airway, liver and 
lymphocytes, which express either none or very little CAR mRNA and ablation of 
CAR-binding from adenoviral vectors do not change their biodistribution in vivo. 
Furthermore, interaction between the fiber and CAR has been suggested to be 
involved in virus escape from the cell rather than attachment (Arnberg 2009). 
Therefore, in vivo, it is likely attachment of adenovirus to receptors other than 
CAR is also required for efficient viral infection. A number of examples include: 
CD46, which is expressed on the apical region of epithelial cells in the 
respiratory tract, lactoferrin, which has been found to facilitate Ad5 transduction 
through bridging interaction with cell surface receptors and HSPGs which are 
ubiquitously expressed (Arnberg 2009). 
 
The peptide motif, RGD is required for interaction with several integrins known 
to act as co-receptors for adenovirus infection. Efficient retargeting of oncolytic 
adenoviruses has been possible via the modification of the “knob” domain within 
the fiber region of Ad5, which binds CAR. CAR-independent pathways mediated 
infection in vitro when a cysteine-enriched RGD motif, RGD"4C was 
incorporated into the H1-loop of the fiber-knob domain (Krasnykh, Dmitriev et al. 
1998). This alteration has been integrated into a number of oncolytic 
adenoviruses to improve transduction. For example, alternative 
complementation mutant viruses with a small deletion in the E1ACR2 region 
such as Ad5Δ24RGD"4C has been retargeted to infect cells expressing 
intergrins which are more widely expressed on cancer cells (Pesonen, Diaconu 
et al. 2012). This oncolytic virus was determined to be safe in a Phase I for 
recurrent ovarian cancers and is currently being investigated in a Phase I trial 
for the treatment of recurrent gliomas (http://clinicaltrials.gov/NCT00805376). As 
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well as conferring higher tropism for cancer cells it also selectively replicates in 
cells with deregulated G1/S checkpoints and pRb signalling pathways due 
deletion of the CR2 domain in the E1A gene. The ΔCR2 mutants do not bind 
pRB preventing the formation of E1A/pRb complexes and blocking S phase 
initiation. In cells with deregulated cell cycle control the E1ACR2 region is 
surplus to requirements and a productive replication will ensue whereas these 
mutants are severely attenuated in non-proliferating cells. Adenoviral mutants 
with a small deletion in the E1ACR2 region such as dl922/947 and AdΔ24 
(Fueyo, Gomez-Manzano et al. 2000; Heise, Hermiston et al. 2000) have shown 
greater efficacy compared with dl1520 mutants in vivo (Lockley, Fernandez et 
al. 2006; Radhakrishnan, Miranda et al. 2010; Bhattacharyya, Francis et al. 
2011). Retargeting using the RGD-motif has also been employed by a more 
advanced version of OBP-301, OBP-405, which exhibited increased transfection 
efficiency in CAR-negative tumours as well as mediating CAR-dependent virus 
entry. It prolonged survival of mice with lung xenografts and selective replication 
was also determined in distant uninjected tumours demonstrating that 
retargeting increased target range by increasing infection efficiency (Taki, 
Kagawa et al. 2005).  
 
Another approach to retargeting is fiber knob switching. By incorporating an 
alternate subtype’s binding domain into a subtype2/5-based vector the chimeric 
adenovirus is able to bind to receptors that are overexpressed on the cell 
surface of cancer cells. One example is Ad5/3-Cox2L-Δ24 where the Ad5 fiber 
gene was substituted with the fiber gene of Ad3. This resulted in the chimeric 
virus binding to the CD46 receptors, which are highly expressed on tumour cells 
(Pesonen, Nokisalmi et al. 2010). Additional modifications include a 24bp 
deletion in the E1ACR2 gene with E1A gene expression under the control of the 
cyclooxygenase 2 promoter. This triple-modified oncolytic adenovirus was found 
to be safe for compassionate use in patients with refractory or progressive solid 
tumours with anti-tumour activity in 61 patients (Pesonen, Nokisalmi et al. 2010). 
An alternative version designated ICOVIR-7 has the same E1ACR2 deletion 
under the control of an E2F-1 promoter designed to confer tumour-selectivity 
and increase E2F dependency on E1A expression. Enhanced infection 
efficiency was conferred by a RGD"4C motif in the fiber-knob region. Both 
viruses were demonstrated safe for the compassionate treatment of patients 
with refractory or progressive solid tumours and conferred anticancer activity 
(Nokisalmi, Pesonen et al. 2010). The use of alternate adenovirus serotypes 
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such as Ad3 may have improved potency in certain preclinical models due to 
affinity to CD46 receptors and lack of pre-existing antibodies to this serotype 
(Hallden and Portella 2012). 
 
Other means of achieving precise selectivity is by harnessing the high affinity 
and specificity found in antibodies. This adapter-based approach involves 
retargeting the oncolytic adenovirus to an alternative surface antigen on the cell 
surface. Bispecific targeting moieties have been developed wherein one site of 
the protein is directed against the viral capsid protein and the other site is 
specific towards a cell surface molecule. Previously, bispecific adapters have 
been complexed with the virus before administration and have shown good 
selectivity and affinity. However this strategy only allows for a single-round of 
infection as the amount of adapter protein is limited. To overcome this, 
replication selective oncolytic adenoviruses has recently been engineered to 
express the bispecific adapters themselves. One such virus (AdΔ24-425S11) 
encodes an anti-EGFR single chain Fv antibody fragment (scFv) 425 and anti-
adenovirus fiber knob (scFV s11) and demonstrated enhanced infectivity and 
anti-cancer properties on EGFR-positive, CAR-negative tumour cells and 
retained native binding to CAR and intergrins (van Beusechem, Mastenbroek et 
al. 2003).  
 
Other strategies have focused on combining retargeting modifications with the 
additional complexity of detargeting adenovirus vectors, which display tropism 
for the liver. Although efficacy can be attained with intratumoural administration, 
substantial challenges are encountered to attain efficacy after systemic delivery. 
Following intravenous delivery, oncolytic adenoviruses interact with high affinity 
to erythrocytes via CAR binding in conjunction with antibodies and complement 
thereby trapping virus in the circulation. Adenovirus binding to CAR also 
facilitates agglutination of erythrocytes resulting in reduced tumour delivery in 
vivo (Coughlan, Alba et al. 2010). In terms of liver tropism, Ad5, via its knob 
domain has been shown to bind a variety of coagulation factors such as FIX, 
FVIII and FX as well as components of the complement system such as C4 
binding protein (C4BP). These interactions as well as binding with HSPG or low-
density lipoprotein receptor on the surface of hepatocytes allow Ad5 to 
transduce these cells (Arnberg 2009). The interaction between adenovirus and 
the vitamin K-dependent zymogen, FX has been mapped to the hexon protein, 
providing a bridge for hepatocyte transduction and may be the major mode by 
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which Ad5 enters hepatocytes giving rise to the toxic side effects within the liver 
which is associated with systemic delivery of adenoviral vectors. Kupffer cells, 
the resident macrophages of the liver are also able to sequester adenovirus 
through opsonization of adenovirus with antibodies and/or complement thereby 
reducing the levels of the virus in circulation (Coughlan, Alba et al. 2010). 
Interactions between adenovirus and cells of the immune system also enhance 
clearance of the virus and most adults will have neutralizing antibodies against 
adenoviruses. Therefore in recent years it has been recognised that detargeting 
adenoviruses from their native receptor binding is as important as developing 
engineered adenoviruses with enhanced tumour cell specificity if systemic 
delivery and targeting of metastatic sites will be possible.  
 
One approach to overcome erythrocyte and liver binding uses polyethylene 
glycol (PEG) conjugated to the surface of the adenovirus resulting in a “stealth” 
adenovirus. PEGylated adenoviruses show increased plasma circulation, 
reduced liver toxicity and decreased innate immune responses. However on its 
own, PEGylation reduces CAR-mediated endocytosis due to steric hindrance 
from the PEG chains resulting in low transduction efficiency (Choi, Lee et al. 
2012). Therefore, to overcome this limitation, PEGylated adenoviruses require 
retargeting and moieties such as RGD peptides or folate ligand have been 
investigated (Choi, Lee et al. 2012). Recently, a replication-selective adenovirus 
(DWP418) assessed in Phase I trials was modified to generate a tumour 
targeted and PEGylated oncolytic virus (Kim, Sohn et al. 2011). Tumour-specific 
replication was controlled with the presence of the hTERT promoter. Potency 
was further enhanced with the deletion of the antiapoptotic E1B19K gene and 
inserting the relaxin gene in the E3 region. Retargeting was achieved using PEG 
conjugated to the human Her2/neu-specific MAb (Herceptin) and DWP418-
PEG-HER was found to specifically kill Her2/neu expressing cells. After 
intravenous injection, enhanced anti-tumour activity was demonstrated 
compared with the non-targeted, naked adenovirus and accumulated in the 
tumour tissue at 58.0x104-fold higher levels than the naked adenovirus. Liver 
uptake of the DWP418-PEG-HER was significantly lower than naked adenovirus 
with 3.7x105-fold less accumulation (Kim, Sohn et al. 2011). Another approach 
for increased tumour transduction is the use of mesenchymal stem cells 
(MSCs), which have intrinsic cancer tropism. Intravenous administration of 
MSCs preloaded with oncolytic adenovirus facilitated the delivery of virus to 
orthotopic breast and lung tumours, increasing the survival of mice. This method 
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has been evaluated in patients with refractory neuroblastoma (Pesonen, 
Kangasniemi et al. 2011). 
 
1.7.1.3. Arming oncolytic adenovirus with therapeutic 
transgenes 
 
Although oncolytic adenoviruses can kill tumour cells through complementation 
deletions in the genome or the introduction of tumour-specific promoters, 
potency can be further enhanced with the introduction of a transgene. These so-
called “armed” replication selective oncolytic adenoviruses have the advantage 
of amplifying the therapeutic gene with the virus so that each virus progeny will 
have inherited the transgene, infect neighbouring cells thus augmenting the 
potency of the oncolytic adenovirus. The insertion of a transgene into a 
replication selective oncolytic adenovirus also has the advantage of tumour cell-
specific restriction of the transgene decreasing the possibility of side effects 
from expression in normal cells.  
 
There have been many approaches to engineering armed oncolytic 
adenoviruses with insertion of transgenes being primarily expressed from the 
E1B or E3 regions of replicating adenoviruses either under the control of the 
corresponding viral promoter or after the insertion of tumour-
specific/heterologous promoters. Various types of transgenes have been 
inserted into oncolytic adenoviruses representing a variety of strategies for 
tumour eradication. It is beyond the scope of this thesis to discuss all of these 
strategies, which include enhanced cell killing, modulation of the tumour 
environment and stimulation of the immune response to the tumour. Here I will 
focus on the recent developments of oncolytic adenoviruses containing prodrug-
converting enzymes currently in clinical trials, promising targeting strategies that 
involve micro RNA (miRNA) as well as the insertion of tumour suppressor 
genes. 
 
1.7.1.3.1. Prodrug-converting enzymes 
 
Insertion of a non-mammalian prodrug-converting enzyme into a tumour-
selective adenovirus augments efficacy when a non-toxic prodrug is 
administered. This is converted to a toxic drug only in infected cells that express 
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the enzyme. Furthermore, cell killing is potentiated by the “bystander effect” 
when the toxic metabolite from the infected cell diffuses to neighbouring cells in 
the tumour through gap junctions. Another advantage of this approach is that it 
also avoids toxic effects of systemic administration of other types of cytotoxic 
therapy. A variety of pro-drug converting enzymes have been introduced into 
replication selective adenoviruses, however only recent outcomes will be 
described here.  
 
Ad5-YCD/mutTKSR39-rep-ADP is a second-generation suicide gene therapy 
replication-selective adenovirus deleted in the E1B55K region. It utilizes double-
suicide gene therapy by expressing yeast cytosine deaminase fused to an 
improved mutant herpes simplex virus thymidine kinase enzyme under the 
control of the cytomegalovirus (CMV) promoter, which converts non-toxic 5-
flurocytosine (5-FC) to 5-FU and ganciclovir to monophosphorylated nucleotides 
respectively. The ADP under the control of CMV promoter replaces the E3 
region for enhanced viral spread (Freytag, Barton et al. 2007). This virus is 
currently being evaluated in Phase II/III trials in newly diagnosed PCa patients in 
combination with 5-FC, ganciclovir and radiotherapy 
(http://clinicaltrials.gov/NCT00583492) after a Phase I trial in patients with 
localised recurrent PCa in combination with radiotherapy demonstrating safety 
and initial efficacy (Freytag, Movsas et al. 2007).  
 
Another variety of pro-drug converting enzyme is the Escherichia coli 
nitroreductase (NTR). This has been incorporated into a replication-defective 
(E1 and E3-deleted) adenovirus (CTL102). Delivery of prodrug CB-1954 
generates a highly toxic DNA cross-linking agent in infected cells. In a Phase I/II 
trial in patients with localised PCa, CTL102 was delivered by intraprostatic 
injection and CB-1954 administered systemically, decreases in PSA levels were 
demonstrated in 14 out of 19 patients (Patel, Young et al. 2009). This result 
suggests NTR enzymes could be incorporated into replication-selective 
adenoviruses.  
 
1.7.1.3.2. Small RNAs 
 
Micro RNA (miRNA) binding sites have been incorporated into replication 
selective adenoviruses with the aim of attenuating viral potency at sites of 
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normal tissue e.g. the liver but retaining wild-type efficacy at sites that do not 
express the relevant miRNA. Four copies of the hepatocyte-selective mir-122 
binding site were inserted at the 3’UTR of the E1A gene transcriptional cassette 
in wild-type adenovirus. Reporter gene expression with E1A fused to luciferase 
showed mir-122 binding sites reduced E1A expression up to 80-fold in murine 
hepatocytes following intravenous administration. In tumour cells, the virus 
retained full anti-tumour activity without the associated toxic effects of replication 
in the liver (Cawood, Chen et al. 2009). Similar findings were demonstrated with 
another mutant, which used six tandem repeats of the mir-122 binding site, 
which was also tumour selective for neuroendocrine tumours. Arrested 
replication of this mutant was demonstrated in normal liver cells demonstrating 
mir-122-mediated detargeting in the liver (Leja, Nilsson et al. 2010). This 
suggests tissue-specific miRNAs may be utilized to inhibit inappropriate E1A 
expression in certain cells types thereby reducing toxic effects. 
 
1.7.1.3.3. Tumour suppressor protein, p53 
 
Insertion of transgenes that have a direct cytotoxic effect is another way of 
improving potency. A variety of cytotoxic genes have been studied, the encoded 
products killing cells by a number of different mechanisms. These include 
overexpression of the viral ADP, which enhances the release and spread of the 
viral progeny and TNF-related apoptosis-inducing ligand (TRAIL), a 
transmembrane protein, which is able to kill tumour cells by initiating an 
apoptotic cascade and also improves viral release and spread in vivo (Cody and 
Douglas 2009). Another strategy is to induce apoptosis by expressing a tumour 
suppressor protein. p53 is an attractive candidate since 50% of human cancers 
are deficient in functional p53. Gene transfer of p53 has been found to be toxic 
in many cancer cell types. In one study, a E3-deleted mutant expressing p53 
from the fiber transcription unit via an internal ribosomal entry site was 
demonstrated to enhance oncolysis, viral release and spread in lung cancer cell 
lines without attenuating replication and was more potent than a mutant 
retaining ADP. It was also found to be less cytotoxic in normal fibroblasts 
(Sauthoff, Pipiya et al. 2002). Another study included p53 in the E3 region of a 
Δ24-mutant adenovirus. This virus was found to kill more efficiently in a variety 
of tumour cells with different p53 status in vitro. In vivo, it demonstrated 
enhanced anti-tumour efficacy in xenografts models of primary glioma (van 
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Beusechem, van den Doel et al. 2002; Geoerger, Vassal et al. 2004). More 
recently, a triple-deleted-mutant expressing p53 (SG600-p53) Δ24-deleted and 
where E1B was under the control of a hTERT promoter, demonstrated superior 
anti-tumour potency in xenografts models of human non-small cell lung cancer 
(Wang, Su et al. 2008). However limitations to p53-based therapy exist and 
certain cell lines are resistant to the effect of p53-mediated enhanced oncolysis. 
This arises from the presence of p53 regulators such as HDM2, which is 
overexpressed in certain cancers including PCa. The intrinsic nature of 
adenovirus to regulated p53 via E1B55K can also attenuate p53 expression. To 
overcome this restriction, p53 variants have been developed that are unaffected 
by HDM2- and E1B55K-mediated degradation. Sauthoff et al, using their 
previous oncolytic construct developed a p53 mutant that was impervious to 
HDM2 and E1B55K-mediated degradation. Although it demonstrated improved 
p53 stability and enhanced cell killing in vitro, anti-tumour efficacy in vivo was 
not substantially different to the control virus suggesting that in the case of this 
oncolytic construct, the presence of E1B19K and E1A were opposing p53 
function (Sauthoff, Pipiya et al. 2006). These studies indicate that introducing a 
potent tumour suppressor protein and transcription factor such as p53 into 
tumours enhances the efficacy of replication-selective adenoviruses. However 
this approach is not without its drawbacks. In designing a strategy to express 
proteins with a tumour suppressor function, the mutations required to create 
replication-selective adenoviruses need to be considered so as to complement 
transgene’s mode of action. This is essential since overlap exists between the 
signalling pathways used by the virus for replications and pathways activated by 
the transgene to mediate growth arrest and/or apoptosis. In the case of the 
transcriptional repressor, Hey1, AR and HDM2 are two targets that Hey1 
potentially uses to regulate cell proliferation and apoptosis. Since these 
pathways are deregulated in cancer, Hey1 is an attractive candidate to harness 
as a transgene for oncolytic therapy. 
 
1.7.1.4. AdΔΔ, an optimised replication-selective 
oncolytic adenovirus 
 
As discussed above, incorporating other modifications to increase cancer 
specificity has enhanced the potency of replication selective mutants. The 
majority contain deletions in either E1B55K or E1ACR2 genes for selective 
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replication in cancer cells. Since dl1520-based mutants resulted in attenuated 
replication and aberrant replication of dl922/947-based mutants occurred in 
normal cells (Heise, Hermiston et al. 2000), further improvements were required 
to enhance potency and specificity of replication-selective adenoviruses. A 
further advancement in adenoviral genetic engineering has entailed deleting the 
anti-apoptotic gene E1B19K gene. As described within section 1.6.3.3.3, 
E1B19K inhibits p53-dependent and –independent apoptosis in virally infected 
cells by preventing receptor-induced induced apoptosis by binding Bax and Bak 
thus preventing oligomerisation of Bax/Bak and mitochondrial pore formation 
(White 2001). Deletion of E1B19K is complemented in cancer cells due to 
frequent inactivation of apoptotic pathways while replication is hindered in 
normal cells since the absence of E1B19K prevents viral spread by TNF-
induced apoptosis (White 2001; Liu, Hallden et al. 2004). Numerous studies 
have demonstrated enhanced efficacy of wild-type and adenoviral mutants when 
combined with a variety of cytotoxic drugs compared with single agent 
treatments. Previous work in our laboratory demonstrated E1B19K-deleted 
mutants were able to sensitise pancreatic and PCa cells to gemcitabine- and 
docetaxel-induced apoptosis (Leitner, Sweeney et al. 2009; Oberg, Yanover et 
al. 2010).  
 
Based on results demonstrating that the removal of E1B19K in E1B55K- or 
E1ACR2-deleted mutants enhanced drug-induced cell killing, a double-deleted 
adenoviral mutant, AdΔΔ, deleted in the E1ACR2 and E1B19K region but 
retaining an intact E3 region was constructed (Oberg, Yanover et al. 2010). The 
genes encoding the E3 region are dispensable for virus replication in vitro 
however as discussed earlier in section 1.6.3.3.4, proteins expressed from this 
region modulate the host’s immune response in vivo. Adenoviral mutants 
retaining the E3 region prevented premature elimination of infected cells by 
macrophages (Wang, Hallden et al. 2003). The E3B-deletion has been 
associated with high levels of macrophage infiltration at the injection site of 
glioblastoma patients (Fulci, Dmitrieva et al. 2007) indicating the reduced 
efficacy of ONYX-015 and other E3B-deleted viruses may be in part due to 
deletions of the E3 genes. This is supported by results from a murine 
immunocompetent model, where E3B-deletion mutants’ demonstrated 
attenuated efficacy and greater virus clearance by macrophage infiltration 
compared with mutants with an intact E3 region (Hallden, Hill et al. 2003; Wang, 
Hallden et al. 2003). Furthermore, attenuated efficacy with E3-deleted mutants 
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could be rescued by combining adenoviral mutants with suboptimum doses of 
cytotoxic drugs (Cheong, Wang et al. 2008).  
 
This suggested that retention of the E3 region in AdΔΔ could further improve 
viral efficacy. Potency of AdΔΔ as a single agent was ascertained to be greater 
or similar to wild-type virus in vitro in prostate, pancreatic and lung cancer cells 
while replication was attenuated more than single-deleted AdΔCR2 in normal 
cells (Oberg, Yanover et al. 2010). AdΔΔ and single-deleted mutants (AdΔCR2 
and AdΔ19K) synergised with docetaxel and mitoxantrone in DU145 while in 
PC3 cells, synergistic cell death was greater for AdΔΔ + drug combinations 
compared with single-deleted mutants. In PC3 and DU145 prostate xenografts 
models, AdΔΔ in combination with docetaxel showed enhanced anti-tumour 
potency compared with respective single agent treatments. In addition, 
adenoviral mutants with intact E3B-genes (AdΔΔ or AdΔCR2) in 
immunocompetent murine mouse models were more efficacious compared with 
their corresponding E3B-deleted mutants with no increase in macrophage 
infiltration detected (Oberg, Yanover et al. 2010).  
 
To date, a large proportion of oncolytic adenoviral mutants entering or already in 
human clinical trials lack the entire E3 region or the E3B gene. By retaining the 
E3 region AdΔΔ offers prolonged efficacy in vivo over current vectors while the 
removal of the E1B19K gene eliminates E1B19K-mediated inhibitory effects of 
drug-induced apoptosis resulting in enhanced cell killing. This therefore makes 
AdΔΔ an ideal candidate for further arming with therapeutic genes. 
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1.8. Research rationale 
 
Treatment with ADT including medical castration and AR antagonists appears to 
be a major driving force in reactivating and deregulating the AR signalling 
pathway. Eventually a PCa phenotype resistant to hormonal deprivation therapy 
emerges and cytotoxic drug chemotherapy eventually becoming ineffective thus 
highlighting the urgent need to develop novel therapies for the treatment of 
CRPC. Crucially, knocking down AR expression in CRPC cells induced 
apoptosis in vitro and reduced tumour growth in xenografts models (Liao, Tang 
et al. 2005; Cheng, Snoek et al. 2006) providing evidence that targeting AR 
therapeutically is highly feasible. Since conventional antagonists such as 
bicalutamide bind AR with low affinity and either cannot supress AR activity in 
CRPC or act as a partial agonist, current strategies have focused on developing 
superior AR antagonists with higher AR binding affinity, reduced AR nuclear 
translocation and lower AR-mediated transactivation of target genes. It is 
however highly likely PCa tumours will develop resistance to these treatments 
as well. Therefore, other approaches aimed at inhibiting AR signalling are 
required. 
 
Recently, a gene expression profiling study has shown that a transcription-
based AR activity signature from androgen-dependent LNCaP cells was 
severely attenuated in CRPC cells (Mendiratta, Mostaghel et al. 2009). 
Genome-wide studies using ChIP-based analyses identified CRPC-specific AR 
binding events associated with a subset of genes that were not present in 
androgen-dependent LNCaP cells, suggesting ligand-free AR in CRPC cells 
regulates another group of genes which could contribute to the progression of 
CRPC (Wang, Li et al. 2009). This could potentially explain why current 
therapies, which block ligand-bound AR, cannot prevent ligand-free AR from 
driving cells through the cell cycle (Wang, Li et al. 2009). This underscores the 
significance of deregulated AR transcriptional activity in CRPC resulting in 
aberrant AR-mediated gene transcription. The identification of the Notch 
effector, Hey1 as a corepressor of AR signalling, presented a novel approach at 
inhibiting abnormal AR signalling. Since Hey1 has been found to be either 
downregulated or restricted to the cytoplasmic compartment in human primary 
PCa tumours, this could be functionally significant in PCa development, 
preventing Hey1-mediated modulation of androgen signalling in the prostate 
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(Belandia, Powell et al. 2005; Wang, Leow et al. 2006; Whelan, Kellogg et al. 
2009). The ectopic expression of the transcriptional corepressor, Hey1 may 
therefore provide a means of targeting and blocking AR-dependent transcription 
thus circumventing the associated problems with other AR inhibitors such as 
antiandrogens. This strategy affords the advantage of enhanced specificity 
through interacting with other proteins unlike the small molecule approach, 
which cannot always guarantee specificity. Moreover Hey1 has been 
demonstrated to bind to the NTD region of AR and therefore has the potential of 
binding to and inhibiting not only ligand-bound AR but also constitutive AR splice 
variants that are deleted in the LBD region. This is the first study using a 
transcription factor corepressor to target AR activity.  
 
We therefore hypothesised whether the introduction of Hey1 into AdΔΔ, an 
optimised replication selective adenovirus generated in our laboratory, may 
enhance viral efficacy in PCa cells. The relatively small size of Hey1 (897bp) 
permits its insertion into the adenoviral genome without compromising viral 
function. We proposed to replace the E3gp19K region of the viral genome with 
Hey1 since it was previously demonstrated deletion of E3gp19K enhanced viral 
gene expression and improved efficacy in an immunocompetent mouse model 
by increasing CTL infiltration (Wang, Hallden et al. 2003). To harness the highly 
temporal nature of viral gene expression Hey1 would be placed under the 
control of the early endogenous E3 promoter. This would be advantageous 
since E3 gene expression does not require virus DNA replication therefore 
allowing Hey1 expression during circumstances when virus replication may be 
attenuated.  
 
A key feature of oncolytic adenovirus therapy is its enhanced efficacy in 
combination with other anticancer agents such as chemotherapy and 
radiotherapy (Hakkarainen, Rajecki et al. 2009; Oberg, Yanover et al. 2010; 
Radhakrishnan, Miranda et al. 2010). This trait has been attributed to E1A 
expression since E1A has been found to synergise with cytotoxic agents with 
distinct mechanisms of action. For example, E1A sensitised cells to DNA-
damaging drugs gemcitabine or cytoskeleton-targeting drugs such as palitaxel 
(Lee, Tai et al. 2003; Liao, Zou et al. 2004; Leitner, Sweeney et al. 2009). The 
exact mechanisms involved in sensitisation are obscure since numerous cellular 
proteins can bind E1A thereby targeting a number of different cellular pathways 
(Frisch and Mymryk 2002; Berk 2005). Furthermore, the individual genetic 
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status present in cancer cells also controls the mechanism of E1A-dependent 
sensitisation. Our laboratory has previously ascertained the E1AΔCR2 deletion 
to be redundant for sensitisation in replication-selective adenoviruses rendering 
the AdΔΔ mutant suitable for further optimisation (Oberg, Yanover et al. 2010; 
Miranda, Maya Pineda et al. 2012). In addition to ascertaining the biological 
effects of Hey1 alone, we also sought to determine the activity of Hey1 in 
combination with chemotherapeutic drugs since the administration of these 
agents are likely to be required for optimum tumour efficacy of AdΔΔ-based 
mutants in vivo. Hey1 was initially inserted into a non-replicating adenoviral 
vector to establish proof-of-concept and to characterise the effects of Hey1 and 
putative mechanisms of action alone and in combination with cytotoxic drugs. 
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1.8.1.  Previous work 
 
Previous work in our laboratory investigated the effect of Hey1 in PCa cells by 
constructing a non-replicating recombinant adenovirus replacing the E1 gene 
with a CMV-Hey1 cassette and which was also deleted for the E3 gene 
(Ad5Hey1; ΔE1 and ΔE3) (Cheong et al, manuscript in preparation). Expression 
of Hey1 was verified in four PCa cell lines, AR-positive 22Rv1 and LNCaP cells 
and AR-negative DU145 and PC3 cells (Figure 12). Expression of Hey1 was 
observed in 22Rv1, LNCaP and DU145 cells from 24h post-infection. Hey1 
expression in PC3 cells was delayed slightly but was evident from 48h post-
infection (Cheong et al, manuscript in preparation). This difference is likely to be 
a reflection in decreased viral transduction in PC3 cells compared with the other 
cell types. 
 
 
Figure 12. Western blot showing Hey1 expression over time in a panel of PCa cell lines 
Cells were infected with Ad5Hey1#1 at 100ppc (22Rv1), and 1000ppc (LNCaP, DU145 and PC3) 
(section 2.7.1). After 2h infection medium was removed and replaced with 10% FBS-containing 
medium. Cell lysates were harvested at 12, 24, 48 and 72h post-infection and prepared for 
separation on polyacrylamide gels. 20µg of protein was loaded per lane and blotted for Hey1 
using a rabbit anti-Hey1 antibody (Chemicon, Millipore, MA, USA) at a dilution of 1/300. KU70 or 
α-actin were used as loading controls (Cheong et al, manuscript in preparation) 
 
To investigate whether Hey1 expressed from a non-replicating adenoviral vector 
was able to repress AR signalling, 22Rv1 cells were transfected with an AR-
responsive luciferase reporter plasmid (MMTV-Luc) and the effect of Ad5Hey1 
on AR transcriptional activity assessed (Figure 13). Addition of the synthetic 
androgen, mibolerone increased AR transcriptional activity compared with 
untreated cells and this was decreased when cells were infected with Ad5Hey1 
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(10-100ppc). The addition of the antiandrogen, bicalutamide partially inhibited 
mibolerone-induced AR activity and this was further decreased in the presence 
of Ad5Hey1 suggesting Hey1 and bicalutamide cooperate to decrease AR 
activity (Cheong et al, manuscript in preparation). 
 
 
Figure 13. Ad5Hey1 represses AR transcriptional activity in 22Rv1 cells and cooperates 
with bicalutamide to further decrease AR activity 
Cells were infected with 10, 30 and 100ppc Ad5Hey1#1. The following day cells were co-
transfected with AR reporter plasmid MMTV-Luc and a renilla luciferase under the control of the 
SV40 promoter (pRL-SV40) for normalisation (section 2.5.1). The next day cells were treated with 
0.1nM mibolerone and/or 1µM bicalutamide. Cells were lysed the following day and luciferase 
expression detected using a dual luciferase reporter assay system. Western blot analysis (insert) 
shows Hey1 expression at 72h post-infection. Data is mean of 3 independent experiments. 
(Cheong et al, manuscript in preparation). 
 
Since Ad5Hey1 was able to decrease AR transcriptional activity in an AR-
positive PCa cell line and AR signalling has been shown to be critical for the 
survival of PCa cells, the potency of Ad5Hey1 to inhibit cell growth was 
evaluated using the MTS cell viability assay. The dose required to kill 50% of 
cells (Effective Concentration; EC50) was assessed. Ad5Hey1 was significantly 
more cytotoxic in the AR-positive cell lines 22Rv1 and LNCaP compared with 
the negative control virus, Ad5GFP (CMV-GFP replaces E1, intact E3) and was 
similar in potency to the apoptosis-inducing adenoviral E1A protein (AdE1A12S; 
CMV-E1A12S replaces E1, ΔE3) (Table 4). Surprisingly, Ad5Hey1 was also 
cytotoxic in AR-negative DU145 cells suggesting Ad5Hey1 is able to kill PCa 
cell via both AR-dependent and AR-independent mechanisms. In contrast, AR-
negative PC3 cells, Ad5Hey1 was no longer as potent as AdE1A12S and 
activity was similar to Ad5GFP (Table 4) indicating Ad5Hey1-dependent 
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cytotoxicity is dependent on a variety of specific genetic alterations in PCa cells 
(Cheong et al, manuscript in preparation).  
 
Table 4. EC50 values for Ad5Hey1, AdE1A12S and Ad5GFP in PCa cell lines 
 Ad5Hey AdE1A12S Ad5GFP p value  
22Rv1 80±40 30±20 2200±600 p<0.05 
LNCaP 17000±6600 13000±6400 65000±1200 p<0.01 
DU145 12000±4400 5100±1700 191000±72000 p<0.05 
PC3 >100000 13000±5300 >100000 ns 
Dose response curves were constructed by treating cells with five-fold serially diluted Ad5Hey1#1, 
AdE1A12S and Ad5GFP and cell death determined by MTS viability assay 6 days post-infection to 
calculate EC50 (particles per cell; ppc). Results are average of 4 independent experiments ± SEM. 
Statistical analysis was carried out using an unpaired Student’s t-test comparing Ad5Hey1 with 
Ad5GFP (Cheong et al, manuscript in preparation). 
 
Many studies have shown enhanced efficacy of replication-selective 
adenoviruses in combination with chemotherapeutic drugs compared to single-
agent treatments. Since the ultimate aim was to construct a Hey1-expressing 
oncolytic adenovirus, potency of Ad5Hey1 in combination with 
chemotherapeutic drugs currently used in the clinic for PCa was assessed. EC50 
values for mitoxantrone and docetaxel with and without fixed virus doses were 
evaluated (Figure 14). After Ad5Hey1 infection, the EC50 values of both drugs 
were significantly decreased in 22Rv1, LNCaP and DU145 but not PC3 cells 
compared with an equal dose of Ad5GFP. As expected, AdE1A12S was even 
more potent at sensitising all cell lines to the chemodrugs, in agreement with 
published data of E1A proteins as a potent sensitising and apoptosis-inducing 
agents (Lowe, Ruley et al. 1993; Liao, Yu et al. 2007; Miranda, Maya Pineda et 
al. 2012). These results indicate that Ad5Hey1 not only sensitises AR-positive 
cells to chemodrugs but that it does so also through AR-independent 
mechanisms in DU145 cells (Cheong et al, manuscript in preparation). 
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Figure 14. Ad5Hey1 sensitises 22Rv1, LNCaP and DU145 but not PC3 cells to docetaxel- 
and mitoxantrone-induced cell killing 
Dose response curves to docetaxel or mitoxantrone with and without fixed dose of Ad5Hey#1, 
AdE1A12S or Ad5GFP (22Rv1, 30ppc, LNCaP, DU145 and PC3; 1000ppc) were generated and 
cell death determined 6 days post-treatment by MTS viability assay. Drug EC50 values were 
calculated for drug alone relative to untreated cells or in combination with each virus relative to the 
percentage of cell death induced by the virus alone. Histograms show relative EC50 values as a 
percentage of drug alone. Results are a mean of triplicate wells from 3 independent experiments ± 
SD. Statistical analysis was carried out using an unpaired Student’s t-test comparing Ad5Hey1 
with Ad5GFP, p<0.05 (*), p<0.01 (**) compared with drug alone (Cheong et al, manuscript in 
preparation). 
 
As administration of non-replicating viruses as single-agents have little efficacy 
in vivo due to their limited viral spread, potency in combination with 
mitoxantrone and docetaxel was assessed to investigate whether the promising 
in vitro data could be translated to PCa xenograft models. In the LNCaP model, 
Ad5Hey1 (5x109vp; virus particles) significantly reduced tumour growth when 
administered as a single agent compared with Ad5GFP and also increased 
median survival from to 54 days (PBS or Ad5GFP) to 92 days (Ad5Hey1). 
Prolonged survival was also observed when Ad5Hey1 was combined with a 
non-efficacious dose of docetaxel (6mg/kg) with 75% of animals still alive after 
110 days compared with 40% of animals after single-agent Ad5Hey1 treatment 
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and no animals alive with docetaxel alone or docetaxel with Ad5GFP (data not 
shown). In the DU145 model, Ad5Hey1 did not inhibit tumour growth when 
administered alone however in combination with a non-efficacious dose of 
docetaxel (10mg/kg), Ad5Hey1 (1x1010vp) significantly reduced tumour growth 
and median survival was prolonged from 62 days for docetaxel or Ad5Hey1 
alone to 96 days when combined (data not shown) (Cheong et al, manuscript in 
preparation).  
 
In summary these results demonstrate that a non-replicating recombinant 
adenovirus construct is effective at expressing Hey1 in a panel of PCa cell lines 
over an extended period of time. In agreement with the literature, Hey1 
expression results in repression of androgen-stimulated AR signalling in 22Rv1 
cells and was also able to cooperate with bicalutamide to further repress AR 
activity. Furthermore, Ad5Hey1 was cytotoxic to 22Rv1, LNCaP and DU145 
cells and sensitised these cells to chemotherapeutic drug-induced cell killing in a 
comparable manner to the positive-control virus, AdE1A12S. Most promisingly, 
Ad5Hey1 demonstrated efficacy in PCa xenograft mouse models as a single 
agent (LNCaP model) and in combination with docetaxel (DU145 and LNCaP 
models) demonstrating the potential use of Hey1 as a therapeutic transgene for 
the treatment of PCa when delivered by a replication-selective adenovirus. 
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1.9. Aims of this thesis 
 
This research project was conducted with the aim to establish whether the 
AR-corepressor, Hey1 delivered from an adenoviral vector could reduce 
AR-driven PCa cell proliferation and be used as a potential novel 
therapeutic for PCa. Based on previously published findings and 
unpublished data generated in our team the following hypotheses for 
Hey-1-mediated mechanisms of action were investigated. 
 
1. Ad5Hey-mediated cytotoxicity may function through inhibition of AR 
activity and activation of p53 signalling in AR and p53-positive 22Rv1 
and LNCaP cells 
2. Ad5Hey1-mediated cytotoxicity may function independently of the AR 
and p53 pathways by inhibiting constitutively active STAT3 to reduce cell 
viability in AR-negative and p53-mutant DU145 cells 
3. In addition to reducing cell viability of 22Rv1, LNCaP and DU145 cells, 
Ad5Hey1 may synergise with chemotherapeutic drugs to enhance 
apoptotic cell death 
4. Ad5Hey1 may cooperate with antiandrogens and remain efficacious in 
the presence of androgens 
5. Ad5Hey1 may be effective in reducing the proliferation of castration- 
resistant PCa cells 
 
Therefore, in this thesis I investigated the mechanism(s) of Ad5Hey1-mediated 
cytotoxicity and sensitisation to cytotoxic drugs in the PCa cell lines 22Rv1, 
LNCaP and DU145. To accomplish this, RNA interference, isogenic cell lines 
and selective small molecule inhibitors were used to identify possible targets 
involved in Ad5Hey1-mediated cytotoxicity. The role of Ad5Hey1 on cell cycle 
progression and cell cycle proteins was assessed and Ad5Hey1 evaluated for 
possible synergy with mitoxantrone and docetaxel. At doses, which resulted in 
synergistic cell death, cell death pathways were characterised and the molecular 
mechanisms underlying this sensitisation investigated. I also sought to assess 
efficacy of Ad5Hey1 in combination with androgens and bicalutamide and also 
assess the potency of Ad5Hey1 in AR-expressing castration resistant PCa cells. 
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2. Methods 
 
2.1. Reagents 
 
The synthetic androgen, mibolerone was acquired from Perkin Elmer (Seer 
Green, UK), dissolved in ethanol to give stock concentration of 1µM, aliquoted 
and stored at -20°C. The antiandrogen, bicalutamide was obtained from Sigma 
Aldrich (Dorset, UK) and was reconstituted in ethanol to give a stock 
concentration of 10mM, aliquoted and stored at -20°C. DHT (Sigma Aldrich) was 
made up to 10mM stock concentration dissolved in ethanol and stored at 20°C. 
Docetaxel was obtained from Fluka (Sigma Aldrich) and dissolved in dimethyl 
sulphoxide (DMSO) (Fisher Scientific, Loughborough, UK) at 6mM, aliquoted 
and stored at 20°C. A solution of mitoxantrone was provided at a 4.5mM stock 
by Onkoterene®, Baxter, Norfolk, UK and kept at 4°C. The small molecule JAK 
inhibitors AG490 and AZD1480 (Stratech Scientific Ltd, Newmarket, UK) were 
dissolved in DMSO to 20mM. Reagents used as positive controls for mitosis 
(nocodazole), apoptosis (staurosporine) and p53 activation (etoposide) (Sigma 
Aldrich) were reconstituted in DMSO to give stock concentrations of 500ug/ml, 
1mM and 50mM respectively. Tetramethylrhodamine ethyl ester percholate 
(TMRE) (Invitrogen, Paisley, UK) was dissolved in DMSO to 1mg/ml. 
 
2.2. Cell culture 
 
The human PCa cell lines 22Rv1, LNCAP, VCaP, DU145 and PC3 were 
obtained from Cancer Research UK Cell Services (Clare Hall, Middlesex, UK 
originally purchased from American Type Culture Collection (ATCC) VA, USA). 
Characteristics of the PCa cell lines are shown in Table 5. Colorectal cell lines, 
HCT116wt and HCT116p53-/- were a kind gift obtained from Dr Spiros 
Linardopoulos, (The Institute of Cancer Research, London), originally from Dr. 
Bert Vogelstein (John Hopkins University Howard Hughes Medical Institute and 
Kimmel Cancer Center, Baltimore, MD, US). The LNCaP sublines 104-S 
(androgen-sensitive) and the androgen ablation-resistant and bicalutamide-
resistant cells 104-R1 and CDXR3 respectively, were a generous gift from Dr 
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John M. Kokontis (University of Chicago, Chicago, USA). Both human 
embryonic kidney (HEK)293 cell line and its sub-clone, JH293s cells were 
obtained from Cancer Research UK Cell Services. HEK293s cells are 
transformed with the first 4344 nucleotides (E1 gene) of Ad5 and were used for 
primary viral expansions of non-replicating adenoviruses to provide the E1 gene 
in trans for virus production. JH293 cells were used for limiting dilution tissue 
culture infectious dose (TCID50) assay. All cell lines with the exception of LNCaP 
cells and sub-lines 104-R1 and CDXR3 were cultured in Dulbecco’s Modified 
Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 
units/ml penicillin, 100mg/L streptomycin and L-glutamine. The DMEM culture 
medium for the LNCaP 104-S, 104-R1 and CDXR3 cells were supplemented 
with 10% charcoal-stripped FBS (Sigma Aldrich) with 0.2nM DHT. Medium for 
104-S, 104-R1 and CDXR3 cell was changed every 2-3 days if cells were not 
passaged. Regular LNCaP cells were cultured in Roswell Park Memorial 
Institute (RPMI) medium supplemented with 10% FBS, 100 units/ml penicillin 
and 100mg/L streptomycin and L-glutamine. Due to their poor adherence these 
cells were grown in CellBIND flasks (Corning, Amsterdam, The Netherlands) 
and seeded on CellBIND 6-well dishes for experiments. Cells were incubated at 
37ºC in a humidified atmosphere with 5% CO2. Experiments were carried out 
using cells between 5 and 30 passages and were sub-cultured every 3-4 days 
by washing the monolayer of cells with phosphate buffered saline (PBS) and 
trypsination. Aliquots of 1x106 cells/ml were frozen in 10% DMSO, 20% FBS and 
70% 10% FBS DMEM medium and stored in liquid nitrogen. All cell culture 
reagents were obtained from PAA Laboratories (Yeovil, UK). 
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Table 5. Characteristics and genetic status of PCa cell lines used in this project 
 22Rv1 LNCaP VCaP DU145 PC3 
Year 
established 
1999 1980 2001 1978 1979 
Reference  (Sramkoski, 
Pretlow et al. 
1999) 
(Horoszewicz, 
Leong et al. 
1980) 
(Korenchuk, 
Lehr et al. 
2001) 
(Stone, 
Mickey et al. 
1978) 
(Kaighn, Narayan 
et al. 1979) 
Origin 1° tumour from 
CRW22Rv 
xenograft 
serially 
passaged in 
mice 
Carcinoma 
supraclavicular 
lymph node 
metastasis 
Vertebral 
metastatic 
lesion serially 
passaged in 
mice 
Carcinoma 
brain 
metastasis 
Grade IV 
adenocarcinoma 
bone metastasis 
Androgen 
dependency 
Androgen 
independent 
but responsive 
Androgen 
sensitive  
Androgen 
independent 
but 
responsive 
Androgen 
independent 
Androgen 
independent 
AR  ✓  
Mutated (exon 
duplication and 
C-terminal 
truncation) 
✓ 
Mutated 
(T877A) 
Promiscuous 
AR binding 
✓ 
Wild-type 
(amplified 
gene locus) 
✗  
No mRNA or 
protein 
expressed 
✗   
No mRNA or 
protein 
expressed 
PSA RNA ✓ ✓ ✓ ✗ ✗ 
PSA protein ✗ ✓ ✓ ✗ ✗ 
IL-6 receptor ✓ ✓ mRNA ✓ ✓ 
IL-6 secreted ✓ ✗ ✓ ✓ ✓ 
p53  Wild-type 
(Q331R 
heterozygous) 
Wild-type Mutated 
(A248W) 
homozygous 
Mutated 
(P223L and 
V274F) 
p53-deficient 
p21  ✓ ✓ Unknown ✓ ✓ 
pRb ✓ ✓  Unknown Mutated ✓ 
HDM2 ✓ ✓ Unknown ✓ ✓ 
AKT ✓ ✓ ✓ ✓ ✓ 
PTEN ✓ ✗ ✓ ✓ ✗ 
STAT3 ✓ ✓ Unknown ✓ ✗ 
Bcl-2  ✓ ✓ ✓ ✓ ✓ 
✓ = expressed, ✗ = not expressed 
(Bookstein, Shew et al. 1990; Isaacs, Carter et al. 1991; Ni, Lou et al. 2000; Tepper, 
Boucher et al. 2002; van Bokhoven, Varella-Garcia et al. 2003; Lu, Zhang et al. 2004; 
Loberg, St John et al. 2006; Skjoth and Issinger 2006; Hodgson, Shao et al. 2011; 
Fahrenholtz, Beltran et al. 2013) 
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2.3. Viruses 
 
2.3.1.  Adenoviral mutants 
 
The experiments described in this thesis were carried out using replication-
defective recombinant adenovirus based on type 5 (Ad5) and deleted for E1 and 
E3 genes (Table 6). For Ad5Hey1, the E1 gene was replaced with Flag-Hey1 
under the control of the cytomegalovirus (CMV) promoter. Dr S.C. Cheong 
previously constructed Ad5Hey1 by PCR amplification of Flag-tagged-Hey1 from 
pSG5-Flag-Hey1 (a kind gift from Dr Charlotte Bevan, Imperial College London, 
London) and cloned into the multiple cloning site of the pShuttle-CMV vector 
(Stratagene, TX, USA). Homologous recombination with pAdEASY-1 vector 
(lacking E1 and E3 genes; Stratagene) generated Ad5Hey1. The cytotoxic gene 
E1A12S, a known inducer or apoptosis and sensitizer to chemotherapeutic 
drugs was inserted into the adenovirus replication-defective backbone 
pAdEASY-1 under the control of the CMV promoter as described for Ad5Hey1, 
and was used as a positive control (AdE1A12S). AdE1A12S was constructed by 
Dr Enrique Miranda wherein RNA was extracted from Ad5-infected A549 cells 
and cDNA synthesised by reverse transcriptase (RT)-polymerase chain reaction 
(PCR) (Dr Enrique Miranda, PhD Thesis, 2009). E1A cDNA was amplified by 
PCR using primers amplifying all E1A mRNAs and separated by gel 
electrophoresis. E1A12S cDNA was then extracted, purified and cloned into the 
pShuttle-CMV vector and recombined with the pAdEASY-1 vector. Ad5GFP was 
used as the negative control virus and was previously constructed at the Centre 
for Molecular Oncology (Prof. N. Lemoine, BCI, QMUL). Ad5GFP contains a 
CMV-GFP cassette replacing the E1 genes and contains an intact E3 region. 
 
During the course of this research project I produced and used three batches of 
Ad5Hey1 (Ad5Hey1#1 - 3) and two/three batches of AdE1A12S (AdE1A12#1 - 
3). I observed a degree of variation between the Ad5Hey1 virus batches in 
terms of potency and transgene expression. Previous work leading up to this 
research was undertaken with the original Ad5Hey1 batch (Ad5Hey1#1). 
Validation of each purified virus batch was carried out in terms of potency (virus 
dose response curves; section 2.4.1), transgene expression and viral activity 
(viral particle (vp)/plaque forming units (pfu); section 2.3.3 and 2.3.4) and these 
 128 
values taken into consideration during experimental design. In this thesis, 
results were obtained using Ad5Hey1#1 and 2 for 22Rv1 cells and Ad5Hey1#2 
and 3 for LNCaP and DU145 cells as indicated in the figure legends. Viral 
particle and pfu values for each batch are listed in Table 7.  
 
Table 6. Adenoviral mutants with their respective transgene and deletions 
Virus Deletions Insertions Reference 
Ad5 - - - 
Ad5Hey1 ΔE1, ΔE3 CMV-FlagHey1 Dr S C Cheong (manuscript in 
preparation) 
AdE1A12S ΔE1, ΔE3 CMV-E1A12S (Miranda, Maya Pineda et al. 
2012) 
Ad5noHey1 ΔE1, ΔE3 Defective CMV-
FlagHey1 
Dr S C Cheong (manuscript in 
preparation) 
Ad5GFP ΔE1 CMV-GFP Prof N. Lemoine’s laboratory 
 
2.3.2.  Large-scale virus production 
 
Primary viral expansions were generated by infecting a sub-confluent T175 flask 
of HEK293 cells with 30µl of purified virus stock. Cells and medium were 
harvested between 48 and 72h after infection after the appearance of cytopathic 
effect (CPE) and stored at -80°C. HEK293 cells were grown to 80% confluence 
in 10% FBS DMEM in ten-layer cell factories (CF-10) (Fisher Scientific) and 
infected with 10ml of the primary expansion in 2% FBS DMEM. Cells and 
medium were harvested 72h after infection or when signs of CPE and 
detachment was observed. Cells and medium were collected and centrifuged for 
10min at 2000rpm at 4°C in a Sigma 6K15 centrifuge (Sigma, Osterode am 
Harz, Germany). Cells were resuspended in 15ml cold PBS and centrifuged for 
10min at 1000rpm and then resuspended in 12ml cold 10mM Tris-HCl (pH8). 
Viral suspensions were freeze-thawed three times to release intracellular viral 
particles and centrifuged at 6000rpm. The supernatants were layered onto 
caesium chloride (CsCl) gradients prepared in 3.5” ultracentrifuge tubes 
(Beckman Coulter, High Wycombe, UK) with 10ml 1.25g/ml CsCl under-layered 
with 7.6ml 1.4g/ml CsCl solution and were spun for 2h at 25000rpm at 15°C in a 
Beckman SW28 swing-out rotor in an Optima LE-80K ultracentrifuge. After 
centrifugation, a 19G needle was used to extract the bottom virus band 
containing encapsulated virus. The top band of cell debris and the second band 
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of empty viral particles were discarded. The virus suspension was layered onto 
2.5ml 1.35g/ml CsCl solution in 2” ultracentrifuge tubes (Beckman) and 
centrifuged overnight at 40000rpm at 15°C in a Beckman SW55Ti swing-out 
rotor. The purified virus was collected using a 19G needle and the volume 
diluted 2-3 fold (up to a maximum of 12ml) with TSG buffer (96mM NaCl, 0.5mM 
Na2-HPO4, 2.8mM KCl, 0.3mM MgCl2, 0.5mM CaCl2 and 30% (v/v) glycerol 
adjusted to pH7.5). The suspension was dialysed using a 3-12ml Slide-a-Lyser 
(Pierce Biotechnology, IL, USA) against a buffer containing 10mM Tris-HCl 
(pH7.5), 1mM MgCl2, 150mM NaCl and 10% (v/v) glycerol for 24h at 4°C. The 
purified virus was then removed from the dialysis chamber, aliquoted and stored 
at -80°C. 
 
2.3.3.  Virus particle count determination 
 
To determine the particle count of purified virus, DNA content was measured 
using the Quanti-iT PicoGreen dsDNA assay kit (Invitrogen) using a Tecan 
Infinite F200 plate reader (Tecan, Mannedorf, Switzerland) and Magellan 
software version 6.3 (Tecan). Viral stocks were diluted 1:2 in Tris-EDTA (TE) 
buffer (10mM Tris-HCl (pH8), 1mM EDTA) containing 0.5% SDS and heated at 
56ºC for 10min. After heat inactivation virus was diluted to 1 in 120 and 1 in 200 
in TE/0.5%SDS so concentrations could be assayed in triplicate. A standard 
curve of Lambda-phage DNA (provided in the kit) starting at 500ng/ml was 
prepared by 5-fold serial dilution using TE. 100µl of each virus or Lamda-phage 
DNA dilution in triplicate was transferred to a well of a 96-well black plate. 
PicoGreen reagent was diluted 200-fold in TE and 100µl added to each well. 
Emission was read at 535nm after excitation. Using the fluorescent 
measurements from the Lambda DNA linear regression curve using Graphpad 
Prism software was constructed by plotting DNA concentration vs. fluorescence 
(linear regression coefficient >0.98). The DNA concentration for each virus 
dilution was calculated using the standard curve taking into consideration the 
dilution factor for each sample. The number of viral particles per ml (vp/ml) for 
the purified virus was determined on the assumption that 1µg DNA is the 
equivalent of 2.7x1010 viral particles. As an internal control Ad5 of known particle 
count was included as a reference. 
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2.3.4.  Infectious particle count 
determination 
 
Viral activity for purified virus particles was determined by measuring viral 
replication using the limiting dilution tissue culture infectious dose (TCID50) 
assay. JH293 cells were seeded in 96-well plates at a cell density of 
1x104cells/well in 200µl/well in 10% FBS in DMEM. The following day purified 
virus was diluted to 1x10-7 (Ad5) or 1x10-5 (non-replicating viruses) in serum free 
DMEM and used to infect the top row of duplicate or triplicate plates (20µl/well) 
and serially diluted down the plate by transferring 20µl/well from one row to the 
row below. The last rows of wells were left uninfected as controls. Plates were 
incubated for 7 to 10 days and each well was scored for signs of CPE. CPE was 
determined as the presence of plaques (indicated by holes in the monolayer) 
within the monolayer and/or when cell layer was rounded up. The titre of each 
plate was calculated in plaque-forming units (pfu)/ml as follows: 
 
Wells exhibiting CPE were counted per dilution row and used in the following 
calculation to determine the TCID50 value (O'Reilly. D 1994): 
 
TCID50 = 10 A-D (S - 0.5) 
TCID50/ml = TCID50 x v 
 
A = Log of the highest dilution showing CPE in more than 50% of wells 
D = Log of the dilution factor 
S = summation of the proportion of CPE-positive wells in each row  
V = infection volume = 0.02ml 
 
pfu/ml = Log TCID50 x µ 
where µ = -In p = 0.69 
 
According to the Poisson distribution: 
µ is the mean concentration of infectious particles at a given dose 
p is the proportion of cultures remaining uninfected, = 0.5 
 
Virus particle/plaque forming units (vp/pfu) ratio was determined for each virus. 
Vp, pfu and vp/pfu values for each virus batch are listed in Table 7. All Ad5Hey1 
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and AdE1A12S batches used had a vp/pfu ratio <225. It was not possible to 
achieve this ratio for Ad5noHey1 or Ad5GFP batches. 
 
Table 7. Particle count and viral titre and calculated vp/pfu ratio for virus batches 
 Virus particle (vp) 
(vp/ml) 
Viral Titre (pfu/ml) Vp/pfu ratio 
Ad5Hey1#1 5.20E+11 2.14E+10 24:1 
Ad5Hey1#2 4.85E+11 2.21E+09 219:1 
Ad5Hey1#3 1.78E+11 1.09E+09 163.3 
AdE1A12S #1 1.91E+11 1.72E+09 111:1 
AdE1A12S#2 1.10E+11 4.91E+08 224:1 
AdE1A12S#3 7.72E+11 5.14E+09 150:1 
Ad5noHey1 7.10E+11 1.33E+09 534:1 
Ad5GFP  2.17E+11 1.53E+08 1418:1 
 
2.3.5.  Confirmation of E1 and E3 gene 
deletions 
 
DNA from purified virus was extracted using the QIAmp DNA Blood Mini Kit 
(Qiagen, Manchester, UK). 20µl of proteinase K (Qiagen) was added to 200µl 
virus. Extraction buffer, buffer AL supplied with the extraction kit was then added 
at a 200µl volumes and incubated at 56°C for 10min. 200µl of ethanol was 
added and the sample mixed by pulse-vortexing for 15s and transferred to a 
QIAmp spin column in a 2ml collection tube. After centrifugation for 1min at 
6000x g, the QIAmp spin column was transferred to a new collection tube and 
500µl wash buffer, buffer AW1 (supplied) was added and the sample centrifuged 
for a further minute at 6000x g and the filtrate discarded. 500µl wash buffer, 
buffer AW2 (supplied) was added to the column and centrifuged at 20000x g for 
3min. The spin column was placed in a sterile microcentrifuge tube and the DNA 
eluted in 70µl distilled H2O at 6000x g for 1min.  
 
Since the viruses used in this project were non-replicating, the absence of the 
E1 and E3 deletions were confirmed for all Ad5Hey1 and AdE1A12S batches 
produced. Polymerase chain reaction (PCR) primer sets identifying the 
adenoviral E1A, E1B and E3 regions were used with DNA extracted from 
adenoviral mutants. PCR products from these reactions were compared with 
PCR fragments generated from the amplification of Ad5 DNA and the 
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pAdEASY-1 backbone plasmid DNA. PCR were set up with 8 primer sets (Table 
8) using the Advantage 2 PCR kit (Takara Bio Europe/Clontech, Saint-Germain-
En-Laye, France). Each reaction contained 50ng purified viral DNA, 2.5µl each 
of forward and reverse primers (10µM), 1µl 50x dNTPS (10mM each), 3µl 10x 
PCR buffer and 1µl Taq polymerase made up to a final volume of 30µl with 
distilled H2O. DNA was amplified by 35 cycles (94°C 40s, 62°C 60s, 72°C 90s) 
in a Gene Amp PCR system 9700 (Applied Biosystems; Thermo Scientific). 
Amplified PCR products were separated on a 1.5% agarose gel with a 100bp 
(New England BioLabs (NEB), Ipswich, UK) and 1kb+ DNA ladder (Invitrogen) 
to determine the size of the PCR products. The expected sizes for Ad5 were 
calculated from the known sizes of each sequence (Table 9). An example of a 
representative PCR gel for Ad5Hey1 and AdE1A12S is shown in Figure 15. 
Faint bands, which were of similar size to Ad5, were observed for Ad5Hey1 and 
AdE1A12S for primer sets 1, 2, 4, 5, 6 and 8. However these bands were also 
obtained when the empty pAdEASY-1 vector was amplified using the same 
primers. Primer set 7 resulted in a strong amplification of a band slightly smaller 
in size than the one generated from Ad5 DNA. This however was also observed 
from amplification from pAdEASY-1 plasmid DNA suggesting non-specific 
binding of primers and/or amplification. Other spurious bands were observed for 
the primer set corresponding to E1A12S from DNA extracted from Ad5Hey1 and 
pAdEASY-1 DNA. The non-specific products derived from these PCR reactions 
may be the result of using PCR primers that were specifically designed to 
amplify gene regions in replicating viruses and not recombinant adenoviral 
plasmids. Further verification by immunblotting for E1A expression verified that 
neither AdHey1 nor AdE1A12S nor AdGFP expressed the E1A proteins (section 
3.2.1, Figure 35).  
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Table 8. PCR primers used to confirm virus deletion status 
Primer set Direction Sequence 
1 5’ forward CCCGGTGAGA TTCCTCAAGAGGCCAC 
3’ reverse CCGGACCCAAGGCTCTCTGCTCTCCGGCTGCTCGGGC 
2 5’ forward GTAATGTTGGCGGTGCAGGAAGGGATTG 
3’ reverse GGGTCCCCCGTATTCCTCCGGTGATAATGAC 
3 5’ forward GTGTTCGCTTTGCTATATGAGGACCTGTGGC 
3’ reverse CCTCGATACATTCCACAGCCTGGCGACGCCCACC 
4 5’ forward CCTGTGATTGCGTGTGTGG 
3’ reverse GACAACAGTAGCAGGCGATTC 
5 5’ forward GCATCTGTGGAGAGCGGTTGTGAGACAC 
3’ reverse GCGCCAGCAGATCAAGCTCATTAGCGC 
6 5’ forward GCTTAATGACCAGACACCGTCCTGAGTG 
3’ reverse GCACCAAGTGA TCGGGCCTCAGCTCC 
7 5’ forward CACCCTCACGCTCATCTGCAGCCTCATCACTGTGG 
3’ reverse CTTCAGACGGTCTTGCGCGCTTCA TCTGC 
8 5’ forward CGCTGGGGTCGCCACCCAAGATGATTAGG 
3’ reverse GAGTAGGGTACAGACCAAAGCGAGCACTG 
E1A12S 5’ forward GCGCGCACCATGAGACATATTATCTGCC 
3’ reverse CTCGAGTTATGGCCTGGGGCGTTTAC 
 
Table 9. Regions of the Ad5 genome targeted by PCR primer sets and expected size of DNA 
fragments 
Primer set 5’ binding site 3’ binding site Target sequence Expected Ad5 size (bp) 
1 476 853 E1A start 377 
2 767 1029 E1A-CR2 262 
3 1069 1453 E1A end 384 
4 1554 2086 E1B-19K 532 
5 2073 2440 E1B-55K 367 
6 2383 3434 E1B-55K 1051 
7 29915 31038 E3B 1123 
8 28715 29135 E3-gp19K 420 
E1A12S 476 1453 E1A 800  
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Figure 15. PCR verification of E1 and E3 deletions for representative batches of Ad5Hey1 
and AdE1A12S 
Amplification of Ad5 (WT), Ad5Hey1 (H), AdE1A12S (12S), pAdEasy-1 (pAd) and AdE1A12S 
original batch (12S*) DNA with primer sets 1-8 and primer set recognising E1A12S. Fragments 
sizes were estimated using DNA ladders (100bp and 1kb+) and for Ad5, compared to the 
expected sizes (Table 9) or analysed for the absence of E1 and E3 PCR products for non-
replicating adenoviral mutants. 
 
2.3.6.  Virus replication 
 
2.3.6.1. Burst assay 
 
To assess the replication status of the non-replicating adenoviral mutants, burst 
assays were performed in 22Rv1 cells followed by the TCID50 assay in JH293 
cells as described in section 2.3.4. Cells were seeded at 3x105 cells/well in 6-
well plates. The next day, cells were infected with 10ppc of Ad5 and 10, 100 and 
1000ppc of Ad5Hey1 or AdE1A12S in serum-free medium for 2h. The infection 
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medium was then removed and replaced with 10% FBS in DMEM, with each 
treatment in duplicate. At 48 and 72h post-infection cells were detached by 
scraping and collected together with the medium and stored at -80°C. Burst 
assay samples were freeze-thawed three times and centrifuged at 1200rpm for 
5min and diluted 1x10-4 or 1x10-3 in serum-free medium for Ad5 and adenoviral 
mutants respectively and assayed by TCID50. 
 
2.3.6.2. Quantitative PCR 
 
22Rv1 cells were seeded and treated as described in section 2.3.6.1 for the 
burst assay. At 24, 48 and 72h post-infection, medium was aspirated from the 
wells and the cells washed with PBS. Cells were scraped into a volume of 200µl 
of PBS per well and DNA immediately extracted using proteinase K and the 
DNA Blood Mini Kit as described in section 2.3.5.  
 
Quantitative PCR (QPCR) quantified viral genome copy number as an indirect 
measurement of viral replication. Fold change of viral genome copies compared 
with Ad5 at 24h post-infection was carried out using the comparative 
quantification (ΔΔCt) method. Primers amplifying the E2A gene of the viral 
genome were used to determine the threshold cycle (Ct) values for E2A 
expression and normalised to an endogenous reference, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Another member of our research group 
had previously validated these primers to ensure amplification efficiencies of 
both primer sets were approximately equal.  
 
Ct values for E2A and GAPDH expression were determined for each sample in 
duplicates using 0.6µl of each forward and reverse primer (10µM) (Table 10) 
with 10µl Power SYBR Green PCR MasterMix (Applied Biosystems) for 2µl 
(10ng/µl) DNA template in a total reaction volume of 20µl. The reactions were 
run on an ABI 7500 RealTime PCR System (Applied Biosystems). Ct values 
were determined using Sequence Detector Software version 1.9.1 (Applied 
Biosystems). 
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Fold change in viral copy numbers was then determined. The amount of E2A, 
normalised to GAPDH and relative to Ad5 at 24h is given by the following 
equation (Livak and Schmittgen 2001): 
 
Fold difference = 2-ΔΔCt 
ΔΔCt = ΔCt sample – ΔCt calibrator 
 
ΔCt sample is the Ct value for a sample, normalised to the endogenous gene: 
Ct E2A – Ct GAPDH = Ct sample 
 
ΔCt calibrator is the Ct value for the calibrator (Ad5 24h), normalised to the 
endogenous gene: 
Ct E2A – Ct GAPDH = ΔCt calibrator 
 
Table 10. Primer sequence of E2A and GAPDH used for QPCR 
Primer Sequence 
E2A (5’) GGATACAGCGCCTGCATAAAAG 
E2A (3’) CCAATCAGTTTTCCGGCAAGT 
GAPDH (5’) TGGGCTACACTGAGCACCAG 
GAPDH (3’)  GGGTGTCGCTGTTGAAGTCA   
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2.4. Cell viability 
 
2.4.1.  Determining virus EC50 values  
 
DU145 (1x104cells/well) or 22Rv1, HCT116wt and HCT116p53-/- cells 
(2x104cells/well) were seeded in 96-well plates in a volume of 200µl/well of 10% 
FBS DMEM. The next day the medium was decanted and replaced with 
90µl/well 2% FBS in DMEM.  Due to poor adherence of LNCaP cells, 
1x104cells/well were seeded in a volume of 90 µl/well of 2% FBS in RPMI and 
the medium was not removed before treatments. The LNCaP sub-lines, 104-S, 
104-R1 and CDXR3 were also seeded in 90 µl/well of 2% charcoal-stripped FBS 
in DMEM and again the medium was not replaced. The next day, cells were 
infected with 5-fold serial dilutions of virus starting at a concentration of 1x105 
particles per cell (ppc). Viability was assessed 3 days post-treatment (4 days 
after seeding) using the MTS viability assay carried out according to the 
manufacturer’s protocol (Promega, Southampton UK). When the tetrazolium salt 
MTS (3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-
sulphophenyl)-2H-tetrazolium) is combined with phenazine methosulphate 
(PMS) it is reduced by mitchochondrial dehydrogenases, present in 
metabolically active cells to a soluble formazan compound. The soluble 
compound absorbs light at 490nm and the number of living cells is proportional 
to the concentration of formazan in the sample. After addition of the MTS 
reagent, cells were incubated at 37ºC for 6h (22Rv1), 4h (LNCaP and sub-
lines), 2-3h (HCT116wt and HCT116p53-/-) and 1-2h (DU145) and read using a 
microplate reader (Opsys MR, Dynex Technologies, VA, US) at a wavelength of 
495nm. Values were corrected against background wells containing medium 
only and expressed as a percentage of cell death compared with untreated 
control cells. 
 
% Cell death = 100 -       Abssample – Absmedium 
                                       Absuntreated – Absmedium 
 
Sigmoidal dose-response curves were generated by non-linear regression 
analysis using GraphPad Prism Version 6.0b for Macintosh (GraphPad 
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Software, San Diego, CA, USA) and used to determine the effective 
concentration (EC)50 values (the dose required to kill 50% of cells) of each virus. 
 
2.4.2.  Determining drug and small 
molecule inhibitor EC50 values 
 
DU145 and LNCaP (1x104cells/well) or 22Rv1, HCT116wt and HCT116p53-/- 
(2x104cells/well) were seeded in 96-well plates as described above. Cells were 
treated with 5-fold serial dilutions of the cytotoxic drugs mitoxantrone, docetaxel 
or 5-FU at a starting dose of 400µM, 80µM and 10µg/ml respectively. The 
starting dose of small molecule JAK inhibitors, AG490 and AZD1480 was 1mM. 
Agents were diluted in serum-free medium and were made up at a 10-fold 
higher concentration. 10µl of each dilution was added to 90µl medium in the well 
in duplicates or triplicates. Medium alone and untreated cells served as controls. 
Cell viability was determined by MTS assay 3 days after treatment as described 
in section 2.4.1 
 
2.4.3.  Combination assays 
 
2.4.3.1. Synergy: Fixed dose of virus and drug 
 
PCa cell lines were treated with a combination of either mitoxantrone or 
docetaxel and non-replicating viruses at fixed concentrations. Mitoxantrone and 
docetaxel were used at sub-optimum doses at 25nM and 5nM respectively 
(22Rv1), 50nM and 5nM (DU145) and 25nM and 2.5nM (LNCaP) determined to 
kill <20% of cells. Mitoxantrone and docetaxel were combined with either 
Ad5Hey1 or AdE1A12S at a dose that resulted in approximately 30% cell death 
(EC30). These viral doses were selected for each cell line based on the dose 
response studies for each virus. The concentrations of drugs and viruses used 
are shown in Table 11. Ad5GFP was used as a negative control at the same 
dose used for Ad5Hey1. 
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Table 11. Adenoviral mutant and drug doses used in PCa cell lines in combination studies 
Treatment 22Rv1 DU145 LNCaP 
Ad5Hey1 480ppc 1800ppc 360ppc 
AdE1A12S 120ppc 900ppc 240ppc 
Ad5GFP 480ppc 1800ppc 360ppc 
Mitoxantrone 25nM 50nM 25nM 
Docetaxel 5nM 5nM 2.5nM 
 
DU145 cells were seeded in 96-well plates at 1x104cells/well, 22Rv1 cells at 
2x104cells/well in 200µl 10% FBS in DMEM and LNCaP cells at 1x104cells/well 
in 90µl 2% FBS in RPMI. The following day medium was decanted in the case of 
DU145 and 22Rv1 cells and replaced with either 80 or 90µl 2% FBS DMEM 
depending on the addition of single or combination treatment to a total volume of 
100µl. The volume of medium for LNCaP cells was adjusted so that after the 
addition of virus and/or dug, the total volume was 100µl. Cells were treated with 
virus and/or drugs in 6 replicate wells per condition. Cell viability was assessed 
by MTS assay 3 days after treatment as described in section 2.4.1. Values were 
corrected against background wells containing medium only and expressed as a 
percentage of cell death compared with untreated control cells. 
 
To determine whether the interaction between Ad5Hey1 and either drug was 
synergistic (i.e. produced supra-additive cell death) the summation method was 
applied wherein the sum of the percentage of cell death for each agent alone 
(theoretical additive effect) was compared with the observed effect. If the 
observed effect was greater than the sum of the effects of each agent alone the 
agents were considered to act synergistically.  
 
The theoretical additive effect was calculated as follows: 
 
E(dadb) = E(da) + E(db) 
 
E(da) = effect of agent a alone at dose d 
E(db) = effect of agent b alone at dose d 
E(dadb) = effect of the combination of agents a and b 
 
Due to the variable nature of the cell viability assay, it was not possible to 
combine the results from more than one experiment and therefore data from 
representative experiments is shown. To obtain the mean theoretical additive 
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effect for one experiment, the lowest percentage of cell death obtained from the 
6 replicates wells for virus single-agent treatment was combined with the lowest 
percentage of cell death for the drug single-agent treatment. This value 
represented the minimum theoretical additive effect between the two agents. 
The maximum theoretical additive effect was calculated by combining the 
highest percentage of cell death for virus and drug single-agent treatments. The 
mean of the minimum and maximum theoretical additive effects was calculated 
and compared with the observed effect.  
 
2.4.3.1.1. PicoGreen cell viability assay 
 
Cell viability was also determined using PicoGreen, which specifically binds to 
double-stranded DNA to determine cell number. Cells were seeded and treated 
as described in section 2.4.3.1 and cell viability measured 3 days after 
treatment. Medium was decanted and cells washed twice with 200µl/well PBS. 
PBS was removed and plates left at -80°C for 30min and which they were 
removed and allowed to return to RT. CyQuant lysis buffer (Invitrogen) and 
PicoGreen was diluted 1/20 and 1/200 respectively with distilled water and 100µl 
added to each well. Emission was read at 535nm after excitation at 485nm on a 
Fluostar Optima (BMG Biotech, MA, USA) microplate reader. Values were 
corrected against background wells containing medium only and expressed as a 
percentage of cell death compared with untreated control cells. 
 
2.4.3.1.2. Sulforhodamine B cell viability assay 
 
Cell viability was assessed by sulforhodamine B (Acid red 52) (Sigma) which 
measures total biomass of cellular proteins by binding basic amino acid residues 
on trichloroacetic-fixed cells. Medium was decanted and cell washed with PBS 
(200µl/well) and then fixed with 100µl/well trichloroacetic (TCA) and incubated at 
4°C for 30min. TCA was then removed and cells washed three times with 
distilled water (100µl/well). Plates were left to air dry at RT and when dry 100µl 
of sulforhodamine B (0.4%) added to each well and left to stain for 20min. 
Sulforhodamine B was discarded and cells washed in 1% acetic acid 
(100µl/well) until the dye was removed. Plates were left to air dry and 100µl 
10mM Tris-HCL (pH9.0) was added to each well and incubated for 5min at RT. 
Absorbance was measured at 560nm using a Wallac 1420 Multilabel counter 
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plate reader (PerkinElmer). Values were corrected against background wells 
and cell survival expressed as a percentage of cell death compared with 
untreated control cells. 
 
2.4.3.2. Sensitisation: Dose response to virus in the 
presence of fixed dose of drug 
 
DU145 and HCT116 cell lines were seeded and infected with a dose response 
of virus as described in section 2.4.1 and treated simultaneously with either 
mitoxantrone, 5-FU, AG490 or AZD1480 at sub-optimum doses wherein they 
induced <30% cell death. This assessed changes in cell sensitivity to virus when 
combined with drugs. 
 
2.4.3.3. Fixed doses of virus in combination with 
mibolerone ± bicalutamide 
 
One day before seeding, cell culture medium was changed to 10% charcoal-
stripped FBS-containing growth medium to remove residual hormones that are 
present in standard FBS. DU145 at 1x104cells/well or 22Rv1 at 2x104cells/well 
were seeded in 96-well plates in 10% charcoal-stripped FBS in DMEM. The 
LNCaP cells and the AR-positive VCaP cells were seeded at 1x104 and 
2x104cells/well respectively in 90µl 2% charcoal stripped FBS in DMEM (VCaP) 
or in RPMI (LNCaP). The following day medium was decanted from 22Rv1 and 
DU145 cells and replaced with 2% charcoal-stripped FBS DMEM. Cells were 
infected with a fixed dose of Ad5Hey1 that would kill approximately 50% of cells 
(EC50) or Ad5GFP (at the same ppc) and combined with 1nM mibolerone ± 5, 10 
or 20µM of bicalutamide. Uninfected and untreated cells were treated with 0.2% 
ethanol as a vehicle control and all other treatments combinations were adjusted 
to contain the same percentage of ethanol. Cell viability was assessed 3 days 
post-treatment by MTS. 
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2.5. Luciferase reporter assay 
 
2.5.1.  Measuring AR transcriptional activity 
in 22Rv1 cells in response to Ad5Hey1 
infection 
 
22Rv1 cells were seeded in 24-well plates at a density of 2x105 cells/well in 1ml 
10% FBS in DMEM. The following day (day 2) medium was removed and cells 
were infected with Ad5Hey1 or Ad5GFP at 0.1, 0.3, 1, 3 and 10ppc in serum-
free medium for 2h after which infection medium was removed and replaced 
with 1ml/well of 10% charcoal stripped FBS in DMEM. The next day (day 3) cells 
were transfected with 0.75µg of the androgen receptor activity reporter plasmid 
MMTV-Luc (kindly provided by Dr Charlotte Bevan) and 0.25µg pRL-SV40 
(generously provided by Dr Spiros Linardopoulos) to normalise for transfection 
efficiency. Transfection was carried out using JetPEI-RGD transfection reagent 
(PeqLab Ltd, Sarisbury Green, UK) according to the manufacturer’s protocol. 
24h later (day 5), medium was removed and cells treated with either 0.1nM 
mibolerone or 0.1% ethanol in 1ml/well in 10% charcoal-stripped FBS in DMEM. 
On the final day (day 6) cells were lysed with passive lysis buffer (Promega) and 
firefly and renilla luciferase activities measured using the Dual-Luciferase 
reporter assay system (Promega) according to the manufacturer’s instructions. 
 
2.6. RNA interference 
 
2.6.1.  siRNA selection 
 
Short interfering RNA (siRNA) was used to silence AR and p53 expression in 
22Rv1 cells. One particular sequence out of four available by Dharmacon 
(Thermo Scientific) was found to knockdown AR more successfully and was 
previously confirmed by Dr S.C. Cheong. To increase the possibility of 
successful knockdown without testing individual sequences we selected the 
SMARTpool On-Target plus siRNA (Thermo Scientific) to specifically silence 
p53. A non-targeting siRNA sequence (Thermo Scientific) was used as a non-
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silencing control. Details of the siRNAs used in this study are summarised in 
Table 12.  
 
Table 12. Sequence of AR, p53 and non-targeting control siRNA 
 Catalog number 
On-Target plus AR siRNA J-003400-08 
SMARTpool On-Target plus p53 siRNA L-003329-00 
SiGenome Non-targeting siRNA pool D-001206-14 
 
On-Target plus AR siRNA, SMARTpool On-Target plus p53 siRNA and 
siGenome Non-targeting siRNA pool were reconstituted in RNAse-free 1x 
siRNA buffer (Thermo Scientific) according to the manufacturer’s protocol to 
obtain a concentration of 20µM. Aliquots were stored at -20°C. 
 
2.6.2.  Transient transfection of siRNA to 
monitor protein knockdown 
 
22Rv1 cells were seeded in 6-well plates at 3x105 cells/well in 2ml/well 10% 
FBS in DMEM without antibiotics. This seeding density resulted in approximately 
30-40% confluency the following day. Transfection of siRNA was performed 24h 
later using Dharmafect 1 transfection reagent (Thermo Scientific) according to 
the manufacturer’s instructions. The final concentration of siRNA per well was 
100nM. Cells were incubated at 37°C and were harvested 24, 48 and 120h post-
transfection and monitored for knockdown efficiency by western blotting 
(described in section 2.7). 
 
2.6.3.  Determining virus EC50 values after 
siRNA-mediated AR knockdown 
 
22Rv1 cells were seeded in a 10cm diameter dish at a density of 3x106 cells in 
10% FBS in DMEM without antibiotics. The following day cells were transfected 
with AR or control siRNA (100nM each) as described in section 2.6.2. 24h later 
cells were trypsinised and reseeded into 96-well plates at 2x104 cells/well in a 
volume of 200µl 10% FBS DMEM. The next day, 48h after the initial 
transfection, medium was decanted and replaced with 2% FBS DMEM and cells 
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infected with 5-fold serial dilutions of Ad5Hey1, AdE1A12S or Ad5noHey1. 
Three days after infection, 120h after initial transfection cell viability was 
determined by MTS. 
 
2.6.4.  Determining the percentage of cell 
death after siRNA-mediated p53 knockdown  
 
22Rv1 cells were seeded in 6-well plate at 3x105 cells/well in 2ml/well 10% FBS 
in DMEM without antibiotics. The format for siRNA transfection was changed to 
a 6-well format after being advised this may increase knockdown efficiency. The 
next day 6 wells were transfected with either p53 or control siRNA (100nM each) 
as described in section 2.6.2. The following day cells from each siRNA 
transfection were trypsinised and pooled. Cells were reseeded into 96-well 
plates at a density of 2x104 cells/well in a volume of 200µl 10% FBS in DMEM.  
The next day, cells were infected with a fixed dose of Ad5Hey1, AdE1A12S or 
Ad5noHey1 that would kill approximately 50% of cells. These doses were 
selected for each virus based on the dose response studies in 22Rv1 cells. 
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2.7. Protein expression levels 
 
2.7.1.  Whole cell extract preparation 
 
DU14, LNCaP, 22Rv1, HCT116wt and HCT116p53-/- cell lines were seeded in 6-
well plates at 1.5x105 (DU145 and LNCaP) and 3.0x105 cells/well (22Rv1, 
HCT116wt and HCT116p53-/-) in 2ml/well 10% FBS supplemented medium. The 
following day, cells were infected for 2h with virus doses shown in Table 13. 
These doses were selected based on the results of the virus dose-response 
studies of Ad5Hey1 and AdE1A-12S. Three fixed doses were chosen so as to 
produce a low, medium or high-degree of cell death by Ad5Hey1. After 2h 
infection medium was removed and replaced with 10% FBS supplemented 
medium and incubated at 37°C. For detection of protein expression levels during 
combination treatment with mitoxantrone or docetaxel, cells were infected and 
treated with virus and drug at doses shown in Table 11. Whole cell lysates were 
collected at 48 and 72h post-infection. 
 
Table 13. Virus doses used for Ad5Hey1 (22Rv1; Ad5Hey1#2, LNCaP, DU145, HCT116wt 
and HCT116p53-/-; Ad5Hey1#3), AdE1A12S#2, Ad5noHey1 and Ad5GFP in virus only studies 
 Dose 22Rv1 
(ppc used) 
LNCaP 
(ppc used) 
DU145 
(ppc used) 
HCT116wt HCT115p53-/- 
Ad5Hey1 1 
2 
3 
10 
100 
1000 
300 
500 
1000 
500 
250 
4500 
1500 
3000 
4500 
1500 
4500 
7500 
1500 
4500 
7500 
AdE1A12S 1 
2 
3 
10 
100 
1000 
300 
500 
1000 
500 
2500 
4500 
1500 
3000 
4500 
1500 
4500 
7500 
1500 
4500 
7500 
Ad5noHey1 1 
2 
3 
10 
100 
1000 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
Ad5GFP 1 
2 
3 
10 
100 
1000 
300 
500 
1000 
500 
2500 
4500 
1500 
3000 
4500 
1500 
4500 
7500 
1500 
4500 
7500 
 
Floating and attached cells were collected; medium containing floating cells was 
collected in 15ml tubes and attached cells washed twice with ice-cold PBS and 
trypsinised and collected with 10% FBS supplemented medium. Cells were 
centrifuged at 1200rpm for 5 min in an Allegra X-22 centrifuge (Beckman 
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Coulter), and medium aspirated. Cells were resuspended in 1ml ice-cold PBS 
and transferred to 1.5ml micocentrifuge tubes and spun down at 1200rpm for 
5min in a benchtop microcentrifuge (5415C, Eppendorf, Stevenage, UK). PBS 
was removed and cells were lysed with 1x Radio Immuno Precipitation Assay 
(RIPA) buffer (25mM Tris-HCL pH8, 150mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS) containing a protease inhibitor cocktail tablet and a 
PhosSTOP phosphatase inhibitor tablet (Roche, Diagnostics, Burgess Hill, UK). 
Lysates were incubated on ice for 30min and centrifuged at 13000rpm at 4°C for 
10min and the supernatant transferred to new microcentrifuge tubes and stored 
at -80°C. 
 
2.7.2.  Determining protein concentrations 
 
Protein concentrations for each sample were determined using the Bradford 
assay (Bio-Rad, Hemel Hempstead, UK) and using Bovine Serum Albumin 
(BSA) (Sigma Aldrich) at a stock of 1mg/ml. Bradford assay 5x reagent buffer 
was diluted with distilled water to obtain a 1x concentration and 200µl added to 
wells of a 96-well plate. One µl per sample was added to duplicate wells. Protein 
standards were prepared by adding 0, 1, 2, 2.5, 3, 3.5 and 4µl BSA into 
duplicate wells. Protein concentrations were determined by absorbance at 
595nm using a microplate reader (Opsys MR). Cell lysates were diluted to 
1µg/µl in protein sample buffer, heated to 95°C for 5min and stored at -20°C. 
Sample buffer was made at 5x with 2% sodium dodecyl sulfate (SDS), 250mM 
Tris-HCl pH7.5, 5mM EDTA, 50% glycerol and bromophenol blue (0.25% w/v). 
β-mercaptoethanol was added fresh (2% v/v) before diluting the samples. 
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2.7.3.  SDS polyacrylamide gel 
electrophoresis and western blotting 
 
Total protein (typically 20µg) from cell lysates was loaded onto 10-12% SDS 
reducing polyacrylamide gels using the Bio-Rad system (Bio-Rad). A PageRuler 
Prestained protein ladder (Fermentas; Thermo Scientific) was used to determine 
protein size. The samples and ladder were separated by electrophoresis at 
120V for 90min in a running buffer containing 25mM Tris pH 7.4, 250mM glycine 
and 0.1% SDS. Proteins were transferred to polyvinylidene fluoride membranes 
(PVDF) (GE Healthcare, Amersham, UK) using the Trans Blot SD semi-dry 
transfer Cell (Bio-Rad) method according to the manufacturers’ instructions. 
Membranes were blocked with either 5% (w/v) dry milk (Marvel, Morrison’s, 
London) or 5% BSA in Tris-buffered saline Tween-20 buffer (TBS-T) containing 
20mM Tris-HCl pH 7.4, 500mM NaCl and 0.05% Tween-20. The membranes 
were incubated overnight at 4°C with primary antibodies (Table 14) in 1.5% BSA 
in TBS-T, washed and incubated with secondary antibodies conjugated to 
horseradish peroxidase (Dako, Stockport, UK) in TBS-T for 1h at room 
temperature. The membranes were washed six times for 5min with TBS-T after 
antibody incubation. Protein bands were visualised on X-ray film (FujiFilm, 
Bedford, UK) using Western Lightening ECL or ECL plus reagent (Perkin Elmer) 
or visualised using G:Box iChemi-XT, Gel Doumentation System (Syngene, 
Cambridge, UK). Images were acquired with GeneSys v.1.2.0.5 software and 
protein bands quantified with GeneTools 4.03(a). Protein bands detected on X-
ray film were scanned and quantified using Image J 1.47. 
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Table 14. Primary antibodies used for western blotting and flow cytometry 
Protein Species and 
Clone 
Clone Catalogue 
Number 
Company Dilution 
β-Actin Goat C-11 sc-1615 Santa Cruz 1/1000 
AR Rabbit N-20 sc-816 Santa Cruz 1/300 
β-tubulin Mouse 
monoclonal 
SAP.4G5 ab11312 Abcam 1/20000 
Bax Rabbit polyclonal N-20 sc-493 Santa Cruz 1/1000 
Cleaved caspase-7 Rabbit polyclonal - 9491 Cell Signaling 1/1000 
Cyclin-B1 Mouse 
monoclonal 
V152 4135 Cell Signaling 1/1000 
Cyclin D1 Rabbit polyclonal M-20 sc-718 Santa Cruz 1/500 
E1A Mouse 
monoclonal 
M58 MS-587-P0 Thermo 
Scientific 
1/1000 
Flag Mouse 
monoclonal 
M2 F3165 Sigma 1/2000 
GFP Mouse 
monoclonal 
B2 Sc-9996 Santa Cruz 1/1000 
KU70 Goat polyclonal C-19 sc-1486 Santa Cruz 1/1000 
p53 Mouse 
monoclonal 
DO-1 sc-126 Santa Cruz 1/1000 
phospho p53 
(ser15) 
Rabbit polyclonal - 9284 Cell Signaling 1/1000 
phospho (ser10)-
histone 3 
Rabbit polyclonal - ab5176 Abcam 1/1000 
PARP (full length 
and cleaved 
forms) 
Rabbit polyclonal - 9542 Cell Signaling 1/1000 
PARP (cleaved 
form) 
Rabbit polyclonal - 9541 Cell Signaling 1/1000 
PCNA Mouse 
monoclonal 
PC10 sc-56 Santa Cruz 1/1000 
STAT3 Rabbit 
monoclonal 
79D7 4904 Cell Signaling 1/2000 
STAT3 (Y705) Rabbit 
monoclonal 
D3A7 9145 Cell Signaling 1/1500 
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2.8. Flow cytometry 
 
2.8.1.  Infectability 
 
Cells were seeded in 24-well plates at a density of 2x105 cells (22Rv1) and 
1x105 cells/well (DU145 and LNCaP) in 1ml volume of 10% FBS supplemented 
medium. The following day cells were infected for 2h with 500ppc Ad5GFP in 
serum-free medium (500µl/well). After infection, medium was removed and 
replaced with 1ml/well 10% FBS supplemented medium. Uninfected cells served 
as controls. Cells were incubated at 37ºC for 48h. Cells were collected by 
trypsinisation and washed twice with 3ml/sample of ice-cold PBS and 
resuspended in 500µl PBS. Cells were kept on ice until analysis by flow 
cytometry. Ten thousand events were acquired by flow cytometry on a 
FACScalibur cytometer (Becton, Dickinson, NJ, USA) with CellQuest Pro v5 
Software (BD Biosciences). The events were analysed by gating forward side 
scatter (FSC) versus right angle side scatter (SSC) and quantifying GFP-
positive cells on a plot of green fluorescence (FL-1) versus FSC and setting the 
marker to encompass <1% of the uninfected control. Post acquisition, data was 
analysed using FlowJo v7 software (Tree Star Inc., OR, USA) and gates set as 
described for acquisition. 
 
2.8.2.  Cell cycle analysis 
  
2.8.2.1. Cell cycle changes in response to Ad5Hey1 in 
22Rv1 and DU145 cells 
 
DU145 and 22Rv1 cells were seeded in 6-well plates at a density of 
1.5x105cells/well and 3x105cells/well respectively. Cells were infected with virus 
using doses shown in Table 15. After 2h, the infection medium was removed 
and replaced with 2ml/well 10% FBS supplemented medium. At 24, 48 and 72h 
post-infection cells were harvested by trypsinisation, washed in PBS and fixed in 
1ml 70% ethanol (Fisher Scientific) at stored at -20ºC overnight. DNA content of 
cells was analysed by washing samples twice with PBS (3ml/sample) and then 
stained with 25μg propidium iodide (PI) and 5μg RNase (Sigma Aldrich) per 
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sample in a final volume of 500μl PBS. Flow cytometry acquisition was carried 
out as follows: Cells were gated on FSC vs. SSC dot blot to exclude cell debris. 
Live cells were gated by pulse-area (FL2-A) vs. pulse-width (FL2-W) to exclude 
doublets. PI fluorescence (FL3-H) was plotted against cell counts on a linear 
scale to differentiate between the different phases of the cell cycle. G1 was set 
to the first peak to define 2N DNA content. The S phase marker included the 
cells between 2N and 4N DNA content. The G2/M marker included cells with 4N 
content and delimited the >4N DNA content. The sub-G1 marker counted cells 
with <2N DNA. Post acquisition, data was analysed using FlowJo software and 
cell cycle markers defined as when acquisition was carried out. 
 
Table 15. Doses of Ad5Hey1#2, AdE1A12S#2 and Ad5noHey1 used for cell cycle analysis 
 Dose 22Rv1 
(ppc used) 
DU145 
(ppc used) 
Ad5Hey1 1 
2 
3 
N/A 
100 
1000 
2000 
5000 
8000 
AdE1A12S 1 
2 
3 
N/A 
100 
1000 
2000 
5000 
8000 
Ad5noHey1 1 
2 
3 
N/A 
100 
1000 
2000 
5000 
8000 
 
2.8.2.2. Cell cycle changes in response to Ad5Hey1 in 
104-S, 104-R1 and CDXR3 cells 
 
The LNCaP sub-lines 104-S, 104-R1 and CDXR3 cells were seeded in 6-well 
plates at 3.0x105 cells/well in 2ml/well 10% charcoal-stripped FBS in DMEM. 
The following day cells were infected with a fixed dose of Ad5Hey1 that could kill 
approximately 30% of cells (EC30). After 2h infection, medium was removed and 
replaced with 10% charcoal-stripped medium supplemented with ethanol or 
0.1nM mibolerone ± 5µM bicalutamide. All treatments contained 0.05% ethanol 
and were treated in duplicates. At 72h cells were collected and treated as 
described in 2.8.2.1. Cell cycle analysis was analysed on a BD LSRFortessa 
Analyzer (Becton, Dickinson) with BD FACS DIVA software (Becton, Dickinson). 
Live cells were gated on FSC vs. SSC dot blot to exclude cell debris and single 
cells discriminated from doublets by gating 560nm yellow green laser (610/20 
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collection filter) pulse-height (YG-610/20-H) vs. YG-610/20 pulse-area (YG-
610/20-A). Cell cycle data was acquired by plotting PI fluorescence (YG-610/20-
A) vs. cell counts on a linear scale. Post acquisition, data was analysed using 
FlowJo software and cell cycle markers defined as described in section 2.8.2.1.  
 
2.8.3.  Intracellular cyclin B1 and pH3 
expression 
 
22Rv1 cells were seeded in 6-well plates at a density of 3x105cells/well. The 
following day cells were infected with viruses at 100 or 1000ppc Ad5Hey1, 
AdE1A12S or Ad5noHey1. After 2h, infection medium was removed and 
replaced with 2ml/well 10% FBS supplemented medium. Cells were treated 
overnight with 100ng/ml nocodazole so as to arrest cell in mitosis. At 48h post-
infection, medium and cells were harvested by trypsinisation, washed in PBS 
(3ml/sample), permeabilised and fixed with 500μl 100% methanol (Fisher 
Scientific) and stored overnight at -20ºC. The next day cells were washed with 
1.0% BSA-containing PBS and stained with either cyclin B1 antibody (1/400) or 
phospho-histone 3 (pH3) antibody (1/1000) (Table 14) diluted in 1% BSA-PBS 
for 1h at RT. Cells were then washed with BSA-PBS and FITC-conjugated anti-
mouse or anti-rabbit secondary FITC-conjugated antibody added at a dilution of 
1/250 for cyclin B1 or pH3 antibodies respectively. Cells were incubated in the 
dark at RT for 30min after which the cells were washed twice with BSA-PBS. 
Cells were resuspended in 500μl PBS containing 25μg PI and 5µg RNase per 
sample. Events were acquired with FACScalibur cytometer. Cells were gated on 
FSC vs. SSC dot blot to exclude cell debris and live cells were gated by pulse-
area (FL2-A) vs. pulse-width (FL2-W) to exclude doublets. Bivariate analysis of 
cyclin B1 or pH3 expression was carried out by plotting FITC fluorescence (Fl-1) 
on a log scale vs PI fluorescence (FL3-H) on a linear scale so as to discriminate 
between DNA content and intracellular protein expression. 10000 single cell 
events were acquired. Post acquisition, data was analysed using FlowJo 
software. 
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2.8.4.  Mitochondrial membrane potential 
depolarization 
 
DU145, LNCaP and 22Rv1 cell lines were seeded in 6-well plates at 1.0x105, 
1.5x105 and 3.0x105 cells/well respectively in 2ml/well 10% FBS supplemented 
medium. The following day, cells were infected as single replicates (time-course 
experiment) or in triplicates (96h stand-alone experiments) with an EC30 dose of 
virus. Two hours later cells were incubated with either normal 10% FBS medium 
or drug-containing medium using the doses that resulted in synergistic cell death 
(Table 11). Treatment overnight with the apoptosis-inducer staurosporine at 
1µM (DU145 and LNCaP) or 0.5µM (22Rv1) served as a positive control. Cells 
and medium were harvested between 24-120h by trypsinisation. Samples were 
washed once with PBS (3ml/sample) and stained with TMRE by adding 5µl 
(22Rv1) or 40 µl (22Rv1 and LNCaP) of 1µg/ml TMRE working stock to cells 
resuspended in 500µl PBS. Sample was mixed thoroughly with TMRE by 
inverting tube 2-3times. Cells were incubated for 30min at 37°C in the dark, 
washed with PBS, resuspended with 500µl PBS and 50µl 1mg/ml 4’,6-
diamidino-2-phenylindole (DAPI) (Invitrogen) was added to exclude necrotic 
cells (disrupted cellular membrane). Cells were analysed by flow cytometry 
using the BD LSRFortessa Cell Analyzer (Becton, Dickinson). Cells were 
analysed by flow cytometry using the BD LSRFortessa Cell Analyzer (Becton, 
Dickinson). Cell debris was excluded by gating on the FSC vs. SSC bivariate 
scatterplot (Figure 16). A 560nm yellow-green laser with a 585/15-bandpass 
filter was used to detect TMRE fluorescence and a 405nm violet laser with a 
450/50-bandpass filter for DAPI fluorescence. A bivariate scatterplot of TMRE 
fluorescence vs. DAPI fluorescence (both on a logarithmic scale) allowed for the 
separation of cells according to live cells (TMRE+/DAPI-), apoptotic cells 
(TMRE-/DAPI-) and necrotic cells (TMRE-/DAPI+) using BD FACS Diva 
software (BD Biosciences). Post acquisition, data was analysed using FlowJo 
software. The percentage of apoptotic cells was plotted as a function of time. 
10000 events were collected when possible on the FSC/SSC gated population.  
 
As cells infected with Ad5GFP were also subject to staining with TMRE, the 
laser and filter for TMRE event collection was selected to ensure minimal 
spectral overlap between the emission wavelength of GFP and TMRE. A 560nm 
excitation laser was selected with a bandpass filter of 585/15 for TMRE 
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(excitation/emission; 549/574nm). To verify that the distribution of TMRE- and 
DAPI-stained cells was not altered when cells were infected with Ad5GFP, GFP 
was excited using a 488nm excitation laser with a bandpass filter of 530/30. 
GFP-negative and GFP-positive cells were gated according to GFP 
fluorescence and bivariate scatterplots of TMRE fluorescence vs. DAPI 
fluorescence constructed for each sub-population of cells (Figure 16B,C). The 
distribution of the each cell population differentially stained by TMRE and DAPI 
was comparable in the GFP-positive population as it was in the GFP-negative 
population (Figure 16C). In addition, similar percentages of cells were found in 
each quadrant of either sub-population indicating GFP did not interfere with the 
behaviour of the mitochondrial probe. 
 
 154 
 
Figure 16. GFP fluorescence of Ad5GFP-infected cells does not interfere with TMRE 
emission 
22Rv1 cells were infected with 1000ppc Ad5GFP and 2h later infection medium removed and 
replaced with 10% DMEM. 48h post-infection cells were harvested and stained with TMRE and 
DAPI according to the protocol above. (A) Cells were gated using SSC vs FSC to gate out cell 
debris. (B) the gated cells were further divided according to GFP fluorescence, GFP-negative or 
GFP-positive. (C) sub-populations were analysed according to TMRE vs. DAPI staining and 
quadrants established to distinguish cells according to mitochondrial Δψm (TMRE) and cell 
membrane integrity (DAPI). (Q1; Live, Q2; Necrotic, Q3; Necrotic, Q4; Apoptotic). 
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2.8.5.  Active caspase-3 detection 
 
Cells were seeded and treated as described section 2.8.4. Cells were treated 
overnight in 0.5µM staurosporine. At 72h post-infection cells and medium were 
collected by trypsinisation and washed with PBS (3ml/sample) and labelled with 
a FITC-conjugated anti-active caspase-3 antibody according to the 
manufacturers’ instructions (Active caspase-3 FITC Mab apoptosis kit 1, BD 
Pharmingen, Becton, Dickinson). Cells were analysed by flow cytometry on a 
FACScalibur cytometer with CellQuest Pro software. Data was analysed by 
gating FSC vs. SSC for live cells and then quantifying GFP-positive cells on a 
plot of green fluorescence (FL-1) versus FSC, setting the marker to encompass 
<1% of the uninfected, untreated control. Post acquisition, data was analysed 
using FlowJo software. 
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2.9. Constructing a replication-
selective AdΔΔHey1 
 
The design of a replicating Hey1 adenovirus (AdΔΔHey1) was based on the 
cancer-selective AdΔΔ backbone described previously (Oberg, Yanover et al. 
2010). For the description of the cloning strategy for AdΔΔHey1 see section 
3.5.1. 
 
2.9.1.  Construction of pSuperShuttle 
LARAHey1 
 
2.9.1.1. PCR amplification of inserts 
 
750bp PCR fragments flanking the E3gp19k region termed the Right Arm (RA) 
and Left Arm (LA) were amplified from Ad5 DNA and the Hey1 from pSG5-Flag-
Hey1 (a kind gift from Dr Charlotte Bevan) using the primer sequences in Table 
16. For RA and LA amplification each reaction contained 10ng purified viral 
DNA, 2.5µl each of forward and reverse primers (10µM), 1µl dNTPs (10mM 
each), 10µl 5x Phusion HF buffer (part of Phusion High-Fidelity DNA 
polymerase kit; Finnzymes, Thermo Scientific) and 0.5µl Phusion DNA 
polymerase made up to a final volume of 50µl with distilled H2O. For 
amplification of Hey1 the pSG5-Flag-Hey1 plasmid (10ng) was used. DNA was 
amplified by 30 cycles (98°C 10s, 58°C 30s, 72°C 30s) in a Gene Amp PCR 
system 9700. Buffers and contaminants in the PCR products were removed 
using QIAquick PCR Purification kit (Qiagen). The PCR products were then 
digested with EcoRV to generate phosphorylated ends (see section 2.9.1.2). 
The EcoRV-digested PCR fragments were run out on a 0.8% agarose gel for 
subsequent gel extraction using the QIAquick Gel Electrophoresis kit (Qiagen) 
and DNA eluted in 30µl distilled H2O. 
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Table 16. Primers used to generate RA and LAHey1 inserts for pSSLARAHey1 construction 
Primer Name Sequence (5’ – 3’) 
E3gp19K RA forward GTACGATATCTTTACTAAGTTACAAAGCTAATGTC 
E3gp19K RA Reverse GTACGATATCCTGGATAAAGGCGATGACCAC 
E3gp19K LA Forward GTACGATATCCCCCCTGCTAGTTGAGCG 
E3gp19K LA Hey1 
Reverse 
GTCATCGTCGTCCTTGTAGTCCATGGTGGCCTTGGGTGGCGACCCCAG 
Hey1 fusion Forward GGACTACAAGGACGACGATGACAAGAAGCGAGCTCACCCCGACTAC 
Hey1 Reverse GTACGATATCTTAAAAAGCTCCGATCTCCGTCCC 
RAseq Reverse GATTCTGTGGATAACCGTATTAC 
 
2.9.1.2. Digestion of pSS and pSSRA by restriction 
enzymes 
 
2µg pSS or pSSRA were linearised with either EcoRV or SnaB1 (NEB) 
respectively. Restriction digests were carried out in a 50µl reaction volume 
containing 5µl 10x NEBuffer 3 (EcoRV) or NEBuffer 4 (SnaBI), 5µl 10x BSA and 
1µl of either EcoRV or SnaBI made up to 50µl with distilled H2O. The reaction 
was incubated at 37°C.  
 
2.9.1.3. Dephosphorylation of linearised pSS or pSSRA 
 
After enzyme digestion, linearised pSS or pSSRA was subjected to 
dephosphorylation using Antarctic Phosphatase (NEB). 5µl 10x Antarctic 
Phosphatase Reaction Buffer and 1µl Antarctic Phosphatase was added to the 
linearised and gel extracted plasmid preparation and incubated at 37°C for 
15min. The linearised and dephosphorylated pSS or pSSRA was run on a 0.8% 
agarose gel and the band gel extracted and DNA eluted in 30µl distilled H2O. 
 
2.9.1.4. Generation of LA-Hey1 insert by PCR SOEing 
 
Seamless fusion of LA and Hey1 was carried out using SOEing PCR before it 
was cloned into pSSRA. After gel extraction, LA and Hey1 PCR products were 
annealed in a 1:1 molar ratio in the presence of DNA polymerase with no 
primers. Annealing conditions were 95°C 4min, 55°C 3min and 72°C 5min. 
Primers E3gp19K LA Forward and Hey1 Reverse were added to the annealed 
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LA–Hey1 and PCR conditions in 2.9.1.1 extended and amplified the fusion 
product. 
2.9.1.5. Ligation of insert into pSS or pSSRA 
 
Ligations were carried out using the Rapid Ligation Kit (Roche) according to the 
manufacture’s instructions. The volumes of linearised and dephosphorylated 
vector DNA and insert were calculated using the equation below: 
 
Insert size (bp)      x   insert intensity   x   volume of vector for ligation    x 3 
Vector size (bp)        vector intensity 
 
Ligations were incubated at RT for 30min and ligation reactions transformed into 
TOP10 chemically competent E.coli (Invitrogen). 
 
2.9.1.6. Transformation of pSS or pSSRA into 
competent E.coli 
 
1µl of ligation reactions of pSS or pSSRA were added to thawed chemically 
competent TOP10 bacteria and incubated on ice for 30min after which they 
were transferred to 42°C water bath for 30s. 250µl of pre-warmed S.O.C. 
medium was added to each transformation and the vials incubated at 37°C with 
agitation for 1h and the bacterial culture plated onto agar plates containing 
20µg/ml of chloramphenicol (Sigma-Aldrich). Plates were inverted and incubated 
overnight at 37°C 
 
2.9.1.7. Screening recombinant clones 
 
Initial screening to assess presence of insert was by crude extraction of DNA 
from the overnight bacterial culture with phenol-chloroform (USB Corporations, 
OH, US). In the case of identifying pSSRA, DNA was run on a 0.8% agarose gel 
along with undigested pSS for size comparison. Orientation was determined by 
carrying out PCR on the culture medium of selected clones. The primers set 
used for RA were E3gp19K RA forward and RAseq reverse primer (recognising 
a sequence outside the EcoRV cloning site in the pSS vector) (Table 16). 
Successful PCR amplification would only result if the RA were in the correct 
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orientation. Successful insertion of LA-Hey1 into pSSRA was initially screened 
with PmeI and SwaI digestion. At each cloning step (pSSRA or pSSLARAHey1), 
sequencing was performed to determine 100% homology and confirm correct 
orientation of RA and LARAHey1 DNA sequences in the shuttle vector. All 
sequence analyses was performed by the Genome Centre at Barts Cancer 
Institute (London). 
 
2.9.1.8. Homologous recombination  
 
pSSLARAHey1 was digested with PmeI using NEBuffer 4 and incubated at 
37ºC for 1h to remove the Origin of Replication (OriR). Digested pSSLARAHey1 
was purified by phenol chloroform extraction and then precipitated with ethanol. 
Digested pSSLARAHey1 and AdΔΔ plasmid were electroporated into BJ5183 
E.coli at 50 and 100ng respectively. 250µl of pre-warmed S.O.C. medium was 
then added to the bacteria and incubated with agitation for 1h at 37°C. Bacterial 
culture was plated onto agar plates containing 25µg/ml chloramphenicol and 
kanamycin each and incubated overnight at 37°C. 
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3. Results 
 
3.1. Investigating the intrinsic 
cytotoxicity of Ad5Hey1-mediated 
cell death in PCa cells 
 
3.1.1.  Ad5Hey1 is cytotoxic to 22Rv1, 
LNCaP and DU145 cells 
 
To verify the potency of Ad5Hey1 and relative toxicity between cell lines, cell 
viability assays were performed in the panel of prostate cancer cells previously 
used. Dose-response curves to replication defective adenoviral mutants were 
generated and cell death assessed three days post-infection to determine the 
dose required to kill 50% of cells (Effective Concentration, EC50) for Ad5Hey1, 
the positive control virus AdE1A12S expressing E1A12S, a recognised inducer 
of apoptosis and the negative control virus, Ad5GFP expressing the non-toxic 
transgene, GFP (Figure 17). Ad5Hey1 showed similar potency to the control 
virus AdE1A12S in all cell lines as determined previously (Cheong et al, 
manuscript in preparation). Furthermore, the AR-positive 22Rv1 and LNCaP 
were more susceptible than the AR-negative DU145 cells to both Ad5Hey1- and 
AdE1A12S-induced cytotoxicity. The EC50 values of Ad5Hey1 and AdE1A12S 
varied between cell lines (Figure 17 and Table 17). One contributing factor is the 
variability in the infectability of the cell lines; a more potent triggering of cell 
death mechanisms occurs in the sensitive 22Rv1 cells compared with the less 
infectable DU145 cells (Figure 18). Furthermore, each PCa cell line has a 
distinctive set of genetic alterations in cell cycle and cell death pathways (Table 
5), which will influence the sensitivity of the cell to a specific transgene. 
Interestingly, in AR-negative PC3 cells only AdE1A12S was able to induce cell 
death whereas Ad5Hey1 did not (section 1.8.1; Table 4, S.C. Cheong et al, 
manuscript in preparation). 
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The potency of Ad5Hey1 varied between the two main virus batches used in this 
thesis (Batches 2 and 3; Table 17; section 2.3.4; Table 7). Ad5Hey1#3 was 
more cytotoxic compared with Ad5Hey1#2 in all tested cell lines while the 
comparative order of sensitivity between the cell lines were the same for both 
Ad5Hey1 batches as well as the relative potency between AdE1A12S and 
Ad5GFP. The sensitivity of 22Rv1 cells and LNCaP cells to Ad5Hey1 was 
similar whereas DU145 cells were the least sensitive (Figure 17). While 
AdE1A12S had lower EC50 values than Ad5Hey1, the relative sensitivity of cells 
to AdE1A12S was the same as to Ad5Hey1; 22Rv1 and LNCaP cells the most 
sensitive and DU145 the least. The negative control mutants AdFlagHey1 or 
Ad5GFP were approximately between 10 to 20-times less potent than Ad5Hey1 
in these cells. 
 
 
Figure 17. Ad5Hey1 possesses intrinsic cytotoxicity in 22RV1, LNCaP and DU145 cells. 
Cells were seeded in 96-well plates and the following day infected in duplicate or triplicate with 
five-fold serially diluted Ad5Hey1#3, AdE1A12S#3 or Ad5GFP. EC50 values are expressed as a 
percentage of Ad5GFP to determine relative potency of Ad5Hey1 and AdE1A12S in each cell line. 
Results were obtained three days post-infection by MTS cell viability assay. Results are mean 
from ≥3 experiments ± SEM. Statistical analysis on raw EC50 values (Table 17) with one-way 
ANOVA using a Dunnet’s post-test p<0.01 (**) and p<0.001 (****) comparing Ad5Hey1 or 
AdE1A12S with Ad5GFP within each cell line. One-way ANOVA using multiple comparisons with 
a Tukey post-test, p<0.01 (§§), p<0.001 (§§§/§§§§) comparing raw Ad5Hey1 or AdE1A12S EC50 
values in 22Rv1 or LNCaP cells with corresponding viruses infected in DU145 cells. 
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Table 17. EC50 values for Ad5Hey1, AdE1A12S, AdFlagHey1 and Ad5GFP in PCa cell lines 
 22Rv1 
Mean    SEM    N 
LNCaP 
Mean    SEM    N 
DU145 
Mean    SEM    N 
Ad5Hey1#2 776   ±    56     7 1988   ±   219     4 7225   ±  640    3 
Ad5Hey1#3 569   ±    94     3 613     ±     86     4 2829   ±  267    8 
AdE1A12S#1 73     ±    19     3 Not performed Not performed 
AdE1A12S#2 Fixed doses used Not performed Fixed doses used 
AdE1A12S#3 307   ±    65     3 428     ±    114    4 1417   ±  135    5 
Ad5noHey1 2594 ±   753    4 >20000               3 29108 ± 4327   3 
Ad5GFP  4633 ±   121    3 14136 ±   2400   4 30056 ± 6553   3 
Dose response curves were constructed by treating cells in duplicate or triplicate with five-fold 
serially diluted Ad5Hey1#2-3, AdE1A12S#1-3, Ad5noHey1 or Ad5GFP and cell death assessed 
by MTS 3 days post-infection. Results are mean of 3-8 independent experiments ± SEM.  
 
 
Figure 18. Infectability of PCa cells  
Cells were seeded in 24-well plates and the following day infected with non-replicating Ad5GFP at 
500ppc. After 2h, medium was removed and replaced with either 10% DMEM (DU145 and 22Rv1) 
or 10% RPMI (LNCaP). At 48h post-infection, cells were harvested for flow cytometry analysis as 
described in section 2.8.1. Results shown are mean of duplicates from one experiment ± SEM. 
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3.1.2.  Hey1 expressed from a non-
replicating adenovirus acts as an AR 
corepressor 
 
Ad5Hey1 was previously demonstrated to repress AR signalling of an MMTV 
reporter construct (MMTV-Luc) in mibolerone-stimulated 22Rv1 cells and 
cooperate with bicalutamide to further decrease AR signalling (section 1.8.1; 
Figure 13). 
 
The response to Ad5Hey1 was not dose dependent at the previously tested 
concentrations of 10-100ppc and as maximal inhibition was already reached at 
10ppc, lower doses of Ad5Hey1 were assessed (Figure 19). A dose dependent 
decrease in AR transcriptional activity was observed with escalating doses 
between 0.1 and 10ppc. Ad5GFP was found to decrease AR activity in one of 
the two experiments presumably through non-specific toxic effects of GFP. This, 
together with the previous findings demonstrates that Hey1 represses AR 
transcriptional activity in a dose-dependent fashion (0.1–10ppc) when 
expressed from a non-replicating adenovirus mutant similar to previous reports 
of Hey1 and HeyL expressed from other vectors in in vitro systems and MCF7 
cells (Belandia, Powell et al. 2005; Villaronga, Lavery et al. 2009). 
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Figure 19. Ad5Hey1 repression of AR transcriptional activity is dose-dependent in 22Rv1 
cells 
Cells were seeded and the following day infected at escalating doses of Ad5Hey1#1 or Ad5GFP 
(0.1, 0.3, 1.0, 3.0 and 10ppc). 24h later cells were co-transfected with AR reporter plasmid MMTV-
Luc and a plasmid expressing renilla luciferase under the control of a SV40 promoter (pRL-SV40) 
for normalisation. 48h after virus infection cells were treated with 0.1nM mibolerone and the 
following day, 72h post virus infection, cells were lysed and luciferase expression detected using a 
dual luciferase reporter assay system. Data shows mean of single replicates from 2 independent 
experiments ± SEM.  
 
3.1.3.  Ad5Hey1-dependent cytotoxicity is 
only partially mediated by repression of AR-
activity 
 
Following verification of Ad5Hey1 as a corepressor to AR, we sought to 
determine to what extent Ad5Hey1-induced cell death was dependent on AR-
expression considering that Ad5Hey1 also induces cell killing in AR-negative 
DU145 cells. To determine the role of AR for Ad5Hey1-mediated cytotoxicity, 
siRNA (previously identified to be specific for AR by Dr S.C. Cheong) was used 
to knockdown AR and cell viability was assessed with and without Ad5Hey1 
infection. Western blotting (Figure 20) confirmed that AR knockdown was 
successful and stable up to 120h (5 days) post-transfection while a non-
targeting control siRNA sequence did not affect AR expression. Knockdown of 
AR in 22Rv1 cells under these conditions resulted in only modest cell death 
(10.0±4.78%) (Figure 21C). A low level of AR expression was still detectable 
after AR knockdown and may have been sufficient to stimulate AR signalling 
and cell growth. 
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After AR knockdown, a dose response curve to Ad5Hey1 was generated to 
determine EC50 values in cells treated with AR siRNA or control siRNA. 
Ad5noHey1 (not expressing Hey1) was used as a negative control instead of 
Ad5GFP due to a problem in Ad5GFP production. The knockdown of AR 
resulted in desensitisation of 22Rv1 cells to Ad5Hey1 (Figure 21A). The extent 
of the desensitisation was observed as a two-fold increase in EC50 value 
compared with cells transfected with control siRNA (Figure 21B). The EC50 
values of AdE1A12S and Ad5noHey1 did not significantly alter when AR was 
knocked down. These data demonstrate that inhibition of the AR only partially 
mediates the potency of Ad5Hey1 in 22Rv1 cells and suggest that additional 
mechanisms are involved. 
 
 
Figure 20. Knockdown of AR by siRNA in 22Rv1 cells 
Cells were seeded and the following day transfected with 100nM AR siRNA. Cell lysates were 
harvested 24h, 48h and 120h post-transfection and prepared for separation on polyacrylamide 
gels. 20µg protein was loaded per lane and immunoblotted for AR and β tubulin as a loading 
control. 
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Figure 21. The sensitivity to Ad5Hey1 decreases when AR is knocked down in 22Rv1 cells 
A) Dose response curves in cells infected with five-fold serially diluted Ad5Hey1#2, AdE1A12S#1 
or Ad5noHey1 48h after transfection with AR or Control siRNA. Cell death was assayed 3 days 
post-infection/5 days post-transfection by MTS assay and expressed as a percentage relative to 
AR siRNA or Control siRNA-treated cells. Results are shown as means of duplicates wells from 2-
3 independent experiments ± SEM. B) Histogram showing relative EC50 values of data from (A) 
compared to control siRNA. Results are means of 2-3 independent experiments ± SEM with two-
way ANOVA statistical analysis using multiple comparisons with a Tukey post-test, p<0.05 (*) and 
p<0.01 (**). C) Percentage of cell death (relative to transfection reagent alone) after treatment with 
siRNA 120h post-infection. Results shown as mean of duplicate wells from 3 independent 
experiments. 
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3.1.4.  The significance of p53 signalling for 
Ad5Hey1-dependent cytotoxicity in 22Rv1 
and LNCaP cells 
 
3.1.4.1. Ad5Hey1 stabilises and activates p53 in 22Rv1 
and LNCaP cells 
 
As suggested in section 3.1.3, repression of AR activity by Ad5Hey1 is likely not 
the sole mechanism for Ad5Hey1-induced cell death in 22Rv1 cells. Previous 
reports have demonstrated overexpression of Hey1 induces inhibition of cell 
proliferation or apoptosis as a consequence of p53 stabilisation through the 
inhibition of HDM2 at the transcriptional level (Huang, Raya et al. 2004; 
Villaronga, Lavery et al. 2009).  
 
Based on these findings I assessed whether overexpression of Hey1 resulted in 
p53 stabilisation in 22Rv1 and LNCaP cells which both express functional p53. 
The doses were selected based on the EC50 values obtained from three-day cell 
viability MTS assays. In 22Rv1 cells, Ad5Hey1 and AdE1A12S resulted in dose-
dependent increases in total p53 expression at 48 and 72h post-infection 
(Figure 22) while Ad5GFP resulted in only a small increase in p53 expression. 
An identical trend in p53 induction was obtained for a further two independent 
experiments at 48h post-infection and one further experiment at 72h post-
infection (Appendix ; Figure_Apx 1 and Figure_Apx 2). The fold-change of p53 
expression varied considerably between experiments, owing to different 
detection systems, different virus batches and western blotting being undertaken 
on different days. Consequently it was not possible to combine results. 
Activation of p53 was confirmed by detection of phosphorylated serine 15 
(Ser15) (Figure 22). Etoposide, a topoisomerase inhibitor was used as a positive 
control as it is a well-known inducer of p53 expression via inhibition of HDM2 
synthesis (Arriola, Lopez et al. 1999).  
 
Although a direct comparison was not made, basal levels of total p53 were 
higher in LNCaP cells compared with 22Rv1 cells. In LNCaP cells, infection of 
Ad5Hey1 or AdE1A12S induced stabilised p53 expression (Figure 23) while p53 
expression in Ad5GFP-infected cells was reduced below basal levels. A similar 
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trend at different virus doses was also observed (Appendix ; Figure_Apx 3). 
Phospho (ser15) p53 expression after Ad5Hey1 or AdE1A12S infection was not 
detected (data not shown). 
 
Upregulation of p53 expression and activation of this pathway in these cells 
supported previous findings that Hey1 and Hey1-related, Hes1 inhibit HDM2 
transcription thereby stabilising p53 (Huang, Raya et al. 2004). Several studies 
have confirmed the presence of HDM2 in both 22Rv1 and LNCaP cells and the 
small- molecule HDM2-inhibitor nutlin-3 has been shown to inhibit HDM2 activity 
and stabilise p53 indicating this pathway is functional in these cell lines (Logan, 
McNeill et al. 2007; Udayakumar, Hachem et al. 2008; Tovar, Higgins et al. 
2011). Upregulation of p53 expression by AdE1A12S has been found to occur 
through multiple cellular targets that converge to activate p53 signalling. These 
include sequestration of pRb by E1A (E1ACR1 and/or E1ACR2-dependent) 
which releases E2F and in turn leads to the induction of p14ARF, a mediator of 
HDM2 inhibition (de Stanchina, McCurrach et al. 1998; Deng, Kloosterbooer et 
al. 2002) as well as interacting with p300/CBP thereby facilitating disruption of 
HDM2-p53 complexes and contributing to p53 stabilisation (Grossman, Perez et 
al. 1998). Additionally, E1A may stabilise p53 through direct binding to the 26S 
proteasome (Turnell, Grand et al. 2000). 
 
Taken together, these findings suggest that stabilisation of p53 could also 
contribute to Ad5Hey1-dependent cytotoxicity in addition to AR inhibition and 
may explain previous findings that p53-null and AR-negative PC3 cells were 
insensitive to Ad5Hey1 (Cheong S.C. et al manuscript in preparation). 
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Figure 22. Ad5Hey1-infection causes stabilisation and activation of p53 in 22Rv1 cells 
Cells were infected with Ad5Hey1#2, AdE1A12S#2 and Ad5GFP at 10, 100 and 1000ppc. After 
2h, infection medium was removed and replaced with 10% FBS DMEM. Cells were treated 
overnight with 10µM etoposide to serve as a positive control. Cell lysates were harvested at 48hpi 
(A) and 72hpi (B) and prepared for separation on polyacrylamide gels. 20µg protein was loaded 
per lane and total p53 and phospho (ser15) p53 blotted for on separate gels. KU70 was used as a 
loading control. Histograms showing total p53 and phospho (ser15) p53 protein expression 
normalised to KU70 and expressed relative to uninfected (UN) cells. A) For total p53. results show 
one blot, representative of 3 independent experiments and for phospho (ser15) p53, one 
experiment. B) For total p53, results show one blot, representative of 2 independent experiments 
and for phospho (ser15) p53, one experiment. 
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Figure 23. Ad5Hey1-infection stabilises p53 in LNCaP cells 
Cells were infected with Ad5Hey1#3, AdEA12S#3 and Ad5GFP at 300, 500 and 1000ppc. After 
2h, infection medium was removed and replaced with 10% FBS RPMI. Cell lysates were 
harvested at 48h post-infection and prepared for separation on polyacrylamide gels. 25µg protein 
was loaded per lane and total p53 blotted with KU70 as loading control. Histogram showing p53 
protein expression normalised to KU70 and expressed relative to uninfected (UN) cells. Results 
show one blot from 2 independent experiments.  
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3.1.4.2. Ad5Hey1-induced cell killing is also mediated 
through p53-dependent pathway in 22Rv1 cells 
 
The observation that Ad5Hey1 infection resulted in p53 activation in 22Rv1 cells 
led us to investigate whether p53 expression is a requirement for mediating 
Ad5Hey1-induced cytotoxicity. A SMARTpool On-Target siRNA specific to p53 
was employed to deplete 22Rv1 cells and assess cell viability after Ad5Hey1 
infection. To preserve viral stocks, fixed doses at EC50 for adenoviral mutants 
were used rather than constructing dose response curves. The use of fixed virus 
doses was also easier and faster to perform with the aim of obtaining more 
reproducible data in less time. Knock down of p53 was confirmed by western 
blotting (Figure 24) and was stable up to 120h post-transfection. Knockdown of 
p53 did not induce significant cell death compared with control siRNA 
presumably due to the activity of other cell survival mechanisms.  
 
Ad5Hey1 infection of p53 knockdown cells resulted in a statistically significant 
decrease in cell death compared with cells transfected with control siRNA: 
24.5% and 53.2% cell death respectively (Figure 25). Knockdown of p53 also 
resulted in a 20.7% reduction of AdE1A12S-induced cell death compared with 
AdE1A12S-mediated cell death in control siRNA-transfected cells (54.8% and 
75.6% cell death respectively), although this was not statistically significant. 
Induction of cell death by Ad5noHey1 (deemed to be non-specific due to the 
high dose of virus used) was not affected by p53 status. These results indicate 
the activation of the p53-pathway in these cells is important for mediating 
Ad5Hey1-dependent cytotoxicity and concurs with similar studies where p53 
was knocked down in U2OS-HEY1 cells preventing Hey1-induced cell growth 
arrest (Villaronga, Lavery et al. 2009). 
 
 
Figure 24. Knockdown of p53 by siRNA in 22Rv1 cells 
Cells were seeded and the following day transfected with 100nM p53 siRNA or Control siRNA. 
Cell lysates were harvested 24h, 48h and 120h post-transfection and prepared for separation on 
24h 48h 120h 
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KU70 (70kDa) 
55 
70 
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polyacrylamide gels. 20µg protein was loaded per lane and blotted for p53 and β-actin! as a 
loading control. 
 
 
Figure 25. Sensitivity to Ad5Hey1 decreases when p53 is knocked down in 22Rv1 cells 
A) Cells were transfected with either p53 siRNA or Control siRNA (100nM) and 48h after 
transfection cells infected with a fixed dose (EC50) of Ad5Hey1#2 (800ppc), AdE1A12S#2 
(150ppc) or Ad5noHey1 (2500ppc). Cell death was assayed 3 days post-infection/5 days post-
transfection by MTS assay and expressed as a percentage relative to p53 siRNA or Control 
siRNA-treated cells. Results are shown are means of 6 replicate wells from 4 independent 
experiments ±!SEM with two-way ANOVA statistical analysis using multiple comparisons with a 
Tukey post-test, p<0.05 (*) and p<0.01 (**) compared to p53 siRNA-treated cells infected with 
Ad5Hey1. p<0.05 (#) compared with control siRNA-treated cells infected with Ad5Hey1. B) 
Percentage of cell death (relative to untreated cells) after treatment with siRNA 120h post-
infection. Results shown as the mean of 4 replicate wells from 4 independent experiments ± SEM.  
 
3.1.4.3. Contribution of AR-and p53-signalling to 
Ad5Hey1-mediated cytotoxicity in 22Rv1 cells 
 
In summary, AR knockdown resulted in a 2-fold increase in the EC50 of 
Ad5Hey1. On the other hand knockdown of p53 desensitised cells to a fixed 
dose of Ad5Hey1 resulting in >50% reduction in Ad5Hey1-dependent cell death 
than when p53 was expressed. Since these two studies were not equivalent, 
parallel with the p53 knockdown studies, AR was knocked down in 22Rv1 cells 
and infected with an identical fixed dose of Ad5Hey1, AdE1A12S and 
Ad5noHey1. To permit a comparison to be made, Ad5Hey1-mediated cell killing 
after AR or p53 knockdown was expressed relative to Ad5noHey1 (Table 18). In 
agreement with results shown in section 3.1.3, knockdown of AR resulted in a 
decrease in Ad5Hey1-mediated cell death relative to Ad5noHey1 (0.69±0.13) 
whereas the absence of AR did not affect AdE1A12S-dependent cell killing 
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(0.99±0.5). Unlike the previous study described section 3.1.3, the reduction of 
Ad5Hey1-mediated cytotoxicity after knockdown of the AR was not statistically 
significant compared with Ad5noHey1. Analysis of the data as shown in Table 
18 showed knockdown of p53 resulted in a statistically significant decrease in 
both Ad5Hey1- and AdE1A12S-induced cell death (0.78±0.04 and 0.64±0.04 
respectively). 
 
Table 18. Relative % cell death with EC50 fixed dose of either Ad5Hey1 or AdE1A12S after 
AR or p53 knockdown 
 AR siRNA 
Mean     SEM     p value 
p53 siRNA 
Mean     SEM    p value 
Ad5noHey1            1.00    0.00        -          1.00     0.00       -       
Ad5Hey1            0.69    0.13       ns          0.78     0.04   p<0.01 
AdE1A12S            0.99    0.50       ns          0.64     0.04   p<0.001 
22Rv1 cells were infected with a fixed dose (EC50) of Ad5Hey1#2 (800ppc), AdE1A12S#2 
(150ppc) or Ad5noHey1 (2500ppc) 48h after transfection with either AR, p53 or control siRNA 
(100nM). Cell death was assayed 3 days post-infection/5 days post-transfection by MTS assay. 
Percentage cell death values resulting from Ad5Hey1 or AdE1A12S in AR or p53 siRNA 
transfected cells was normalised to percentage cell death of similarly virus-infected cells 
transfected with control siRNA. Normalised data was then expressed relative to Ad5noHey1 as a 
mean of 4 independent experiments ± SEM. Statistical significance was assessed with a one-way 
ANOVA comparing values with Ad5noHey1 for either AR or p53 knockdown. 
 
In conclusion, the potency of Ad5Hey1-mediated cytotoxicity in 22Rv1 cells is 
significantly decreased when p53 is removed suggesting that in these cells, 
Ad5Hey1-dependent cytotoxicity functions by a p53-mediated mechanism in 
addition to inhibiting AR signalling. I have endeavoured to assess the relative 
significance of each pathway in Ad5Hey1-mediated cytotoxicity and have 
determined both AR and p53 play a role in facilitating cell killing by Ad5Hey1. 
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3.1.5.  Ad5Hey1-infected 22Rv1 cells but 
not DU145 cells accumulate in G2/M phase 
 
As discussed in section 3.1.1, Ad5Hey1 possesses intrinsic cytotoxicity in cells 
expressing AR and wild-type p53 (22Rv1 and LNCaP) as well as AR-negative 
DU145 cells which express a non-functional form of p53. This suggests 
Ad5Hey1 has a mechanism of action that does not always require the presence 
of either functional AR or p53. This is of significance since 50% of most human 
cancer possess mutations in p53 rendering cells either devoid of p53 expression 
or harbouring non-functioning p53 (Vogelstein, Lane et al. 2000). In PCa, p53 
mutations occur more frequently in advanced PCa including CRPC (Shen and 
Abate-Shen 2010). Commonly cancer cells with mutated p53 are more resistant 
to cytotoxic agents (Velculescu and El-Deiry 1996). 
 
Ad5Hey1-mediated upregulation/stabilisation and activation of p53 in 22Rv1 and 
LNCaP cells suggest cells are driven towards cell cycle arrest or cell death. 
Therefore, cell cycle changes in response to Ad5Hey1 infection were assessed 
in 22Rv1 and compared with DU145 cells to establish whether Ad5Hey1 had a 
role in abrogating the cell cycle in cells of contrasting genetic background.  
 
Cell cycle progression was examined by flow cytometry using propidium iodide 
(PI) between 24 and 72h post-infection using increasing doses of virus (Figure 
26). The range of doses selected for each cell line were based on the EC50 
values obtained for Ad5Hey1 after 3 days of infection. Cells were infected with 
Ad5noHey1 at the same doses as Ad5Hey1 to control for the presence of the 
virus particles.  
 
At 24h, infection with Ad5Hey1, AdE1A12S or Ad5noHey1 resulted in decreased 
proportions of 22Rv1 cells in G1 and an increase in the fraction of cells in S and 
G2/M phases suggesting that the presence of a virus particle alone has an 
effect on the cell cycle (Figure 26). At 48h more discernable changes in the cell 
cycle of Ad5Hey1- and AdE1A12S-infected cells were observed (Figure 27). 
Significant increases in the fraction of cells in G2/M were observed for 
Ad5Hey1-infected cells compared with uninfected cells (a two-fold difference in 
Ad5Hey1-infected cells, a smaller increase for AdE1A12S-infected cells) (Figure 
27). The Ad5Hey1-induced G2/M population was also significantly higher than 
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for cells infected with Ad5noHey1 (Figure 27). Another distinct feature was the 
accumulation of AdE1A12S-infected cells with a >4N DNA content compared 
with cells infected with Ad5Hey1. At 72h, Ad5Hey1-infected cells resulted in an 
increase in the proportion of cells with >4N content and sub-G1 fraction (Figure 
26) suggesting apoptosis was occurring.  
 
I have shown that Ad5Hey1 causes p53-dependent stress, which may result in 
cells accumulating in G2/M. Since EC50 values indicate AdE1A12S is a more 
potent inducer of cell death compared with Ad5Hey1 (307.4±65.6 and 
776.1±56.2 respectively) it is interesting to note that at 1000ppc of Ad5Hey1 a 
larger fraction of cells in G2/M accumulated at all time points and was more 
prominent at 48h, compared to an equal dose of AdE1A12S (Figure 26 and 
Figure 27). p53 expression is induced at 48h to a similar extent by both viruses 
at the higher dose (1000ppc) and knockdown of p53 by siRNA resulted in 
significant attenuation for Ad5Hey1- and AdE1A12S-mediated cytotoxicity 
(Table 18). In view of the fact AdE1A12S has been reported to induce cell death 
through p53-independent mechanisms in addition to p53-dependent processes 
we cannot exclude the possibility that AdE1A12S-dependent cell cycle changes 
are as a result of functional alterations to non-p53 targets by AdE1A12S leading 
to an increase of cell cycle progression to >4N and sub-G1 in these cells.  
 
In contrast, Ad5Hey1 produced no discernable changes in the cell cycle of 
DU145 cells compared with Ad5noHey1 (Figure 26). As DU145 harbour 
mutations in pRb and p53, both the G1 and G2/M checkpoints are defective. At 
48h (Figure 28), only AdE1A12S infection resulted in statistically significant 
dose-dependent decreases in cells in G1 and subsequent increases of cells 
entering S phase, indicative of cell cycle progression (Berk 2005). Changes 
resulting by Ad5Hey1 in terms of G1, S and G2/M-phase cell fractions also 
occurred after infection with Ad5noHey1. The dose equivalent to the EC50 of 
AdE1A12S, 2000ppc, resulted in a significant increase in the proportion of cells 
in G2/M and this was enhanced further at supra-optimal doses. However, doses 
approximately equivalent to the EC50 of Ad5Hey1 and AdE1A12S (8000 and 
2000ppc respectively) induced a similar degree of changes in the population of 
cells with >4N resulting in a significant increase in cells with a >4N DNA content 
compared with uninfected and Ad5noHey1-infected cells. Higher doses of 
AdE1A12S further increased the proportion of cells with this phenotype.  
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Figure 26. Time-dependent effects of Ad5Hey1 on cell cycle progression in 22Rv1 and 
DU145 cells 
Cells were infected with escalating doses of Ad5Hey1#2, AdE1A12S#2 and Ad5noHey1. A) 
22Rv1; 100 and 1000ppc B) DU145; 2000, 5000 and 8000ppc. After 2h infection, medium was 
removed and replaced with 10% FBS DMEM. Cell cycle analysis was performed at 24, 48 and 
72h post-infection by flow cytometry. Results are shown as the mean of single replicates from 3 
independent experiments ± SEM 
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Figure 27. Dose-dependent effects of Ad5Hey1 on G1, S, G2/M and >4N cell populations at 
48h after infection in 22Rv1 cells 
22Rv1 cells were infected with Ad5Hey1#2, AdE1A12S#2 and Ad5noHey1 at 100 and 1000ppc. 
After 2h, infection medium was removed and replaced with 10% FBS DMEM. Cell cycle analysis 
was performed at 48h post-infection by flow cytometry. Results were extracted from Figure 26 and 
separated into phases of the cell cycle G1 (A), S (B), G2/M (C) and >4N DNA content (D). One-
way ANOVA statistical analysis was performed using multiple comparisons with a Tukey post-test, 
p<0.05 (*), p<0.01 (**), p <0.001 (****) compared to uninfected cells (UN), p<0.05(#) compared 
with 1000ppc Ad5noHey1.  
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Figure 28. Dose-dependent effects of Ad5Hey1 on G1, S, G2/M and >4N cell populations at 
48h after infection in DU145 cells 
DU145 were cells infected with Ad5Hey1#2, AdE1A12S#2 and Ad5noHey1 at 2000, 5000 and 
8000ppc. After 2h infection, medium was removed and replaced with 10% FBS DMEM. Cell cycle 
was performed at 48h post-infection by flow cytometry. Results were extracted from Figure 26 and 
separated into phases of the cell cycle G1 (A), S (B), G2/M (C) and >4N DNA content (D). One-
way ANOVA statistical analysis was performed using multiple comparisons with a Tukey post-test, 
p<0.05 (*), p<0.01 (**), p <0.001 (***/****) compared to uninfected cells (UN). 
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3.1.6.  Ad5Hey1 accumulates cells in G2 
phase and delays mitotic entry 
 
Numerous studies have implicated the importance of G2/M checkpoint 
abrogation or arrest in enhancing the effect of DNA damaging agents or that 
enhanced cytotoxicity is associated with cell cycle arrest (DiPaola 2002; Bucher 
and Britten 2008). I therefore sought to elucidate the mechanism by which 
Ad5Hey1 kills prostate cancer cells. Since Ad5Hey1 infection in DU145 cells did 
not exhibit any appreciable differences in cell cycle progression I did not 
examine the proteins involved in the cell cycle in this cell line.  
 
As discussed in section 3.1.5, Ad5Hey1 demonstrated a dose-dependent 
increase in the proportion of cells in G2/M in 22Rv1 cells. To verify this 
observation cell cycle proteins involved in this phase of the cell cycle were 
assessed after Ad5Hey1 infection. Cyclin B1 levels are tightly regulated by 
transcription and degradation. Cyclin B1 accumulates during S and G2 phases 
due to transcriptional activation (Pines and Hunter 1991) and inactivation of the 
ubiquitin-mediated degradation pathway (Peters 2002). Levels decrease at the 
beginning of the metaphase-anaphase transition during mitosis and continue 
decreasing until G1 (Pines and Hunter 1991; Peters 2002). 
 
Cyclin B1 expression was assessed at 48 and 72h post-infection by western 
blotting at 100 and 1000ppc of Ad5Hey1 or AdE1A12S in 22Rv1 cells (Figure 
29). A dose dependent increase in cyclin B1 expression was observed in 
response to Ad5Hey1 infection at both time points confirming our cell cycle data. 
Upregulation of cyclin B1 expression in AdE1A12S –infected cells was more 
prominent at 48h and decreased slightly to that above basal levels by 72h 
suggesting these cells may have progressed through the G2/M checkpoint as 
suggested by the cell cycle analysis (Figure 26). Together with Ad5Hey1-
dependent increases of total and activated p53, accumulation of cyclin B1 
suggests Hey1 activates the p53 checkpoint in 22Rv1 cells resulting in cell cycle 
arrest. Therefore I endeavoured to establish whether Ad5Hey1 infection resulted 
in a G2 block thereby preventing cells from entering mitosis or if Ad5Hey1 could 
halt cells during mitosis resulting in a mitotic catastrophe-like cell death. 
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Figure 29. Dose-dependent induction of cyclin B1 protein expression at 48h and 72h in 
22Rv1 cells 
Cells were infected at 10, 100 and 1000ppc Ad5Hey1#2, AdE1A12S#2 and Ad5GFP. After 2h 
infection, medium was removed and replaced with 10% FBS DMEM. Cell lysates were harvested 
at 48 and 72h post-infection and prepared for separation on polyacrylamide gels. 20µg protein 
was loaded per lane and cyclin B1 was blotted for KU70 used as a loading control. Results show 
one blot, representative of 3 independent experiments.  
 
Since cyclin expression detected by western blotting cannot be correlated to a 
specific cell cycle phase, intracellular cyclin B expression was assessed by flow 
cytometry to exclude the possibility of an “unscheduled” mode of expression. 
Cells were permeabilised, stained with an anti-cyclin B1 antibody and then 
stained with a FITC-labelled secondary antibody. Finally, cells were treated with 
PI so as to simultaneously monitor cell cycle changes. At 48h, Ad5Hey1 induced 
a dose- dependent increase in cyclin B1 expression at G2/M (Figure 30) with an 
accumulation of 52.1±2.5% at 1000ppc compared with 25.7±2.2% for uninfected 
control cells and 37.8±3.4% for Ad5noHey1-infected cells. AdE1A12S infection 
resulted in a smaller accumulation of cyclin B1 expression of 45.4±3.7% 
probably reflecting the lesser extent to which AdE1A12S mediated p53-
dependent cell cycle changes. 
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Figure 30. Ad5Hey1 results in a dose-dependent increase in cyclin B1 expression at G2/M 
in 22Rv1 cells 
Cells were infected with 100 or 1000ppc Ad5Hey1#2, AdE1A12S#2 or Ad5noHey1. After 2h 
infection, medium were replaced with 10% FBS DMEM. Cells were treated overnight with 
nocodazole (100ng/ml) to arrest cells in mitosis. At 48h post-infection cells were harvested and 
analysed by flow cytometry. Cells were first stained with anti-cyclin B1 primary antibody and then 
FITC-conjugated anti-mouse secondary antibody. Prior to analysis, cells were treated with PI and 
RNase for simultaneous detection of the cell cycle in addition to cyclin B1 expression. Cyclin B1 
was plotted relative to DNA content (PI). Cyclin B1-positive cells were gated at G2/M (red oval) 
and the percentage of cyclin B1 calculated (shown in red adjacent to the gate). Alongside each 
sample are histograms for their respective cell cycle profiles. Bivariate dot blot diagrams and cell 
cycle profiles are representative of 3 independent experiments. Histogram shows mean of single 
replicates from 3 independent experiments ± SEM. One-way ANOVA statistical analysis was 
performed using multiple comparisons with a Tukey post-test, p<0.05 (*), p < 0.001 (***/****) 
compared to uninfected cells. p<0.05(#) compared with 1000ppc Ad5noHey1. 
 
Western blotting confirmed cyclin B1 expression was maintained at the later 
time point of 72h (Figure 29) suggesting a mitotic arrest had occurred; cyclin B1 
degradation would be expected if cells had overcome this arrest. For this reason 
expression of the mitotic marker, phospho-serine 10-histone H3 (pH3) was 
C
yc
lin
 B
1 
(F
IT
C
) 
DNA (PI) 
Co
un
t&
DNA (PI) 
Uninfected 
23.5% 
Nocodazole (100ng/ml) 
C
yc
lin
 B
1 
(F
IT
C
) 
DNA (PI) 
86.2% Co
un
t&
DNA (PI) 
C
yc
lin
 B
1 
(F
IT
C
) 
1000ppc Ad5Hey1 
Co
un
t&
DNA (PI) DNA (PI) 
48.0% 
1000ppc AdE1A12S 
DNA (PI) 
Co
un
t&
DNA (PI) 
36.9% 
C
yc
lin
 B
1 
(F
IT
C
) 
DNA (PI) DNA (PI) 
C
yc
lin
 B
1 
(F
IT
C
) 
Co
un
t&
1000ppc Ad5noHey1 
34.8% 
UN Noc 100 1000 100 1000 100 1000
0
20
40
60
60
70
80
90
100
C
el
ls
 e
xp
re
ss
in
g 
cy
cl
in
 B
1 
at
 G
2/
M
 (%
)
*** **
#****
Ad5Hey1 AdE1A12S Ad5noHey1
 183 
assessed since phosphorylation of histone 3 accompanies chromosome 
condensation and the onset of mitosis (Hans and Dimitrov 2001). Expression of 
pH3 after infection with 100-1000ppc of virus was assessed at 48h concurrent 
with detection of the phases of the cell (Figure 31). Nocodazole-treated cells 
stained with pH3 functioned as a positive control for mitotic cells. Determining 
the proportion of cells expressing pH3 and calculating this as a total number of 
cells in G2/M generated a mitotic index. Uninfected control cells had a mitotic 
index of 15.1±1.9% and nocodazole-treated cells an index of 65.9±6.7%. 
Infection of 22Rv1 cells with 1000ppc Ad5Hey1 or AdE1A12S increased the 
mitotic index to 28.9±0.8% and 23.1±3.1% respectively. A mitotic index of 
15.6±2.5% for Ad5noHey1-infected cells was similar to control cells. The 
population of cells with a high fluorescence of pH3 staining located at the top of 
the gate in uninfected and virus-infected cells are most likely to be cells 
undergoing mitosis. The trail of pH3-positive cells observed in Ad5Hey1- and 
AdE1A12S-infected cells that enter into the bottom half of the gate are perhaps 
cells about to enter mitosis and since phosphorylation of histone 3 is first 
detected at late G2 in pericentrometric heterochromatin (Hans and Dimitrov 
2001), this population of cells may be indicative of cells undergoing a delay in 
G2. This is in contrast to the location of exclusively mitotic pH3-positive cells in 
nocodazole-treated cells, which are all found within the gate. 
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Figure 31. Dose dependent increase in phospho-histone H3 levels in Ad5Hey1-infected 
22Rv1 cells at 48h 
Cells were infected with 1000ppc Ad5Hey1#2, AdE1A12S#2 or Ad5noHey1 for 2h after which 
infection medium was removed and replaced with 10% FBS DMEM. Cells were treated overnight 
with nocodazole (100ng/ml) to arrest cells in mitosis. Cells were harvested at 48h post-infection 
and analysed for the mitotic marker, pH3 by staining cells with anti-pH3 primary antibody and then 
a FITC-conjugated anti-mouse secondary antibody. Cells were treated with PI and RNase and 
analysed by flow cytometry and pH3 plotted relative to DNA content (PI). A mitotic index (values in 
red) was calculated by gating the pH3-positive cells (red oval) as a percentage of the cells in 
G2/M phase. Alongside each sample are histograms for their respective cell cycle profiles. 
Bivariate dot blot diagrams and cell cycle profiles are representative of 3 independent 
experiments. Histogram shows mean of single replicates from 3 independent experiments ± SEM. 
One-way ANOVA statistical analysis was performed using multiple comparisons with a Tukey 
post-test, p <0.001 (****) compared with uninfected cells.  
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3.1.7.  Ad5Hey1 does not replicate in 22Rv1 
cells 
 
It has been previously reported that high loads of E1A-deleted adenoviral 
mutants can replicate in certain cell lines through complementation of 
transcription factors (Shenk 2001). To verify that the Ad5Hey1-mediated 
cytotoxicity and cell cycle changes were caused solely by Hey1 expression I 
investigated whether Ad5Hey1 could replicate in 22Rv1 cells. To this end 22Rv1 
cells were infected with 100 or 1000ppc Ad5Hey1 or AdE1A12S or 10ppc Ad5. 
After 24-72h of infection, medium and cells were collected and replication 
determined by the limiting dilution TCID50 assay measuring intracellular and 
released viral particles. Replication was not detected after 48 or 72h post-
infection for either Ad5Hey1 or AdE1A12S (Figure 32). AdE1A12S had 
previously been confirmed replication-defective in 22Rv1 and DU145 cells in our 
laboratory (Miranda, Maya Pineda et al. 2012). 
 
Further verification was undertaken using quantitative PCR (QPCR) to assess 
amplification of the viral genome by detection of the E2A product (Figure 33), an 
early gene encoding a DNA-binding protein that activates early and late viral 
promoters and also essential for viral DNA replication (Shenk 2001). DNA 
isolation from 22Rv1 cells infected with 1000ppc Ad5Hey1 or AdE1A12S yielded 
minimal DNA amplification for Ad5Hey1 and a small degree of amplification for 
AdE1A12S. This may be explained by the presence of E2 in the pAdEASY-1 
backbone from which the non-replicating viruses were constructed. It is known 
that E1A is able to activate the E2A promoter through its TATA binding motif 
(Shenk 2001). Additionally, cellular transcription factor E2F can also bind the E2 
promoter via two inverted E2F-binding sites upstream of the TATA binding 
(Kovesdi, Reichel et al. 1986; Yee, Reichel et al. 1987). Binding of E2F and E1A 
to the E2 promoter is likely to have resulted in a cooperative effect on its 
transactivation leading to enhanced E2A gene amplification but not viral 
replication or propagation of the AdE1A12S mutant. PCR characterisation of the 
Ad5Hey1 genome confirmed the absence of E1 in Ad5Hey1 viral stocks (section 
2.3.5; Figure 15) and transactivation of E2A does not occur, reflected in 
absence of viral DNA amplification and viral replication. 
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It can therefore be concluded that Hey1 and E1A12S expression cause the 
observed delay in the G2/M phase in 22Rv1 cells. Furthermore, the increase in 
G2/M is greater with Ad5Hey1 (48-72h post-infection). AdE1A12S-mediated 
abrogation of cell cycle checkpoints with formation of a >4N population may 
therefore account for this difference. 
 
 
Figure 32. Ad5Hey1 and AdE1A12S do not replicate in 22RV1 cells 
Cells were infected with 10ppc Ad5 and 10, 100 and 1000ppc Ad5Hey1#1 or AdE1A12S#1. Two 
hours after infection, medium was removed and replaced with 10% FBS DMEM. Cells and 
medium were harvested at 48 and 72h post-infection and lysates frozen at -80°C. Before viral 
titres were determined by TCID50 assay, cell lysates were freeze-thawed twice to lyse cells and 
release viral particles. Cell lysates were spun down and the supernatant diluted 1:10000 and 
1:1000 for Ad5 and adenoviral mutants respectively and used to serially infect JH293 cells seeded 
in 96-well plates. Results show mean of duplicate 96-well plates per condition for one experiment. 
* indicates replication was below the detection limit for this assay of <1pfu/cell. 
 
 
Figure 33. Viral genome amplification does not occur during Ad5Hey1 infection in 22Rv1 
cells 
Cells were infected at 10ppc of Ad5 or 1000ppc of Ad5Hey1#1 or AdE1A12S#1. Two hours after 
infection, medium was removed and replaced with 10% FBS DMEM. Cells were harvested at the 
indicated time points. DNA was extracted, quantified and analysed by quantitative PCR for viral 
genome amplification (E2A) relative to cellular GAPDH. Results are expressed as a fold change 
relative to Ad5 at 10ppc at 24h post-infection. Results are mean ± SEM of duplicates for one 
experiment.  
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3.2. Ad5Hey1 enhances cell killing in 
prostate and colorectal cancer cells 
in combination with 
chemotherapeutic agents 
 
3.2.1.  At fixed concentrations Ad5Hey1 
and cytotoxic drugs produce synergistic 
cell death in 22Rv1 and DU145 cells 
 
Previous experiments in 22RV1, DU145 and LNCaP cells demonstrated 
Ad5Hey1 sensitised these cells to mitoxantrone- and docetaxel-mediated cell 
death suggesting Ad5Hey1 and chemotherapeutic drugs, indicated for the 
treatment of PCa, could work in a synergistic manner (Figure 14 in section 1.8.1 
and S.C. Cheong et al, manuscript in preparation). 
 
To enable investigation of the cellular mechanisms involved in the sensitisation, 
I opted to use fixed doses of virus and drug combinations rather than complete 
synergy assays employing isobole analysis from which combination index 
values can be calculated. The latter approach is performed by combining 5-fold 
serially diluted drug and viruses at a range of fixed ratios and cell viability 
determined usually at 6 day post-infection (previously ascertained in our group 
to produce optimum synergy). This method, although quantitative and stringent, 
does not allow tangible treatment doses to be determined that allow for 
mechanistic studies. Therefore combination treatments that produced synergy at 
fixed concentrations at 72h as assessed by the MTS assay were selected as the 
experimental setup.  
 
Fixed-dose combination studies to evaluate Ad5Hey1 in combination with 
mitoxantrone and docetaxel were carried out in 22Rv1, LNCaP and DU145 
cells. Sub-optimum doses of drugs which induced <20% cell death were 
selected and combined with fixed doses of Ad5Hey1 or AdE1A12S that killed 
<30% of cells (Figure 34). Virus doses were selected based on EC50 values 
calculated from dose response curves of Ad5Hey1 and AdE1A12S (Table 17). 
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Sub-optimal doses of mitoxantrone and docetaxel were derived from EC50 
values generated from dose response curves after 3 days of treatment (Table 
19). All cell lines were more sensitive to docetaxel compared with mitoxantrone. 
The cells most sensitive to mitoxantrone were DU145 and LNCaP (no difference 
between these) and the least sensitive, 22Rv1. LNCaP cells were the most 
sensitive to docetaxel and DU145 and 22Rv1 cells the least sensitive. The fixed 
doses of mitoxantrone used for 22Rv1 and DU145 cells (25nM and 50nM 
respectively) did not reflect the EC50 order of sensitivity but where chosen based 
also on observations from my assessment of drug-induced mitochondrial 
membrane potential (∆Ψm) (discussed in section 3.3.1). Preliminary experiments 
indicated ∆Ψm in 22Rv1 cells was extremely sensitive to mitoxantrone at 50nM 
and I therefore decided to lower the dose to 25nM. Infected 22Rv1 and DU145 
cells expressed high levels of Hey1 or E1A12S (Figure 35). To control for the 
effect of foreign transgene expression, Ad5GFP was used at the same doses as 
Ad5Hey1. 
 
 
Figure 34. The effects of cell viability at fixed doses of adenoviral mutants and drugs used 
for combination studies 
22Rv1, DU145 and LNCaP cells were infected with Ad5Hey1#2 (22Rv1) or Ad5Hey1#3 (DU145 
and LNCaP), AdE1A12S#3 and Ad5GFP using doses in Table 11. Cell viability was assessed at 3 
days post-infection by MTS assay. Results are the mean of 6 replicate wells from 3-4 independent 
experiments ± SEM. 
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Table 19. EC50 values for mitoxantrone and docetaxel in PCa cell lines 
Drug 22Rv1 
Mean    SEM      N 
DU145  
Mean    SEM      N 
LNCaP 
Mean    SEM      N 
Mitoxantrone 293.0 ± 17.3      3 184.0 ±  21.7      2 197.2 ± 36.9      3 
Docetaxel 42.3 ±   8.0      3 55.1 ±  10.6      2 17.1 ± 0.34      3 
Dose response curves were constructed by treating cells in triplicate with five-fold serially diluted 
mitoxantrone or docetaxel and cell death assessed by MTS 3 days post-infection. Results are 
mean of 2-3 independent experiments ± SEM. 
 
 
Figure 35. Western blots showing Hey1, E1A12S and GFP expression in 22Rv1, DU145 and 
LNCaP cells at 48h 
Cells were infected with Ad5Hey1#2, AdE1A12S#3 and Ad5GFP at 10, 100 and 1000ppc (22Rv1) 
and Ad5Hey1#3, AdE1A-2S#3 and Ad5GFP (DU145; 1500, 3000 and 4500ppc and LNCaP, 300, 
500 and 1000ppc). After 2h infection, medium was removed and replaced with 10% FBS DMEM. 
Cells lysates were harvested at 48h post-infection and prepared for separation on polyacrylamide 
gels. 20µg protein (22Rv1 and DU145) or 25µg (LNCaP) was loaded per lane and blotted for Flag, 
E1A, GFP expression and KU70 or PCNA as a loading control. 
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In 22Rv1 and DU145 cells, supra-additive (synergistic) effects were observed 
when Ad5Hey1 was combined with either mitoxantrone or docetaxel at the 
selected doses (section 2.4.3.1; Table 11) improving cell-killing efficacy (Figure 
36). Synergistic cell death was also observed for AdE1A12S with both drugs as 
previously observed (Miranda, Maya Pineda et al. 2012). No supra-additive 
effect was detected with Ad5GFP demonstrating Hey1 or E1A12S expression is 
required for chemosensitisation. Due to the variable nature of the cell viability 
assay, the percentage of cell death induced by Ad5Hey1 and AdE1A12S varied 
between experiments, however the extent of cell death induced by combination 
treatments was consistently greater than the theoretical additive effect over >3 
independent experiments in 22Rv1 cells and for two independent experiments in 
DU145 cells. 
 
Although previous work suggested that Ad5Hey1 could sensitise LNCaP cells to 
mitoxantrone and docetaxel-induced cell killing (Figure 14), no synergistic cell 
death with the selected doses was observed (Figure 36). When Ad5Hey1 was 
combined with mitoxantrone or docetaxel slightly more or less cell death for 
each drug respectively was induced compared with virus alone. However in the 
presence of AdE1A12S, less cell death was induced with either drug-
combination compared with virus alone. These observations suggest the 
selected doses of mitoxantrone or docetaxel with Ad5Hey1 have negligible 
effects on cell death enhancement when combined or an antagonistic effect 
when AdE1A12S is present. This irregularity was puzzling considering previous 
sensitisation experiments suggested greater cell death would occur when 
Ad5Hey1 or AdE1A12S was combined with cytotoxic drugs (Figure 14 and 
Cheong et al, manuscript in preparation). Studies have demonstrated significant 
inconsistencies when using MTS- or MTT-based assays when determining anti-
proliferative activity of agents compared with ATP and DNA-based methods in 
LNCaP cells. MTS and MTT-assays are a measure of mitochondrial activity and 
some chemicals and plant-based agents have been found to alter mitochondria 
dehydrogenase activity (Lee, Zhan et al. 2003; Wang, Henning et al. 2010). For 
this reason I measured cell viability in LNCaP cells after combination treatment 
using either picogreen, a DNA-based method or sulforhodamine B, a measure 
of cellular protein mass. However under the selected conditions in LNCaP cells 
using the alternative viability assays, similar trends in cell killing as described 
above were observed (data not shown). In conclusion, the chosen fixed doses in 
LNCaP cells did not cause synergistic cell death while the drug EC50 values 
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were clearly lower in the presence of either Ad5Hey1 or AdE1A12S (Figure 14). 
Extensive further testing at various dose-combinations would be necessary to 
establish synergy at one fixed dose combination. 
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Figure 36. The effect on cell viability by mitoxantrone (A) or docetaxel (B), viral mutants or 
a combination of both in 22Rv1, DU145 and LNCaP cells 
Cells were infected with Ad5Hey1#2 (22Rv1) or Ad5Hey1#3 (DU145 and LNCaP), AdE1A12S#3 
or Ad5GFP and/or treated with drug and at the doses shown in Table 11. Black bars indicate the 
percentage of cell death caused by the drug alone. Red, blue and green bars indicate the 
percentage of cell death by Ad5Hey1, AdE1A12S or Ad5GFP respectively as single agents. White 
and hatched bars in respective colours for each virus represent the theoretical additive cell death 
and the observed cell death when virus and drug were combined respectively. Virus and drug 
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were added simultaneously and cell viability assayed 3 days post-infection and the percentage of 
death calculated relative to untreated cells. Results shown are means of 6 replicate wells ± SEM 
from one experiment with one-way ANOVA statistical analysis using multiple comparisons with a 
Tukey post-test, p<0.05 (*), p<0.01 (**) and p<0.001 (***/****) compared with theoretical additive 
effect. p<0.001(####) combination treatments compared with its respective virus and drug. 
p<0.001(§§§§) compared with Ad5GFP alone. p<0.001($$$$) compared with drug alone. Results 
are representative of >3 independent experiments (22Rv1), 2 experiments (DU145) and >3 
experiments (LNCaP). 
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3.2.2.  Investigating the intrinsic 
cytotoxicity and sensitising role of Ad5Hey1 
in colorectal p53 isogenic HCT116 cell lines 
 
3.2.2.1. Ad5Hey1 possess intrinsic cytotoxicity in p53-
deficient HCT116 cells as well as HCT116wt cells 
 
In chapter 3.1 I concluded Ad5Hey1-dependent cytotoxicity was mediated in 
part, through the AR-inhibition (22Rv1 cells) and activation of p53 signalling in 
wild-type p53 expressing cells (22Rv1 and LNCaP). However, Ad5Hey1 was 
also able to kill DU145 cells known to harbour mutant non-functional p53 
(Isaacs, Carter et al. 1991). Since the PCa cell lines in this study vary widely in 
terms of their genetic alterations we sought to establish the absolute 
requirement of the HDM2-p53 feedback loop in Ad5Hey1-dependent 
sensitisation and toxicity. To this end I employed the isogenic colorectal cancer 
cell lines, HCT116wt (p53+/+) and the knockout, HCT116p53-/-. These cells are 
devoid of AR expression (Figure 37) allowing us to assess the p53-dependence 
of Ad5Hey1-mediated cytotoxicity without AR-mediated effects on cell growth. 
 
 
Figure 37. The p53 and AR status of HCT116wt and HCT116p53-/- cells 
HCT116wt, HCT116p53-/- and 22Rv1 cells were seeded and left untreated. Cell lysates were 
harvested 48h later and prepared for separation on polyacrylamide gels. 20µg protein was loaded 
per lane and blotted for AR, total p53 and β-actin as a loading control. n=1 
 
Dose-response curves of Ad5Hey1, AdE1A12S and Ad5 were generated and 
cell death was assessed three days post-infection to determine EC50 values. 
Ad5 virus was used as an internal control since it kills cells independently of p53 
status (Shiina, Lacher et al. 2009) resulting in similar EC50 values for both cell 
AR (112kDa) 
total p53 (53kDa) 
  
AR (truncated 70-80kDa) 
β actin (43kDa) 
!
HCT116 
70 
100 
55 
35 
 195 
lines (Figure 38). Ad5Hey1 and AdE1A12S EC50 values were normalized 
against EC50 values obtained for the reference virus, Ad5 and expressed as 
ratios (Figure 39A). Transgene expression for Ad5Hey1 and AdE1A12S was 
similar in both cell lines (Figure 39C). Stabilisation of p53 by Ad5Hey1 was 
induced at the lowest dose of 1500ppc and near maximum expression of p53 
was attained at this dose. In agreement with the comparative levels of p53 
stabilisation between Ad5Hey1 and AdE1A12S in 22Rv1 cells, infection by 
AdE1A12S was not as potent as Ad5Hey1 in stimulating p53 expression since a 
dose of 4500ppc was required for AdE1A12S-induced p53 stabilisation (Figure 
39C). 
 
Interestingly, in contrast to the reduction in cell death by Ad5Hey1 when p53 
was knocked down in 22Rv1 cells, Ad5Hey1 was as potent in HCT116p53-/- cells 
as in HCT116wt cells agreeing with our earlier results of a Ad5Hey1-mediated 
p53-independent mechanism of cell death observed in DU145 cells. Potency of 
AdE1A12S increased in cells devoid of p53 (Figure 39B) suggesting optimal 
potency of AdE1A12S is via a p53-independent mechanism in HCT116 cells in 
contrast to desensitisation to AdE1A12S-mediated cytotoxicity in 22Rv1 cells 
when p53 was absent. These results therefore suggest that Ad5Hey1 can 
regulate factor(s) other than p53 and AR not present in DU145 cells. 
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Figure 38. Ad5Hey1 is cytotoxic in HCT116wt and HCT116p53-/- cells 
Representative virus dose-response assays in HCT116wt and HCT116p53-/- cells of triplicate 
samples ± SEM. Cells were infected with serial dilutions of Ad5 (grey), Ad5Hey1#3 (red) and 
AdE1A12S#3 (blue). Cell death was determined by MTS 3 days post-infection and EC50 values 
(ppc) were calculated (table inset). Graph and table shows mean of triplicates from one 
experiment, representative of six.  
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Figure 39. Ad5Hey1 is as potent as AdE1A12S in HCT116wt cells. Absence of p53 
sensitises cells to AdE1A12S while potency of Ad5Hey1 is similar to HCT116wt cells 
Histogram showing EC50 values of Ad5Hey1#3 and AdE1A12S#3 expressed as a ratio of Ad5 in 
HCT116wt and HCT116p53-/- cells. Results are the mean of six independent experiments ± SEM. 
Statistical analysis was carried out with two-way ANOVA using multiple comparisons with a Tukey 
post-test p<0.05 (*). (B) Ad5Hey1 and AdE1A12S EC50 values were normalised to the EC50 value 
of Ad5 and the normalised EC50 values of Ad5Hey1/AdE1A12S expressed as a ratio for each cell 
line. Results shown are mean of six independent experiments ± SEM with statistical analysis 
using two-tailed, unpaired Student t-test, p<0.05 (*). (C) Western blots showing Flag, E1A12S and 
GFP expression in HCT116wt and HCT116p53-/- cells at 48h post-infection. Cells were infected 
with virus at 1500, 4500 and 7500ppc for 2h. After infection, medium was removed and replaced 
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with 10% FBS DMEM. Cell lysates were collected at 48h post-infection and prepared for 
separation on polyacrylamide gels. 20µg protein was loaded per lane and blotted for Flag, E1A 
and GFP expression and in the case of HCT116wt cells, total p53 and phospho (ser15) p53 
blotted on separate gels. KU70 expression was used as a loading control. UN = uninfected. 
 
3.2.2.2. Ad5Hey1 sensitises HCT116 cells to 5-FU and 
mitoxantrone by p53-dependent and –independent 
mechanisms 
 
We and others have shown that overexpression of Hey1 in wild-type p53-
expressing tumour cells has a sensitising effect to a range of chemotherapeutic 
agents, namely mitoxantrone and docetaxel (Cheong et al, manuscript in 
preparation and section 3.2.1) as well as platinum-based cisplatin and 
anthracycline derivative doxorubicin (Villaronga, Lavery et al. 2009). 
Furthermore, I provide evidence that Ad5Hey1 sensitises mutant p53 DU145 
cells to mitoxantrone and docetaxel leading to synergistic cell death (section 
3.2.1). To investigate the requirement of p53 in Ad5Hey1-mediated sensitisation 
to cytotoxic drugs, HCT116wt and HCT116p53-/- cells were infected with 
Ad5Hey1 to generate dose-response curves and treated with sub-optimal fixed 
concentrations of 5-FU or mitoxantrone that induced <30% cell death alone. Cell 
viability was assessed after 3 days post-treatment and EC50 values for the 
viruses were calculated with and without the drugs and expressed as a 
percentage of the EC50 of virus alone (Figure 40). 
 
At the selected doses, 5-FU and mitoxantrone produced similar toxicity in both 
cell lines. HCT116p53-/- cells were slightly more resistant to drug treatment 
although not statistically significant at these concentrations (Figure 40A). Loss of 
p53 conferred resistance to mitoxantrone and 5-FU as indicated by increased 
EC50 values for drugs in HCT116p53-/- compared with HCT116wt cells (data not 
shown) confirming previous reports (Bunz, Hwang et al. 1999). Sensitisation by 
mitoxantrone and 5-FU to Ad5Hey1-mediated cell killing in HCT116wt cells was 
extensive reducing the EC50 value of Ad5Hey1 by 59 and 49% respectively 
(Figure 40B). Sensitisation of HCT116wt cells by mitoxantrone to AdE1A12S-
induced cell death was comparable to combination treatment with Ad5Hey1. 
Interestingly, sensitisation by 5-FU resulted in a smaller decrease in the EC50 
value (24%) compared with Ad5Hey1 (49%).  
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As anticipated and in agreement with our findings in DU145 cells, sensitisation 
by mitoxantrone and 5-FU to Ad5Hey1 was also observed in HCT116p53-/- cells 
resulting in 25 and 39% reductions in the EC50 value of Ad5Hey1 respectively 
(Figure 40C). The extent of sensitisation was less than with HCT116wt cells 
indicative of enhanced sensitivity to the Ad5Hey1 when p53 is expressed. 5-FU 
sensitised both HCT116wt and HCT116 p53-/- similarly to Ad5Hey1 whereas 
sensitisation by mitoxantrone was significantly less in HCT116 p53-/- compared 
with HCT116wt cells (Table 20). Notably, the absence of p53 did not impact on 
the extent of sensitisation when AdE1A12S was combined with mitoxantrone (a 
68 and 67% reduction in the EC50 value of AdE1A12S in HCT116wt and 
HCT116p53-/- respectively) but 5-FU had a significantly greater sensitising effect 
on HCT116p53-/- cells when combined with AdE1A12S (Table 20). This 
suggests optimum AdE1A12S-mediated cell killing in a p53-deficient 
background is dependent on the type of chemotherapeutic used and its 
mechanisms of action whereas Ad5Hey1-mediated cell killing was optimal when 
p53 was expressed. In the case of Ad5Hey1, 5-FU was also better in 
HCT116p53-/- cells at sensitising cells to Ad5Hey1 compared with mitoxantrone. 
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Figure 40. Ad5Hey1 sensitises HCT116wt and HCT116p53-/- cells to 5-FU and mitoxantrone 
(A) Histogram showing percentage of cell death at fixed concentrations of 5-FU or mitoxantrone 
72h after treatment relative to untreated cells. Results show mean for 3 independent experiments 
± SEM. (B) & (C) Dose response curves to Ad5Hey1#3 or AdE1A12S#3 with and without 5-FU or 
mitoxantrone were generated and cell death determined 3 days post-infection by MTS viability 
assay. Virus EC50 values were calculated for virus alone relative to uninfected cells or in 
combination with each agent relative to the percentage of cell death induced by the drug alone. 
Histograms show relative EC50 values as a percentage of virus alone in (B) HCT116wt cells and 
(C) HCT116p53-/- cells. Results are a mean of duplicate wells from 3 independent experiments ± 
SD. All histograms were analysed by two-way ANOVA statistical analysis using multiple 
comparisons with a Tukey post-test, p<0.05 (*), p<0.01 (**) p<0.001 (***/****). p<0.05 (#) was 
compared with Ad5Hey1 + 0.4ug/ml 5-FU. p<0.001 (§§§) was compared with Ad5Hey1 + 200nM 
mitoxantrone. 
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Table 20. Comparing %EC50 values of Ad5Hey1 or AdE1A12S treated with fixed doses of 5-
FU or mitoxantrone between HCT116p53wt and HCT116p53-/- cells 
Treatment 
Ad5Hey1 AdE1A12S 
p53+/+ 
mean±SD 
p53-/- 
mean±SD 
 
p value 
p53+/+ 
mean±SD 
p53-/- 
mean±SD 
 
p value 
Virus only 100±0.00 100±0.00 ns 100±0.0 100±0.0 ns 
+ 0.4µg/ml 5-
FU 
51.0±0.75 61.2±4.56 ns 76.2±14.8 32.1±13.5 p<0.01 
+ 200nM Mitox 42.05±18.8 75.1±14.4 p<0.01 32.0±4.43 33.3±11.8 ns 
Results extracted from Figure 40A and C and analysed using a two-way ANOVA statistical 
analysis comparing %EC50 values obtained in HCT116p53wt cells with those in HCT116p53-/- cells 
using a bonferroni post-test, p<0.01 (**), p<0.001 (***). Results shown are mean of 3 independent 
experiments ± SD. 
 
To summarise, cytotoxic drugs sensitised both HCT116wt and HCT116p53-/- 
cells to Ad5Hey1-mediated cell killing and the extent of sensitisation was similar 
to that of AdE1A12S in HCT116wt cells. In the absence of p53, significantly 
more cell killing by AdE1A12S occurred in combination with drugs than with 
Ad5Hey1+drug combinations suggesting optimum AdE1A12S-mediated cell 
killing occurs in a p53-deficient background. Interestingly sensitisation to 
Ad5Hey1 or AdEA12S was independent of p53 status when cells were treated 
with 5-FU and mitoxantrone respectively highlighting the importance of the 
specific interactions between toxic transgene- and drug-activated cell signalling 
pathways.  
 
Thus far I have determined that Ad5Hey1-dependent cell death in AR-positive 
and p53 wild-type, 22Rv1 cells requires the presence of both AR and p53 for 
effective cytotoxicity. However, in AR-negative p53 isogenic HCT116 cells, 
Ad5Hey1 kills these cells to a similarly extent irrespective of p53 status. 
Ad5Hey1 effectively stimulated the stabilisation of p53 in HCT116wt cells in 
agreement with Huang et al however since Ad5Hey1 was cytotoxic in 
HCT116p53-/- cells this suggests activation of p53 signalling is not the sole 
mechanism by which Ad5Hey1 kills. Therefore Ad5Hey1 must function through 
other pathways in AR-negative and p53-deficient DU145 and HCT116p53-/- 
cells to induce cell death and sensitisation to chemotherapeutic drugs. 
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3.2.3.  Ad5Hey1-mediated targeting of 
constitutively active STAT3 in DU145 cells 
 
3.2.3.1. Ad5Hey1 decreases levels of phospho-STAT3 
and levels of STAT3-target, cyclin D1  
 
In light of the results obtained in the p53 isogenic HCT116 cell lines I sought to 
investigate the mechanism of Ad5Hey1 action in DU145 cells. As discussed in 
the Introduction (section 1.5.1), Notch signalling is a central regulator of gene 
expression. Crosstalk between Notch signalling and other pathways such as the 
BMP/TGF-β, JAK/STAT, Ras and hypoxia induced factor (HIF) signalling have 
been found to enhance activation and expression of hairy and Enhancer of split 
bHLH protein subfamilies, Hes and Hey (Fischer and Gessler 2007). These and 
other reports suggest that exogenous expression of Hey1 could transduce and 
participate in signalling from numerous pathways. Hairy-related proteins interact 
with a wide range of other binding partners including bHLH proteins, histone 
deacetylases and also form complexes with transcription factors thus turning 
these into transcriptional co-repressors (Fischer and Gessler 2007). 
 
A common feature of prostate cancer is the dependence on STAT3 for survival. 
Activation of the transcription factor has been demonstrated to be involved in 
malignant progression of prostate cancer cells (Ni, Lou et al. 2000; Barton, 
Murphy et al. 2001). Hes1 and Hes5 were found to mediate Notch-induced 
activation of STAT3 signalling by forming a complex with JAK2 and STAT3. 
Maximum binding to STAT3 and activation was mapped to the bHLH and 
Orange domain (Figure 5) resulting in STAT3 phosphorylation and activation 
(Kamakura, Oishi et al. 2004). Overexpression of Hey1 and Hey2 in COS-1 cells 
in the same study induced phosphorylation of STAT3 and activated STAT3-
dependent transcriptional activity (Kamakura, Oishi et al. 2004). 
 
Since the related Hes1 protein was found to regulate STAT3 activity and is 
structurally conserved with Hey1, I hypothesised whether Ad5Hey1 may 
regulate constitutively active STAT3 signalling in DU145 cells (Ni, Lou et al. 
2000; Barton, Murphy et al. 2001). I also postulated whether the reason for the 
lack of Ad5Hey1-mediated cytotoxicity and sensitisation in PC3 cells was due to 
the absence of STAT3 expression in these cells (Clark, Edwards et al. 2003; 
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Yuan, Guan et al. 2005). Western blotting for phosphorylation of STAT3 on 
conserved tyrosine residue 705 (a measure of STAT3 dimerization; an indirect 
measure of STAT3 activity) and total STAT3 confirmed the absence of STAT3 
expression in PC3 cells used in our laboratory, in agreement with the literature 
reports (Figure 41). 
 
 
Figure 41. Differential expression of STAT3 between PC3 and DU145 cells 
PC3 and DU145 cells were seeded and left untreated. Cell lysates were harvested 48h later and 
prepared for separation on polyacrylamide gels. 20µg protein was loaded per lane and blotted for 
phospho (Y705) STAT3 and β-actin as a loading control. The membrane was later stripped and 
probed for total STAT3 expression. n=1 
 
I analysed phospho-STAT3 in response to increasing doses of Ad5Hey1 in 
DU145 cells at 48h post-infection. Treatment with resveratrol, an established 
inhibitor of STAT3 signalling in DU145 cells through inhibition of Src tyrosine 
kinase activity was used as a control (Kotha, Sekharam et al. 2006). I found 
Ad5Hey1 decreased phospho-STAT3 in a dose-dependent fashion (Figure 42A) 
compared with Ad5GFP where no change in phospho-STAT3 levels was 
observed. Western blotting membranes in Figure 42A were stripped to remove 
phospho-STAT3 antibody and reprobed with an antibody recognising total 
STAT3. No changes in total STAT3 levels were observed for cells infected with 
Ad5Hey1- and Ad5GFP. A decrease in the STAT3-target gene, cyclin D1 
(Figure 42B) indicated that Ad5Hey1 also reduced expression of a downstream 
STAT3 target gene. Total STAT3 levels shown in Figure 42B were reduced for 
both Ad5Hey1 and Ad5GFP-infected cells compared with uninfected cells. This 
is puzzling as this trend was not observed in Figure 42A and the untreated 
control sample may have been incorrect or mislabelled. Additional experiments 
are required to establish the effect of Ad5Hey1 on STAT3 target gene 
expression. In summary, my data suggests Ad5Hey1 might regulate STAT3 
activity by either direct binding to STAT3 thus preventing phosphorylation of 
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STAT3 and downstream activation of STAT3 target genes or indirectly inhibiting 
STAT3 signalling. 
 
Cells treated with escalating doses of AdE1A12S similarly exhibited a dose-
dependent decline in phospho-STAT3 expression as well as a decrease in total 
STAT3 levels and cyclin D1 expression (Figure 42). This reduction agrees with 
current knowledge of E1A-mediated inhibition of STAT protein activity. E1A 
circumvents the host defence mechanisms by blocking the JAK/STAT pathway 
by either indirectly interfering with the transcriptional activity of STAT proteins 
(Takeda, Nakajima et al. 1994; Paulson, Pisharody et al. 1999) or by direct 
binding to STAT proteins disrupting their interaction with other cofactors (Look, 
Roswit et al. 1998; Chatterjee-Kishore, van Den Akker et al. 2000). AdE1A12S-
mediated inhibition of STAT3 signalling could be one mechanism by which 
AdE1A12S induced cell killing and sensitisation to cytotoxic drugs in DU145 
cells. 
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Figure 42. Ad5Hey1 decreases phospho (Y705) STAT3 and cyclin D1 at 48h in DU145 cells 
A) Cells were infected with 500-4500ppc Ad5Hey1#3, AdE1A12S#3 or Ad5GFP. Two hours after 
infection, medium was replaced with 10% FBS DMEM. Cells were treated overnight with 50µM 
resveratrol overnight as a positive control for STAT3 dephosphorylation. At 48h post-infection, cell 
lysates were harvested and prepared for separation on polyacrylamide gels. 20µg protein was 
loaded per lane and blotted for phospho (Y705) STAT3 and PCNA as a loading control. The 
membrane was later stripped and probed for total STAT3 expression. Results show one blot, 
representative of 2 independent experiments. Histograms showing expression levels of phospho 
(Y705) STAT3 (top graph) and total STAT3 (middle graph) normalised to loading control and 
expressed relative to uninfected (UN) cells. Phospho (Y705) STAT3 expression levels were then 
normalised to total STAT3 and expressed relative to uninfected cells (bottom graph). Results 
show mean of 2 independent experiments ± SEM. B). Cells were treated as describe in A). Cell 
lysates harvested at 48h post-infection were prepared for separation on polyacrylamide gels. 20µg 
protein was loaded per lane and blotted for total STAT 3 and cyclin D1. Histograms showing total 
cyclin D1 (top graph) and STAT3 (bottom graph) protein expression normalised to PCNA and 
expressed relative to uninfected (UN) cells. Results are of one experiment.  
  
cyclin D1 (36kDa) 
PCNA (36kDa) 
50
0 
25
00
 
45
00
 
50
0 
25
00
 
45
00
 
50
0 
25
00
 
45
00
 
Ad5Hey1 AdE1A12S Ad5GFP 
UN 
total STAT3 (86kDa) 
B 
100 
70 
35 
35 
cyclin D1 48h image J reanalysed
UN  50
0
25
00
 45
00  50
0
25
00
 45
00  50
0
25
00
 45
00
0.0
0.5
1.0
1.5
Ad5Hey1 AdE1A12S Ad5GFP
cy
cl
in
 D
1/
PC
N
A
total STAT3 48h image J reanalysed
UN  50
0
25
00
 45
00  50
0
25
00
 45
00  50
0
25
00
 45
00
0.0
0.5
1.0
1.5
Ad5Hey1 AdE1A12S Ad5GFP
to
ta
l S
TA
T3
/P
C
N
A
 207 
3.2.3.2. Ad5Hey1 targets the JAK/STAT pathway in 
DU145 cells 
 
To determine whether a decrease in STAT3 activity by Ad5Hey1 may play a role 
in Ad5Hey1-mediated cytotoxicity and sensitisation, two JAK inhibitors were 
used to determine whether there was any affect on Ad5Hey1-induced cell killing 
when STAT3 was inhibited. Impeding upstream tyrosine kinases such as (JAK1 
and JAK2) is an efficient method to prevent STAT3 activation. Since constitutive 
STAT3 activity in DU145 cells may also occur as a result of upstream signalling 
pathways activating JAK proteins (e.g. EGFR) (Russell, Bennett et al. 1998), 
inhibition of JAK1 or JAK2 was approached at two levels; firstly using the small 
molecule inhibitor AG490, a selective inhibitor of EGFR, HER2/neu as well as 
JAK2 (Gazit, Osherov et al. 1991; Meydan, Grunberger et al. 1996) and 
secondly with AZD1480, an ATP-competitive inhibitor which targets JAK1/2 
(Hedvat, Huszar et al. 2009). 
 
DU145 cells were treated with Ad5Hey1 or AdE1A12S to generate dose 
response curves and treated with and without fixed concentrations of AG490 or 
AZD1480 that induced <30% cell death alone. Cell death after combination 
treatments was evaluated 3 days post-infection. Interestingly I observed clear 
sensitisation for both Ad5Hey1 and AdE1A12S in the presence of AG490 
(Figure 43) whereas treatment with AZD1480 did not sensitise cells to Ad5Hey1 
and AdE1A12S-mediated cell killing (Figure 44). A dose-dependent decrease in 
Ad5Hey1 EC50 was observed when cells were treated with 10 and 25µM AG490 
with a reduction of 47 and 73% respectively Similarly the EC50 of AdE1A12S 
decreased by 46 and 81% respectively (Figure 43D). In contrast, AZD1480 
increased the EC50 value of Ad5Hey1 by 28% (Figure 44D) while increasing 
doses of the inhibitor restored cell killing by Ad5Hey1 to similar levels to that 
induced by the virus alone (no significant differences). Likewise, cells treated 
with increasing doses of AZD1480 were desensitised to AdE1A12S-mediated 
cell killing with 1µM and 25µM resulting in the greatest desensitising effect. 
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Figure 43. The EGFR/HER2/JAK2 inhibitor, AG490 sensitises Ad5Hey1-infected DU145 cells 
to enhanced cell death 
Representative virus dose response curves in DU145 cells for Ad5Hey1#3 (A) and AdE1A12S#3 
(B). Cells were infected with serial dilutions of virus with and without AZDG490 (10 and 25µM). 
Cell death was assayed by MTS viability assay 3 days post-infection and data shown is mean of 
duplicates ± SEM from one experiment representative of 2-4. (C) Percentage of cell death 
(relative to untreated cells) after treatment with 10 and 25µM AG490 after 3 days of treatment. 
Results show mean of duplicate wells for 3 independent experiments ± SEM. (D) Histogram 
showing relative EC50 values as a percentage of virus alone. Virus EC50 values were calculated for 
virus alone relative to uninfected cells or in combination with each agent relative to the percentage 
of cell death induced by the drug alone. Results show mean of duplicate wells for 2-4 independent 
experiments ± SEM. Statistical analysis was carried out using two-way ANOVA using multiple 
comparison with a Tukey post test. p<0.01 (**) and p<0.001 (***/****) compared with each 
respective virus alone. 
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Figure 44. The JAK1/2 inhibitor, AZD1480 does not sensitise Ad5Hey1-infected DU145 cells 
to further cell death 
Representative virus dose response curves in DU145 cells for Ad5Hey1#3 (A) and AdE1A12S#3 
(B). Cells were infected with serial dilutions of virus with and without AZD1480 (1, 10 and 25µM). 
Cell death was assayed by MTS viability assay 3 days post-infection and data shown is mean of 
duplicates ± SEM from one experiment representative of 2-3. (C) Percentage of cell death 
(relative to untreated cells) after treatment with 1, 10 and 25µM AZD1480 after 3 days of 
treatment. Results show mean of duplicate wells for 2-3 independent experiments ± SEM. (D) 
Histogram showing relative EC50 values as a percentage of virus alone. Virus EC50 values were 
calculated for virus alone relative to uninfected cells or in combination with each agent relative to 
the percentage of cell death induced by the drug alone. Results show mean of duplicate wells for 
2-3 independent experiments ± SEM. Statistical analysis was carried out using two-way ANOVA 
using multiple comparison with a Tukey post test. p<0.01 (**) compared with each respective virus 
alone. 
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Following the results described in Figure 43, I acknowledged that although the 
combination of AG490 with Ad5Hey1 generated interesting results suggesting a 
possible synergistic interaction, inhibition of EGFR and HER2/neu signalling was 
likely to have an effect on other survival pathways in DU145 cells such as the 
PI3K/AKT signalling (Zheng, Ren et al. 2009). Therefore, AG490 would not be a 
suitable tool from which to determine Ad5Hey1-specific effects on the JAK/STAT 
pathway. I therefore focused on AZD1480 due to its greater selectivity for the 
JAK/STAT signalling pathway. In addition, I recognized small molecule inhibitors 
commonly have a short half-life such that it was likely AZD1480 had degraded 
by the end of the time course. For this reason phospho-STAT3 expression was 
monitored over 12h (Figure 45) with phospho-STAT3 expression levels being 
restored by 12h. 
 
 
Figure 45. Dose- and time-dependent effects of AZD1480 treatment levels of phospho-
STAT3 in DU145 cells 
Cells were treated with AZD1480 at the indicated doses in 10% FBS DMEM and cell lysates 
harvested at 3, 8 and 12h post treatment and prepared for separation on polyacrylamide gels. 
20µg of protein was loaded per lane and blotted for phospho-STAT3 expression and actin as a 
loading control. The membrane was later stripped and reprobed for total STAT3 expression. UN = 
untreated. Results of one experiment. 
 
Considering the short inhibitory effect of phospho-STAT3 in response to 
AZD1480, probably due to a short half-life of the inhibitor, I changed the 
treatment schedule. AZD1480 was added simultaneously to virus infection on 
day 1 with further additions every 24h and cell viability was assessed 72h after 
initial treatment (Figure 46). Despite increasing the level of active AZD1480 in 
the culture medium for the duration of the experiment, the presence of AZD1480 
did not sensitise cells to Ad5Hey1 and AdE1A12S-mediated cell death as before 
(Figure 44). From these preliminary experiments, it was possible to hypothesise 
further inhibition of STAT3 by AZD1480 does not occur since Ad5Hey1 or 
AdE1A12S are already targeting the JAK/STAT signalling pathway. 
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Figure 46. Continuous inhibition of STAT3 activity by AZD1480 desensitises DU145 cells to 
Ad5Hey1-mediated cell death 
Virus dose response curves in DU145 cells for Ad5Hey1#3 (A) and AdE1A12S#3 (B). Cells were 
infected with serial dilutions of virus with and without AZD1480 (10 and 25µM) the following day 
(day 1). Further additions of inhibitor were added on days 2 and 3. Cell death was measured by 
MTS assay 3 days post-infection and data shown is mean of duplicates ± SEM from one 
experiment. (C) Percentage of cell death (relative to untreated cells) after treatment with 10 and 
25µM AZD1480 after 3 days of treatment with drug added on days 1, 2 and 3. Results show mean 
of duplicate wells over 2 plates for one experiment. (D) Histogram showing relative EC50 values as 
a percentage of virus alone. Virus EC50 values were calculated for virus alone relative to 
uninfected cells or in combination with each agent relative to the percentage of cell death induced 
by the drug alone. Results show mean of duplicate wells from one experiment.  
 
To further clarify the significance of our initial findings, Ad5Hey1 at a dose which 
resulted in reduced levels of phospho-STAT3, was combined with AZD1480 (10 
or 25µM) and levels of phospho-STAT3 assessed by western blotting. This was 
carried out 24h post-treatment with cells treated every 12h to maintain levels of 
active AZD1480. 
 
At 24h, both doses of AZD1480 completely ablated phospho-STAT3 levels in 
DU145 cells (Figure 47). However all viruses including Ad5GFP result in a 
decrease in phospho-STAT3 levels compared with untreated cells suggesting 
that that this is a non-specific effect of virus infection. We have shown Hey1 is 
expressed at this time point (section 1.8.1; Figure 12), however presumably 24h 
may be too early for a Hey1-mediated effect on STAT3 activity as was shown in 
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higher phospho-STAT3 levels suggesting Ad5Hey1 was increasing STAT3 
activity. This is in contrast to combination treatment with AdE1A12S, which 
maintained phospho-STAT3 to similar levels compared to drug alone. Ad5GFP 
infection with AZD1480 resulted in an intermediate level of phospho-STAT3 
suggesting the presence of viral particles may have a positive correlation with 
STAT3 activity. Combining Ad5Hey1 or AdE1A12S with 25µM AZD1480 
resulted in contrasting effects; the higher more toxic dose of AZD1480 (Figure 
46C) counteracted the effect of Ad5Hey1 on phospho-STAT3 resulting in lower 
phospho-STAT3 expression whereas AdE1A12S seemed to increase phospho-
STAT3 activity. Since STAT3 activity is associated with survival in DU145 cells 
the levels of phospho-STAT3 observed for combination treatment with Ad5Hey1 
and AdE1A12S at the selected doses of AZD1480 correlate with the increase in 
cell viability with Ad5Hey1 and AdE1A12S when combined with AZD1480 
(Figure 46D). 
 
 
Figure 47. Ad5Hey1 and AdE1A12S upregulate phospho-STAT3 levels in DU145 cells in the 
presence of JAK1/2 inhibitor, AZD1480 
Cells were infected with Ad5Hey1#3 (4500ppc), AdE1A12S#3 (500ppc) or Ad5GFP (4500ppc). 
Two hours later infection medium was replaced with 10% FBS DMEM or medium containing 10 or 
25µM AZD1480. At 12h post-infection medium was replaced with fresh medium containing 
AZD1480. At 24h post-infection cell lysates were harvested and prepared for separation on 
polyacrylamide gels. 20µg protein was loaded per lane and blotted for phospho (Y705) STAT3 
and β-actin as a loading control. Results for one experiment. 
 
In summary, I have determined Ad5Hey1 dose–dependently reduced phospho-
STAT3 expression in DU145 cells and that the JAK1/2 small molecule inhibitor, 
AZD1480 did not sensitise cells to Ad5Hey1 or the positive control virus, 
AdE1A12S. Assessment of phospho-STAT3 expression during concurrent 
treatment with Ad5Hey1 and AZD1480 suggested upregulation of phospho-
STAT3 in the presence of the inhibitor. Therefore inhibition of JAK1/2 by 
AZD1480 disrupts the effect Ad5Hey1 or AdE1A12S has on STAT3 signalling 
suggesting that Hey1 or E1A12S works through the same pathway as the small 
molecule inhibitor and could be inhibiting JAK/STAT signalling in DU145 cells. 
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3.3. Characterisation of cell death 
mechanisms under synergistic 
conditions 
 
The chemotherapeutic drugs mitoxantrone and docetaxel cause toxicity in most 
cell types by inducing apoptosis (Bellosillo, Colomer et al. 1998; Mhaidat, Zhang 
et al. 2007; Fabbri, Amadori et al. 2008; Symes, Kurin et al. 2008). E1A12S is a 
potent inducer of apoptosis and sensitiser to chemotherapeutic drugs (Debbas 
and White 1993; Lowe and Ruley 1993; Lowe, Ruley et al. 1993; Grand, Grant 
et al. 1994; Sabbatini, Lin et al. 1995) and in combination with mitoxantrone and 
docetaxel cause synergistic cell killing (Miranda, Maya Pineda et al. 2012). 
Considering that AdHey1 could stabilise p53 and inhibit AR-activity I speculated 
whether the synergistic cell death of Ad5Hey1 when combined with 
mitoxantrone and docetaxel (section 3.2.1) occurred as a result of an 
augmented apoptotic process induced by these drugs. 
 
3.3.1.  Ad5Hey1-mediated enhancement of 
drug-induced apoptosis is drug- and cell 
line-dependent 
 
3.3.1.1. Mitochondrial membrane depolarisation 
 
The intrinsic apoptotic pathway is stimulated by a range of non-receptor-
mediated pro-apoptotic signals resulting in intracellular signalling and 
destabilization of the mitochondrial outer membranes. The formation of the 
pores, including the permeability transition pore (PTP) leads to dissipation of the 
mitochondrial membrane potential (Δψm) and subsequent release of 
intermembrane space apoptogenic factors such as cytochrome C, 
Smac/DIABLO and apoptosis-inducing factor (AIF) (Kroemer, Galluzzi et al. 
2007). Depolarisation of the Δψm is characteristically deemed an early stage in 
apoptosis preceding DNA degradation, reactive oxygen species (ROS) 
production and membrane permeability (Darzynkiewicz, Juan et al. 1997). 
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Respiring mitochondria generate a proton gradient (Δp) across the inner 
mitochondrial membrane via the electron transport chain (ETC) resulting in a pH 
(ΔpHm) and electrochemical gradient (Δψm) (Cottet-Rousselle, Ronot et al. 2011). 
Cationic dyes used as mitochondrial probes preferentially localise in the 
mitochondrial matrix according to the electrochemical gradient established by 
the Nernst equation (Ehrenberg, Montana et al. 1988). 
 
 
 
Physiological values for Δψm range from 120 to 180mV (mitochondrial matrix 
being electronegative) result in the concentration of cations in the mitochondrial 
matrix being 2-3 logs higher compared with the cytosol (Kroemer, Galluzzi et al. 
2007). Tetramethylrhodamine ethyl ester (TMRE) was employed in these 
studies to measure Δψm as it accumulates rapidly in living cells due to its 
lipophilic nature; it is highly fluorescent and has low toxicity. It is highly specific 
to mitochondria and does not form aggregates nor display binding-dependent 
changes in fluorescence efficiency as well as having the lowest ETC inhibition of 
all the Δψm-sensitive probes (Ehrenberg, Montana et al. 1988; Cottet-Rousselle, 
Ronot et al. 2011; Perry, Norman et al. 2011). 
 
Cells were treated with Ad5Hey1 or AdE1A12S in combination with either 
mitoxantrone or docetaxel at the doses determined to have produced synergistic 
cell killing in 22Rv1 and DU145 cells (Section 3.2.1, Table 11). Since Ad5Hey1 
was previously shown to sensitise LNCaP cells to cytotoxic drug-induced cell 
death (section 1.8.1), this cell line was also included using fixed doses (Table 
11). Cells were collected between 24 and 120h and analysed by flow cytometry 
for Δψm using TMRE and the exclusion dye, DAPI. Viable cells were defined as 
the highly fluorescent population (Figure 28; I, high TMRE and low DAPI) 
whereas apoptotic cells with depolarised Δψm were identified as the population 
with lower fluorescence (Figure 48; III, low TMRE and low DAPI). Cells were 
treated with staurosporine to serve as positive controls for apoptosis and to 
V = -   RT 
ZF 
ln Ci Co 
V = membrane potential 
Z = ion charge 
R = ideal gas constant 
T = absolute temperature 
F = Faraday constant 
Ci = concentration inside cell 
Co = concentration outside cell  
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distinguish the live and apoptotic populations (Figure 48). Since transient loss of 
Δψm may occur under certain physiological circumstances, a static comparison 
between relative Δψm of untreated and treated cells was assessed and plotted as 
a function of treatment duration (Figure 49 and Figure 50).  
 
 
Figure 48. Assessment of Δψm depolarisation by TMRE flow cytometry 
Flow cytometry analysis of DU145 cells treated with 0.5µM staurosporine overnight. Cell 
populations were classified according to TMRE and DAPI staining. Quadrant I represents live cells 
(TMRE+ve/DAP-ve) and III apoptotic cells (TMRE-ve/DAPI-ve). Necrotic cells (DAPI+) are gated 
in quadrants II and IV. 
 
The tendency of Δψm to depolarise in PCa cells varied between cell types (Figure 
49). In 22Rv1 cells, 8.3% of cells were without an intact Δψm at the start of the 
time course whereas in LNCaP and DU145 cells <1% of cells had lost Δψm 
reflective of the different properties and genetic backgrounds of the cell lines. 
 
3.3.1.2. Mitochondrial depolarisation in cells treated 
with docetaxel and infected with viruses 
 
In 22Rv1 cells, Ad5Hey1 and AdE1A12S alone were able to induce changes to 
the Δψm (Figure 49). By 96h, the percentage of cells that had lost Δψm increased 
to 33% and 25.1% for Ad5Hey1 and AdE1A12S respectively compared with 
11.6% of untreated cells. At 48h, 17.8% of cells treated with docetaxel had lost 
their Δψm and this was increased to 41.6% by 96h. The effect of combining 
Ad5Hey1 with docetaxel increased the proportion of cells that had lost Δψm; 96h; 
55.7% compared with 41.6% and 33% for docetaxel and Ad5Hey1, respectively. 
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A similar trend was observed for the combination treatment with AdE1A12S 
although the percentage of cells with depolarised Δψm was slightly lower than the 
Ad5Hey1 combination treatment at 52.8%. No augmentation of Δψm was 
observed when Ad5GFP was combined with the drug. 
 
In LNCaP cells, none of the viruses significantly depolarised Δψm at any time 
point. Treatment with docetaxel enhanced Δψm depolarisation and by 120h, 
30.8% of cells were without an intact Δψm. Surprisingly, in contrast to the results 
obtained in the cell viability studies, Ad5Hey1 in combination with docetaxel 
increased the number of cells with depolarised Δψm (96-120h). At 120h, 57.5% 
of cells had lost Δψm when treated with Ad5Hey1 and docetaxel compared with 
30.8% for cells treated with docetaxel alone. A similar trend was observed for 
AdE1A12S in combination with docetaxel. A small increase in Δψm depolarisation 
was also seen when Ad5GFP was combined with docetaxel indicating that the 
expression of a non-toxic transgene in this cell line had an impact on cell 
survival, resulting in partial augmentation of Δψm depolarisation.  
 
In DU145 cells, neither Ad5Hey1 nor AdEA12S affected Δψm depolarisation. 
Treatment with docetaxel resulted in 21.7% of cells with no Δψm compared with 
6.3% of untreated cells by 96h. When Ad5Hey1 was combined with docetaxel, 
the proportion of cells at 96h undergoing Δψm depolarisation increased by a third 
and more than doubled when AdE1A12S was present. Δψm in response to 
Ad5GFP with docetaxel did not increase compared with drug alone.  
 
In conclusion, Ad5Hey1 was able to enhance docetaxel-induced Δψm 
depolarisation in all three PCa cell lines examined. The extent of augmentation 
appeared to be dependent on cell type. Ad5Hey1-mediated enhancement was 
similar to that of AdE1A12S in 22Rv1 and LNCaP. The differences between 
Ad5Hey1 and AdE1A12S were more apparent in DU145 cells, presumably due 
to mechanism-based variations in these cells. 
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Figure 49. Ad5Hey1 augments docetaxel-dependent Δψm depolarisation in 22Rv1, LNCaP 
and DU145 cells 
Cells were infected with Ad5Hey1#2 (22Rv1) or Ad5Hey1#3 (DU145 and LNCaP), AdE1A12S#3 
or Ad5GFP and/or treated with docetaxel in 10% FBS medium at the doses shown in Table 11. At 
the indicated times, cells were harvested for flow cytometry analysis as described in the Materials 
and Methods and stained with TMRE and DAPI. Cells that lost TMRE staining (inactive 
mitochondria) and remained negative for DAPI (intact cellular membrane) were considered 
“apoptotic.” Results shown are single replicates for each condition, representative of 2-3 
independent experiments showing a similar trend. 
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3.3.1.3. Mitochondrial depolarisation in cells treated 
with mitoxantrone and infected with viruses 
 
In 22Rv1 cells, mitoxantrone alone induced loss of Δψm (50.2%) at 96h 
compared with 11.6% of untreated cells (Figure 50) and the presence of 
Ad5Hey1 augmented drug-induced Δψm depolarisation resulting in 72.3% of cell 
at 96h without an intact Δψm. AdE1A12S enhanced the drug-induced Δψm 
depolarisation, in agreement with previous findings (Miranda, Maya Pineda et al. 
2012). Surprisingly, the mitoxantrone-induced augmentation of mitochondrial 
depolarisation was greater with Ad5Hey1. Again, Ad5GFP did not augment the 
loss of Δψm in combination with mitoxantrone.  
 
In LNCaP cells, mitoxantrone was not a strong inducer of Δψm dissipation in 
contrast with the docetaxel data. The proportion of cells with Δψm depolarisation 
was less than basal levels. Visual assessment indicated that cells were growth 
arrested in response to mitoxantrone-treatment at this low dose (25nM); cells 
were sparser in comparison with untreated cells and were not rounded as is 
typical of dying cells. This suggests that mitoxantrone at this dose had a 
cytostatic effect on cell viability. Nevertheless, combination of mitoxantrone with 
AdHey1 resulted in a distinct increase in Δψm depolarisation from 72h onwards; 
26.3% of cells had lost Δψm compared with 3.0% when treated with mitoxantrone 
alone after 120h. Combination treatment with AdE1A12S resulted in an even 
greater enhancement in Δψm depolarisation (52.2%). Ad5GFP in combination 
with mitoxantrone did not augment Δψm in contrast to the docetaxel–combination 
(Figure 49).  
 
In DU145 cells, mitoxantrone induced Δψm depolarisation in 45.0% of cells after 
96h. Intriguingly, Ad5Hey1 combined with mitoxantrone reduced the proportion 
of depolarised cells (Δψm=32.6%; 96h) indicating that expression of Hey1 had a 
protective effect. In agreement with published results, AdE1A12S enhanced Δψm 
depolarisation compared with drug alone (Miranda, Maya Pineda et al. 2012). 
The presence of Ad5GFP slightly increased the drug-induced Δψm changes 
suggesting that the observed Ad5Hey1-mediated inhibition of drug-induced 
depolarisation is specific.  
 
In summary, Ad5Hey1 augmented mitoxantrone-induced Δψm depolarisation in 
22Rv1 and LNCaP cell but not DU145. The sensitising function of Ad5Hey1 in 
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mitoxantrone-combinations was greater than AdE1A12S in 22Rv1 cells but not 
in LNCaP. In DU145 cells, Ad5Hey1 protected cells from mitoxantrone-mediated 
Δψm depolarisation an effect that suggests synergistic cell death with this 
combination treatment is a result of alternative modes of cell death. 
 
 
Figure 50. Ad5Hey1 enhances mitoxantrone-induced Δψm depolarisation in 22Rv1 and 
LNCaP but not DU145 cells. 
Cells were infected with Ad5Hey1#2 (22Rv1) or Ad5Hey1#3 (DU145 and LNCaP), AdE1A12S#3 
or Ad5GFP and/or treated with mitoxantrone in 10% FBS medium at the doses shown in Table 11. 
At the indicated times, cells were harvested for flow cytometry analysis as described in the 
Materials and Methods and stained with TMRE and DAPI. Cells that lost TMRE staining (inactive 
mitochondria) and remained negative for DAPI (intact cellular membrane) were considered 
“apoptotic.” Results shown are single replicates for each condition, representative of 3 
independent experiments showing a similar trend. 
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3.3.1.4. Apoptosis and necrosis contribute to the 
enhanced cell death in combination-treated cells 
 
The relative proportion of live, apoptotic and necrotic cells were assessed at 96h 
post treatment when the greatest distinction between single agent and 
combination treatment was detected. This was undertaken to gain further insight 
into the comparative differences by which the cytotoxic drugs killed cells in the 
presence or absence of Hey1 or E1A12S expression.  
 
The effects of mitoxantrone and docetaxel on Δψm were dependent on cell type 
(Figure 51). Mitoxantrone induced greater cytotoxic effects in DU145 than 
LNCaP cells; stimulating a greater proportion of cells to undergo Δψm 
depolarisation and accumulation of necrotic cells. Whereas docetaxel-induced 
cell death was largely via Δψm depolarisation in LNCaP cells, in DU145 cells 
more necrotic cells accumulated. Both drugs had similar effects in 22Rv1 cells in 
terms of accumulation of necrotic cells although mitoxantrone was more potent 
in enhancing Δψm depolarisation.  
  
In 22Rv1 cells, both apoptotic and necrotic cells accumulated in response to 
Ad5Hey1 or AdE1A12S infection alone. The effect was greatest with Ad5Hey1 
with less live cells than with AdE1A12S, however this study does not take into 
account the differences in cell death kinetics by the viruses. The proportion of 
cells undergoing Δψm depolarisation after combination treatment with both drugs 
corresponded to our observations from the time course experiments (Figure 49 
and Figure 50). Ad5Hey1 caused a greater increase of apoptotic cells whereas 
AdE1A12S-infection resulted in accumulation of more necrotic cells in 
mitoxantrone-combinations possibly as a result of variations in mechanisms of 
sensitisation of Ad5Hey1 or AdE1A12S when mitoxantrone was present. In 
contrast, the proportion of necrotic cells in docetaxel-combinations was similar 
for both viral mutants indicating that the mechanism of drug action has an 
impact on mode of cell death in 22Rv1 cells.  
 
In LNCaP cells, toxicity resulting from combination treatments resulted in an 
increase in both apoptotic and necrotic cells with either drug. However, in 
combination with Ad5Hey1 or AdE1A12S a greater increase in apoptotic and 
necrotic cells was noted in the presence of mitoxantrone than docetaxel. 
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In DU145 cells, depending on drug context, the effect of Hey1 expression 
resulted in different effects on the extent of Δψm depolarisation and the 
proportion of necrotic cells (Figure 51). When combined with mitoxantrone, the 
protective effect of Ad5Hey1 on Δψm was accompanied by an increase in the 
percentage of necrotic cells (41.2%) compared with drug alone (34.4%). 
Synergistic cell death in combination with Ad5Hey1 and mitoxantrone could 
therefore not be attributed to an enhanced drug-induced apoptosis suggesting 
alternative non-apoptotic cell death mechanisms may be occurring. However, 
combination with AdE1A12S showed a clear increase in apoptotic cells. In 
combination with docetaxel, Ad5Hey1 resulted in an increase in cells with 
depolarised Δψm and necrotic cells compared with drug alone. However, 
although statistically significant, this trend was also observed when the drug was 
combined with Ad5GFP. This is inconsistent with the results obtained for the 
time course experiment (Figure 49) where no difference in Δψm depolarisation 
was observed between Ad5GFP and docetaxel and drug alone. 
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Figure 51. Changes in the live, apoptotic or necrotic cells 96h after treatment with 
docetaxel or mitoxantrone, viral mutants or combination treatments 
Cells were infected with Ad5Hey1#2 (22Rv1) or Ad5Hey1#3 (DU145 and LNCaP), AdE1A12S#3 
or Ad5GFP and/or treated with either docetaxel (A) or mitoxantrone (B) in 10% FBS medium at 
the doses listed in Table 11. At 96h post-treatment cells were harvested and stained with TMRE 
and DAPI and analysed by flow cytometry. Results shown are for triplicate wells for each 
condition, representative for 1-2 independent experiments. Statistical analysis was carried out 
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using a one-way ANOVA statistical analysis using multiple comparisons with a Tukey post-test for 
either “live”, “apoptotic” or “necrotic” populations. p<0.05 (*), p<0.01 (**) p<0.001 (***/****) 
compared with untreated cells p<0.05 (#), p<0.01 (##) p<0.001 (###/####) was compared with 
respective single drug treatment. Dashed line refers to the percentage of apoptotic cells resulting 
from drug only treatment and dashed/dotted line the percentage of necrotic cells. 
 
3.3.1.5. Hyperpolarisation of Δψm by drug treatment is 
drug- and cell-line dependent 
 
During the course of the Δψm studies, I observed an increase in TMRE 
fluorescence under certain conditions, revealing additional effects on the 
membrane potential. Either drug- or virus-treatment revealed an increase in 
TMRE fluorescence compared with untreated cells. As well as detecting 
depolarisation of Δψm, TMRE is also sensitive to an increase in negative charge 
within the mitochondrial matrix resulting in a hyperpolarised Δψm (McGowan, 
Alling et al. 2011; Perry, Norman et al. 2011). 
 
In response to Ad5Hey1 and AdE1A12S (but not Ad5GFP), TMRE fluorescence 
intensity increased in LNCaP cells compared with untreated cells but not in 
22Rv1 or DU145 cells (Figure 52, Table 21). In line with AdE1A12S as a potent 
inducer of apoptosis, a second lower peak was also detected for LNCaP cells 
corresponding to a proportion of cells exhibiting no TMRE fluorescence. This 
was also observed in 22Rv1 cells in response to Ad5Hey1- or AdE1A12S-
infection but not in DU145 cells 
 
When LNCaP or DU145 cells were treated with docetaxel, 2 peaks were noted, 
one corresponding to cells with enhanced TMRE fluorescence compared with 
untreated cells and the other consistent with cells with depolarised Δψm. This 
was reflected in an increase in relative mean fluorescence intensity (MFI) of 
TMRE in LNCaP cells but not in DU145 (Table 21). A decrease in the proportion 
of cells with enhanced TMRE fluorescence was observed in both cell lines when 
treated with docetaxel-combinations (Figure 52, Table 21). In contrast, 22Rv1 
cells treated with docetaxel did not exhibit an increase in TMRE fluorescence. 
 
As with docetaxel, mitoxantrone treatment in LNCaP cells resulted in a 
proportion of cells displaying enhanced TMRE fluorescence compared with 
untreated cells (Figure 52, Table 21) while the addition of Ad5Hey1 or 
AdE1A12S increased the proportion of cells with depolarised Δψm. Unlike with 
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docetaxel-combinations, this did not result in a concomitant decrease in the 
proportion of cells with enhanced TMRE fluorescence and mitoxantrone-induced 
hyperpolarisation was maintained during Ad5Hey1- or AdE1A12S-mediated 
augmentation of apoptosis. Conversely, in DU145 cells only a small increase of 
TMRE fluorescence by mitoxantrone was noted, the majority of cells undergoing 
Δψm depolarisation after single or combination treatment. As before, 22Rv1 cells 
displayed only decreases in Δψm in response to mitoxantrone-combination 
treatments.  
 
In conclusion, drug- and virus-induced Δψm hyperpolarisation in PCa cells 
appears to be cell-line dependent. Both drugs resulted in Δψm hyperpolarisation 
in LNCaP and DU145 but only LNCaP cells were sensitive to Ad5Hey1 or 
AdE1A12S-mediated Δψm hyperpolarisation. 22Rv1 cells did not exhibit Δψm 
hyperpolarisation in response to either virus or drug and as discussed in section 
3.3.1.1 a greater proportion of untreated cells exhibited Δψm depolarisation 
compared with the other two cells lines.  
 
The implication of drug-induced enhancement of TMRE fluorescence and 
mitochondrial hyperpolarisation (Maldonado, Patnaik et al. 2010) was beyond 
the scope of this research project but does allow us to postulate the potential 
modes of action these drugs have on mitochondrial dysfunction and hypothesise 
by what cell-type specific mechanisms of cell death are enhanced when a 
cellular or viral gene is overexpressed. It is not possible to make direct 
inferences on respiratory status or ΔpHm solely by measuring Δψm. Other 
measurements on mitochondrial function are necessary to ascertain the reasons 
behind drug-induced Δψm hyperpolarisation. This may be due to enhanced Δp, 
resulting in a greater ATP generating capacity or instead, rising cytosolic [Ca2+] 
as a consequence of Ca2+ release from endoplasmic reticulum (ER) or 
mitochondrial stores (Perry, Norman et al. 2011). 
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Figure 52. Drug treatment of PCa cells result in 
differential effects on Δψm polarisation 
Data shown in Figure 49 and Figure 50 for 22Rv1 and 
DU145 (96h) and LNCaP (120h) displayed as a 
histogram of TMRE fluorescence vs. number of events 
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Table 21. Table showing relative geometric mean of TMRE fluorescence intensity after treatment 
with virus, drug or a combination at 96h (22Rv1 and DU145) or 120h (LNCaP) !! 22Rv1! LNCaP! DU145!
Untreated! 1.0  ± 0.0! 1.0 ± 0.0! 1.0 ± 0.0!
Ad5Hey1! 0.51 ± 0.02! 1.63 ± 0.06! 1.07 ± 0.10!
AdE1A12S! 0.51 ± 0.00! 1.40 ± 0.11! 1.12 ± 0.18!
Ad5GFP! 0.89 ± 0.07! 1.09 ± 0.19! 1.02 ± 0.00!
 
 22Rv1 LNCaP DU145 
Docetaxel 0.35 ± 0.03 1.98 ± 0.45 0.46 ± 0.04 
Ad5Hey1 + Doc 0.20 ± 0.05 0.30 ± 0.13 0.33 ± 0.03 
AdE1A12S+Doc 0.22 ± 0.04 0.16 ± 0.05 0.20 ± 0.07 
Ad5GFP+ Doc 0.45 ± 0.01 0.51 0.47 ± 0.01 
 
 22Rv1 LNCaP DU145 
Mitoxantrone 0.25 ± 0.02 7.73 ± 0.22 0.21 ± 0.09 
Ad5Hey1 + Mitox 0.14 ± 0.02 1.59 ± 0.26 0.23 ± 0.03 
AdE1A12S + Mitox 0.17 ± 0.02 0.18 ± 0.05 0.11 ± 0.06 
Ad5GFP + Mitox 0.21 7.68 ± 0.59 0.10 ± 0.00 
The relative mean fluorescence intensity (MFI) of TMRE fluorescence was determined by flow cytometry 
and expressed relative to untreated cells. Results show average relative geometric mean values for 2-3 
independent experiments ± SEM. When no SEM value is given, n=1 
 
3.3.2.  Caspase-3 activation 
 
Reduction of Δψm on its own is not an absolute indicator of apoptosis as dissipation of 
Δψm may also occur as a result of stress-induced inhibition of mitochondrial respiration. 
Further confirmation of apoptosis was undertaken by detection of activated caspases. 
The extrinsic and intrinsic apoptotic pathways culminate with activation of the execution 
caspases and mark the final stage of apoptosis. I investigated levels of active caspase-
3, a central executioner caspase activated by the initiator caspases, caspase-8 or -10 
(extrinsic pathway) or caspases-9 (intrinsic pathway). 
 
Cells were treated with Ad5Hey1 or AdE1A12S with and without chemotherapy as 
before and cells harvested and stained for active caspase-3 and examined by 
cytometric analysis at 72h post treatment. Ad5GFP was not included in this study since 
the active caspase-3 antibody was labelled with a fluorescein (FITC) tag. Induction of 
caspase activation was also examined by western blot (section 3.3.3). 
 
Treatment with staurosporine indicated relative activation levels of caspase-3 varied 
between cell lines with 22Rv1 cells the least resistant (66.6% of cells) and DU145 cells 
the most resistant (45.6% of cells) (Figure 53). In agreement with the Δψm studies, 
induction of active caspase-3 by adenoviral mutants or drugs alone varied between cell 
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lines and the extent of relative caspase-3 activation mirrored the degree of Δψm 
depolarisation for each agent. In 22Rv1 and LNCaP cells, adenoviral mutants 
significantly induced active caspase-3 over that of untreated cells whereas in DU145 
cells they did not.  
 
The differences between combination treatments and single drug treatment reflected 
the results obtained in the Δψm studies. In 22Rv1 cells, Ad5Hey1 significantly enhanced 
docetaxel and mitoxantrone-induced activation of caspase-3 compared with drug 
treatment alone. However Ad5Hey1 alone was also able to stimulate active caspase-3 
in 55.6% of cells and was more potent than AdE1A12S (28.8%). Although high levels 
of active capase-3 was generated by the adenoviral mutants, combination with 
cytotoxic drugs did not produce an additive effect with respect to active caspase-3 
levels rather the presence of Ad5Hey1 augmented drug-induced capase-3 activation. 
 
Although treatment with mitoxantrone did not result in Δψm depolarisation in LNCaP 
cells, a small but significant proportion of cells expressed active caspase-3 (9.0%) 
compared with 2.7% in untreated cells suggesting mitoxantrone may be activating the 
extrinsic apoptotic pathway. Ad5Hey1 and AdE1A12S induced similar levels of active 
caspase-3 to mitoxantrone (10.4 and 15.8% respectively). Docetaxel, the more potent 
of the two drugs in stimulating Δψm depolarisation, induced activate caspase-3 in 20.8% 
of cells. The expression of Hey1 in combination with either drug significantly increased 
levels of active caspase-3 compared with drug alone (mitoxantrone; 22.7% of cells and 
docetaxel; 36.5%). AdE1A12S in combination with either drug also increased the 
proportion of cells with active caspase-3, 39.2% when combined with mitoxantrone and 
53.7% with docetaxel.   
 
DU145 cells were resistant to adenoviral-mediated caspase-3 activation (<5% of cells) 
but were sensitive to cytotoxic drug treatment with 29.8% or 73.4% of cells with active 
caspase-3 after treatment with docetaxel and mitoxantrone respectively. Ad5Hey1 in 
combination with mitoxantrone resulted in a significant decrease in the proportion of 
cells with activated caspase-3 (50.4%) in agreement with the time course data, 
compared with drug alone and corresponded with the decrease in Δψm depolarisation. 
Conversely, Hey1 expression with docetaxel treatment resulted in a small increase in 
the percentage of cells with active caspase-3 (36.0%) compared with drug alone. In 
line with results obtained in 22Rv1 and LNCaP cells, AdE1A12S was able to enhance 
both mitoxantrone and docetaxel-mediated accumulation of cells with active caspase-
3. 
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Figure 53. Ad5Hey1 enhances mitoxantrone and docetaxel-induced active caspase-3 in 22Rv1 and 
LNCaP cells but only docetaxel-induced active caspase-3 in DU145 cells 
Cells were infected with Ad5Hey1#2 (22Rv1) or Ad5Hey1#3 (DU145 and LNCaP) or AdE1A12S#3 and/or 
treated with either mitoxantrone or docetaxel in 10% FBS medium at the doses listed in Table 11. Cells 
were treated with 0.5μM staurosporine overnight as a positive control for apoptosis. At 72h cells were 
harvested, permeabilised and stained with a FITC-labelled specific for active caspase-3 antibody and 
analysed by flow cytometry. Results are shown for duplicate wells ± SEM for one experiment, 
representative of two independent experiments. Statistical analysis was carried out using one-way ANOVA 
with multiple comparisons Tukey post-test.p<0.01 (**) p<0.001 (***/****) compared with untreated cells 
p<0.05 (#), p<0.01 (##) p<0.001 (###/####) compared with respective single drug treatment.  
 
3.3.3.  Expression levels of proteins involved in 
apoptosis increase during combination 
treatment 
 
Expression levels of proteins involved in synergistic cell death were investigated to 
verify whether Ad5Hey1 sensitised PCa cells to drug-induced apoptosis. Cells were 
treated with the same doses of virus and drugs as used in the Δψm and active capsase-
3 studies and lysates harvested 48h post-treatment and prepared for western blot 
analysis. In 22Rv1 cells, increased expression of total p53 and phospho-p53 was 
detected in Ad5Hey1-infected combination treatments compared with single agent 
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treatments (Figure 54). Synergy between Ad5Hey1 and drugs resulted in enhanced 
p53 activation compared with AdE1A12S-infected combinations supporting the theory 
that Ad5Hey1-mediated mechanisms of sensitisation is facilitated through increased 
p53 signalling compared with AdE1A12S. Confirmation of increased cell death by 
combination treatment with Ad5Hey1 in 22Rv1 cells was indicated by a decrease in 
expression levels in full-length poly ADP ribose polymerase (PARP) and an increase in 
levels of cleaved PARP compared with drug or virus alone treatments (Figure 54). 
Enhancement of apoptotic cell death in combination treatments was corroborated by 
increased expression of cleaved caspase-7. No cleaved PARP and low levels of 
cleaved caspase-7 was observed in the Ad5GFP-infected treatments confirming 
sensitising effect of Hey1 or E1A12S was specific (Figure 54). To characterise the 
apoptotic mechanism of cell death further, protein expression of Bax, a pro-apoptotic 
protein associated with the mitochondria was analysed. Bax, functions with Bak or tBid 
to form channels in the outer mitochondrial membrane to facilitate mitochondrial 
membrane permeabilisation (Taylor, Cullen et al. 2008). A trend towards an increase in 
Bax expression at approximately 23kDa was observed after treatment with either drug, 
Ad5Hey1 or AdE1A12S alone. Interestingly, a small faint band (~15KDa) was also 
detected with these treatments, which was not present in untreated cells or the 
Ad5GFP-infected sample. Combination treatment with mitoxantrone or docetaxel 
increased expression of the lower band and more expression was observed in the 
Ad5Hey1 or AdE1A12S-infected samples compared with Ad5GFP combinations. It is 
not possible to confirm whether the smaller band represents a smaller isoform or a 
cleaved form of Bax although expression patterns seem to correlate with enhanced 
apoptosis in these samples. This was observed in only one experiment and therefore 
further experiments would be necessary to confirm this trend. A stauroporine-treated 
control would indicate whether this is a product of apoptosis. 
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Figure 54. Ad5Hey1 enhances drug-induced p53 signalling resulting in increased expression of 
proteins involved in apoptosis in 22Rv1 cells 
22Rv1 cells were infected with Ad5Hey1#2 (480ppc), AdE1A12S#3 (120ppc) and Ad5GFP (480ppc). After 
2h, medium was removed and replaced with either standard 10% FBS DMEM or medium containing 25nM 
mitoxantrone or 5nM docetaxel. Lysates were harvested 48h post-treatment and prepared for separation 
on polyacrylamide gels. 20μg of protein was loaded per lane and probed for PARP, cleaved caspase-7 or 
Bax expression. Membranes were blotted for phospho (ser15) p53 first and then stripped before being 
probed for total p53. PCNA was used as a loading control. Histograms showing mean total p53, phospho 
(ser15) p53 and cleaved caspase-7 protein expression normalised to PCNA and expressed relative to 
untreated (UN) cells of two independent experiments ± SEM. Blots showing total, phospho (ser15) p53 
and cleaved caspase-7 expression are representative of 2 independent experiments. Blots showing PARP 
cleavage and Bax expression are from one experiment.   
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From the results of one experiment in DU145 cells, docetaxel-induced apoptosis was 
enhanced in Ad5Hey1-infected cells as detected by increased levels of cleaved PARP 
and caspase-7 levels (Figure 55). In agreement with the caspase-3 studies, levels of 
cleaved PARP and caspase-7 were increased when Ad5Hey1 was combined with 
mitoxantrone compared with single drug treatment. PARP cleavage occurs by 
caspase-dependent and –independent means (other proteases include calpains, 
cathespins, granzymes and matrix metalloproteinases) and the resulting PARP 
fragments mediate diverse mechanisms of cell death (Chaitanya, Steven et al. 2010). 
The modes of PARP-mediated cell death in DU145 cells are unknown, it is conceivable 
that in this cell line the main mechanism of PARP cleavage is caspase-dependent and 
therefore it would not be surprising to detect a reduction in PARP fragmentation under 
these circumstances. Consequently alternative mechanisms of cell death when 
Ad5Hey1 is combined with mitoxantrone should be considered.  
 
 
Figure 55. Ad5Hey1 enhances docetaxel- but not mitoxantrone-induced apoptosis in DU145 cells 
DU145 cells were infected with Ad5Hey1#3 (1800ppc), AdE1A12S#3 (900ppc) and Ad5GFP (1800ppc). 
After 2h, medium was removed and cells treated with standard 10% FBS DMEM or medium containing 
50nM mitoxantrone or 5nM docetaxel. Lysates were harvested 48h post-treatment and prepared for 
separation on polyacrylamide gels. 20μg of protein was loaded per lane and blotted for PARP or cleaved 
caspase-7. PCNA was used as a loading control.  
 
Observations from one experiment in LNCaP cells demonstrated Ad5Hey1 or 
AdE1A12S in combination with either mitoxantrone or docetaxel increased phospho-
p53 levels compared with respective drug treatments alone (Figure 56). At the doses of 
Ad5Hey1 and AdE1A12S used as single agent treatments, phosphorylation of p53 was 
not significantly induced and was similar to Ad5GFP. Enhancement of apoptosis when 
Ad5GFP was combined with docetaxel (Figure 49) was also reflected in phospho-p53 
levels indicating the presence of GFP might enhance p53 signalling in these cells and 
could also account for the small increase of apoptotic cells observed in the TMRE time 
course study. An increase in phospho-p53 was also observed for Ad5GFP combined 
with mitoxantrone. However from the loading control this might be due to more protein 
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being present in this lane. Increased cell death when Ad5Hey1 was combined with 
drugs was observed through increased expression of cleaved caspase-7 in the 
presence of mitoxantrone (but no PARP cleavage) and both increased cleaved 
caspase-7 (multiple forms) and PARP cleavage in the presence of docetaxel.  
 
 
Figure 56. Ad5Hey1 augments drug-induced p53 signalling resulting in increased apoptosis in 
LNCaP cells 
LNCaP cells were infected with Ad5Hey1#3 (360ppc), AdE1A12S#3 (240ppc) and Ad5GFP (360ppc). 
After 2h, medium was removed and cells treated with standard 10% FBS RPMI or medium containing 
25nM mitoxantrone or 5nM docetaxel. Lysates were harvested 48h post-treatment and prepared for 
separation on polyacrylamide gels. 20μg of protein was loaded per lane and blotted for phospho (ser15) 
p53, PARP or cleaved caspase-7. PCNA was used as a loading control.  
 
3.3.4.  Summary of apoptotic cell death studies 
 
The results obtained from the Δψm depolarisation and active caspase-3 studies indicate 
the level of apoptosis induced by chemotherapeutic drugs or adenoviral mutants was 
cell line-dependent. In terms of virus-induced apoptosis, 22Rv1 cells were the most 
sensitive stimulating both Δψm depolarisation and caspase-3 activation to similar 
degrees. In LNCaP cells, neither virus induced Δψm depolarisation while both activated 
caspase-3 similarly. In DU145 cells, neither virus mutant stimulated Δψm depolarisation 
or caspase-3 activation above basal levels. Sensitivity of cells to drugs appeared to be 
dependent on the mechanism of action employed by the drug. 22Rv1 cells were the 
most sensitive to drug-induced apoptosis and both drugs depolarised Δψm and activated 
caspase-3 to a similar degree. LNCaP and DU145 cells were less sensitive to 
docetaxel-induced Δψm depolarisation than 22Rv1 cells whereas mitoxantrone-induced 
Δψm depolarisation in DU145 cells was similar to 22Rv1 cell and no mitoxantrone-
induced Δψm depolarisation was observed in LNCAP cells. Levels of activated caspase-
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3 paralleled this cell line-dependent relationship for docetaxel in both LNCaP and 
DU145 cells and only in DU145 for mitoxantrone. Mitoxantrone treatment induced a 
small increase in caspase-3 activation in LNCaP cells indicating activation of apoptosis 
via non-mitochondrial pathways. 
 
Combining Ad5Hey1 with docetaxel or mitoxantrone in 22Rv1 and docetaxel in LNCaP 
cells resulted in augmentation of drug-induced Δψm depolarisation and activation of 
caspase-3. Combining Ad5Hey1 with mitoxantrone in LNCaP cells resulted in 
significant Δψm depolarisation not seen with either virus or drug alone. This suggests 
cooperation between Ad5Hey1- and mitoxantrone-induced modes of cell death. These 
differences were accurately reflected on the protein level in 22Rv1 cells 48h post-
treatment; enhanced PARP cleavage and cleaved caspase-7 in combination with 
Ad5Hey1 with either docetaxel or mitoxantrone. In LNCaP cells, cleaved caspase-7 
protein levels were increased in either drug combination treatment, in agreement with 
the active caspase-3 studies. Curiously, no PARP cleavage was observed when 
Ad5Hey1 was present although this was detected for the AdE1A12S combination. 
 
In DU145 cells, Ad5Hey1-mediated enhancement of drug-induced apoptosis was not 
as well defined as with cells expressing functional p53. Ad5Hey1 enhanced docetaxel-
induced Δψm depolarisation and increased PARP and caspase-7 cleavage above levels 
induced by docetaxel alone. On the other hand, combination treatment with Ad5Hey1 
and mitoxantrone in DU145 cells resulted in a decrease in Δψm depolarisation and 
active caspase-3 compared to cells treated with mitoxantrone alone despite synergistic 
cell death demonstrated at these doses of virus and drug (section 3.2.1). Apoptotic 
protein expression levels were in agreement with these findings; reduced levels of 
PARP and caspase-7 cleavage. Ad5Hey1 seemed to have a protective effect on 
apoptosis with this treatment combination as significantly more necrotic cells were 
detected than drug alone indicating cells were dying by a non-apoptotic process. As 
expected, AdE1A12S enhanced both docetaxel and mitoxantrone-induced apoptosis in 
line with previous findings (Miranda, Maya Pineda et al. 2012).  
 
In conclusion, Ad5Hey1 enhanced docetaxel-induced apoptosis in all cell lines but 
augmented mitoxantrone-induced apoptosis only in 22Rv1 and LNCaP cells. In DU145 
cells, Ad5Hey1 sensitised cells to mitoxantrone-induced cell killing through non-
apoptotic cell death mechanisms. Docetaxel and mitoxantrone have differential effects 
on cell growth inhibition; a cytotoxic effect in 22rv1 and DU145 cells and at the low 
dose in these experiments, a cytostatic effect in LNCaP cells. Since the cytostatic 
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effect was observed visually, examination of the cell cycle in response to mitoxantrone 
in these cells is required. These contrasting drug-induced effects on cell viability may 
influence the mode of cell death during sensitisation with Ad5Hey1. The analysis of 
drug-induced Δψm hyperpolarisation in LNCaP and DU145 cells may pertain to possible 
action on mitochondrial function 
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3.4. Efficacy of Ad5Hey1 in androgen-
responsive and androgen-ablation 
resistant PCa cells 
 
3.4.1.  Ad5Hey1 attenuates mibolerone-
stimulated cell growth and cooperates with 
bicalutamide to reduce growth of AR-positive 
cells 
 
I have demonstrated (section 3.1.2) that Ad5Hey1 decreased AR transcriptional activity 
in a dose-dependent manner in 22Rv1 cells, specifically in response to Hey1 
expression. In addition, Ad5Hey1 cooperated with bicalutamide to further decrease AR 
signalling in this cell line. Ad5Hey1-mediated cytotoxicity was partially dependent on 
the expression of AR and knockdown of AR resulted in a reduction of Ad5Hey1-
dependent cell death (section 3.1.3). Considering most PCa evolve into antiandrogen 
resistance phenotypes (CRPC), I hypothesised that Ad5Hey1 could sensitise AR-
expressing and hormone ablation-resistant PCa to drugs such as bicalutamide. 
 
Ad5Hey1-mediated reduction in cell viability was assessed in three AR-positive cell 
lines, LNCaP, 22Rv1 and VCaP cells each reflecting a different point of AR re-
activation in the transition of androgen-dependent PCa to CRPC. LNCaP and 22Rv1 
both possess mutations in their AR whereas VCaP cells contain an amplified AR gene 
locus that encodes wild-type AR protein (section 2.2; Table 5). As well as studying the 
effect of Ad5Hey1 in combination with bicalutamide, I also stimulated cells with 
mibolerone to assess the efficacy of Ad5Hey1 under conditions that induced cell 
growth. This aspect of the experimental setup was to re-establish a more physiological 
setting since CRPC tumours have been found to be receptive to very low levels of 
androgens allowing them to grow during ADT. 
 
Cells were infected with a fixed dose of Ad5Hey1 (EC50) or an equal dose of Ad5GFP 
(negative control) in the presence of 1nM mibolerone ± 5, 10 or 20µM bicalutamide and 
cell viability measured 3 days post treatment. The doses of bicalutamide selected have 
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previously been used by others (Cai, He et al. 2011; De Leon, Iwai et al. 2011) and in 
this study were shown not to cause significant cell killing alone. 
 
In agreement with the literature, mibolerone stimulated growth of androgen-sensitive 
LNCaP cells (146.7±7.1% relative to vehicle-treated; 100%) (Figure 57). Bicalutamide 
reduced both mibolerone-stimulated and basal growth in a dose-dependent manner. All 
conditions with bicalutamide reduced growth below basal levels except for 1nM 
mibolerone+5µM bicalutamide. Infection with Ad5Hey1 inhibited mibolerone-induced 
cell growth by 60% (to 86.2±9.6%) below levels of mibolerone-treated cells whereas 
infection with Ad5GFP remained similar (146.2±11.4%). Higher doses of bicalutamide 
(10 and 20µM) cooperated with Ad5Hey1 to further decrease mibolerone-stimulated 
cell growth (10µM; 66.9±4.0% and 20µM; 54.2±0.75%) and resulted in less cell growth 
compared with the corresponding conditions without AdHey1. Interestingly, no 
additional growth inhibition was observed with 5µM bicalutamide in the presence of 
AdHey1 and mibolerone. In the absence of mibolerone, 5µM bicalutamide further 
repressed Ad5Hey1-mediated growth inhibition from 42.8±4.5% to 33.8±5.0%; no 
further improvement was observed with higher doses of bicalutamide. This reduction 
was significant compared with uninfected cells treated with 5µM bicalutamide 
(79.7±3.9%). A small degree of non-specific toxic effects occurred as a result of 
infection with Ad5GFP alone (75.4±2.6%), however no statistical difference was 
observed between Ad5GFP combination treatments and uninfected cells treated with 
bicalutamide at any dose.  
 
The 22Rv1 cells, androgen-responsive but independent, were less sensitive to the 
effects of mibolerone than LNCaP cells resulting in 120.5±2.6% cell growth (Figure 57). 
Increasing doses of bicalutamide inhibited mibolerone-stimulated growth in a dose 
dependent fashion (5µM; 107.8±3.7%, 10µM; 104.6±3.2%, 20µM; 97.6±3.3%). 
However, in the absence of mibolerone growth was not affected by bicalutamide at any 
dose. Surprisingly, stimulating 22Rv1 cells with mibolerone resulted in a sensitising 
effect to Ad5Hey1-dependent cell growth inhibition (Ad5Hey1; 43.2±3.7%, AdHey1 with 
mibolerone; 31.8±3.8%) not observed with Ad5GFP (Ad5GFP; 93.2±0.5%, with 
mibolerone; 108.4±3.2%). Interestingly, the addition of bicalutamide to mibolerone and 
Ad5Hey1 treatment did not contribute any further benefit to cell growth inhibition. This 
was unexpected based on the cooperative effects Ad5Hey1 and bicalutamide had on 
AR transcriptional activity (section 1.8.1, Figure 13). In contrast, bicalutamide slightly 
prevented androgen-dependent growth stimulation in Ad5GFP-infected cells. In the 
absence of mibolerone, Ad5Hey1 in combination with bicalutamide resulted in further 
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decreases in cell growth compared with the virus alone however a trend towards 
biphasic growth (peaking at 10µM) was observed with bicalutamide, which was not 
observed in uninfected or Ad5GFP-infected cells. 
 
The VCaP cells were introduced into this study as an additional AR-positive cell line. 
These cells are more responsive to mibolerone stimulation than LNCaP cells 
(160.4±2.3%) (Figure 57). However addition of 5 or 10µM bicalutamide did not result in 
cell growth inhibition. Only the highest dose of 20µM partially reversed the growth 
effect of mibolerone (141.95%). Basal growth was also unaffected by bicalutamide 
treatment. Infection of Ad5Hey1 efficiently killed cells as a single agent. However, in 
the presence of mibolerone Ad5Hey1 did not significantly reduce androgen-stimulated 
cell growth (129.3±14.3%; compared to mibolerone alone, 160.4±2.3%) in contrast to 
the decrease observed in LNCaP cells. Encouragingly however, additional treatment 
with bicalutamide cooperated with Ad5Hey1 to further reduce cell growth (5µM; 
96.1±11.9%, 10µM; 79.3±8.8% and 20µM; 72.3%). As with LNCaP, VCaP cells were 
more sensitive to growth inhibitory effects of Ad5GFP (73.2±1.6%). Nevertheless, 
combination treatment with mibolerone and bicalutamide in the presence of Ad5GFP 
resulted in effects that were more similar to those noted for uninfected cells. 
 
As anticipated, AR-negative and androgen independent DU145 cells were not 
responsive to either mibolerone or bicalutamide although were efficiently killed by 
Ad5Hey1 (Figure 57). These findings suggest that, cell growth-inhibition in AR-positive 
cell lines in response to Ad5Hey1 in combination with mibolerone and/or bicalutamide 
are caused by AdHey1-mediated effects on the AR proliferation pathway.  
 
In summary, the effectiveness of Ad5Hey1 in the presence of growth stimulating 
conditions appeared to be cell-line dependent and may be reliant on factors such as 
the AR mutation status and/or AR copy number of the particular cell line. From the 
point of view of a therapeutic application, Ad5Hey1 was able to cooperate with 
bicalutamide in the presence of mibolerone to inhibit growth or when mibolerone was 
absent, Ad5Hey1 did not counteract the effects of bicalutamide which would be 
relevant in the context of castrate serum levels of testosterone when levels of 
circulating androgens are very low (<50ng/dL/1.7nmol/L) (Heidenreich 2012). 
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Figure 57. Ad5Hey1 in combination 
with mibolerone and bicalutamide has 
differential effects on cell growth 
inhibition in AR-positive LNCaP, 
22Rv1 and VCaP cells 
Cells were infected with a fixed dose 
(EC50) of Ad5Hey1#2 (22Rv1; 800ppc) or 
Ad5Hey1#3 (LNCaP; 600ppc, VCaP; 
6000ppc and DU145; 1800ppc) and 
treated with either vehicle (0.2% ethanol) 
or 1nM mibolerone (Mib) ± 5, 10 or 20µM 
bicalutamide (Bic) in 0.2% ethanol. Cell 
viability was assessed 3 days post-
treatment by MTS assay and cell growth 
expressed as a percentage relative to 
vehicle control. Results shown are means 
of duplicate wells from 6 independent 
experiments (22Rv1 and LNCaP 1nM 
mibolerone ± 5-10µM bicalutamide), 2 
independent experiments (22Rv1 and 
LNCaP 1nM Mib ± 20µM Bic and VCaP, 
except 20µM Bic conditions, n=1) ± SEM 
and duplicate wells of one experiment ± 
SEM (DU145). One way ANOVA 
statistical analysis was carried out using 
multiple comparisons with a Tukey post-
test, p<0.01 (**) and p<0.001 (***/****) 
compared to vehicle. p<0.05 (#), p<0.01 
(##) and p<0.001 (###/####) compared 
with mibolerone-treated cells. p<0.01 (§§) 
compared with 5µM Bic (LNCaP), 
p<0.001 (§§§§) compared with 5,10 and 
20µM Bic (22Rv1), p<0.05 (§) compared 
with 5µMBic, p<0.05 ($), p<0.01 ($$) 
compared with 10µM Bic (VCaP). 
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3.4.2.  Androgen-independent and androgen 
ablation-resistant PCa cells, 104-R1 and CDXR3 
are more sensitive to Ad5Hey1 than parental 104-
S 
 
I demonstrated in the studies above, that Ad5Hey1 could cooperate with bicalutamide 
to enhance growth inhibition in androgen-sensitive LNCaP and androgen-responsive 
VCaP cells. I therefore sought to explore the effect of Ad5Hey1 in androgen-
independent, bicalutamide-insensitive cell lines. LNCaP cells were chosen since 
historically androgen-independent sub-clones of this cell line have been well 
characterised. We obtained three LNCaP cell lines designated 104-S, 104-R1 and 
CDXR3. The parental cell line, androgen-sensitive LNCaP 104-S is stimulated and 
repressed by androgen and bicalutamide, respectively, while the sub-clones 104-R1 
and CDXR3 are paradoxically repressed by androgen and unresponsive to 
bicalutamide (Kokontis, Takakura et al. 1994; Kokontis, Hay et al. 1998; Kokontis, Hsu 
et al. 2005). 104-R1 cells were established by long-term culturing of 104-S cells in 
androgen-depleted conditions. To more closely mimic the clinical situation, 104-S were 
cultured in androgen-deficient medium supplemented with 5µM bicalutamide to derive 
CDXR3 cells (Kokontis, Hsu et al. 2005). Both 104-R1 and CDXR3 cells have been 
reported to express elevated AR protein levels and exhibit increased AR transcriptional 
activity however selection of CDXR3 cells by antiandrogen treatment is thought to 
bypass the intermediary 104-R1 stage and are considered more advanced in terms of 
disease progression (Kokontis, Takakura et al. 1994; Kokontis, Hsu et al. 2005; Chuu, 
Kokontis et al. 2011). 
 
Virus dose response curves were generated for Ad5Hey1 and the percentage of cell 
death assessed three days post-infection to determine EC50 values. In this study 
Ad5GFP was not included as incomplete dose response curves (not shown) made it 
impossible to accurately calculate EC50 values. For this reason I used Ad5 as a suitable 
reference and comparable cell killing was induced by Ad5 infection in all cell lines 
(Figure 58A). Interestingly, I found the androgen ablation-resistant and antiandrogen-
resistant sub-lines were more sensitive to Ad5Hey1-mediated cytotoxicity compared 
with the parental 104-S cells (Figure 58B). 
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Figure 58. Sensitivity to Ad5Hey1 is enhanced in androgen ablation-resistant LNCaP sublines 
compared with parental 104-S cells 
A) Representative virus dose response curves for Ad5 and Ad5Hey1 in 104-S, 104-R1 and CDXR3 cells. 
Cells were infected with serial dilutions of Ad5 (grey) and Ad5Hey1 (red) and cell death assayed by MTS 3 
days post-infection. EC50 values (ppc) calculated (table inset). Data shown is mean of duplicate wells from 
one experiment representative of 5-6. (B) Histogram on the left shows mean EC50 values of Ad5Hey1 in 
104-S, 104-R1 and CDXR3 cells from 5-6 independent experiments ± SEM. Histogram on the right shows 
EC50 values of Ad5Hey1 expressed as a ratio of Ad5 for 3 independent experiments ± SEM. Statistical 
analysis was carried out using the one-way ANOVA with multiple comparisons with a Tukey post test, 
p<0.05 (*) and p<0.01 (**). 
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3.4.3.  Proliferation of 104-R1 and CDXR3 cells 
are repressed by mibolerone and insensitive to 
bicalutamide treatment 
 
It was encouraging to detect enhanced sensitivity to Ad5Hey1-mediated cytotoxicity in 
104-R1 and CDXR3 cells. Since I observed a cooperative effect between Ad5Hey1 and 
bicalutamide in LNCaP and VCaP cells I investigated whether Ad5Hey1 could also 
sensitise ablation-resistant and antiandrogen insensitive cells to bicalutamide. As the 
design of the study required treating cells with mibolerone and bicalutamide it was 
essential to confirm the response of the 104-S sub-lines to these agents before 
investigating the effect of Ad5Hey1 in combination.  
 
To verify that the response of these cells to androgen and bicalutamide corresponded 
to the published literature I used the same doses of androgen and bicalutamide (0.1nM 
mibolerone and 5µM bicalutamide) and measured cell proliferation by the percentage 
of cells in S phase. In agreement with previous studies by Kokontis et al, 0.1nM 
mibolerone stimulated cell cycle progression in androgen-sensitive 104-S cells 
measured by an increase in cells in S phase (12.5%) compared with control (5.6%) 
(Figure 59) (Kokontis, Hay et al. 1998; Kokontis, Hsu et al. 2005). A higher dose of 
10nM resulted in a decrease in the proportion of cells in S phase compared with control 
cells indicative of an antiproliferative effect owing to the biphasic nature of androgens 
on LNCaP cell growth (de Launoit, Veilleux et al. 1991). The proportion of cells in S 
phase was noticeably higher in 104-R1 and CDXR3 cells compared with 104-S cells 
reflecting the high proliferative index of these cells.  In agreement with the published 
literature (Kokontis, Hay et al. 1998; Kokontis, Hsu et al. 2005), the proportion of 104-
R1 cells in S phase was repressed by 0.1nM mibolerone to 20.6 compared with control 
(25.8%) and was similarly repressed in CDXR3 cells to 17.6% compared with control 
(22.9%) (Figure 59). The higher dose of mibolerone at 10nM also repressed cell growth 
in agreement with previous reports (Kokontis, Hay et al. 1998). Treatment with 5µM 
bicalutamide repressed mibolerone-stimulated growth and basal growth of 104-S cells 
whereas it had no effect on the proliferation index of 104-R1 and CDXR3 cells. 
Conversely bicalutamide was able to reverse the repressive effect when treated with 
0.1nM mibolerone in agreement with previous reports suggesting androgen-mediated 
repression of proliferation of 104-R1 and CDXR3 cells is mediated through the AR  
(Kokontis, Hay et al. 1998; Kokontis, Hsu et al. 2005). The dose of bicalutamide in this 
study was not sufficient to over come the inhibitory effects of 10nM mibolerone in the 
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104-R1 and CDXR3 cells indicating bicalutamide-mediated release of mibolerone-
induced repression was dose-dependent. 
 
 
Figure 59. The effect of mibolerone ± bicalutamide on the percentage of cells in S phase in 104-S, 
104-R1 and CDXR3 cells 
Cells were seeded and the next day incubated in medium containing ethanol vehicle (control; 0.05% 
ethanol), 0.1nM and 10nM mibolerone ± 5µM bicalutamide for 96h. Cells were harvested and analysed by 
cell cycle analysis. Data shows single replicates representative of two independent experiments.  
 
3.4.4.  Ad5Hey1 infection induces an 
accumulation of cells in G1 in 104-R1 and CDXR3 
cells 
 
The effect of Ad5Hey1 on cell cycle distribution was assessed in the 104-S sub-lines. 
Doses of Ad5Hey1 determined to kill <30% of cells were selected based on EC50 
values calculated from dose-response curves. Cells were infected with 3000ppc (104-
S) or 1200ppc (104-R1 and CDXR3) of Ad5Hey1 or Ad5GFP and then treated with 
0.1nM mibolerone with and without 5µM bicalutamide. Cell cycle progression was 
assessed 72h after infection/treatment. 
 
At the doses selected, Ad5Hey1 infection of 104-R1 and CDXR3 cells resulted in a 
striking decrease in the percentages of cells in S phase with a corresponding increase 
of the proportion of cells in G1 (Figure 60). As expected, uninfected 104-S cells were 
responsive to mibolerone-induced S phase accumulation however in this particular 
experiment, the growth-inhibitory affects of bicalutamide were not apparent. However 
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in cells infected with Ad5Hey1 or Ad5GFP the stimulatory and repressive effects of 
mibolerone and bicalutamide respectively were more noticeable. In Ad5Hey1-infected 
cells an increase in the sub-G1 fraction was observed compared with uninfected or 
Ad5GFP-infected cells for all treatment combinations indicating the dose was effective 
at killing cells. In cells infected with Ad5Hey1 and treated with mibolerone a larger sub-
G1 fraction was observed compared with other Ad5Hey1 combination treatments 
(Ad5Hey1 with mibolerone; 4.7%, Ad5Hey1 alone; 1.7%). Cells were still receptive to 
mibolerone stimulation as demonstrated by the larger S and G2/M phases compared 
with Ad5Hey1 alone. The addition of bicalutamide decreased the proportion of cells in 
the S and G2/M fractions indicating cells remain responsive to bicalutamide treatment.  
 
On the other hand, Ad5Hey1 induced 104-R1 and CDXR3 cells to accumulate in G1. In 
Ad5Hey1-infected 104-R1 cells, 65.5% of cells accumulated in G1 phase compared 
with 49.6% of uninfected cells and 55.0% of GFP-infected cells. In CDXR3 cells, the 
difference was even more pronounced, 92.1% of cells were in G1 following Ad5Hey1-
infection compared with 58.7% of uninfected cells and 74.7% for Ad5GFP-infected 
cells. The expression of GFP has a modest non-specific effect on cell cycle 
progression compared with uninfected cells that will require further investigation. A 
small increase in sub-G1 fraction also accompanied Ad5Hey1 infection in both cell 
lines that was not present in uninfected of Ad5GFP-infected cells. In this study, the 
androgen-mediated suppression of S phase was only observed for 104-R1 cells and 
not CDXR3. I cannot account for the anomaly in CDXR3 cells. However, in 104-R1 
cells, androgen-mediated suppression of S phase was no longer apparent when cells 
were infected with Ad5Hey1, possibly due to the over-riding effects on cell cycle-
dependent proteins mediated by Ad5Hey1.  
 
To conclude, I have demonstrated Ad5Hey1 to have advantageous effects in an 
androgen-independent LNCaP cancer progression model as proved by enhanced 
sensitivity to Ad5Hey1-mediated cytotoxicity in 104-R1 and CDXR3 cells compared 
with parental 104-S cells. Mechanisms contributing to this effect have been explored 
and may be as a result of Ad5Hey1-mediated reduction on proliferative index as 
consequence of cells accumulating in G1. These initial promising results will require 
further investigation including studies assessing the temporal and dose-dependent 
effects of Ad5Hey1 infection on cell cycle distribution, TUNEL assay to determine in 
which phase the cells may be dying and confirmation of apoptotic cell death by 
caspase cleavage. 
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Figure 60. Androgen ablation-resistant 104-R1 and CDXR3 cells are more susceptible than parental 
104-S cells to Ad5Hey1-mediated growth arrest 
Cells were infected with either 3000ppc Ad5Hey1#3 or Ad5GFP (104-S) or 1200ppc Ad5Hey1#3 or 
Ad5GFP (104-R1 and CDXR3). After 2h, infection medium was removed and replaced with 10% FBS 
DMEM containing either vehicle (0.05% ethanol) or 0.1nM mibolerone and/or 5µM bicalutamide (total 
ethanol, 0.05%). Cells were harvested at 72h by trypsination and fixed in 70% ethanol. Cell cycle analysis 
was performed with PI staining. Results shown are single replicates representative of 2 independent 
experiments 
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3.5. Construction of a replication-
selective oncolytic virus expressing 
Hey1 (AdΔΔHey1) 
 
The replication-selective double-deleted Ad5 mutant (AdΔΔ) has recently been 
characterised in our research laboratory (Oberg, Yanover et al. 2010). AdΔΔ is deleted 
in the E1ACR2-region for selective replication in cancer cells with deregulated cell 
cycle control (e.g. pRb and p16 alterations) and is also deleted for E1B19K, an anti-
apoptotic Bcl-2-homologue which is commonly deregulated in tumour cells (Leitner, 
Sweeney et al. 2009; Oberg, Yanover et al. 2010). As discussed (section 1.7.1.4), it is 
advantageous to preserve the E3B genes in oncolytic adenoviruses to prevent 
premature elimination of infected cells by macrophages and thus maintaining anti-
tumour efficacy.  
 
Two main strategies are used for engineering transgene-expressing oncolytic 
adenoviruses: either the insertion of a transgene cassette with a promoter and 
polyadenylation signal or insertion as part of a viral transcription unit. We selected the 
latter method since this exploits endogenous viral gene expression for transgene 
expression (nuclear export and translation of capped cellular mRNA are supressed 
during late adenovirus replication) and allow the highly regulated nature of the lytic life 
cycle to be harnessed for temporal specific expression of the transgene. This approach 
removes the requirement of exogenous regulatory sequences since the adenovirus 
genome can only stably package an additional 5% of the genome (approximately 
1.8kb) (Heise, Hermiston et al. 2000). However, placement of the therapeutic 
transgene is restricted since early genes E1, E2 and E4 are required for viral 
replication and late structural genes are essential for viral assembly.  
 
Previously it was demonstrated that adenoviruses deleted for the E3A gene product 
E3gp19K (dl704) demonstrated enhanced viral gene expression and increased CTL 
infiltration in an immunocompetent mouse model and resulted in improved efficacy 
(Wang, Hallden et al. 2003). Based on these findings, we hypothesized that replacing 
E3gp19K with the Flag-Hey1 (Hey1) transgene in the AdΔΔ backbone would improve 
selectivity and potency for the treatment of PCa on a number of levels. Firstly, the 
E1ACR2 and E1B19K deletions ensure viral replication only occurs within tumour cells. 
Secondly, the majority of the E3 region remains intact thereby improving viral potency 
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in the presence of an immune response with the E3gp19K gene deletion enhancing the 
CTL response. Thirdly, the expression of a transcriptional corepressor such as Hey1 
may provide additional specificity to oncolytic adenovirus-induced cell killing in PCa 
cells, which often have deregulated Notch signalling pathways. By modulating the 
crosstalk between Notch signalling and other aberrant signalling pathways in PCa such 
as p53, AR and JAK/STAT, Hey1 may be able to therapeutically rewire PCa cells to 
inhibit cell proliferation and also sensitise cells to established chemotherapeutic drugs. 
Expression of Hey1 from the E3 promoter would be advantageous from the point of 
view of ensuring early expression of the cytotoxic transgene in the event of abortive 
viral replication. 
 
3.5.1.  Cloning strategy 
 
The generation of Ad5 mutants by homologous recombination was previously 
established and described (Chartier, Degryse et al. 1996). Construction of AdΔΔHey1 
was based on a cloning strategy developed by Dr Daniel Öberg, Barts Cancer Institute, 
London. A shuttle vector, pSuperShuttle (pSS), designed and constructed by Dr Daniel 
Öberg (manuscript in preparation) to facilitate gene-deletions and insertions was used 
to transfer the cDNA sequence of Hey1 into the AdΔΔ backbone. To facilitate 
homologous recombination, sequences flanking the E3gp19K region in the Ad5 
genome (termed left arm (LA) and right arm (RA)) were placed either side of Hey1 to 
produce pSSLARAHey1. Co-transfection of pSSLARAHey1 and plasmid AdΔΔ 
genome would generate the recombinant AdΔΔHey1 plasmid (Figure 61). Subsequent 
linearization of AdΔΔHey1 and transfection into A549 cells would result in virion 
particles of AdΔΔHey1 that could then be expanded and produced in bulk (section 
2.3.2).  
 
Due to unforeseen technical issues during the construction of AdΔΔHey1 and time 
constraints, only the pSSLARAHey1 was constructed and the homologous 
recombination stage attempted. The implications of the use of a replication selective 
oncolytic virus armed with Hey1 for the treatment of CRPC will be considered within the 
discussion. 
  
 248 
 
Figure 61. Cloning strategy for generating AdΔΔHey1 
A) pSuperShuttle (pSS) with multiple cloning sites. Right arm (RA), left arm (RA) and Hey1 products were 
PCR amplified. Insertion of RA was via EcoRV digestion. LA and Hey1 fused by PCR SOEing and then 
inserted into pSS via SnaBI digestion. (B) pSSLARAHey1 was digested with PmeI to remove the origin of 
replication (OriR) (C) Linearised pSSLARAHey1 and plasmid DNA of AdΔΔ were co-transfected into 
BJ5183 to undergo homologous recombination (D) Recombinant plasmid AdΔΔHey1 can be identified with 
double chloramphenicol and kanamycin selection. Extracted DNA from overnight cultures of plasmid 
AdΔΔHey1 is digested with SwaI to remove chloramphenicol selection and the plasmid can be 
retransformed into electrocompetent bacteria and selected using kanamycin. Sequencing of the E3 region 
will confirm the presence of the Flag-Hey1 sequence (E) AdΔΔHey1 is transfected into A549 cells to 
produce virion particles. Supernatant is collected 7-14 days post-transfection after CPE is observed. 
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4. Discussion 
 
The rationale behind this research was to introduce Hey1 into PCa cells through 
adenoviral-mediated delivery as a means of readdressing the balance between 
deregulated Notch and AR signalling. Belandia et al showed Hey1 to be 
excluded from the nucleus in PCa tumours and localised to the cytoplasm, 
mislocalisation of Hey1 thus possibly contributing to the development of CRPC 
(Belandia, Powell et al. 2005). Other studies demonstrated Hey1 was 
downregulated in PCa specimens further strengthening the concept that 
deregulated Hey1 might be important in PCa tumourigenesis (Wang, Leow et al. 
2006; Whelan, Kellogg et al. 2009). In this study, we postulated whether the 
action of Hey1 as an AR corepressor might inhibit cell growth and proliferation of 
PCa cells.  
 
The data presented in this thesis demonstrates that a non-replicating adenovirus 
expressing Hey1 is cytotoxic to the PCa cell lines 22Rv1, LNCaP and DU145 
cells. RNA interference targeting AR or p53 determined Ad5Hey1-mediated 
cytotoxicity required the expression of both these proteins for optimum efficacy 
in 22Rv1 cells. Experiments performed with the p53 isogenic HCT116wt and 
HCT116p53-/- cells revealed neither AR nor p53 expression were essential for 
Ad5Hey1-mediated cytotoxicity or sensitisation to cytotoxic drugs, verifying our 
observations of Ad5Hey1-induced cell killing in AR-negative and p53-mutant 
DU145 cells. In DU145 cells, Ad5Hey1 decreased the levels of phosphorylated 
STAT3 and cyclin D1 and when the JAK1/2 inhibitor AZD1480 was added, no 
sensitisation was observed, implying Ad5Hey1 may interfere with JAK/STAT 
signalling.  
 
In view of the fact that combination therapy approaches are likely to be the most 
feasible treatment option for oncolytic adenoviral therapy, I also investigated 
whether Ad5Hey1 could enhance drug-induced cell death. In 22Rv1, LNCaP 
and DU145 cells, synergistic cell killing was demonstrated when Ad5Hey1 was 
combined with sub-optimal doses of docetaxel or mitoxantrone. Enhanced cell 
killing was attributed to Ad5Hey1-mediated enhancement of drug-induced 
apoptosis in combination with either drugs in 22RV1 and LNCaP cell lines but 
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only with docetaxel in DU145 cells. Interestingly, in DU145 cells, I observed a 
reduction in apoptotic cell death when Ad5Hey1 and mitoxantrone were 
combined suggesting synergistic cell death was as a consequence of other non-
apoptotic cell death mechanisms.  
 
Since adrenal derived androgen synthesis and de novo androgen synthesis in 
CRPC maintains AR signalling despite castrate serum levels of testosterone, 
second-line bicalutamide treatment remains a therapy option for these patients. 
The degree of Ad5Hey1 potency when AR-positive cells were stimulated with 
androgen was cell-line dependent, however in the presence of bicalutamide, 
greater inhibition of cell growth was observed in LNCaP and VCaP cells 
compared with Ad5GFP-infected or non-infected cells suggesting Ad5Hey1 
cooperated with bicalutamide. I further clarified the potential of Ad5Hey1 in an 
androgen-independent LNCaP cancer progression model. These cells were 
found to be more sensitive to Ad5Hey1-induced cell killing compared with the 
androgen-dependent cell line resulting in an accumulation of cells in G1 phase 
of the cell cycle. This evidence suggests that Ad5Hey1 is a potent cytotoxic 
agent for androgen-independent and castration-resistant PCa cell lines. From 
this data, I propose that the expression of Hey1 from a replication-selective 
adenoviral vector remains a promising treatment for CRPC. 
 
4.1. Ad5Hey1 represses androgen-
dependent and -independent AR 
activity in 22Rv1 cells 
 
An AR-responsive luciferase reporter assay system previously determined 
Ad5Hey1 repressed androgen-dependent AR transcriptional activity in 22Rv1 
cells (Cheong et al, manuscript in preparation). No dose response was observed 
between 10 and 100ppc since maximum repression was observed at 10ppc. 
Evaluating lower doses confirmed Ad5Hey1 repressed AR activity in a dose-
dependent manner. Identical doses of Ad5GFP resulted in a limited decrease in 
AR activity as well. Non-replicating adenoviruses such as Ad5GFP and the E1A-
deleted dl312 virus result in non-specific effect on cell viability as a result of the 
presence of the virus particle, which in turn may affect AR transcriptional activity 
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to a certain extent. However the current data suggests the response of Ad5GFP 
is not dose-dependent and consequently non-specific in contrast to Ad5Hey1-
mediated repression. This study is the first demonstration that Hey1 expressed 
from an adenoviral vector is able to represses the activity of endogenous AR in 
PCa cells and is in concordance with published literature of Hey1 repressing 
transcriptional activity of the AR using in vitro systems and repression of 
endogenous AR in breast cancer MCF7 cells (Belandia, Powell et al. 2005). I did 
not assess the levels of SRC1 in these cells but it is presumed Hey1 binds to 
the bHLH-PAS domain of SRC1 and either inhibits recruitment of this 
coactivator to the AF-1 domain in the AR or competes with SRC1 for AF-1 
binding (Belandia, Powell et al. 2005) thus regulating the activity of AR through 
recruitment of additional corepressor proteins to the transcriptional complex. 
 
Androgen-independent 22Rv1 cells express three AR variants: one full length 
and two alternatively spliced, constitutively active, AR ΔLBD species (Dehm, 
Regan et al. 2007) . It was previously demonstrated by Belandia et al that Hey1 
was able to repress SRC1-mediated activation of an AR ΔLBD mutant 
(Belandia, Powell et al. 2005). This suggests that Hey1 may interact and repress 
transcriptional activity of all three isoforms in 22Rv1 cells. It was previously 
demonstrated in the absence of mibolerone, Ad5Hey1 at doses >10ppc 
decreased androgen-independent AR transcriptional activity (Cheong et al, 
manuscript in preparation). Overall, it can be concluded from this study that 
Ad5Hey1 is able to repress AR transcriptional activity of both androgen-
dependent and –independent AR isoforms in 22Rv1 cells. Encouragingly, we 
also observed further suppression of AR activity in the presence of bicalutamide 
suggesting possible cooperation between these agents. On this basis, growth 
inhibition was assessed in combination treatments with bicalutamide in AR-
positive PCa cell lines. The results will be discussed later in this chapter.  
 
The effect of Hey1 as an AR corepressor in LNCaP cells was not assessed, 
however it might be expected that Hey1 could also function as an AR 
corepressor in these cells. Hey1 targeted repression of the AF-1 region for AR 
transactivation may be of benefit for eliminating PCa tumours which harbour a 
mutated AR-LBD and provides a promising tool for targeting AR-positive PCa 
tumours in circumstances of promiscuous ligand-dependent activation of the 
AR.  
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4.2. AR and p53 are required for 
Ad5Hey1-mediated cytotoxicity in 
22Rv1 cells 
 
4.2.1.  The intrinsic cytotoxicity of Ad5Hey1 
is partially mediated by AR in 22Rv1 cells 
 
As maximum repression of androgen-dependent AR activity was achieved at a 
low dose, I hypothesised whether the corepressor action of Hey1 could also 
affect constitutively active AR splice variants. AR was knocked down to assess 
the absolute requirement of AR for Ad5Hey1-mediated cytotoxicity. RNA 
interference directed towards the N-terminal region of AR was employed to 
knockdown all AR splice variants in 22Rv1 cells. I found that knockdown of AR 
desensitised cells to Ad5Hey1-dependent cytotoxicity and resulted in a 
significant two-fold increase in Ad5Hey1 EC50 value compared with control 
siRNA-treated cells. In addition, non-specific cell death induced by the negative 
control virus, Ad5noHey1 at high viral doses was not affected by the knockdown 
of AR. As concluded above, Ad5Hey1 is able to repress androgen-dependent 
and –independent AR transcriptional activity. Therefore knockdown of all AR 
isoforms and the resulting desensitisation to Ad5Hey1-induced cytotoxicity 
suggests Ad5Hey1-mediated repression of full-length AR and AR splice variants 
in 22Rv1 cells may partially account for Ad5Hey1-mediated cytotoxicity in these 
cells. Since cell death was not completely inhibited this suggested the AR 
repressor function of Hey1 and inhibition of AR signalling was not entirely 
responsible for the intrinsic cytotoxicity of Ad5Hey1. It is highly likely that 
unidentified targets, amenable to Hey1 repression, are also regulated. This is 
evident since Ad5Hey1 is cytotoxic in AR-negative DU145 cells.. Despite 
western blotting demonstrating good knockdown, a small subpopulation of cells 
expressing AR still remain and these cells would be sensitive to Ad5Hey1-
dependent cytotoxicity and affect the final EC50 value. In addition, although 
adenovirus efficiently transduces 22Rv1 cells (~65% infected), some cells will 
not be infected also influencing the final EC50 value. 
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binding and sequestration of p300/CBP (Aarnisalo, Santti et al. 1999; Debes, 
Schmidt et al. 2002). Interestingly, the potency of the positive control virus, 
AdE1A12S was not affected by the absence of AR demonstrating that AR is not 
important for AdE1A12S-dependent cell death in 22Rv1 cells. It has previously 
been shown in our laboratory that AdE1A12S was able to decrease AR 
expression in 22Rv1 cells (Dr Enrique Miranda, PhD Thesis, 2009). It is 
speculated that this may be as a consequence of E1A opposing the activity of 
AR regulators, p300, HDAC and HDM2 resulting in HDM2-mediated AR 
degradation. However, AdE1A12S-dependent effect on AR levels did not 
correlate with enhanced potency since non-replicating AdE1A12S mutants with 
N-terminal regions deleted, did not downregulate AR protein levels, 
demonstrating comparable cytotoxicity with that of AdE1A12S (Dr Enrique 
Miranda, PhD Thesis, 2009). Taken together, other E1A12S-dependent 
mechanism are likely to play a part in mediating cell killing and in contrast to 
Ad5Hey1, AR was not required for AdE1A12S-mediated cell death. 
 
Numerous studies have shown that knockdown of AR through transient and 
stable knockdown methods have resulted in significant cell death indicating 
inhibition of AR is sufficient to induce cell death in AR-positive cells (Liao, Tang 
et al. 2005; Cheng, Snoek et al. 2006). I did not observe this in my studies with 
22Rv1 cells. One obvious reason for the differences are the use of different cell 
lines - the majority of studies previously reported were in the LNCaP cell line, 
which are more dependent on AR for cell proliferation than the 22Rv cells. 
Under our conditions, knockdown of AR resulted in approximately 10% cell 
death. This is in contrast to a recent study, which demonstrated AR knockdown 
could inhibit growth of 22Rv1 cells by up to 50% (Azuma, Nakashiro et al. 2010). 
This disparity is probably because of different cell culture conditions, cell line 
passages and degree of knockdown between the two studies. I found that the 
22Rv1 cells were highly sensitive to cytotoxic agents for several passages after 
recovery from liquid nitrogen and therefore our AR knockdown studies were 
carried out after 4-5 passages. It is now realised that AR signalling crosstalks 
with a number of different other signalling pathways. A recent study identified 
reciprocal regulation between AR and the PI3K/AKT pathway where RNA 
interference of AR or treatment with antiandrogen, MDV3100 enhanced AKT 
activity in PTEN-negative LNCaP cells and the PTEN-/- PCa mouse model 
through the downregulation of the androgen-regulated FKBP5 protein which 
itself is a negative regulator of AKT activity (Carver, Chapinski et al. 2011). 
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Depletion of AR in LNCaP cells can also result in PI3K-independent activation of 
AKT through elevated levels of calcium/calmodulin-dependent kinase II 
(CaMKII) (which is usually repressed by AR signalling) (Rokhlin, Taghiyev et al. 
2007). Another factor to consider are growth factors in the cell culture medium. 
22Rv1 cells express both EGFR and HER2/neu receptors in complete medium 
(Pignon, Koopmansch et al. 2009). Interestingly in this study, siRNA targeting 
the N-terminal of AR resulted in reduction of EGFR but an increase in HER2/neu 
expression. This was found to correlate with a reduction in cell growth compared 
with untreated or siRNA specific to the full-length AR isoform in steroid-depleted 
medium (Pignon, Koopmansch et al. 2009). However, as I carried out the 
experiments in complete medium, stimulation of HER2/neu receptor might be 
occurring resulting in enhanced cell growth. In light of these results, we should 
be mindful that deregulated AR signalling by RNA interference could influence 
other signalling pathways, which might affect the outcome of Ad5Hey1-mediated 
cytotoxicity. 
 
4.2.2.  Ad5Hey1 induction of p53 
contributes to Ad5Hey1-dependent 
cytotoxicity in cells expressing functional 
p53 
 
In view of the partial desensitisation of 22Rv1 cells to Ad5Hey1-mediated 
cytotoxicity after AR knockdown, I reasoned additional Hey1-mediated 
regulatory mechanisms must contribute to Ad5Hey1-dependent cell killing in this 
cell line. As discussed in section 1.5.3.3, genome-wide functional analysis 
identified Hey1 as a p53 regulator and Hey1-mediated inhibition of HDM2 
expression was credited as the mechanism by which Hey1 indirectly regulated 
p53 stabilisation and activation (Figure 62) (Huang, Raya et al. 2004; Villaronga, 
Lavery et al. 2009). Furthermore, upregulation of p53 by Hey1 was correlated to 
induction of apoptosis in vivo in a zebrafish and an avian developmental model 
(Huang, Raya et al. 2004) or inhibited growth of U2OS cells when Hey1 
expression was induced (Villaronga, Lavery et al. 2009). On this basis, I found 
Ad5Hey1 dose-dependently increased levels of total p53 in 22Rv1, LNCaP and 
HCT116wt cells in agreement with Hey1-dependent upregulation of p53 in 
U2OS-HEY1 (Villaronga, Lavery et al. 2009). In addition, HDM2 levels where 
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previously found to decrease modestly after Ad5Hey1 infection in 22Rv1 cells 
(Cheong et al, manuscript in preparation) in accordance with the results 
demonstrated in the U2OS-HEY1 cells (Villaronga, Lavery et al. 2009). As a 
consequence of our adenoviral-mediated expression system, Hey1 expression 
is prolonged compared with other in vitro systems and will lead to further HDM2 
expression due to the auto-regulatory feedback loop (Chène 2003). This might 
explain the more modest decrease in HDM2 expression after prolonged 
activation of p53. 
 
 
Figure 62. Regulation of p53 stabilisation by HDM2 and Hey1 
Hey1 induces p53 stabilisation by inhibiting HDM2 expression though transcriptional repression of 
the HDM2 promoter. Hey1 binding to the promoter is indirect and facilitated by as yet unidentified 
protein binding partners (Huang, Raya et al. 2004). p53 and HDM2 form an auto-regulatory 
feedback loop wherein HDM2 expression is regulated by p53 Various signals including DNA 
damage and oncogenic activation of p14ARF induce p53. HDM2 blocks p53 activity through a 
number of mechanisms: 1) stimulation of p53 degradation by ubiquitination, 2) promoting nuclear 
export of p53 and 3) inhibiting p53 transactivation. Figure adapted from (Chène 2003). 
 
Since p53 activity is regulated by a series of posttranslational modifications, the 
phosphorylation status of p53 on ser15 was also assessed. Phosphorylation at 
this residue has been demonstrated to enhance the interaction of p53 with 
transcriptional coactivators such as p300/CBP and PCAF for subsequent 
acetylation and stabilisation of the protein (Dumaz and Meek 1999). In response 
to increasing doses of Ad5Hey1, expression of phospho-ser15-p53 was 
enhanced in 22Rv1 and HCT116wt cells. The transcriptional activity of p53 was 
not assessed since it is well established that phospho-ser15-p53 is an adequate 
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marker for p53 activation (Dumaz and Meek 1999). Furthermore other 
laboratories have shown Hey1-induced p53 expression is transcriptionally active 
(Villaronga, Lavery et al. 2009).  
 
The results obtained in my study in relation to p53 phosphorylation status are in 
contrast to those demonstrated after ectopic expression of Hey1 in Ewing’s 
sarcoma TC252 cells which did not result in phosphorylation of ser15-p53 (Ban, 
Bennani-Baiti et al. 2008). Inhibiton of HDM2 by mechanisms other than 
transcriptional repression have yielded similar results. For example, depletion of 
HDM2 by RNA interference caused induction of p53 transcriptional activity in the 
absence of p53 phosphorylation or acetylation (Giono and Manfredi 2007) while 
the small molecule inhibitor of HDM2, Nutlin-3, also stimulated p53 activity in the 
absence of phosphorylation at specific residue sites associated with stress-
induced p53 activation (Thompson, Tovar et al. 2004). Phosphorylation of p53 at 
ser15 is as a result of phosphorylation by checkpoint protein, ataxia 
telangiectasia mutated (ATM), a serine/theronine kinase activated as 
consequence of the DNA-damage response (DDR) pathway. I did not 
characterise the activation status of this pathway, however it is conceivable that 
DDR is triggered through Hey1 and E1A-specific mechanisms which are not 
activated in response to Ad5GFP-infection since no phospho-ser15-p53 was 
detected in these samples.  
 
As discussed in section 1.6.3.3.2, E1A stabilises p53 levels through a variety of 
mechanisms through p300/CBP and pRb-dependent binding as well as direct 
interaction with regulators of p53. In both 22Rv1 and HCT116wt cells, 
AdE1A12S did not stabilise p53 as effectively as Ad5Hey1 – higher doses of 
AdE1A12S were required to stabilise p53 to a similar degree suggesting the 
main mechanism of AdE1A12S-induced cell death in not p53-mediated. In 
contrast, AdE1A12S-mediated upregulation of p53 expression in LNCaP cells 
was greater than for Ad5Hey1-infected cells highlighting that the extent to which 
Hey1 and AdE1A12S stabilise p53 in cells with functional p53 differ between cell 
lines. It is possible that constitutive activation of the PI3K/AKT pathway in 
LNCaP cells might result in upregulation of HDM2 activity through AKT-
mediated phosphorylation preventing more complete stabilisation of p53. 
 
Previous studies have determined phosphorylation and activation of p53 is 
linked to the loss of pRB or overexpression of E2F1 (Pan, Yin et al. 1998). 
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Infection of an adenoviral vector expressing E1A resulted in the formation of 
γH2AX foci, a marker of DNA double-stranded breaks. This observation was 
consistent with E1A-mediated accumulation of E2F3 resulting in 
autophosphorylation and activation of ATM, through the DDR pathway and 
subsequent phosphorylation of p53 (Hong, Paulson et al. 2008). Therefore the 
ability of E1A to override the cellular control of pRb-E2F is one possible 
mechanism that could account for AdE1A12S-mediated activation of p53 in 
22Rv1 and HCT116wt cells. In a different study, knockdown of both pRb alleles 
in mouse adult fibroblasts resulted in E2F1 accumulation, ATM activation and 
subsequent phosphorylation of p53 and apoptosis. However this occurred in the 
absence of ATM autophosphorylation and without formation of γH2AX foci. This 
indicated E2F1 was able to activate ATM through a mechanism distinct from 
agents that induce double-stranded DNA breaks and DDR factors can also 
contribute to oncogenic stress-induced signalling to p53 (Powers, Hong et al. 
2004). Since ATM is known to be activated through pathways other than DNA 
damage (Bakkenist and Kastan 2003), it would be of interest to assess the 
activation status of ATR, ATM and γH2AX in response to Ad5Hey1 infection.  
 
In view of the fact that Ad5Hey1-dependent cytotoxicity was accompanied by 
the activation of the p53 pathway over an extended time period, this suggested 
Ad5Hey1 might mediate p53-dependent apoptosis. To assess whether p53 was 
important for Ad5Hey1-dependent cytotoxicity, 22Rv1 cells were transfected 
with siRNA directed towards p53 and cell viability determined. We observed a 
50% decrease in the percentage of cell death stimulated by a fixed dose of 
Ad5Hey1 after cells were depleted of p53. This is in agreement with an earlier 
study which observed a reduction in Hey1-mediated cell growth inhibition in 
siRNA-p53-transfected U2OS-HEY1 cells (Villaronga, Lavery et al. 2009). This 
laboratory later extended their studies to the involvement of the ATF/CREB 
transcription factor, CREBZF in Hey1-mediated growth inhibition. siRNA 
directed towards CREBZF partially rescued the proliferation arrest caused by 
Hey1 expression (López-Mateo, Villaronga et al. 2012). CREBZF levels were 
not assessed in my study however this may be of interest in the future since 
CREBZF was found to interact with both Hey1 and p53 in vitro and cooperated 
with Hey1 to activate and stabilise p53 (López-Mateo, Villaronga et al. 2012). 
This and other unidentified Hey1-interacting proteins, which bridge p53 with 
Hey1, may provide an alternative explanation for the observed Ad5Hey1-
induced phosphorylation of p53. 
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The purpose of reanalysing the data produced from this study was to assess the 
importance of p53 and AR in Ad5Hey1-mediated cell killing in 22Rv1 cells. 
Overall it was demonstrated that knockdown of either protein abrogated 
Ad5Hey1-dependent cell death. A dual knockdown approach was not carried out 
in this study however it may substantiate the requirement of both proteins in 
Ad5Hey1-mediated cytotoxicity. Recent studies have shown that crosstalk exists 
between the AR and p53 signalling pathways. In both 22Rv1 and LNCaP cells, it 
was previously shown that both induction of p53 expression or inhibition of p53 
activity resulted in a decrease in AR-mediated transactivation suggesting 
physiological levels of p53 are required to stabilise AR signalling (Cronauer, 
Schulz et al. 2004). Conversely, treatment with DHT was shown to decrease 
p53 protein levels in LNCaP cells and inhibit apoptosis in a dose-dependent 
manner while serum starvation also resulted in decrease in p53 protein 
expression (Rokhlin, Taghiyev et al. 2005). In light of this, it should be taken into 
account that my data, which demonstrated Ad5Hey1-dependent decrease in AR 
transcriptional activity in 22Rv1 cells may partly be a consequence of Ad5Hey1-
induced p53 activation. In a study by Alimirah et al, p53 was found to associate 
with a 5’ regulatory region of the AR gene when LNCaP cells were stimulated 
with etoposide suggesting p53 negatively regulates AR expression in these cells 
(Alimirah, Panchanathan et al. 2007). It is also hypothesised that depletion of 
p53 by siRNA described in this thesis could, analogously to the results reported 
by Cronauer et al, inhibit AR signalling in 22Rv1 cells. If this is the case, indirect 
downregulation of AR may have resulted in desensitisation to Ad5Hey1-induced 
cytotoxicity. Alternatively in another study, knockdown of p53 in LNCaP cells 
resulted in enhanced AR expression compared with mock-treated cells (Rokhlin, 
Taghiyev et al. 2005). Therefore, complex context-specific mutual regulation of 
expression occurs between AR and p53. In this thesis I have presented 
evidence that in 22Rv1 cells, which express endogenous AR and functional p53, 
both must be functional for optimal Ad5Hey1 potency. The proposed 
mechanisms of Ad5Hey1-mediated cytotoxicity in these cells are presented in 
Figure 63.  
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Figure 63. A schematic diagram illustrating the mechanisms of Ad5Hey1-mediated 
cytotoxicity in 22Rv1 cells. 
A). Hey1 expressed from an adenoviral vector functions as a corepressor of full length AR and 
ΔLBD splice variants by interacting with the NTD region and modulating the levels of corepressor 
and coactivators at androgen-dependent and-independent AR transcription complexes thus 
downregulating AR-dependent growth. Repressive activity of Hey1 occurs through HDAC-
dependent mechanisms interacting with mSin3A and NCoR and recruitment of HDACs (Iso, 
Sartorelli, 2001) as well as HDACI/II-independent mechanisms (Nakagawa, McFadden et al. 
2000; Takata and Ishikawa 2003). Binding of Hey1 to coactivator SRC1 also regulates SRC1 
binding to AR and/or sequesters SRC1 from the AR transcription complex (Belandia, Powell et al. 
2005). B) Hey1 can inhibit HDM2 transcription independent of DNA-binding by recruitment of other 
corepressors and/or sequestering coactivator proteins by forming non-functional complexes 
resulting in inhibition of HDM2-mediated negative regulation of p53 and induction of apoptosis 
(Huang, Raya et al. 2004). C) Crosstalk between AR and p53 signalling pathways exist in PCa 
cells (Cronauer, Schultz et al. 2004). I hypothesise that at doses of Ad5Hey1, which do not result 
in stabilisation of p53, Hey1 functions as a corepressor of AR. However at doses sufficient to 
result in p53 transactivation, downregulation of AR signalling possibly through the association of 
p53 with a regulatory region of the AR gene (Alimirah, Panchanathan et al. 2007) occurs in 
addition to p53-dependent apoptotic responses.  
 
I also demonstrated that AdE1A12S-dependent cytotoxicity in 22Rv1 cells was 
partly mediated through p53-dependent activation of cell death pathways since 
AdE1A12S-induced cell death decreased after depletion of p53. In agreement 
with our results, a similar study also found E1A-induced cytotoxicity of ovarian 
clear cell carcinoma (CCC) cells was partly dependent on p53 after siRNA 
targeted to p53 resulted in a decrease in E1A-mediated cell death (Itamochi, 
Kigawa et al. 2007). Further evidence to support a p53-dependent mechanism 
of cytotoxicity, was a modest increase in the expression of Bax, a target gene of 
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p53 transactivation. Expression levels of p53-independent cellular targets 
induced by AdE1A12S were not assessed. E1A has been implicated in 
downregulating EGFR expression through binding to p400 and decreasing Mcl-1 
expression as a consequence of the DNA damage response (Cuconati, 
Mukherjee et al. 2003; Flinterman, Mymryk et al. 2007). As 22Rv1 cells have an 
activated EGF signalling pathway and express Mcl-1 (Kharaziha, Rodriguez et 
al. 2012), it would be of interest to assess the E1A12S-specific modulation of 
these pathways with and without p53 knockdown. This may prove useful in 
defining the significance of p53-independent pathways of cell death, which 
presumably contribute to AdE1A12S-induced cell death since p53 knockdown 
did not abrogate cell killing completely. 
 
4.3. Ad5Hey1 induces a G2 cell cycle 
delay in 22Rv1 cell but not in DU145 
cells  
 
Activated p53 in addition to inducing apoptosis, also causes cells to undergo 
growth arrest and for this reason I investigated whether Ad5Hey1 had an effect 
on the cell cycle distribution of 22Rv1. In parallel, the effects of Ad5Hey1 on the 
cell cycle in DU145 cells was also assessed since these cells express mutated 
p53. In contrast to another study where ectopically expressed Hey1 in Ewing’s 
sarcoma cell line, TC252 induced a p53-dependent G1 cell cycle arrest (Ban, 
Bennani-Baiti et al. 2008), Ad5Hey1-infected 22Rv1 cells resulted in a dose-
dependent decrease in the proportion of cells in G1. It is probable that variation 
in cell cycle defects between cancer cells account for the contrasting effects of 
Hey1 on cell cycle regulation between these two studies. Although 22Rv1 cells 
express both functional pRb and p53, the G1 checkpoint appears to be non-
functional and cells infected with either Ad5Hey1 or AdE1A12S showed a 
signficant increase in G2/M populations.  
 
Cell cycle analysis of 22Rv1 cells infected with increasing doses of Ad5Hey1 
resulted in a significant increase in the proportion of cells in G2/M in a dose- and 
time-dependent manner. This cell cycle distribution was in keeping with the cell 
cycle profile of U2OS-HEY1 cells where there was a reduction in the proportion 
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of cells in G1 and an increase in the percentage of cells in S and G2 phase 
(Villaronga, Lavery et al. 2009). Both the data presented in this thesis and the 
findings reported by Villaronga et al, show a correlation between increased 
population of cells in G2/M phase and increased p53 activation. Corresponding 
to the accumulation of G2/M, I observed a dose- and time-dependent increase 
in cyclin B1 levels. Together, this indicates Hey1 may activate the G2-
checkpoint through the accumulation of p53 and in 22Rv1 cells and U2OS cells 
The importance of p53 in G2 checkpoint control is recognised from earlier 
studies using isogenic p53 HCT116 cell lines demonstrating p53 was essential 
for long-term G2-arrest while p53-deficient cells eventually entered mitosis after 
G2 arrest (Bunz, Dutriaux et al. 1998). 
 
Since I did not see a decrease in cyclin B1 levels up to 72h post-infection, this 
suggested Ad5Hey1 may delay cell cycle progression into mitosis. It has been 
reported that cyclin B1, which is in a complex with Cdk1, remains mainly in the 
cytoplasm during interphase (Pines and Hunter 1991). During mitosis, 
Cdk1/cyclin B1 complexes are activated on centrosomes and are imported into 
the nucleus with breakdown of the nuclear envelope coinciding with the 
activation of the nuclear pool of Cdk1/cyclin B1 (Bailly, Pines et al. 1992; Gavet 
and Pines 2010). Therefore, since cyclin B1 levels are reported to be still high 
until degradation begins at the metaphase-anaphase stage of mitosis, I 
endeavoured to establish whether Ad5Hey1 induced a block in G2 or if an arrest 
was occurring at the beginning of mitosis. I assessed levels of phospho-Ser10-
histone H3 (pH3), which correlates with chromatin condensation at mitosis 
(Juan, Traganos et al. 1998), for clarification on whether a delay in mitosis was 
occurring. Concurrent with the increase of cyclin B1 levels, the percentage of 
Ad5Hey1-infected cells, which were positive for pH3, doubled compared with 
uninfected and Ad5noHey1-infected cells. To interpret these results, the time at 
which phosphorylation of histone H3 occurs on the chromosomes requires 
consideration. Several studies have reported that during chromosome 
assembly, phosphorylation of histone H3 by aurora A and aurora B kinases 
occurs in a controlled manner. Phosphorylation in mammalian cells, starts at 
late G2 phase at the pericentromeric heterochromatin and during mitosis, 
extends throughout the whole chromosome. Phosphorylation ceases in late 
prophase but is sustained through metaphase. Dephosphorylation of histone H3 
begins in anaphase and ends early telophase (Hans and Dimitrov 2001). From 
the bivariate analysis of pH3 vs. PI, I observed a large population of cells 
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arrested in mitosis in the nocodazole-treated sample in agreement with 
nocodazole arresting at the prometaphase stage in MCF7 cells (Choi, Fukui et 
al. 2011). In contrast, the pH3 distribution in G2/M for Ad5Hey1- and 
AdE1A12S-infected cells appeared to reflect an intermediary stage of pH3 
staining, between that obtained for nocodazole-treated cells and for control 
cells. Therefore, I was not able to conclusively deduce whether Ad5Hey1-
infected cells are delayed at late G2 or early mitosis. Our current hypothesis is 
that Ad5Hey1 induces a delay at late G2. A trail of pH3-positive cells can be 
observed in the cells infected with Ad5Hey1 or AdE1A12S. Since 
phosphorylation of histone H3 occurs in a stepwise manner, this may reflect 
cells whose chromosomes have not yet been widely phosphorylated on the 
histone H3 tails. Therefore, the trail may correspond to cells in a late G2 stage 
of the cell cycle and are undergoing a delay into mitosis. The population of cells 
directly above the trail are cells in mitosis and the size and density of this 
population remains similar between all treatments with the exception of 
nocodazole.  
 
A more definitive answer to whether Ad5Hey1 stimulates a G2 delay will be to 
assess activation status of Cdk1 since activation of the Cdk1/cyclin B1 complex 
triggers transition from interphase to mitosis (Lindqvist, Rodríguez-Bravo et al. 
2009). During G2, Wee1 and Myt1 execute inhibitory phosphorylation on 
tyrosine 15 and threonine 14 of Cdk1 respectively. This preserves Cdk1 activity 
until DNA replication is completed. Cdk1/cyclin B1 is activated upon abrupt 
dephosphorylating by Cdc25 phosphatases and drives cells irreversibly into 
mitosis (Lindqvist, Rodríguez-Bravo et al. 2009). In addition, the subcellular 
localisation of cyclin B1 may shed more light on the presence of a delay, as 
cyclin B1 is primarily located in the cytoplasm during G2. It would also be 
interesting to assess the putative G2 population at later time points to determine 
their fate – whether they will eventually override the delay that the G2/M 
checkpoint has imposed or die because of apoptosis. A small >4N DNA content 
population was observed at the later stages of Ad5Hey1 infection. It is possible 
the putative G2 delay may supress mitotic catastrophe (cell death that results 
from abnormal mitosis), which would facilitate the accumulation of polyploidy 
cells. This usually arises from either mitotic slippage, where a cell escapes 
mitosis and slips into the next interphase, or through failed cytokinesis after a 
cell has gone through aberrant mitosis (Yamada and Gorbsky 2006; Vitale, 
Galluzzi et al. 2011). 
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For AdE1A12S-infected cells, at the same dose used for Ad5Hey1, I also 
observed a p53-dependent accumulation of cells in G2/M but the increase was 
smaller than with Ad5Hey1 and was accompanied by a larger >4N DNA and 
sub-G1 fraction. The smaller accumulation of cells in G2/M may be a reflection 
of the observed lower level of activation of p53 by AdE1A12S compared with 
Ad5Hey1. Furthermore, at 72h both phospho-p53 and cyclin B1 levels were 
reduced suggesting AdE1A12S was able to overcome the G2/M checkpoint and 
enter mitosis. The replicating ONYX-015, which does not express E1B55K, 
similarly resulted in the accumulation of transcriptionally active p53 and was 
able to overcome the G1 and G2 checkpoints in normal cells resulting in the 
accumulation of cells with >4N DNA content (Cherubini, Petouchoff et al. 2006). 
It is probable that AdE1A12S abrogated the spindle checkpoint since enhanced 
polyploidy is correlated with its deregulation (Suijkerbuijk and Kops 2008). One 
mechanism through which this checkpoint is hindered is through the 
overexpression of Mad2, a gene target of E2F transcription, which leads to 
hyperactivation of the checkpoint (Hernando, Nahlé et al. 2004). MEFs 
transfected with an E1A vector overexpressed Mad2 which correlated with 
increased >4N DNA content and an aberrant number of chromosomes 
(Hernando, Nahlé et al. 2004). In another study, ectopic expression of E1A in 
chronic myeloid leukaemia K562 cells was reported to overcome G2/M arrest 
induced by etoposide by promoting the expression and activation of Cdk1 
(Stiewe, Parssanedjad et al. 2000). Additionally the polyploidy population could 
also arise from E1A-mediated inhibition of pRb, which is also required for the 
p53-dependent, postmitotic spindle checkpoint (Lanni and Jacks 1998).  
 
A strict p53-dependence for Hey1-mediated arrest was reasoned after Ewing’s 
sarcoma cells with mutant p53 failed to reduce the percentage of cells in S 
phase (Ban, Bennani-Baiti et al. 2008). I also found no major differences in the 
cell cycle profile of DU145 cells after infection with Ad5Hey1 other than an 
significant increase in the proportion of cells with >4N DNA. It is therefore 
possible Ad5Hey1 may, induce mitotic slippage as a result of defective G1 and 
G2 checkpoints in these cells (DU145; p53mut, pRbmut, p16-) (Isaacs, Carter et al. 
1991; Skjoth and Issinger 2006). Cells with defective p53 commonly undergo 
polyploidization compared with their wild-type counterparts resulting in 
multipolar division of tetraploid cells leading to aneuploidy and genomic 
instability (Senovilla, Vitale et al. 2009; Vitale, Senovilla et al. 2010). Untreated 
DU145 cells possess a noticeable proportion of cells with a polyploidy 
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phenotype compared with 22Rv1 cells. Infection with either Ad5Hey1 or 
AdE1A12S resulted in a larger proportion of DU145 cells than 22Rv1 cells 
accumulating with a >4N DNA content suggesting functional p53 in 22Rv1 cells, 
supresses formation of aneuploidy. A previous study demonstrated that 
inactivation of p53 in primary rat embryo (REF-52) fibroblasts resulted in 
tetraploid cells, which did not arrest in G1 and rapidly progressed to aneuploidy 
(Andreassen, Lohez et al. 2001). Enhanced polyploidy has been linked to 
chromosomal instability and as a result, the genome of DU145 cells is inherently 
unstable, carrying numerous chromosomal breaks (Beheshti, Karaskova et al. 
2000).  
 
In DU145 cells, significant differences in cell cycle perturbations were observed 
for cells infected with AdE1A12S at all doses. It should be noted however, that 
the extent of cell cycle changes induced by AdE1A2S and Ad5Hey1, at doses 
equivalent to their EC50 value (2000 and 8000ppc respectively), were not entirely 
different - although statistical significance could be attributed to AdE1A12S-
mediated effects on G1 and G2/M in addition to the >4N DNA population. E1A 
binds to numerous cellular proteins to drive cells into S phase. Since pRb is 
mutated in these cells, E2F is deregulated and hence the pRb-binding function 
of E1A12S is redundant. However, E1A is still able to stimulate cell cycle 
progression in non-functional pRb backgrounds. The p400/TRRAP-binding 
region of E1A has been reported to induce expression and stabilisation of E2F1, 
independent of pRb-binding through sequestering p400 away from E2F1 in 
primary transformed retinal cells (Helgason, O'Prey et al. 2010). Furthermore, c-
Myc is also a target of E1A-mediated deregulation. E1A binding to both p300 
and p400 have been reported to drive c-Myc expression and stabilisation 
respectively. Sequestration of p300 alleviates the repression exerted by HDAC 
complexes on the c-Myc promoter while binding to p400 binding site facilitates 
stabilisation of p400/c-Myc complex enhancing expression of c-Myc target 
genes (Tworkowski, Chakraborty et al. 2008; Sankar, Kadeppagari et al. 2009). 
Therefore the attenuated G1 and G2 checkpoints in these cells and the 
deregulation of c-Myc by AdE1A12S may ultimately result in enhanced 
polyploidy. It has also been reported that overexpression of c-Myc with the 
combined loss of p53 is a mechanism of tetraploidization (Yin, Grove et al. 
1999). 
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In conclusion, my data suggests that Ad5Hey1 can abrogate the cell cycle 
checkpoints in PCa cells and cause only a putative G2 delay in p53-expressing 
22Rv1 cells followed by mitotic entry. In DU145 cells, Ad5Hey1 enhanced 
mitotic slippage resulting in a higher proportion of aneuploid cells with increased 
genomic instability. This may be a potential mechanism for Ad5Hey1 to sensitise 
cells to chemotherapeutic drugs leading to enhanced cell death by attenuating 
cellular checkpoints and enable cells to progress through the cell cycle in the 
presence of DNA-damage and virus infection.  
 
4.4. Ad5Hey1-mediated cytotoxicity 
and cooperation with 
chemotherapeutic drugs by p53-
dependent and –independent 
mechanisms 
 
Together with previous reports and the data presented in this thesis, there is 
compelling evidence that overexpression of Hey1 results in p53-dependent cell 
growth inhibition and cell death. However, Ad5Hey1-mediated cytotoxicity and 
synergy with chemotherapeutic drugs was also observed in DU145 cells which 
express mutant p53. The p53 isogenic HCT116 cell lines were used to 
definitively assess the requirement of p53 for Ad5Hey1-dependent cell death 
and sensitisation. These cells did not express AR therefore circumventing the 
Hey1-specific regulation of the AR. 
 
No difference in Ad5Hey1-induced potency was observed between the matched 
cell lines confirming the earlier p53-independent mechanism of action of 
Ad5Hey1 in DU145 cells. AdE1A12S was more potent in HCT116p53-/- cells 
than the wild-type counterpart indicating the lack of p53 renders the cells more 
sensitive to E1A-mediated cell killing. Villaronga and colleagues proposed that 
upregulation of p53 activity as a consequence of overexpression of Hey1 in 
U2OS cells was a mechanism by which Hey1 sensitised cells to cisplatin and 
doxorubicin (Villaronga, Lavery et al. 2009). In agreement with these results and 
in addition, I have shown that Ad5Hey1 synergised with docetaxel and 
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mitoxantrone in PCa cell lines both with and without functional AR and p53 
pathways. Morover I defined that p53 activation was not a prerequisit for 
sensitisation as 5-FU and mitoxantrone sensitised HCT116p53-/- cells and 
HCT115wt cells to Ad5Hey1-mediated cytotoxicity. 
 
An interesting relationship emerged when Ad5Hey1 or AdE1A12S was 
combined with either 5-FU or mitoxantrone in p53 isogenic HCT116 cells. 
Results suggested the p53 status of cells and the drug mechanism of action 
were important for optimal sensitisation to Ad5Hey1 or AdE1A12S-induced 
cytoxicity. The activity of p53 has previously been found to have a significant 
impact on the response of cells to chemotherapeutic agents and that the 
response varies depending on the drug (Bunz, Hwang et al. 1999). Sensitisation 
by mitoxantrone or 5-FU to Ad5Hey1-mediated cytotoxicity was greater in 
HCT116wt cells than HCT116p53-/- cells. However, sensitisation by 5-FU to 
Ad5Hey1 in p53-deficient cells was not decreased significantly suggesting 
sensitisation by 5-FU to Ad5Hey1 occurred independent of p53. Conversely, 
when AdE1A12S was combined with 5-FU, optimum sensitisation was observed 
in HCT116p53-/- whereas minimum sensitisation occurred in HCT116wt cells. 
Potent sensitisation to AdE1A12S in both cell lines was demonstrated when 
combined with mitoxantrone. 
 
The therapeutic efficacy of 5-FU derives from its role in inhibiting DNA synthesis 
and repair as well as incorporation into RNA, inhibiting processing of ribosomal 
RNA (rRNA) and preventing splicing of pre-mRNA (Zhang, Yin et al. 2008). In 
accordance with Bunz et al, I found HCT116p53-/- cells to be more resistant to 5-
FU induced cytotoxicity (Bunz, Hwang et al. 1999) however, at the sub-optimal 
doses used in this study (wherein 15-30% of cells are killed), p53 status did not 
significantly affect the potency of 5-FU or mitoxantrone. Later studies reported 
that 5-FU possesses p53-dependent and –independent mechanisms of action, 
both of which might contribute to the sensitisation of HCT116 cells to Ad5Hey1-
mediated cytotoxicity. As 5-FU affects RNA processing, this results in inhibition 
of rRNA biogenesis and nucleolar stress activating the p53 pathway thereby 
keeping deregulated cell growth in check (Zhang and Lu 2009). The resulting 
ribosomal stress results in liberation of the ribosomal L proteins (L5, L11 and 
L23), which directly bind to the central acidic region of HDM2 and inhibit HDM2-
mediated ubiquitination of p53 in U2OS cells (Sun, Dai et al. 2007). 
Consequently, sensitisation of HCT116wt cells by 5-FU to Ad5Hey1-dependent 
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cell killing may be as a result of a convergence of pathways, which together 
inhibit the HDM2-p53 regulatory loop. Thus, Ad5Hey1 inhibits HDM2 expression 
leading to p53 activation whereas 5-FU will block the resulting HDM2-p53 
feedback circuit by releasing ribosomal proteins, which inhibit the ubiquitin 
ligase activity of HDM2, and leading to stabilisation of p53. Since Sun et al 
identified that the ribosomal proteins L5, L11 and L23 were involved in 
mediating 5-FU-induced p53 activation it would be interesting to assess whether 
knocking down these proteins would desensitise HCT116wt cells to Ad5Hey1 
and 5-FU combination treatment.  
 
Earlier reports using normal fibroblast cells demonstrated E1A-dependent 
sensitisation occurred as a result of E1A-mediated induction of p19ARF (the 
mouse homologue of human p14ARF) through E2F release resulting in p53 
stabilisation. A functional p19ARF/p53 pathway was required for this since ARF-
null cells abrogated this effect (Lowe and Ruley 1993; de Stanchina, McCurrach 
et al. 1998). The significance of p14ARF in E1A-dependent p53 activation may 
explain the poor induction of p53 by AdE1A12S in HCT116wt cells since the 
p14ARF gene is defective in these cells (Burri, Shaw et al. 2001). This also 
underscores the distinct mechanism by which Ad5Hey1 and AdE1A12S induce 
p53 activation, Ad5Hey1 by directly inhibiting HDM2 at the transcriptional level 
while AdE1A12S indirectly regulates posttranslational HDM2 activity through 
p14ARF upregulation. The sub-optimal stabilisation of p53 by AdE1A12S in these 
cells may also explain the reduced sensitisation when combined with 5-FU 
suggesting E1A-binding to p300, HDMX and the 26S proteasome do not 
efficiently activate p53, in this cell line at least. In 22Rv1 and LNCaP cells, 
combination treatment with Ad5Hey1 or AdE1A12S enhanced levels of total 
and/or phospho-ser15-p53 with both docetaxel and mitoxantrone. Greater p53 
stabilisation was observed when drugs were combined with Ad5Hey1 than in the 
presence of AdE1A12S in 22Rv1 cells.  Since the levels of expression of Hey1 
and E1A were comparable in the 22Rv1 cells under these conditions, these 
observations support our hypothesis that Ad5Hey1-dependent cytotoxicity and 
sensitisation is mediated through p53 signalling to a greater extent than 
AdE1A12S. In contrast, in LNCaP cells, activation of p53 for combination 
treatments with Ad5Hey1 did not supersede those induced with AdE1A12S 
combinations possibly as a result of enhanced HDM2 activity. 
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It was recently shown that treatment of HCT116p53-/- cells with 5-FU resulted in 
the stabilisation of the proapoptotic isoform of p73, TAp73α and the induction of 
p53-inducible genes (Vilgelm, Washington et al. 2010). This could be a potential 
mechanism by which 5-FU sensitises HCT116p53-/- cells to Ad5Hey1-dependent 
cytotoxicity since induction of TAp73 in a p53-deficient background permits 
regulation of downstream effectors which overlap with transcriptional targets of 
p53 in response to cytotoxic stress. Similarly, it is possible that Ad5Hey1 exerts 
its effects through induction of TAp73 activity in a p53-deficient background. 
Overexpression of Hey1 in HCT116p53-/- inhibited HDM2 transactivation and 
decreased HDM2 protein levels indicating regulation of HDM2 in a p53-deficient 
background (Huang, Raya et al. 2004). HDM2 interacts with other proteins such 
as CBP/p300, pRb, p73 and E2F1 that regulate the cell cycle, apoptosis and 
tumourigenesis independently of p53 (Bartel, Taubert et al. 2002). Inhibition of 
HDM2 by Nutlin-3 was shown to induce apoptosis in HCT116p53-/- cells by 
relieving HDM2-mediated inhibition of TAp73α (Lau, Nugent et al. 2008). An 
attractive hypothesis for a mechanism of sensitisation for these agents in 
HCT116p53-/- cells might be that both agents are targeting HDM2 as proposed in 
HCT116wt cells. This could potentially explain why sensitisation, irrespective of 
p53 status is observed for 5-FU in combination with Ad5Hey1. It would therefore 
be interesting to determine the importance of TAp73 for Ad5Hey1-dependent 
cytotoxicity and sensitisation as a putative mechanism in p53-deficient cells. In 
parallel, it would also be appropriate to assess the activity of Ad5Hey1 on E2F1 
stabilisation as Nutlin-3a-treated HCT116p53-/- cells enhanced expression of 
E2F1 and co-immunoprecipitation of HDM2 demonstrated loss of E2F1 binding 
after Nutlin-3a treatment (Ambrosini, Sambol et al. 2007). E2F1 has also been 
demonstrated to induce expression of p73, caspases and BH3 proteins of the 
Bcl-2 family resulting in E2F1-mediated apoptosis through p53-independent 
mechanisms (Irwin, Marin et al. 2000; Nahle, Polakoff et al. 2002). Therefore if 
Ad5Hey1 relieves HDM2-mediated inhibition of TAp73 and/or E2F1 resulting in 
stabilisation of one or both of these proteins this may confer a potential 
mechanism through which it could cooperate with cytotoxic drugs in p53-
deficient cells. In the context of HCT116wt cells, inhibition of HDM2 and 
subsequent stabilisation of E2F1 would not result in p14ARF expression thereby 
precluding the additional suppressive effects of p14ARF on HDM2 activity in this 
cell line.  
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Antisense therapy to HDM2 in LNCaP, DU145 and PC3 cells have 
demonstrated broad-spectrum antitumour activity irrespective of p53 status 
(Zhang, Li et al. 2003). Importantly, when DU145 cells, which overexpress 
HDM2, were transfected with antisense oligonucleotides directed towards 
HDM2, the expression of p21 and E2F1 was upregulated, and was 
accompanied with apoptosis. Antisense towards HDM2 also sensitised cells to 
cytotoxic agents in vitro as well as increasing efficacy of chemotherapeutic 
agents in a DU145 xenograft model (Wang, Yu et al. 2003; Zhang, Li et al. 
2003). Therefore, analogous to Zhang and colleagues knocking down HDM2 
expression in DU145 cells, Ad5Hey1-dependent regulation of HDM2 expression 
might have resulted in deregulation of HDM2 effector proteins in this cell line. 
Since Ad5Hey1 has no intrinsic cytotoxicity in PC3 cells, which also express 
HDM2, this may be an auxiliary role of Ad5Hey1-mediated action and not the 
main mechanism by which Ad5Hey1 executes cell killing in DU145 cells. 
Putative mechanisms through which Ad5Hey1 might mediate p53-independent 
inhibition of cell viability are explored in Figure 64. In this thesis I also 
investigated the potential role of Ad5Hey1 inhibiting STAT3 signalling in DU145 
cells which will be discussed later.  
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Figure 64. A schematic diagram demonstrating putative mechanisms of Ad5Hey1-mediated 
cytotoxicity in p53-deficient cell lines. 
As demonstrated in cells with functional p53, Hey1 is able to inhibit HDM2 transcription in 
HCT116p53-/- cells (Huang, Raya et al. 2004). Based on this, I hypothesise that through 
repression of HDM2 transcription, Hey1 relieves HDM2-mediated inhibition of E2F1 and TAp73. 
E2F1-dependent apoptotic activities include transactivation of TAp73, caspases and BH3-only 
proteins (Bax, Noxa, Puma). Due to the functional overlap between TAp73 and p53, TAp73 
regulates the expression of some p53-regulated genes leading to cell cycle arrest and apoptosis. 
Therefore the E2F1-TAp73 pathway may function in place of p53 signalling when p53 is defective 
underscoring the potential for targeting this pathway in tumours lacking functional p53. The 
CDKN2A and Rb loci are defective in HCT116p53-/- and DU145 cells respectively (dashed lines 
for p16INK, p19ARF and pRb in figure) indicating a deregulated pRb-E2F1 pathway. However these 
cells remain responsive to HDM2 inhibition by either nutlin-3a (HCT116p53-/-) or HDM2 antisense 
therapy (DU145) leading to increased E2F1 activity and apoptosis (Zhang, Li et al. 2003; 
Ambrosini, Sambol et al. 2007). This does not exclude the possibility of Hey1 targeting other 
pathways, which are not amenable to HDM2 regulation. Hey1 may also target the JAK-STAT 
pathway and both DU145 cells and HCT116 cells express STAT3.  
 
The molecular mechanisms essential for E1A-mediated sensitisation have not 
been defined owing to numerous cellular pathways regulated by E1A-binding 
and the molecular alterations of the tumour cells. I have demonstrated that the 
degree of sensitisation also varies depending on the cytotoxic agent used. In 
general, the consequence of E1A12S-binding to p300/CBP results in the 
transcriptional repression of cellular genes (Frisch and Mymryk 2002). Work 
carried out in our laboratory determined E1A-dependent sensitisation to 
mitoxantrone and docetaxel was highly dependent on binding to p300/CBP as a 
non-replicating AdE1A12S mutant defective for p300/CBP binding in the CR1 
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region failed to sensitise PCa cells to these drugs irrespective of functional p53 
status (Miranda, Maya Pineda et al. 2012). In this thesis I have shown that 
AdE1A12S has a preference of inducing cell death or sensitisation to drugs in a 
p53-deficient background. However as discussed above, the absence of 
functional p14ARF in HCT116 cells may have weakened AdE1A12S-mediated 
cytotoxic effects in the p53-expressing cell line and as a consequence the 
potency of AdE1A12S alone and in combination with drugs are similar to 
Ad5Hey1.  
 
I did not characterise the specific mechanisms by which AdE1A12S functioned 
independently of p53 in HCT116p53-/- cells. A number of studies have shown 
that E1A mediates proapoptotic and sensitising mechanisms through 
downregulation of proteins involved in growth and survival and could provide an 
explanation for our observations. As discussed earlier, E1A has been shown to 
inhibit transactivation of the EGFR promoter. Epithelial tumour cells frequently 
overexpress receptors for the EGF family including HCT116 and DU145 cells 
(Zheng, Ren et al. 2009; van Houdt, Hoogwater et al. 2010). In p53-mutant 
breast cancer cells overexpressing HER2/neu, E1A and paclitaxel demonstrated 
synergistic cell killing through E1A-mediated downregulation of HER2/neu 
expression (Ueno, Yu et al. 1997). E1A also sensitises cells to death receptor-
mediated apoptosis. Upon activation of receptors of the TNF superfamily (e.g. 
Fas receptor; FasR) by they cognate ligand (Fas Ligand; FasL), the adaptor 
protein, FADD is recruited to intracellular portion of FasR, which in turn 
associates with monomeric procaspase-8 forming the death-inducing complex 
(DISC). When c-FLIP levels are high after, for example, TNF receptor 1 
activation, procaspase-8 recruits c-FLIP to form caspase-8-c-FLIP heterodimers 
limiting autocatalytic caspase-8 activation (Elmore 2007). Sensitisation by E1A 
targets c-FLIP expression by preventing c-FLIP transcription and also promoting 
ubiquitination and degradation of c-FLIP proteins (Perez and White 2003). This 
also occurs in unstimulated cells; E1A-mediated inhibition of c-FLIP is sufficient 
to result in homodimer formation of procaspase-8 resulting in cleavage and 
autocatalytic activation of caspase-8. Consequently, downstream executioner 
caspases are cleaved and activated. Caspase-8 also cleaves Bid to generate 
tBid resulting in oligomerisation of Bak and Bax and subsequent mitochondrial 
membrane permeabilisation. Thus Bid integrates the extrinsic and intrinsic 
apoptotic signalling (Elmore 2007). Although not shown in conjunction with 
cytotoxic agents, E1A also upregulates TAp73 resulting in expression of the 
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p53/p73 targets, and induction of cell death (Flinterman, Guelen et al. 2005; 
Klanrit, Flinterman et al. 2008). 
 
4.4.1.  Ad5Hey1-mediated targeting of 
STAT3 in DU145 cells  
 
The potent cell killing by Ad5Hey1 in HCT116p53-/- cells devoid of AR or p53 
was in accordance with our observations of Ad5Hey1-mediated cytotoxicity in 
DU145 cells. Besides crosstalk between Notch and the AR and p53 pathways, 
Notch signalling also regulates the JAK/STAT pathway. Stimulation of Notch 
signalling using either an active form of Notch, Hes1 or Hes5 activated STAT3 
signalling in neuroepithelial cells and the addition of EGF resulted in synergistic 
activation (Kamakura, Oishi et al. 2004). Activation of STAT3 occurred through 
direct binding of the bHLH and Orange domain of Hes1 to STAT3, inducing 
phosphorylation and activation of STAT3 by recruitment of JAK2 (Kamakura, 
Oishi et al. 2004). Data from this study suggested Hes proteins might function 
as scaffold protein that permits JAK2 to phosphorylate STAT3. Although the 
authors of this study did not demonstrate direct binding of Hey1 with STAT3, 
Hey1 induced STAT3 phosphorylation and STAT3 transcriptional activity in a 
COS-1 in vitro system (Kamakura, Oishi et al. 2004). I therefore investigated 
whether Hey1 could regulate constitutively active STAT3 in DU145 cells  
 
The detection of active STAT3 in PCa specimens but not in adjacent tissue has 
implicated constitutively active STAT3 in contributing to the progression of PCa 
(Ni, Lou et al. 2000; Barton, Murphy et al. 2001; Barton, Karras et al. 2004). 
STAT3 is typically activated by an array of ligands including interleukins such as 
IL-6 through cytokine receptors, growth factor activation of receptor tyrosine 
kinases (e.g. EGFR) and non-receptor tyrosine kinases (e.g. Src). Upon ligand 
binding of the receptor, associated JAK kinases mediate tyrosine 
phosphorylation at the membrane-distal part of the receptor thereby recruiting 
STAT3. JAK kinases phosphorylate STAT3 at Y705 facilitating 
homodimerization and translocation to the nucleus. STAT3 is also serine 
phosphorylated and acetylated with additional modifications in the nucleus, 
which regulate its activity (Mohr, Chatain et al. 2012). Constitutive activation of 
STAT3 in DU145 cells is as a consequence of autocrine IL-6 signalling due to 
expression of IL-6 receptors and secretion of IL-6 (Okamoto, Lee et al. 1997). 
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STAT3 activation in DU145 cells drives expression of antiapoptotic genes 
including Bcl-2, Bcl-xL and Mcl-1 contributing to the survival and proliferation of 
these cells and to a chemotherapy resistant phenotype (Gurumurthy, 
Vasudevan et al. 2001; Hu, Lee et al. 2008). Inhibition of STAT3 activity was 
correlated with decrease viability and apoptosis in PCa cell lines making STAT3 
a promising target for PCa therapy (Barton, Karras et al. 2004; Gao, Zhang et al. 
2005; Shodeinde and Barton 2012). 
 
At 48h post-infection I observed dose-dependent decrease in levels of phospho-
STAT3 in response to Ad5Hey1 and AdE1A12S. The decrease was 
accompanied by a reduction in the STAT3 gene target, cyclin D1. From these 
results I inferred that Ad5Hey1 could be repressing STAT3 activity thereby 
reducing the expression of target genes such as cyclin D1. I hypothesise this 
could occur through one or more of the following mechanisms: Firstly, Hey1 may 
function as a corepressor of STAT3 activity and inhibit target gene transcription. 
Secondly, Hey1 could be targeting STAT3 for proteosomal degradation. Thirdly, 
Hey1 could be preventing STAT3 phosphorylation thereby preventing 
transcriptional activity with subsequent downregulation of STAT3-inducible gene 
expression. With regards to E1A-mediated regulation of total and phospho-
STAT3 levels, early studies demonstrated E1A binding to p300 inhibited STAT3 
transcriptional activity and prevented p300-mediated activation of STAT3 
(Takeda, Nakajima et al. 1994; Paulson, Pisharody et al. 1999). The 
transcriptional activation of STAT3 relies on interaction with coactivator, 
p300/CBP (Wang, Cherukuri et al. 2005). Therefore, E1A-mediated 
transcriptional repression of STAT3 may account for the decrease in cyclin D1 
and phospho-STAT3 levels. E1A can also directly interact with the C-terminal 
transactivation domain of STAT1 (Look, Roswit et al. 1998; Chatterjee-Kishore, 
van Den Akker et al. 2000). Although binding of E1A to STAT3 as yet has not 
been shown, E1A-mediated inhibition by this mechanism might result in 
decreased STAT3 activity and reduced target gene expression.  
 
Combining Ad5Hey1 with the small molecule inhibitors, AG490 and AZD1480 in 
DU145 cells delivered contrasting results. AG490 was able to sensitise cells to 
Ad5Hey1 and AdE1A12S resulting in significant decreases in the viral EC50 
values. This was interesting from a therapeutic point of view however due to the 
less specific nature of AG490 it was likely Ad5Hey1 and AG490 were inhibiting 
distinct signalling pathways, converging to enhance cell killing. AG490, as well 
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as inhibiting JAK2 kinase activity also inhibits EGFR and HER2/neu. It is 
therefore probable that by inhibiting EGF receptors, AG490 is impeding 
signalling of other pathways such as the MAPK and AKT/PI3K pathways, which 
are downstream of EGF signalling (Zheng, Ren et al. 2009; Kumar, Srinivasan 
et al. 2010). 
 
On the other hand, in the presence of the JAK1/2 kinase inhibitor, AZD1480, no 
sensitisation was observed. Ad5Hey1 and AdE1A12S EC50 values increased 
slightly in the presence of AZD1480. In Ad5Hey1-infected cells, phospho-STAT3 
levels were higher than for drug alone when in combination with the low drug 
dose but were comparable to drug alone at the higher drug dose. Interestingly, 
phospho-STAT3 levels when AdE1A12S was combined with the higher dose of 
drug increased and were similar to untreated cells. A possible reason for this 
might be that Hey1 and E1A in the presence of AZD1480 could be attenuating 
the transcription and degradation of STAT3 and the observed phospho-STAT3 
is not as a result of new phosphorylation but rather, previously formed phospho-
STAT3. Further investigations are therefore required to clarify the role of Hey1 in 
mediating STAT3 signalling.  
 
The precise mechanism as to how Hey1 might act to inhibit the JAK/STAT3 
pathway is still to be determined and putative mechanisms are illustrated in 
Figure 65. Approaches other than using small molecule inhibitors to block 
STAT3 activity include using oligonucleotides, dominant-negative expression 
vectors and siRNA against STAT3, which may provide a more specific approach 
to determine whether Hey1 targets STAT3. Dependent on these results, this 
study could be extended to assess whether Hey1, as a transcriptional 
corepressor, represses STAT3 activity. SRC1 has been demonstrated to 
function as a coactivator of STAT3 together with p300/CBP and co-
immunoprecipitated with STAT3 following IL-6 stimulation in hepatoma cells 
(Giraud, Bienvenu et al. 2002). As Hey1 binds to SRC1, it is possible that it is 
functioning as a corepressor and inhibiting activation of STAT3. Furthermore, 
the conserved bHLH and Orange domain might interact with STAT3 providing 
an additional structural link between these transcription factors. Intriguingly, 
Hey1 was found to attenuate the cooperative action of Notch and Toll-like 
receptor-mediated induction of IL-6 in macrophages thus functioning as a 
feedback inhibitor and repressor of Notch-induced gene activation (Hu, Chung 
et al. 2008). Suppression of IL-6 expression by Hey1 was mapped to the E-box 
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binding site within the IL-6 promoter (Hu, Chung et al. 2008). This may provide 
an indirect mechanism by which Ad5Hey1 reduces STAT3 activity.  
 
Ad5Hey1- and AdE1A12S-mediated reduction in STAT3 activity may reflect a 
possible mechanism, in part, by which these viruses synergise with docetaxel 
and mitoxantrone in DU145 cells. As PC3 cells do not express STAT3, this 
could therefore provide an explanation as to why Ad5Hey1 cannot kill or 
sensitise these cells to cytotoxic drugs and could be explored in future studies. 
 
 
Figure 65. Schematic diagram illustrating the possible mechanisms through which Hey1 
might downregulate constitutively active STAT3 in DU145 cells.  
A) STAT3 activation is initiated by binding of ligand (IL-6) to gp-130/IL-6R with subsequent 
dimerization of the receptor and activation of associated JAK kinases. Activated JAK kinases 
phosphorylate the cytoplasmic region of the receptor and recruit STAT3. Hey1 may bind to STAT3 
via the bHLH and orange domain in a similar fashion to Hes1 (Kamakura, Oishi et al. 2004) and 
prevent JAK kinase-mediated phosphorylation of STAT3 at Y705 thus preventing dimerization of 
STAT3, translocation to the nucleus and transactivation of STAT3 target genes. B) Alternatively, 
Hey1 may behave as corepressor to STAT3 by direct interaction with STAT3 and/or binding to 
SRC1, a coactivator to STAT3-mediated transactivation (Giraud, Bienvenu et al. 2002) thus 
preventing coactivator recruitment to STAT3 transcription complexes. C) Hey1 may directly bind to 
an E-box binding site within the proximal promoter of IL-6 and inhibit E box-RBP-J-mediated 
transcription (Hu, Cheng et al. 2008) thus inhibiting transcription of IL-6 and blocking autocrine 
stimulation of growth by IL-6 in DU145 cells. Therefore indirect regulation of the JAK/STAT 
pathway will also culminate in the decrease of STAT3 activity.  
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4.4.2.  Ad5Hey1 and AdE1A12S synergise 
with docetaxel and mitoxantrone in PCa 
cells 
 
Using a fixed dose combination approach, sub-optimal dose of either docetaxel 
or mitoxantrone resulted in synergistic cell killing in combination with Ad5Hey1 
in 22Rv1 and DU145 cells. As described previously, AdE1A12S also resulted in 
synergistic cell death with both drugs in DU145 cells (Miranda, Maya Pineda et 
al. 2012). However, although Ad5Hey1 and AdE1A12S were shown previously 
to sensitise LNCaP cells to docetaxel- and mitoxantrone-induced cell death 
(Cheong et al, manuscript in preparation), no synergy was observed at the 
selected doses for either virus in LNCaP cells. I speculated whether this was as 
a consequence of drug-induced increases in mitochondrial activity since the 
MTS viability assay was previously shown to underestimate the antiproliferative 
effect of the green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG) in 
LNCaP cells compared with adenosine triphosphate (ATP), DNA or trypan-blue 
based assays (Wang, Henning et al. 2010). Furthermore treatment of LNCaP 
cells with bicalutamide maintained mitochondrial dehydrogenase activity and did 
not result in Δψm depolarisation unless in serum-free medium suggesting trophic 
factors attenuate the process of bicalutamide-dependent Δψm dissipation (Lee, 
Zhan et al. 2003). It is possible that the previous sensitisation experiments 
involving a fixed dose of Ad5Hey1 combined with a dose response to drugs 
overcame the limitation of the MTS assay. Interestingly when LNCaP cells were 
treated with either cytotoxic drug, Δψm hyperpolarisation was detected. In a 
previous study, Δψm hyperpolarisation was associated with an increase 
mitochondrial biomass (McGowan, Alling et al. 2011). The majority of literature 
report cytotoxic drug treatment results in Δψm depolarisation. However, drug-
induced proliferation of mitochondria has also been cited sporadically in a 
number of studies including the rat mammary adenocarcinoma cell line (MTLn3) 
treated with doxorubicin or mitoxantrone (Kluza, Marchetti et al. 2004) 
confirming a link between apoptosis and changes in the structure and mass of 
mitochondria. However, despite measuring cell viability with picogreen or 
sulforhodamine B similar trends in combination treatments were observed in 
LNCaP cells. Further assessment is therefore necessary to assess whether 
Ad5Hey1 is able to synergise with these drugs at other selected fixed dose-
combinations. As well as testing various dose combinations, the order of the 
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addition of each agent should also be assessed. Previously in our laboratory, 
additional dose combinations of replicating Ad5 and docetaxel or mitoxantrone 
were found to be synergistic in LNCaP cells when the drugs were added 24h 
before the addition of the virus (Radhakrishnan, Miranda et al. 2010) suggesting 
p53 induction by cytotoxic drug treatment in certain cell lines may sensitise cells 
to Ad5-induced cell death.  
 
The therapeutic efficacy of mitoxantrone is primarily through intercalation of 
DNA and as an inhibitor of topoisomerase IIA, preventing religation of cleaved 
DNA and causing double-stranded DNA breaks. Docetaxel binds to β-tubulin 
monomers resulting in microtubule stabilisation, impairing mitosis and driving 
the cell into mitotic catastrophe, an irreversible state that leads to cell death 
commonly through apoptosis. Both drugs induce changes in cell cycle 
progression, induction of oxidative stress and DNA damage, which finally leads 
to apoptosis. The exact nature of drug-induced deregulation of the cell cycle 
depends on genetic alterations of the tumour cell and drug dosage resulting in 
either G1 or G2/M arrest. Using similar doses to those used in this thesis, 
colleagues in our research group have observed that treatment with 
mitoxantrone or docetaxel result in an accumulation of cells in G2/M for DU145 
and 22Rv1 cells (Radhakrishnan, Miranda et al. 2010; Miranda, Maya Pineda et 
al. 2012). E1A-dependent increases in p53 activity and p53-independent 
mechanisms are likely to contribute to synergistic cell killing with cytotoxic drugs. 
However E1A-dependent effects on cell cycle checkpoints also play a role. 
Interactions of E1A with p300 and p400 and inactivation of p21 as discussed in 
section 1.6.3.3.1 and earlier in this chapter promotes cell cycling. Enhanced S 
phase activity may therefore intensify apoptosis by promoting DNA damage 
during DNA synthesis in the presence of drugs. A dose-dependent increase in S 
phase was observed after infection of AdE1A12S in 22Rv1 and DU145 cells 
indicating E1A12S enhances cell cycle progression. Previously, AdE1A12S was 
found to increase mitoxantrone-induced accumulation of cells in G2/M in 22Rv1, 
DU145 and PC3 cells with enhanced polyploidy in combination treatments in 
DU145 cells (Miranda, Maya Pineda et al. 2012).  
 
No obvious increase in S phase was observed after Ad5Hey1 infection as a 
single treatment for either cell line. However, studies have implicated the 
importance of G2/M checkpoint abrogation or arrest in enhancing the effect of 
DNA damaging drugs (Bucher and Britten 2008). Therefore, the putative delay 
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in G2 after infection with Ad5Hey1 might contribute to the sensitisation to 
chemotherapeutic drugs. Cyclin B1 expression in PCa cell lines has been 
correlated to their responsiveness to treatment with docetaxel (Gomez, de Las 
Pozas et al. 2007). Future experiments might clarify whether Ad5Hey1 delays 
drug-treated cells in G2/M and to what extent the Ad5Hey1-mediated G2 delay 
contributes to this. LNCaP cells expressing high levels of cyclin B1 were more 
sensitive to apoptosis after treatment with docetaxel compared with DU145 and 
PC3 cells, which express comparatively low levels of cyclin B1. Cell death was 
reduced after cyclin B1 knockdown or inhibition of Cdk1 activity (Gomez, de Las 
Pozas et al. 2007). As a function of doxetaxel-induced G2/M arrest and 
subsequent mitotic catastrophe-mediated cell death, docetaxel increases cyclin 
B1 expression and associated Cdk1 activity in PCa cells (Perez-Stable 2006). 
Consequently, the Ad5Hey1-induced increase in cyclin B1 expression in 22Rv1 
cells sensitise cells to treatment with docetaxel. Furthermore overexpression of 
E2F1 has been correlated with an increase in cyclin B1 and Cdk1 activity 
resulting in sensitisation to paclitaxel (Russo, Magro et al. 2006). At present this 
correlates with our knowledge of E1A-dependent release of E2F1 from pRb and 
suggests AdE1A12S increased cyclin B1 levels as a consequence of E2F1 
regulation. Considering that Hey1 might also increase E2F1 stabilisation this 
could explain Ad5Hey1-mediated increase in cyclin B1 expression. For future 
studies it will be important to determine how the putative Ad5Hey1-dependent 
G2 delay contributes to cell cycle deregulation when combined with docetaxel 
and mitoxantrone and the involvement of Ad5Hey1 in DDR pathway. 
 
Recent studies have reported docetaxel and paclitaxel inhibit AR expression 
and activity in 22Rv1 and LNCaP cells (Gan, Chen et al. 2009; Kuroda, Liu et al. 
2009). The mechanism of reduced AR activity by paclitaxel was attributed to a 
reduction in AR nuclear translocation possibly as a result of AR binding to 
tubulin (Zhu, Horbinski et al. 2010). Reduction of AR signalling in docetaxel-
treated cells therefore provides an additional targeting mechanism that may be 
complemented with Ad5Hey1-dependent mechanisms.  
 
It has been reported by members of our laboratory that E1A expressed from 
AdE1A12S increased in the presence of mitoxantrone in DU145 cells (Dr 
Enrique Miranda, PhD Thesis, 2009). This could be a function of enhanced 
transcription of E1A12S from the CMV promoter. I did not assess Hey1 
expression after combination treatment however in support of a drug-induced 
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effect on CMV transcription it was recently shown that doxorubicin-induced 
response to cellular stress and DNA damage results in activation of NFκB which 
in turn binds and transactivates the CMV promoter and enhances transgene 
expression (Kim, Kang et al. 2007). This was also found in the context of 
adenovirus-mediated gene delivery after treatment with cisplatin-enhanced 
expression from the CMV promoter as a consequence of persistent DNA 
damage (Zacal, Francis et al. 2005). Increased transcriptional activation of the 
CMV promoter has also been associated with docetaxel. In combination with a 
prostrate-restricted oncolytic virus, docetaxel increased CMV activity and 
enhanced transgene expression. This was associated with increased p38 MAPK 
activity and was independent to adenovirus-binding receptors and replication (Li, 
Liu et al. 2010).  
 
Currently, our intention is to insert Hey1 into the potent, replication-selective 
AdΔΔ viral vector. In this context Hey1 will be under the control of the viral E3 
promoter to ensure early transgene expression independent of viral late gene 
expression and replication. In addition, it is now recognised that CMV promoters 
are less suitable in vivo because of time-limited transcriptional activity through 
cytokine-mediated repression of the promoter resulting in reduced transgene 
expression (Qin, Ding et al. 1997). Previously we have shown that cytotoxic 
agents including docetaxel and mitoxantrone enhance E1A expressed from the 
native viral promoter, which together with increased infection and replication 
rates contributed to synergistic cell killing in a cell line and drug-dependent 
manner (Cheong, Wang et al. 2008; Radhakrishnan, Miranda et al. 2010). 
Furthermore, when the drugs enhance E1A-expression, the activity of the E3 
promoter would also increase since transcription is partly dependent on E1A in 
addition to cellular factors such as NFκB. It will be interesting to realize the 
extent of Hey1 expression in the context of a replication-selective virus 
(AdΔΔHey1).  
  
4.4.3.  Ad5Hey1 primarily enhances drug-
induced apoptosis in PCa cells 
 
In 22Rv1, DU145 and LNCaP cells, Ad5Hey1 augmented docetaxel-induced 
apoptosis. In combination with mitoxantrone, Ad5Hey1 enhanced drug-induced 
apoptosis in 22Rv1 and LNCaP cells but not in DU145 cells. Apoptosis was 
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characterised by greater Δψm depolarisation and increased activation of 
caspase-3 and caspase-7. In DU145 cells, Ad5Hey1 in combination with 
mitoxantrone resulted in a reduction in the levels of these apoptotic markers 
compared with mitoxantrone alone. In all cell lines AdE1A12S enhanced 
docetaxel and mitoxantrone-induced apoptosis. This is in accordance with a 
previous study showing AdE1A12S enhanced mitoxantrone-induced Δψm 
depolarisation in DU145 cells (Miranda, Maya Pineda et al. 2012). In addition, 
AdE1A12S enhanced mitoxantrone-induced apoptosis through the mitochondrial 
pathway in 22Rv1 cells as well which was previously believed not to be involved 
in AdE1A12S-mediated sensitisation (Miranda, Maya Pineda et al. 2012). This 
disparity is a result of differences in drug dose and concentration of TMRE used 
to measure Δψm.  
 
Resistance to apoptosis occurs when a variety of blocks on the apoptotic 
pathways are imposed. Proteins involved in the regulation of apoptosis such as 
Bcl-2, Bax and p53 are differentially expressed in the cell lines used in this 
research (Gurumurthy, Vasudevan et al. 2001; Skjoth and Issinger 2006). This 
affects their propensity to undergo cell death, the mechanism of which is 
influenced by the mutational background of the cells as well as the cytotoxic 
agent and dose used. Therefore, the induction of apoptosis in DU145 cells is 
independent of p53 status, while 22Rv1 and LNCaP cells, which express 
functional p53, probably require p53 activation to undergo efficient cell death. 
This seems the case with regards to Ad5Hey1 and AdE1A12S-mediated cell 
death in 22Rv1 cells since cell death was reduced after ablation of p53. 22Rv1 
overexpress the p53-antagonist, Bcl-2 (Skjoth and Issinger 2006), however, this 
did not impact on their capacity to undergo apoptosis in response to the viruses 
and/or drugs. In general, apoptosis was induced to a greater extent in these 
cells compared with DU145 and LNCaP cells. With regards to virus-induced cell 
death in 22Rv1 cells, their enhanced permissiveness to adenoviral infection is 
likely to have contributed to this. Both drugs induced apoptosis to a similar 
degree in these cells. Furthermore, Ad5Hey1 infection induced greater Δψm 
depolarisation and caspase-3 activation compared with an equivalent dose of 
AdE1A12S. This is not unexpected as it is in line with our observations that 
Ad5Hey1 induced p53 stabilisation to a greater extent than AdE1A12S. This 
also suggests that the degree of apoptosis in these cells is dependent on p53 
activity. The capacity of 22Rv1 cells to readily undergo Δψm depolarisation may 
be as a consequence of a more functional mitochondrial pathway compared with 
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DU145 and LNCaP cells. p53 activity is known to enhance the propapoptotic 
activity of Bax either by promoting its expression, repressing transcription of Bcl-
2 or Bcl-xL expression or through direct binding of Bcl-2 or Bcl-xL at the outer 
mitochondrial membrane. Although not assessed, p53 also transactivates BH3-
only proapoptotic Bcl-2 family members (e.g. Bid, Puma and Noxa), which 
mediate mitochondrial membrane permeabilisation (Kroemer, Galluzzi et al. 
2007). In addition to the increase in Bax expression after single virus or drug 
treatment, enhanced expression of a small form of Bax was detected after 
combination treatments. Proteolytic cleavage of Bax in response to 
chemotherapeutic agents was previously demonstrated (Yeo, Cha et al. 2002). 
In another study, Bax cleavage by calpain yielded a p18 Bax product that was 
more potent in inducing apoptosis compared with full-length Bax. It was 
proposed that cleavage of Bax might enhance oligomerization in the outer 
mitochondrial membrane thus serving as an amplification step to accelerate 
apoptosis (Cao, Deng et al. 2003). I did not verify whether this could be the case 
in my study. Cell fractionation would clarify whether the product was associated 
with the mitochondria and hence be putatively correlated with mitochondrial 
pathway. AdE1A12S-dependent enhancement of drug-induced cell death and 
sensitisation was similar to that induced by Ad5Hey1 suggesting the transgenes 
activate similar pathways.  
 
Interestingly, in LNCaP and DU145 cells, I observed Δψm hyperpolarisation in 
response to docetaxel and mitoxantrone. Recently, tubulin stabilisation by 
paclitaxel was found to promote hyperpolarisation whereas tubulin-
depolymerizing agent, nocodazole stimulated depolarisation in tumour cells 
(Maldonado, Patnaik et al. 2010). Tubulin is known to reversibly bind to voltage-
dependent anion channel (VDAC), an abundant protein residing in the outer 
mitochondrial membrane. In the tubulin-blocked state, VDAC is impermeable to 
ATP/ADP and as a consequence the function of the ATP synthase is inhibited 
resulting in the accumulation of H+ in the intermembrane mitochondrial space 
promoting Δψm hyperpolarisation (Rostovtseva, Sheldon et al. 2008). Therefore 
agents that modify the equilibrium between polymerised and dimeric tubulin alter 
Δψm potential. Both docetaxel and mitoxantrone have an affinity for tubulin (Ho, 
Law et al. 1991; Ringel and Horwitz 1991), and in these cells, drug-induced 
alterations to the microtubule dynamics may account for the Δψm 
hyperpolarisation. No Δψm hyperpolarisation was observed in 22Rv1 cells. The 
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drug-induced effect on Δψm may be a consequence of mitochondrial dysfunction 
and it is possible 22Rv1 cells have a more intact mitochondrial pathway.  
 
DU145 cells do not express Bax and this has been correlated with their 
resistance to staurosporine-induced cell death and delayed caspases activation 
and PARP cleavage (Marcelli, Marani et al. 2000; Gurumurthy, Vasudevan et al. 
2001). In these cells, mitoxantrone was more efficient at inducing apoptosis 
through Δψm depolarisation and caspase-3 and -7 activation than docetaxel and 
this might reflect the different mechanisms by which these drugs induce cell 
death. Microtubule stabilisation induced by docetaxel triggers apoptosis through 
mitotic catastrophe, with the deregulation of tubulin dynamics impacting on 
mitochondrial function through the phosphorylation and inhibition of Bcl-2 
(Fabbri, Amadori et al. 2008). Mitotic catastrophe has been linked to the 
activation of caspase-2 and in DU145 cells active caspase-2 was detected in 
response to docetaxel treatment (Fabbri, Amadori et al. 2008). In a separate 
study, reduction of cell viability by docetaxel was only partially abrogated with a 
pan caspase inhibitor suggesting docetaxel induces cell death through caspase-
independent pathways (Mediavilla-Varela, Pacheco et al. 2009).  
 
In DU145 cells, neither Ad5Hey1 nor AdE1A12S induced obvious changes to 
Δψm depolarisation or caspase-3 activation suggesting that the cytotoxicity 
induced solely by transgene expression occurred through alternative cell death 
pathways. However, expression levels of active caspase-7 were similar for virus 
infected cells compared to cells treated with docetaxel suggesting a preference 
for caspase-7 activation in response to Hey1 or E1A12S expression as opposed 
to caspase-3 activation. This is in keeping with Walsh et al. who determined the 
activities of these caspases engage in non-redundant roles during apoptosis 
(Walsh, Cullen et al. 2008). Activation of caspase-7 may not entirely account for 
the cell death by the viruses and other modes of cell death may be occurring. 
Necrosis (or necroptosis) is a possibility. Marcelli et al. also observed 
morphological characteristics reflecting necrosis after DU145 cells were treated 
with stauroporine (Marcelli, Marani et al. 2000). 
 
Whereas Ad5Hey1 increased caspase-dependent cell death in combination with 
docetaxel in DU145 cells, in combination with mitoxantrone, Ad5Hey1 reduced 
levels of all apoptotic markers including PARP cleavage. However as the PARP 
antibody recognised only the 89kDa cleaved form, which is associated with 
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apoptotic cell death and cathepsin B and D cleavage (Chaitanya, Steven et al. 
2010), it is not surprising that PARP cleavage reproduced the caspase-
dependent trends detected for this combination treatment. Future studies are 
required to determine the alternative pathways of cell death that might account 
for the synergistic cell killing with this Ad5Hey1 drug combination. Alternative 
cell death mechanisms under consideration for future examination are 
necroptosis and autophagy. 
 
Although LNCaP cells express wild-type p53, they also possess a deregulated 
PI3K/AKT pathway due to a loss of PTEN expression (Gurumurthy, Vasudevan 
et al. 2001; Skjoth and Issinger 2006). Activation of AKT prevents apoptosis by 
phosphorylating and inhibiting proapoptotic factors Bad, pro-caspase-9 and 
preventing the expression of Bim (Dijkers, Medema et al. 2000; Gurumurthy, 
Vasudevan et al. 2001). It also prevents release of cytochrome C thereby 
preventing the initiation of the caspase cascade (Kennedy, Kandel et al. 1999). 
Therefore AKT inhibits apoptosis by maintaining mitochondrial integrity. 
Docetaxel and mitoxantrone had contrasting effects on Δψm depolarisation in 
these cells. Docetaxel efficiently induced dissipation of Δψm while mitoxantrone 
had no effect. Similarly, Ad5Hey1 and AdE1A12S had no effect on Δψm. 
Treatment with mitoxantrone or either virus did however induce activation of 
caspase-3 without Δψm depolarisation suggesting activation of caspase-3 by the 
extrinsic pathway. Mitoxantrone and other anthracycline-based agents were 
found to upregulate expression of FasL in LNCaP cells (Liu, Rubin et al. 1998) 
indicating the cell death receptor pathway may be activated in response to 
mitoxantrone treatment which enhances the susceptibility of cells to apoptosis in 
these cells. The presence of Ad5Hey1 sensitised mitoxantrone-treated cells to 
enhanced cell death through the mitochondrial pathway. This may be a 
consequence of p53 activation, which as discussed above results in expression 
of proapoptotic mitochondrial-associated proteins and inhibition of Bcl-2. This 
could therefore “prime” the mitochondria for Δψm depolarisation through the 
cleavage of Bid by FasR/FasL-mediated activation of procaspase-8. Therefore 
Ad5Hey1 was able to trigger apoptosis via the mitochondrial pathway in the 
presence of mitoxantrone which at the dose used, primarily functioned as a 
cytostatic agent in these cells. Deregulation of E2F activity by E1A is directly 
coupled to the components of the apoptotic pathway (Nahle, Polakoff et al. 
2002). Caspase expression is a direct target of E2F, potentially increasing levels 
over that of inhibitor of apoptosis (IAP) proteins to trigger caspase activation. 
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Alternatively. E1A-induced E2F expression could also increase caspase-8 
expression and sensitise cells to death-inducing ligands. Thus E1A has an 
additional method of cooperating with p53-dependent apoptosis to amplify 
apoptosis (Nahle, Polakoff et al. 2002).  
 
It is evident that the various genetic alterations of the various PCa cell lines 
resulted in differential outcomes in the specific apoptotic mechanism triggered 
by Ad5Hey1 and drug treatments. I have demonstrated that Ad5Hey1 in 
combination with either drug results in supra-additive cell death in all of the PCa 
cell lines, which were receptive to Ad5Hey1. Ad5Hey1 enhanced apoptosis 
produced by sub-optimal doses of the drug with the exception of mitoxantrone in 
DU145 cells where alternative cell death mechanism are presumed to occur as 
a consequence of this combination treatment. The studies in this thesis 
therefore demonstrate the potential for Hey1 as a therapeutic transgene in 
future adenoviral gene therapy studies. 
  
4.5. Ad5Hey1 is efficacious in a 
translational setting 
 
The majority of CRPC tumours, despite castrate serum levels of testosterone, 
are still subject to low-level androgen stimulation by conversion of adrenal 
androgens to testosterone or through intraprostatic de novo androgen synthesis. 
CRPC tumours may overexpress AR or harbour mutant AR with these 
alterations modifying the response of the cancer cells to ADT therapy. It was 
therefore important to assess the potency of Ad5Hey1 during androgen 
stimulation and in the presence of bicalutamide to further validate Hey1 for the 
treatment of PCa.  
 
Ad5Hey1 decreased cell growth of androgen-responsive LNCaP and VCaP cells 
when AR signalling was stimulated with mibolerone. In LNCaP cells, growth was 
inhibited to below basal levels. This result is in agreement with another study, 
which showed HeyL inhibited growth of androgen-stimulated LNCaP cells 
stably, expressing inducible HeyL (Lavery, Villaronga et al. 2011). Ad5Hey1 only 
partially inhibited androgen-stimulated growth in VCaP cells. VCaP cells contain 
an amplified wild-type AR gene locus, which may explain the enhanced 
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androgen-stimulated growth compared with LNCaP cells. Therefore it is not 
unexpected that a more limited growth inhibition by Ad5Hey1 is observed. 
 
Intriguingly, mibolerone sensitised 22Rv1 cells to Ad5Hey1-dependent growth 
inhibition. 22Rv1 cells differ from the other AR-positive cell lines by expressing 
androgen-independent AR isoforms. It is attractive to hypothesise that the 
androgen-independent isoforms in 22Rv1 cells may have additional roles other 
than androgen-independent transcriptional activity. For example in the LNCaP 
104-R1 cells, non-genomic activity of AR has been implicated in promoting AR-
mediated translocation of ectopically expressed Bax to the mitochondria of 104-
R1 cells (Lin, Kokontis et al. 2006). This effect was potentiated with androgen 
stimulation while bicalutamide blocked the androgen-specific sensitising effect 
indicating the transcriptional activity of AR only enhanced the AR-dependent 
effect on Bax and apoptosis (Lin, Kokontis et al. 2006). In addition, ligand-
independent functions related to the apoptotic pathway have been associated 
with an orphan member of the steroid-thyroid hormone nuclear receptor, 
Nur77/TR3 which binds Bcl-2 and converts its antiapoptotic role to one of 
proapoptotic, possibly through the activation of Bax (Kroemer, Galluzzi et al. 
2007). In a recent study, induction of mitochondrial fission by Ca2+ efflux 
inhibition in LNCaP cells was further enhanced by pre-treatment with androgen. 
This was found to be related to the action of the androgen-regulated, dynamin-
related protein, Drp1, which is involved in mitochondrial fission (Choudhary, 
Kaddour-Djebbar et al. 2011). It is therefore conceivable that mibolerone-
activation of the AR and/or AR isoforms in 22Rv1 cells could enhance this 
Ad5Hey1-mediated effects on mitochondrial dysfunction. As the growth 
stimulatory effects of androgens on LNCaP and VCaP cells are more profound, 
potential proapoptotic effects by androgens/AR will be offset by cell growth. 
 
The effectiveness of bicalutamide as an antiandrogen is dependent on AR 
mutation status and copy number. Bicalutamide is converted to a partial agonist 
when AR is overexpressed leading to alteration in coactivator and corepressor 
recruitment to the AR transcriptional complex at target genes (Chen, Welsbie et 
al. 2004). In LNCaP cells overexpressing AR, recruitment of NCoR to the 
promoters of AR target genes, PSA of KLK2 was reduced or absent respectively 
after bicalutamide treatment (Chen, Welsbie et al. 2004). This may explain the 
ineffectiveness of bicalutamide on basal and androgen-stimulated growth in 
VCaP cells. On the other hand in LNCaP cells, bicalutamide functioned as a 
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potent AR antagonist. Nevertheless, in VCaP and LNCaP cells, combination of 
Ad5Hey1 and bicalutamide under mibolerone stimulation resulted in a beneficial 
effect over uninfected or Ad5GFP-infected cells. Furthermore bicalutamide 
further sensitised LNCaP cells to Ad5Hey1-mediated growth inhibition. 
Bicalutamide binds at the AR LBD whereas Ad5Hey1 targets the N-terminal AF-
1 domain. The separate binding site for these agents affords the potential of 
cooperation thereby enhancing Ad5Hey1-mediated inhibition of AR 
transcriptional activity. However it should be considered that N-terminal 
mutations within the AR could abrogate Hey1 binding thereby decreasing 
efficacy. Further studies will be required to assess the effect of Ad5Hey1 and 
bicalutamide on AR transcriptional activity at the doses used in this study in 
VCaP and LNCaP cells. Importantly, Ad5Hey1 was able to work in concert with 
bicalutamide in the presence of androgen stimulation and did not antagonise the 
effect of bicalutamide. These results indicate Ad5Hey1 is able to inhibit cell 
growth and furthermore might control for further tumour growth. 
 
An androgen-independent LNCaP progression model (Kokontis, Takakura et al. 
1994; Kokontis, Hay et al. 1998; Kokontis, Hsu et al. 2005), which reflects the 
clinical state of CRPC was employed to assess the potency of Ad5Hey1. It has 
been demonstrated using tumour xenograft models that 104-R1 and CDXR3 
sub-clones reflect an intermediary stage of CRPC. After being subjected to 
androgenic suppression, these cell clones relapsed as either androgen-
stimulated or androgen-independent models respectively. Therefore, CDXR3 
cells are thought to imitate a more advanced stage of disease progression than 
104-R1 cells (Kokontis, Takakura et al. 1994; Kokontis, Hsu et al. 2005; Chuu, 
Kokontis et al. 2011). It was encouraging to find that 104-R1 and CDXR3 cell 
were more susceptible to cell killing by Ad5Hey1 than the parental, 104-S cells. 
Preliminary data indicates the growth inhibitory effects by Ad5Hey1 in the 104-
R1 and particular, CDXR3 cells could be a consequence of an accumulation of 
cells in G1. It has been previously determined that CDXR3 xenograft tumours 
relapsed less frequently than 104-R1 tumours after testosterone treatment 
possibly due to the slower proliferation rate of CDXR3 cells and enhanced 
apoptosis induced in these cells compared with 104-R1 cells (Kokontis, Hay et 
al. 1998; Kokontis, Hsu et al. 2005; Chuu, Kokontis et al. 2011). This highlights 
the differences between 104-R1 and CDXR3 cells in terms of their outcome to 
androgen treatment, which may also translate to differential outcomes in 
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response to other treatments. These differences could account for why a greater 
accumulation of CDXR3 cells in G1 after Ad5Hey1 infection was observed.  
 
Androgenic suppression through the activity of the AR was shown by Kokontis 
and colleagues to induce a prolonged G1 arrest in 104-R1 cells (Kokontis, Hay 
et al. 1998). Although CDXR3 cells have not been similarly assessed with 
respect to complete cell cycle analysis, CDXR3 cells were similarly repressed by 
androgen in terms of proportion of cells in S phase and cell viability (Kokontis, 
Hsu et al. 2005). It was not possible to replicate the androgen-induced G1 arrest 
in 104-R1 and CDXR3 cells in this particular study possibly because of variation 
in cell culture conditions. Under our conditions, the population of cells in G1 in 
response to Ad5Hey1 was potentially overriding the suppressive effects of 
androgen in these cells. Furthermore, an increase in the sub-G1 fraction was 
observed for Ad5Hey1-infected 104-R1 and CDXR3 cells.  
 
In 104-R1 and CDXR3 cells the androgen-stimulated G1 cell cycle arrest was 
partly attributed to a sustained expression of p27 (Kokontis, Hay et al. 1998; 
Kokontis, Hsu et al. 2005) maintained through androgen-dependent 
downregulation of Skp2, a protein of the SCF ubiquitin ligase complex. 
Androgen exposure also downregulated c-Myc expression in 104-R1 cells 
contributing to G1 arrest (Kokontis, Takakura et al. 1994). Therefore, it is 
possible Ad5Hey1 is mediating an accumulation of cells in G1 through activation 
of p53 and subsequent p27 induction. I did not see any notable changes in the 
cell cycle profile of 104-S cells after Ad5Hey1 infection. Androgen treatment of 
104-S cells releases cells from an androgen deprivation-induced G1 arrest by 
upregulating Skp2 expression resulting in an increase in protesomal degradation 
of p27 and p21 (Kokontis, Takakura et al. 1994; Wang, Sun et al. 2008). 
Therefore, the androgen-regulated decrease in Cdk inhibitor expression may, to 
a certain extent, oppose the growth inhibitory effects of Ad5Hey1 which may be 
why I do not detect an accumulation of 104-S cells in G1. However, Ad5Hey1 
infection resulted in an increase in the the fraction of cells in sub-G1 indicating 
Ad5Hey1 was able to kill these cells. The sub-G1 fraction was further increased 
in the presence of mibolerone, demonstrating that under certain circumstances 
androgen stimulation sensitises cells to cytotoxic agents. These studies are 
ongoing and evaluation of Ad5Hey1 in the LNCaP progression model used in 
this thesis provides a valuable method of assessing the effect of Ad5Hey1 and 
in the future, AdΔΔHey1 in a treatment-resistant PCa model. 
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4.6. Concluding remarks 
 
The data in this thesis have demonstrated that overexpression of the Notch 
signalling effector protein, Hey1, inhibited growth and confirmed the tumour 
suppressor role of Hey1 in several PCa cell lines. The multiple modes of action 
for Ad5Hey1 are likely to have contributed to efficient cell death and highlights 
the numerous and potentially far-reaching actions of Hey1. In agreement with 
published results, Ad5Hey1 demonstrated crosstalk with AR, p53 and 
JAK/STAT signalling demonstrating the effectiveness of ectopically expressed 
Hey1 in a range of genetic backgrounds. Although not explored in this thesis, it 
is hypothesised Hey1-mediated inhibition of HDM2 may result in activation of 
p53-independent mechanisms of cell death through upregulation of E2F1 and 
TAp73. Combination treatments with chemotherapeutic drugs showed that 
Ad5Hey1 functioned as a sensitising agent and this upholds the rationale for use 
of Hey1 as a therapeutic transgene in adenoviral gene therapy. In addition, 
Ad5Hey1 and bicalutamide treatment of a range of AR-positive PCa cell lines, 
differing in their responsiveness to bicalutamide treatment, could work together 
to inhibit mibolerone-induced growth stimulation. Finally, preliminary data using 
Ad5Hey1 in an androgen-independent LNCaP progression model demonstrated 
promising findings for inhibiting cell growth. Together, this data reveals the 
potential use of a transcription cofactor as a therapeutic transgene for the 
treatment of CRPC. 
 
4.7. Future directions 
 
In light of the crosstalk between the AR and p53 signalling pathways it would be 
interesting to simultaneously knockdown AR and p53 in 22Rv1 cells to 
determine whether depletion of both proteins will ablate Ad5Hey1-mediated 
cytotoxicity. Considering that the stabilisation of p53 by Ad5Hey1 in LNCaP cells 
was not as pronounced as in 22Rv1 and HCT116wt cells, it would be of interest 
to repeat the AR and p53 knockdown studies in this cell line. It would also be 
valuable to assess the activation status of p53 through the detection of phospho 
(ser15) p53 after Ad5Hey1 infection. Since these cells are more dependent on 
AR signalling for cell growth, we might expect differential regulation of AR and 
p53 by Ad5Hey1 compared with 22Rv1 cells. As discussed above, the limited 
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induction of p53 expression by Ad5Hey1 may be a consequence of AKT-
induced inhibition and destabilisation of p53 through AKT-dependent promotion 
of HDM2 activity. It would therefore be of interest to realise whether inhibition of 
AKT by RNA interference of selective AKT inhibition would sensitise these cells 
further to Ad5Hey1-dependent cytotoxicity. 
 
In view of the p53-independent activities of HDM2, in particular inhibition of 
E2F1 and TAp73α, we propose to explore whether Ad5Hey1-mediated inhibition 
of HDM2 will enhance the activity of these proteins in HCT116p53-/- cells since 
these cells express p73 and have a functional pRb/E2F1 pathway. Expression 
levels of bona fide targets of E2F1 targets, cyclin E and p73 will be assessed in 
response to Ad5Hey1-infection as well as TAp73α protein levels since the 
activity of this protein is also under the control of HDM2. The expression status 
of p73 in DU145 cells has not been established therefore, if we find these cells 
express p73 we will establish whether p73 activation might play a role in 
Ad5Hey1-dependent cell killing.  
 
I endeavoured to investigate the AR and p53-independent mechanism of 
Ad5Hey1 mode of action in DU145 cells in the context of STAT3 signalling. This 
aspect of Ad5Hey1-mediated regulation requires further analysis. Initial 
experiments will involve assessing the combined effect of Ad5Hey1 and 
AZD1480 on phospho-STAT3 and cyclin D1 levels after 48h. Cells will be 
treated with AZD1480 for a small window of time prior to the end of the time 
course to allow any potential combined effect on STAT3 signalling with these 
agents to be observed. RNA interference towards STAT3 in DU145 cells 
provides an alternative, more specific way of blocking STAT3 activity. If 
Ad5Hey1 does mediate its effects through inhibition of STAT3 signalling, siRNA 
towards STAT3 might desensitise cells to Ad5Hey1-dependent cell killing. 
However alternatively, knocking down STAT3 could sensitise cells to other 
Ad5Hey1-dependent effects of other Hey1 targets such as inhibition of HDM2. 
Therefore other detailed studies to elucidate the potential mechanism Hey1 
might employ on STAT3 signalling are required. To clarify whether Hey1 could 
be repressing STAT3 transactivation, the activity of a STAT3-inducible reporter 
system in the presence of Ad5Hey1 would prove informative. Likewise, co-
immunoprecipitation studies between Hey1 and STAT3 might demonstrate a 
direct relationship. Dependent on the results of these studies we would finally 
 290 
transfect PC3 cells with STAT3 to investigate whether the presence of STAT3 
would sensitise these cells to Ad5Hey1-mediated cytotoxicity. 
 
Further investigation into Ad5Hey1-dependent effects on cell cycle deregulation 
in 104-R1 and CDXR3 cells is required as well as confirming whether Ad5Hey1-
mediated cell death occurs via apoptosis. The molecular mechanisms by which 
Ad5Hey1 is delaying cell cycle progression will also be explored. To extend the 
study assessing activity of Ad5Hey1 in response to androgen and bicalutamide 
treatment in AR-positive PCa cells (section 3.4.1), we plan to assess the 
response of Ad5Hey1 in 104-R1 and CDXR3 cells in the presence of these 
agents. It would also be valuable to evaluate AR transcriptional activity using our 
AR-responsive luciferase reporter plasmid after Ad5Hey1 infection in these 
cells. Furthermore, it would be of interest to assess the sensitivity of the 
resistant 104-R1 and CDXR3 cell lines to cytotoxic drug treatment and if found 
to be more resistant to drugs than 104-S cells, to assess the effect of these cells 
in combination with Ad5Hey1.   
 
Finally, we also plan to complete construction of AdΔΔHey1 and evaluate 
against AdΔΔ for efficacy as a single agent and in combination with cytotoxic 
drugs by assessing cell viability and viral replication in vitro. Sensitivity of 
AdΔΔHey1 to human prostate epithelial cells will also require evaluation to 
ensure AdΔΔHey1 is attenuated in normal cells. Dependent on in vitro findings, 
we plan to verify the efficacy of AdΔΔHey1 in vivo using DU145 and LNCaP 
androgen-ablation and bicalutamide-resistant xenografts. 
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5. Appendix  
 
Figure_Apx 1. Ad5Hey1-infection stabilises p53 in 22Rv1 cells at 48h 
Cells were infected with Ad5Hey1#2 (A) or Ad5Hey1#3 (B), AdE1A12S#2 and Ad5GFP at 10, 100 
and 1000ppc. After 2h, infection medium was removed and replaced with 10% FBS DMEM. Cell 
lysates were harvested at 48h post-infection and prepared for separation on polyacrylamide gels. 
20µg protein was loaded per lane and total p53 blotted. KU70 was used as a loading control. 
Histogram showing total p53 protein expression normalised to KU70 and expressed relative to 
uninfected (UN) cells. Results show blots from two independent experiments. 
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Figure_Apx 2. Ad5Hey1-infection stabilises p53 in 22Rv1 cells at 72h 
Cells were infected with Ad5Hey1#2, AdE1A12S#1 and Ad5noHey1 at 10, 100 and 1000ppc. After 
2h, infection medium was removed and replaced with 10% FBS DMEM. Cell lysates were 
harvested at 72h post-infection and prepared for separation on polyacrylamide gels. 20µg protein 
was loaded per lane and total p53 blotted. KU70 was used as a loading control. Histograms 
showing total p53 protein expression normalised to KU70 and expressed relative to uninfected 
(UN) cells. Results are from one experiment. 
 
 
Figure_Apx 3. Ad5Hey1-infection stabilises p53 in LNCaP cells 
Cells were infected with Ad5Hey1#3, AdE1A12S#3 and Ad5GFP at 10, 100 and 1000ppc. After 
2h, infection medium was removed and replaced with 10%FBS RMPI. Cell lysates were harvested 
at 48h post-infection and prepared for separation on polyacrylamide gel. 20µg protein was loaded 
per lane and total p53 blotted. The membrane was stripped and blotted for β-tubulin as a loading 
control. Histogram showing total p53 expression normalised to β-tubulin and expressed relative to 
uninfected (UN) cells. Results are from one experiment. 
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